Making what counts be counted: evaluating the use of preference-based outcome measures in Parkinson’s disease by Xin, Yiqiao
 
 
 
 
 
 
 
 
 
Xin, Yiqiao (2018) Making what counts be counted: evaluating the use of 
preference-based outcome measures in Parkinson’s disease. PhD thesis. 
 
 
https://theses.gla.ac.uk/30697/  
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
Making what counts be counted: 
evaluating the use of preference-based 
outcome measures in Parkinson’s 
disease  
 
 
Yiqiao Xin 
MSc Health Technology Assessment and Management, BSc Pharmacy 
 
 
Submitted in fulfilment of the requirements for the degree of 
 
Doctor of Philosophy 
 
 
 
Health Economics and Health Technology Assessment (HEHTA) 
 
Institute of Health and Wellbeing 
 
College of Medical, Veterinary and Life Science 
 
University of Glasgow 
 
July 2018 
  
  II 
Abstract 
Parkinson’s is a common neurodegenerative disorder that can have a significant 
impact on an individual’s health, quality of life (QoL), and wellbeing, causing 
substantial economic burden on patients, their caregivers, the health service, and 
broader social and community services. Whilst Parkinson’s wide range of QoL and 
financial impacts have been well documented relatively little research has 
explored to what extent such impacts have been appropriately incorporated into 
economic evaluations.  
Economic evaluation is used by the National Institute for Health and Care 
Excellence (NICE) in the UK to guide health-care resource allocation in the NHS. 
It uses preference-based outcome measures to measure and value the health 
outcomes of different interventions. These health utilities are combined with 
durations to estimate quality-adjusted life-years. The important role of the 
preference-based outcomes requires them to be accurately capturing the benefit 
of interventions, otherwise the estimation of cost-effectiveness of interventions 
will be not be reflecting true preference/choice between interventions. This may 
lead to mistakes in funding decisions and insufficient allocation of resources.  
Despite the importance of accurately capturing the benefit of interventions, the 
existing generic preference-based measures (e.g., the EQ-5D measure as 
recommended by NICE) are sometimes criticised for their ‘health-related’ nature 
as insufficient to capture all the QoL aspects that are affected by the disease or 
the intervention. This raises a question of “is the generic ‘prescribed’ measure 
appropriate for all disease areas and all interventions?” For diseases that have 
broad impact on people’s health and wellbeing such as Parkinson’s, a broadly 
scoped preference-based wellbeing instrument which could measure the impact 
of intervention beyond health may potentially fill the gap of the limited scope of 
the ‘health-related’ preference-based measures (if any).  Meanwhile, there are 
concerns relating to their relevance and sensitivity to specific health aspects and 
their validity in general to be used in the healthcare context. Given this, the aim 
of this thesis is to examine the performance of the existing preference-based 
outcomes in people with Parkinson’s, and evaluate the potential of using a generic 
preference-based capability-wellbeing measure, ICECAP-O, in this population.  
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This thesis conducted a systematic review of the existing preference-based 
measures to assess their construct validity and responsiveness in people with 
Parkinson’s. Two empirical studies explored these properties of the ICECAP-O 
measure in people with Parkinson’s. Construct validity and responsiveness are the 
two key psychometric properties relevant to preference-based measures for their 
use in economic evaluations.  Data for both empirical analyses were obtained from 
the PD MED large-scale randomised controlled trial. 
This thesis has identified evidence of limited responsiveness of the existing 
preference-based measures in people with Parkinson’s and suggested that the 
current commonly used preference-based health-related QoL measures may 
underestimate the value placed on the mental and social wellbeing aspects that 
Parkinson’s populations are affected by. This limited ability of the utility values 
to differentiate health states may have an impact on resource allocation decisions. 
Especially as this relates to the cost-effectiveness of interventions that have the 
capacity to influence the mental and social wellbeing aspects of people’s lives. 
This highlights the need for consideration of a broadly scoped measure such as the 
ICECAP-O to incorporate such aspects in economic evaluations of diseases such as 
Parkinson’s. This thesis established the construct validity and responsiveness of 
the ICECAP-O instrument and demonstrated that there are valued capability 
wellbeing attributes in Parkinson’s beyond those quality of life attributes 
reflected by the EQ-5D instrument. It contributes to understanding the use of 
broadly scoped outcome measures for economic evaluations in Parkinson’s by 
showing that the ICECAP-O capability wellbeing instrument was able to provide a 
preference-based assessment of these under-represented aspects in the 
Parkinson’s population, without compromising its sensitivity to the clinical and 
specific physical QoL dimensions in this patient group. While further exploration 
of the role of ICECAP-O in economic evaluation and decision making through the 
work of assessing ‘sufficient capability’ is required, this thesis establishes initial 
foundations for the use of the ICECAP-O as a preference-based instrument to 
measure the impact of interventions in Parkinson’s populations.  
 
  IV 
Table of Contents 
Abstract ................................................................................................................. II 
Table of Contents ................................................................................................. IV 
List of Tables ......................................................................................................... X 
List of Figures ..................................................................................................... XII 
Acknowledgement ............................................................................................. XIII 
Author’s Declaration .......................................................................................... XV 
Publications, Working Papers and Presentations ......................................... XVI 
Abbreviations ................................................................................................... XVII 
Chapter 1 Context and rationale ...................................................................... 1 
1.1 Introduction ............................................................................................... 1 
1.2 Parkinson’s disease .................................................................................. 2 
1.2.1 Prevalence and mechanism .............................................................. 2 
1.2.2 Symptoms ......................................................................................... 4 
1.2.3 QoL and broader wellbeing in Parkinson’s ........................................ 6 
1.2.4 Management of Parkinson’s .............................................................. 7 
1.2.5 The economics of Parkinson’s ......................................................... 10 
1.3 Priority setting and economic evaluations ............................................... 13 
1.3.1 Priority setting .................................................................................. 13 
1.3.2 Market failure ................................................................................... 14 
1.3.3 Economic evaluation ....................................................................... 16 
1.4 Outcome measurement .......................................................................... 18 
1.5 Rationale of this thesis ............................................................................ 19 
1.5.1 Assessing the use of current measures ........................................... 19 
1.5.2 Incorporating broader aspects ......................................................... 20 
1.5.3 Capability wellbeing and the ICECAP-O instrument ........................ 21 
1.5.4 Construct validity and responsiveness ............................................ 23 
1.6 Research questions ................................................................................ 24 
1.7 Structure of thesis ................................................................................... 26 
Chapter 2 Outcome measurement in economic evaluations ...................... 30 
2.1 Introduction ............................................................................................. 31 
2.2 Economic evaluation in healthcare ......................................................... 32 
2.2.1 Cost effectiveness analysis ............................................................. 32 
2.2.2 Cost utility analysis .......................................................................... 33 
  V 
2.2.3 Cost benefit analysis ....................................................................... 35 
2.3 Health, Qol and HrQoL ........................................................................... 36 
2.3.1 Definition of Health .......................................................................... 37 
2.3.2 QoL and HrQoL ............................................................................... 38 
2.3.3 QoL outcome measures .................................................................. 41 
2.4 Health utility and preference-based QoL measures ................................ 42 
2.4.1 Health utility ..................................................................................... 42 
2.4.2 Preference elicitation ....................................................................... 44 
2.4.3 PbQoL measures ............................................................................. 47 
2.4.4 The EQ-5D instrument ..................................................................... 48 
2.5 Critiques of the use of the QALY in outcome measurement ................... 50 
2.5.1 Evaluative scope ............................................................................. 50 
2.5.2 Comparison of different preference-based measures ...................... 52 
2.5.3 Whose preferences matter? ............................................................ 53 
2.6 Alternatives to health-related generic preference-based measures ........ 54 
2.6.1 Mapping from non-preference based measures .............................. 54 
2.6.2 Valuation of condition-specific QoL measures ................................. 56 
2.6.3 Bolt-on attributes ............................................................................. 57 
2.6.4 Wellbeing measures ........................................................................ 58 
2.7 The ICECAP-O instrument ..................................................................... 59 
2.7.1 Sen’s capability approach ................................................................ 59 
2.7.2 ICECAP-O ....................................................................................... 61 
2.7.3 Use of the ICECAP-O in economic evaluation ................................ 62 
2.8 Chapter summary ................................................................................... 64 
Chapter 3 Construct validity and responsiveness: theory and assessment 
methods 65 
3.1 Introduction ............................................................................................. 66 
3.2 Overview: psychometric properties ......................................................... 67 
3.2.1 Reliability ......................................................................................... 68 
3.2.2 Validity ............................................................................................. 70 
3.2.3 Other properties............................................................................... 72 
3.2.4 COSMIN checklist ........................................................................... 73 
3.3 Construct validity .................................................................................... 75 
3.3.1 History of construct validity .............................................................. 76 
3.3.2 Definition of construct validity .......................................................... 78 
3.4 Methods to assess construct validity ...................................................... 80 
  VI 
3.4.1 A five-step model for construct validation ........................................ 80 
3.4.2 Statistical methods for testing construct validity .............................. 82 
3.5 Responsiveness ..................................................................................... 87 
3.5.1 Why we measure change ................................................................ 88 
3.5.2 How responsiveness should be defined .......................................... 89 
3.5.3 Minimally important differences ....................................................... 91 
3.5.4 Why responsiveness is important for PbQoL instruments ............... 92 
3.6 Methods to assess responsiveness ........................................................ 93 
3.6.1 Anchor selection .............................................................................. 94 
3.6.2 Anchor group formation ................................................................... 95 
3.6.3 Statistical methods for testing responsiveness ................................ 99 
3.7 Chapter summary ................................................................................. 102 
Chapter 4 A systematic review of the use of preference-based measures in 
Parkinson’s and assessment of their construct validity and 
responsiveness ................................................................................................. 103 
4.1 Introduction ........................................................................................... 104 
4.2 Objectives ............................................................................................. 107 
4.3 Methods ................................................................................................ 108 
4.3.1 Assessment criteria ....................................................................... 108 
4.3.2 Databases and search strategy ..................................................... 112 
4.3.3 Eligibility criteria and data extraction ............................................. 114 
4.4 Results .................................................................................................. 115 
4.4.1 Search results ............................................................................... 115 
4.4.2 Assessment of the construct validity and responsiveness ............. 121 
4.4.3 Performance of PbQoL measures in economic evaluations .......... 137 
4.4.4 Mapping algorithms ....................................................................... 138 
4.5 Summary of results ............................................................................... 141 
4.6 Discussion ............................................................................................ 142 
4.7 Chapter summary ................................................................................. 143 
Chapter 5 Case studies: justification, data source and methodological 
challenges 145 
5.1 Introduction ........................................................................................... 146 
5.2 Justification for the case studies ........................................................... 146 
5.3 Case studies: data source .................................................................... 148 
5.3.1 Trial design .................................................................................... 148 
5.3.2 Inclusion/exclusion criteria and recruitment ................................... 149 
  VII 
5.3.3 Outcome measures ....................................................................... 150 
5.3.4 The PDQ-39 instrument ................................................................. 151 
5.4 Methodological challenges of the assessment of the construct validity and 
responsiveness of ICECAP-O in Parkinson’s .................................................. 152 
5.4.1 No criterion .................................................................................... 152 
5.4.2 How to validate ‘preferences’? ...................................................... 153 
5.4.3 No prior information ....................................................................... 155 
5.4.4 Heterogeneity within the sample ................................................... 155 
5.5 Chapter summary ................................................................................. 156 
Chapter 6 Testing the construct validity of the ICECAP-O instrument and 
exploring its relationship with the EQ-5D-3L and the PDQ-39 ...................... 157 
6.1 Introduction ........................................................................................... 158 
6.2 Aims and objectives .............................................................................. 158 
6.3 Data for this chapter ............................................................................. 160 
6.4 Methods ................................................................................................ 160 
6.4.1 Hypotheses ................................................................................... 160 
6.4.2 Statistical analysis ......................................................................... 165 
6.5 Results .................................................................................................. 168 
6.5.1 Sample description ........................................................................ 168 
6.5.2 Known-group comparison .............................................................. 170 
6.5.3 Convergent validity ........................................................................ 177 
6.5.4 Hypotheses tests ........................................................................... 181 
6.6 Summary of results ............................................................................... 181 
6.7 Results in the context of existing evidence ........................................... 182 
6.8 Chapter summary ................................................................................. 183 
Chapter 7 Testing the responsiveness of the ICECAP-O and comparison 
with the EQ-5D-3L ............................................................................................. 184 
7.1 Introduction ........................................................................................... 185 
7.2 Aims and objectives .............................................................................. 186 
7.3 Methods ................................................................................................ 188 
7.3.1 Data ............................................................................................... 188 
7.3.2 The anchor based method ............................................................. 189 
7.3.3 Change group formation ................................................................ 191 
7.3.4 Missing data and multiple imputation ............................................. 194 
7.3.5 Statistical analysis ......................................................................... 196 
7.4 Results .................................................................................................. 200 
7.4.1 Patient characteristics ................................................................... 201 
  VIII 
7.4.2 Missingness prediction .................................................................. 209 
7.4.3 Scatter plot of the change in ICECAP-O/EQ-5D-3L....................... 210 
7.4.4 Correlation ..................................................................................... 212 
7.4.5 Effect size statistics ....................................................................... 214 
7.4.6 Regression analysis ...................................................................... 225 
7.4.7 Sensitivity analysis ........................................................................ 226 
7.5 Summary of results ............................................................................... 229 
7.6 Discussion ............................................................................................ 230 
7.6.1 Interpretation of results .................................................................. 230 
7.6.2 Critique of previous studies assessing responsiveness of ICECAP-O
 231 
7.6.3 Methodological considerations ...................................................... 234 
7.7 Chapter summary ................................................................................. 241 
Chapter 8 Discussion and conclusion ........................................................ 242 
8.1 Introduction ........................................................................................... 243 
8.2 Summary of the findings ....................................................................... 244 
8.2.1 Evaluating the performance of existing PbQoL measures in 
Parkinson’s ................................................................................................ 244 
8.2.2 The performance of the ICECAP-O instrument in Parkinson’s ...... 246 
8.3 Strengths and limitations of this thesis ................................................. 248 
8.3.1 Strengths ....................................................................................... 248 
8.3.2 Limitations ..................................................................................... 248 
8.4 Implications of research for policy making ............................................ 251 
8.4.1 Limitations of the use of EQ-5D in Parkinson’s ............................. 251 
8.4.2 Sensitivity of EQ-5D levels ............................................................ 253 
8.4.3 Use of ICECAP-O instrument for decision-making ........................ 254 
8.5 Implications and recommendations for future research ........................ 257 
8.5.1 Choice of preference-based outcomes .......................................... 257 
8.5.2 The necessity of setting up hypotheses ......................................... 258 
8.5.3 Outcome measures for defining health state in decision-analytic 
modelling ................................................................................................... 258 
8.6 Areas for further research ..................................................................... 259 
8.6.1 Comparison between EQ-5D-3L and ICECAP-O measure in 
economic evaluation in Parkinson’s population ......................................... 259 
8.6.2 Validation of ‘preference’ ............................................................... 259 
8.6.3 Developing robust methods of demonstrating psychometric 
properties for generic PbQoL measures .................................................... 260 
8.6.4 Value of qualitative research ......................................................... 262 
  IX 
8.7 Contribution of the thesis ...................................................................... 263 
8.8 Conclusions .......................................................................................... 264 
References ........................................................................................................ 266 
Appendices........................................................................................................ 302 
Appendix A: Search strategy ........................................................................... 302 
Appendix B: Stata codes for multiple imputation ............................................. 309 
Appendix C: Results of statistical tests for the comparison of correlation 
coefficients using the R cocor package. .......................................................... 311 
Appendix D: Calculation of Pearson correlation coefficient of the imputed 
dataset ............................................................................................................ 314 
Appendix E: Checking normality of residuals .................................................. 315 
Appendix F: Regression analysis of responsiveness: complete case analysis 319 
Appendix G: Permission for including published materials in this thesis ......... 320 
 
  X 
List of Tables 
Table 4-1: Measures used in the included studies .......................................................... 119 
Table 4-2: Characteristics of the health-related QoL instruments in the included studies
 ........................................................................................................................................ 120 
Table 4-3: Characteristics of included studies – assessment of ‘known-group’ validity 
(n=7) ................................................................................................................................ 124 
Table 4-4: Characteristics of included studies – assessment of convergent validity (n=5)
 ........................................................................................................................................ 129 
Table 4-5: Characteristics of included studies – assessment of responsiveness (n=13) 133 
Table 4-6: Characteristics of studies mapping PDQ-39/PDQ-8 scores to EQ-5D-3L utility 
values .............................................................................................................................. 139 
Table 4-7: Summary of PDQ dimensions included in each mapping algorithm .............. 140 
Table 5-1: Baseline and follow-up assessments of the PD MED trial outcomes ............. 151 
Table 6-1: Hypotheses, rationale and testing methods ................................................... 162 
Table 6-2: Sample characteristics (complete case)......................................................... 169 
Table 6-3: Early versus Later group: mean differences of ICECAP-O, EQ-5D-3L and the 
PDQ-39 ........................................................................................................................... 171 
Table 6-4: Responsesa on ICECAP-O for the Early group and Later group .................... 172 
Table 6-5: Odds ratio (OR) between the levels of ICECAP-O attributes (Later group / Early 
group) .............................................................................................................................. 173 
Table 6-6: Responsesa on EQ-5D-3L for the Early group and Later group ..................... 174 
Table 6-7: Odds ratio (OR) between the levels of EQ-5D-3L attributes (Early group / Later 
group) .............................................................................................................................. 175 
Table 6-8: Mean score of PDQ-39 eight dimensions for the Early group and Later group 
(complete casea) .............................................................................................................. 176 
Table 6-9: Mean difference (Later – Early) of the PDQ-39 attributes .............................. 177 
Table 6-10: Pearson correlations between overall score of ICECAP-O, EQ-5D-3L and 
PDQ-39 ........................................................................................................................... 179 
Table 6-11: Pearson correlation coefficients matrix – attributes of ICECAP-O, PDQ-39 and 
EQ-5D-3L ........................................................................................................................ 180 
Table 6-12 Results of hypotheses testing ....................................................................... 181 
Table 7-1: Criteria for forming change groups in the base case analysis: H&Y and PDQ-
39-SI and eight dimension scores ................................................................................... 192 
Table 7-2: Participant characteristics, at baseline and two-year follow-up (complete case)
 ........................................................................................................................................ 202 
Table 7-3: Distribution of H&Y scores, at baseline and two-year follow-up (complete case)
 ........................................................................................................................................ 203 
Table 7-4: Responses (percentages) for each of the ICECAP-O attributes, at baseline and 
two-year follow-up (complete case) ................................................................................. 206 
Table 7-5: Responses (percentages) for each of the EQ-5D-3L attributes, at baseline and 
two-year follow-up (complete case) ................................................................................. 206 
Table 7-6: PDQ-39 eight dimension scores, at baseline and two-year follow-up (complete 
case) ................................................................................................................................ 208 
  XI 
Table 7-7: Predictors for the probability of missing values (0: missing, 1: non-missing) for 
PDQ-39-SI ....................................................................................................................... 210 
Table 7-8: Correlation coefficients between the change scores of the ICECAP-O, EQ-5D-
3L and PDQ-39 ............................................................................................................... 214 
Table 7-9: Change group formation: PDQ-39-SI in each change group anchored by PDQ-
39-SI ................................................................................................................................ 215 
Table 7-10: Change score of the ICECAP-O and EQ-5D-3L over the two years for each of 
the five change groups (anchored by PDQ-39-SI) .......................................................... 216 
Table 7-11: ES and SRM statistics of ICECAP-O and EQ-5D-3L with the anchor PDQ-39-
SI ..................................................................................................................................... 216 
Table 7-12: Change group formation: H&Y in each change group anchored by H&Y .... 218 
Table 7-13: Change score of the ICECAP-O and EQ-5D-3L over two years (anchored by 
H&Y) ................................................................................................................................ 219 
Table 7-14: ES and SRM statistics of ICECAP-O and EQ-5D-3L with the anchor H&Y . 219 
Table 7-15: Change groups formed by PDQ-39 dimensions: PDQ-39 dimension score in 
each change group anchored by that dimension............................................................. 221 
Table 7-16: ES and SRM statistics of ICECAP-O and EQ-5D-3L, anchored by the PDQ-39 
eight dimensions ............................................................................................................. 223 
Table 7-17: Regression analysis to predict the change of ICECAP-O index score from the 
change of the PDQ-39 eight dimensions ......................................................................... 225 
Table 7-18: Regression analysis to predict the change of EQ-5D-3L index score from the 
change of the PDQ-39 eight dimensions ......................................................................... 226 
Table 7-19: Sensitivity analysis – comparing the impact of different imputation strategies 
to the result of responsiveness ........................................................................................ 227 
Table 7-20: Sensitivity analysis – results of three change groups (as versus five change 
groups in the base case) and 3*MID (as versus 5*MID in the base case) ...................... 228 
 
  
  XII 
List of Figures 
Figure 1-1: Cost of Parkinson’s. ........................................................................................ 12 
Figure 1-2 Visualisation of the thesis structure ................................................................. 29 
Figure 3-1: Relationship between measurement properties. ............................................. 74 
Figure 3-2: Trend line of number of publications of validation studies. ............................. 77 
Figure 3-3: A five-step model for construct validation. ...................................................... 81 
Figure 4-1: Flowchart of study screening process ........................................................... 116 
Figure 6-1: Distribution of ICECAP-O, EQ-5D-3L and PDQ-39 in the Early group and the 
Later group. ..................................................................................................................... 170 
Figure 6-2: Response on ICECAP-O for the Early group and Later group. ..................... 172 
Figure 6-3: Response on EQ-5D-3L for the Early group and Later group. ...................... 174 
Figure 6-4: Responses on PDQ-39 eight attributes for the Early group and Later group.
 ........................................................................................................................................ 176 
Figure 6-5: Scatter plots of ICECAP-O - PDQ-39, EQ-5D-3L – PDQ-39 and ICECAP-O – 
EQ-5D-3L. ....................................................................................................................... 178 
Figure 7-1: The distribution of the change of ICECAP-O, EQ-5D-3L and PDQ-39 ......... 204 
Figure 7-2: Change of the distribution of responses for each of the ICECAP-O attributes 
over the two years (complete case) ................................................................................ 205 
Figure 7-3: Change of the distribution of responses for each of the EQ-5D-3L attributes 
over the two years (complete case) ................................................................................ 207 
Figure 7-4 : PDQ-39 eight dimension scores, at baseline and two-year follow-up (complete 
case) ................................................................................................................................ 209 
Figure 7-5: Scatter plot of the change of ICECAP-O and PDQ-39-SI ............................. 211 
Figure 7-6: Scatter plot of the change of EQ-5D-3L and PDQ-39SI ................................ 212 
Figure 7-7: An example for checking the normality of the regression residual to choose 
between Pearson correlation and Spearman correlation: ICECAP-O change score vs. 
PDQ-39 change score (m=10) ........................................................................................ 213 
Figure 7-8: SRM (SE) of ICECAP-O and EQ-5D-3L in the five change groups anchored by 
PDQ-39-SI ....................................................................................................................... 217 
Figure 7-9: SRM (SE) of ICECAP-O and EQ-5D-3L in the five change groups anchored by 
H&Y ................................................................................................................................. 220 
 
  
  XIII 
Acknowledgement 
This Ph.D. journey has been a rewarding and enriching adventure in my life, full 
of ups and downs, pride and tears. With the utmost sincerity, I wish to thank the 
many people who have seen me through this journey. 
First and foremost, I would like to express my earnest gratitude to my supervisors 
Professor Emma McIntosh and Dr. Jim Lewsey for their continued and timely 
support, insightful advice, immense knowledge, patience and motivation 
throughout the process of my Ph.D. pursuit. As both my line manager for projects 
and PhD supervisor, besides her invaluable academic guidance, Emma is always 
being so understanding, listening to my needs, looking after me, and ‘protecting’ 
my time for PhD as much as she can. In particular, I am extremely grateful for all 
the time she has taken (in between her millions of projects) to improve my 
academic writing and correct my English, and also, after all that extra tedious 
work, she would tell me “Your English writing is good. I’m not worrying about it!” 
to protect my confidence. I cannot imagine a more patient, understanding and 
kind supervisor like her. 
I am extremely grateful for Jim’s statistical advice that I benefited immeasurably 
from our discussions. Jim is like the ‘the needle that pacifies the oceans’ (‘Ding 
hai shen zhen’, which may sound weird, but it is a huge compliment) in Chinese 
idioms from the ‘Monkey King’ legend as he is always so calm, wise and incisive 
when I am panicking about statistics. Also, Jim’s encouragement and the positive 
feedback at the writing up stage of this thesis are greatly appreciated. 
I would like to thank Professor Olivia Wu for opening HEHTA’s door to me five 
years ago when I was still a master student in Canada knowing almost nothing 
looking for initial opportunities of research in HTA. I also would like to thank Olivia, 
Professor Elizabeth Fenwick and Professor Andrew Briggs for providing me the 
opportunity to pursue my PhD in such a world leading, dynamic and friendly 
research group. An essential contribution was given by my group HEHTA, that 
funded this PhD. 
I addition, I want to emphasize my gratitude to Emma and Olivia for their 
emotional support and allowing me the time to write up the thesis at HEHTA. They 
have been generous and inspirational mentors for me. I wouldn’t forget about 
  XIV 
those long meetings or long chats with the burst of all the emotions at the toughest 
moments of my PhD process when Emma or Olivia was ‘rescuing’ my falling hope 
and help me re-establish my confidence. 
I would also like to acknowledge the PD MED trial team, Professor Carl Clarke at 
the University of Birmingham, Professor Richard Gray, Professor Alastair Gray and 
Professor Crispin Jenkinson at the University of Oxford for providing me their 
expert opinions on matters regarding Parkinson’s, statistics, and outcome 
measurement, as well as their encouragement. Special thanks to Professor Joanna 
Coast at University of Bristol for her invaluable advice and feedback on the 
analysis of ICECAP in this thesis. Also special thanks to Dr. Philip Kinghorn at 
University of Birmingham for his feedback and support on this work during the 
Health Economics Study Group conference. I also want to thank Ms. Smitaa Patel 
and Dr. Caroline Rick at the University of Birmingham Clinical Trials Unit (BCTU) 
for provision of the PD MED data for this analysis.  
HEHTA is a wonderful place to work in with the most friendly, supportive and 
international environment provided by my lovely and fun academic colleagues and 
most amazing admin team here and at the University. Thank you so much for all 
the get-togethers where we share our excitement, confusions, anxiety, stress and 
happiness at work and life. We shake the blues off, and head forward together. 
Another special thanks must go to my wonderful Chinese PhD friends for their 
‘family like’ support, which I treat as a remedy for my homesickness. I spent the 
most relaxing time with you guys and there are too many unforgettable moments 
through every week’s badminton and dinner, trips, and all the fun in the past four 
years. 
I am indebted to my parents for their selfless and unconditional love. Whenever I 
meet obstacles, I know you are always behind me and you are the strongest back 
of me. Also, to my two grandmas, I wish you both know you have my deepest love. 
Finally, I would like to thank Ewan, as a fellow health economist, for proof 
reading/peer reviewing my thesis, with the risk of ‘challenging’ me as my partner. 
More importantly, thank you for your love, caring, patience with my swinging 
mood close to the finish of my thesis, and for all the inspiring academic chats. You 
are the best person I’ve ever known. Thank you truly for everything. 
  XV 
Author’s Declaration 
I declare that, except where explicit reference is made to the contribution of 
others, that this dissertation is the result of my own work and has not been 
submitted for any other degree at the University of Glasgow or any other 
institution. 
Signed:   
Printed name: Yiqiao Xin  
  XVI 
Publications, Working Papers and Presentations 
The following publications, working papers and presentations were developed as 
part of this thesis: 
Publications: 
Xin Y & McIntosh E. (2017) Assessment of the construct validity and responsiveness 
of preference-based quality of life measures in people with Parkinson's: a 
systematic review. Quality of Life Research, 26(1): 1-23. (doi:10.1007/s11136-
016-1428-x)  
Working papers (and being drafted for submission): 
Xin Y, Lewsey J, Gray R, Clarke C, Coast J, Rick C and McIntosh E. Testing the 
responsiveness of ICECAP-O in People with Parkinson’s and a comparison with EQ-
5D-3L and a Parkinson’s specific quality of life measure PDQ-39. Health Economists’ 
Study Group, Aberdeen, June 2017. 
Xin Y, Lewsey J, Gray R, Clarke C, Coast J, Rick C and McIntosh E. Testing the 
construct validity of the ICECAP-O instrument in Parkinson’s and exploring its 
relationship with the EQ-5D-3L and the Parkinson’s specific quality of life 
questionnaire the PDQ-39. Health Economists’ Study Group, Gran Canaria, June 
2016. 
Conference presentations: 
[Published abstract] Xin Y, Lewsey J, Gray R, Clarke C, Coast J, Rick C and 
McIntosh E (2017). Too broad to be sensitive? exploring the responsiveness of the 
ICECAP-O capability wellbeing measure compared to the EQ-5D-3L to the change 
of clinical and quality of life aspects in People with Parkinson’s? International 
Society Pharmacoeconomics and Outcome Research, Glasgow, November 2017. 
Value in Health, 20(9): A763.(doi: http://dx.doi.org/10.1016/j.jval.2017.08.2165) 
[Published abstract] Xin Y, Lewsey J, Gray R, Clarke C.E., McIntosh E (2016). 
Broadening the evaluative scope of quality of life in Parkinson’s: Testing the 
construct validity of the ICECAP-O instrument. International congress of 
Parkinson’s disease and movement disorders. Berlin, Germany. June 2016. Mov 
Disord. 2016; 31 (suppl 2).  
Xin Y & McIntosh E. What matters to people with Parkinson’s? A systematic review 
of preference-based measures used in Parkinson’s. Health Economists’ Study 
Group, Glasgow, June 2014.  
  XVII 
Abbreviations 
ADL  Activities of daily living 
AQoL  Assessment of Quality of Life 
ASCOT Adult Social Care Outcome Toolkit 
AUD  Australian dollars 
CBA  cost-benefit analysis 
CEA  cost-effectiveness analysis 
CS-PBM condition specific preference-based measure 
CUA  cost-utility analysis 
DALY  disability-adjusted life year 
DBS  deep brain stimulation 
DCE  discrete choice experiments 
DDI  Disability and Distress Index 
EQ-5D  EuroQol 5 Dimensions 
EQ-5D-3L EuroQol 5 Dimensions – 3 Levels 
EQ-5D-5L EuroQol 5 Dimensions – 5 Levels 
ES  effect size 
SRM  standardised response mean 
HrQoL  health-related quality of life 
HTA  health technology assessment 
HUI  Health Utilities Index 
H&Y  Hoehn and Yahr scale 
ICECAP-A Investigating Choice Experiments for the Preferences of Adult 
ICECAP-O Investigating Choice Experiments for the Preferences of Older 
people 
ICER  incremental cost-effectiveness ratio 
MID  minimally important difference 
MCID  minimally clinically important difference 
MAR  missing at random 
MCAR  missing completely at random 
MCDA  multi-criteria decisions analysis 
MI  multiple imputation 
NHS  National Health Service 
NICE  National Institute for Health and Care Excellence 
MNAR  missing not at random 
PRISMA Preferred Reporting Items for Systematic reviews and Meta-
Analyses 
PbQoL  preference-based quality of life 
PD  Parkinson’s disease 
PDQ-39 Parkinson’s Disease Questionnaire – 39 items 
PDQ-39-SI Parkinson’s Disease Questionnaire – 39 items Summary Index 
PDQL  Parkinson’s Disease Quality of Life questionnaire 
PDQUALIF Parkinson’s Disease QUAlity of LIFe scale 
PIMS  Parkinson’s IMpact Scale 
PwP  people with Parkinson’s 
QALY  quality-adjusted life-year 
QoL  quality of life 
RCT  randomised controlled trial 
  XVIII 
SF-6D  Short Form – 6 Dimensions 
SD  standard deviation 
SG  standard gamble 
SRM  standardised response mean 
TTO  time trade-off 
UK  United Kingdom 
UPDRS  Unified Parkinson’s Disease Rating Scale 
USD  US dollars 
VAS  visual analogue scale 
WHO  World Health Organization 
WTP  willingness-to-pay 
 
 
   
Chapter 1 Context and rationale 
1.1 Introduction 
“Not everything that can be counted counts, and not everything that counts can 
be counted.” (1) 
William Bruce Cameron (not Albert Einstein) (2), sociologist, 1963  
Parkinson’s Disease (or Parkinson’s 1 ) is the second most common 
neurodegenerative disorder after Alzheimer’s disease (3). It has a wide range of 
motor and non-motor symptoms which can have significant impact on patients’ 
health, quality of life (QoL), and wellbeing (4-7) . Due to the life-changing 
symptoms, unclear mechanisms and the chronic progressive nature of the disease, 
management of Parkinson’s is not merely complicated and difficult, but also costly. 
The cost of illness escalates as Parkinson’s progresses, placing an increasing 
economic burden on the healthcare system, society and patients themselves (8-
10). 
With limited health care budget, in the UK, the health technology assessment 
(HTA) agencies, National Institute for Health and Care Excellence (NICE) and the 
Scottish Medicine Consortium (SMC) use economic evaluation methods to make 
recommendations to the National Health System (NHS) in England and Scotland 
respectively regarding resource allocation across and within budgets and judge 
whether an intervention is value for money (11, 12). In this process, to be able to 
compare the ‘value’ of interventions for priority setting purpose, a generic health-
related quality of life (HrQoL) outcome is recommended by NICE/SMC for 
measuring the benefit of interventions across and within disease areas.  
NICE defines HrQoL as ‘a combination of a person’s physical, mental and social 
wellbeing; not merely the absence of disease’ (13). Nevertheless, many HrQoL 
measures, including the one that recommended by NICE (i.e. EQ-5D (14)) (15), 
                                            
1 Parkinson’s UK recommends researchers to refer PD by ‘Parkinson’s’ only and therefore 
‘Parkinson’s’ as a term to refer to PD is used throughout in this thesis. 
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actually measure ‘self-perceived health status’ and not broader ‘wellbeing’ (16). 
Wellbeing relates to the ‘presence of positive emotions and moods (e.g., 
contentment, happiness), the absence of negative emotions (e.g., depression, 
anxiety), satisfaction with life, fulfilment and positive functioning’ 2 (17). 
Because of the narrowly implemented scope of ‘HrQoL’ in practice, a growing 
number of concerns are raised from patients, researchers and clinicians regarding 
whether such a generic health-related measure is capable of reflecting the value 
of improvements in health and wellbeing by various interventions in economic 
evaluation (18-23). If important domains are missing from the health-related 
generic measures the benefit of the intervention cannot be property measured. 
This would lead to cost-effectiveness estimates which may be inaccurate and 
consequently to errors in funding decisions. The resulting inefficient allocation of 
resources negatively impacts patient’s health and wellbeing and society overall. 
Parkinson’s is one particular area of concern (18). 
This chapter will firstly introduce Parkinson’s, its symptoms and their mechanisms, 
and the impact on QoL and overall wellbeing. Treatment options will be described. 
The economic burden caused by the disease to patients, their families and the 
NHS system will be reviewed. This provides a background to the next section; 
general principles of priority setting, market failure, and the role of economic 
evaluation in decision making. Whilst cost is tangible to measure, many challenges 
and issues are raised in outcome measurement for economic evaluation in the 
Parkinson’s population, which provides the rationale of this thesis. The chapter 
concludes with the aims, research questions and structure of this thesis. 
1.2 Parkinson’s disease 
1.2.1 Prevalence and mechanism 
 “With Parkinson's, it's like you're in the middle of the street and you're stuck there 
in cement shoes and you know a bus is coming at you, but you don't know when. 
You think you can hear it rumbling, but you have a lot of time to think. And so you 
                                            
2 These terms will be discussed in-depth in Chapter 2 (Section 2.3 for ‘QoL’ and 2.6.4 for 
‘wellbeing’). 
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just don't live that moment of the bus hitting you until it happens. There's all kinds 
of room in that space.” (24) 
Michael J. Fox, Canadian-American actor 
“Parkinson’s is my toughest fight… it doesn’t hurt. It’s hard to explain.” (24) 
Muhammad Ali, former boxing champion 
“I have a form of Parkinson's disease, which I don't like. My legs don't move when 
my brain tells them to. It's very frustrating.” (25) 
George H. W. Bush, 41th Present of the United States (1989-1993), 2012 
Parkinson’s is a progressive neurodegenerative condition resulting from the death 
of dopamine-containing cells of the substantia nigra in the brain. The worldwide 
prevalence of Parkinson’s increases with age; a recent meta-analysis showed that 
41 per 100,000 population aged 40-50 years have Parkinson’s, and this number 
increases to 1,903 in the age group >80 years (26). Parkinson’s was firstly 
identified as a condition by an English doctor, James Parkinson, in a monograph 
entitled ‘An Essay on the Shaking Palsy’ published in 1817 (27). It described the 
characteristics of Parkinson’s by detailing the six patients with ‘involuntary 
tremulous motion with lessened muscular power, in parts not in action even when 
supported, with a propensity to bend the trunk forward and to pass from a 
walking to a running pace’ (James Parkinson 1817) (p223)(27). Dopamine transmits 
signals between areas in the brain, and lack of dopamine causes the signal in some 
areas of the brain to not be transmitted properly. The most commonly affected 
part of the brain is the section responsible for controlling body balance and muscle 
movement, and thus the motor aspects of Parkinson’s, such as akinesia, 
bradykinesia, tremor, rigidity, and postural imbalance, are the defining 
characteristics of the disease (28). These motor symptoms along with the non-
motor symptoms are introduced in detail in Section 1.2.2. 
Apart from motor symptoms, patients with Parkinson’s suffer from a wide range 
of non-motor symptoms, such as depression, sleep problems, and bladder and 
bowel problems, which significantly affect their QoL. The neuropathological basis 
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of non-motor Parkinson's is less clear than the motor symptoms. A few studies 
suggest that the non-motor symptoms are associated with dysfunction in non-
dopaminergic processes, which may originate from the degeneration of the 
dopaminergic process which gradually damages other brain sections, such as the 
lower brain stem that affects autonomic functions and sleep (7, 29). Jellinger KA, 
a well-known neuropathologist, stated in a paper published in Movement Disorder 
in 2012 that “Parkinson’s disease….is no longer considered a complex motor 
disorder characterised by extrapyramidal symptoms 3 , but a progressive 
multisystem or-more correctly-multiorgan disease with variegated neurological 
and nonmotor deficiencies.” (31) This signals that the traditionally developed 
interventions targeting at dopaminergic process may not be effective in 
controlling the non-motor symptoms and these symptoms require greater 
attention from clinicians and researchers. 
1.2.2 Symptoms 
1.2.2.1 Motor symptoms 
Parkinson’s is characterized by varied motor and non-motor features. Motor 
symptoms are the symptoms that are related to movement, the core features of 
which are tremor, bradykinesia and rigidity. A resting tremor is most often 
recognized by patients and caregivers (32-34), which occurs in approximately two 
thirds of PD patients (6). It can be present in the hand (pill-rolling tremor), lower 
limbs, toes, and jaws. The tremor can be exacerbated in stressful situations or 
when the patients were asked to perform a mental task (6). Compared to tremor, 
the other two motor features, rigidity and Bradykinesia, are considered to be more 
disabling (35, 36). Bradykinesia is presented as slowness of movement in the speed, 
gait and amplitude of a repetitive action involving voluntary movements (37, 38). 
Patients with bradykinesia may also demonstrate shuffling when walking, dragging 
one or both feet when walking, or freezing as muscle reactions may slow to the 
point that the muscles become immobile. Patients may also present hastening of 
their gait, which is described as “their walking speed increases with small, rapid 
steps in an effort to ‘catch up’ with their displaced center of gravity” (6, 35, 38-
                                            
3
 Symptoms that are related to biological neural network that is part of the motor system causing 
involuntary actions (30). 
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40). The third main motor feature is rigidity, which is presented as increased 
muscle tone or amplified resistance to a passive range of motion (6). Rigidity and 
bradykinesia may affect other part of the body, among which the most noticeable 
ones are the facial movement, which can display a ‘masked’ expression, as well 
as speaking, as patients lose their ability to speak clearly (41). 
1.2.2.2 Non-motor symptoms 
Besides motor symptoms, Parkinson’s is associated with a broad spectrum of non-
motor symptoms, which also have a substantial influence on patients’ QoL (42-44). 
Sometimes these non-motor symptoms are more bothersome than motor 
symptoms, as quoted in a paper said by a patient: “I have Parkinson’s. I would like 
you to address the following symptoms that bother me the most: sleep, pain and 
then my movement disorder.” (7) 
Non-motor symptoms can be classified into two groups based on the manifestation: 
physical non-motor symptoms (in contrast to the motor symptoms which affect 
patients’ movement), and neuropsychiatric symptoms. The former includes 
swallow and saliva control, speech and communication issues, bladder and bowel 
problems, disturbances of sleep-wake cycle regulation, fatigue, dizziness, muscle 
cramps and dystonia, low blood pressure, sexual dysfunction etc, and the latter 
includes disorders of mood / apathy, depression, cognitive dysfunction, 
hallucination, etc (45, 46). In the Non-Motor Symptoms Scale (NMSS) developed by 
the Movement Disorder Society in 2006, nine domains of non-motor symptoms 
were identified from patients, clinicians and experts, and they are: cardiovascular, 
sleep/fatigue, mood/apathy, perceptual problems; attention/memory, 
gastrointestinal, urinary, sexual function and miscellaneous (47). 
While the physical non-motor symptoms are tangible, mixed views exist for the 
aetiology of neuropsychiatric symptoms in Parkinson’s (48-50). Whilst depression 
may occur reactively as a consequence of the deteriorating physical symptoms, 
there is consensus that these neuropsychiatric symptoms are also directly linked 
with the neurobiology of the illness (50-52). Pathophysiology studies suggested 
that the link is complex, which probably involves dopaminergic dysfunction, 
change of cerebrospinal fluid levels of neurotransmitter metabolites, and 
noradrenergic structure change (50-52). These findings provide evidence that the 
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neuropsychiatric symptoms in people with Parkinson’s are caused by not merely 
the psychosocial stress of the physical disabling impact of this chronic disease, but 
also the intrinsic link to the dysfunction of the brain caused by the change of the 
neurobiological environment. Consequently, this suggests that interventions that 
aim to manage the physical aspects can only partly relieve the neuropsychiatric 
symptoms and measures need to be taken focusing on these invisible non-motor 
symptoms. Furthermore, owing to the connection between ‘mind’ and ‘body’ (53, 
54), studies have shown that patients with major depression left untreated had 
faster progression of Parkinson’s:  earlier initiation of dopaminergic therapy (55), 
greater cognitive decline (56), greater deterioration in activities of daily living 
(ADL) and motor complications (55, 56), and increased mortality (57). Treating 
non-motor symptoms is therefore of great importance to improve patients’ QoL 
and, thereby, measures that are capable of sufficiently reflecting the benefit of 
treatment are required.  
Among all the motor and non-motor symptoms, depression is the most frequently 
identified symptom that leads to decrease of patients’ QoL, as reported in a study 
which summarized sixteen studies that assessing factors influencing HrQoL in 
people with Parkinson’s (5). A meta-analysis pooled the prevalence of depressive 
disorders in Parkinson’s from 36 studies and found that 17% of patients 
experienced major depressive disturbance, 22% had minor depression, 13% had 
dysthymia, and 35% of the patients presented clinically significant depressive 
symptoms (58). Apart from depression, the other factors that found to be 
significantly associated with patient’s QoL, are disease severity, anxiety, mood 
disorders, postural instability, insomnia, apathy, psychosis and cognitive 
impairment (5, 50, 59).  
1.2.3 QoL and broader wellbeing in Parkinson’s 
Parkinson’s is not immediately life-threatening, but, it is life-disabling. The 
distinguishing feature of Parkinson’s from other common chronic conditions is its 
wide range of symptoms, with each potentially affecting patients’ health, QoL and 
their overall wellbeing. These impacts are not simply tremor, involuntary 
movement, speech and language problems and depression, but also relate to 
patients’ self-perception, family relationships and social functioning. Parkinson’s 
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had the largest impact on QoL as shown with the lowest scores on EQ-5D-3L and 
15D (a PbQoL measure developed in Finland (60)) among 29 conditions, including 
heart failure, stroke, cancer, diabetes (4). 
Individuals with Parkinson’s may lose trust in their body as it can be unpredictable 
and uncontrollable (61, 62) and lose hope in their future with the worsening 
symptoms over time (63). It also can affect family relationships; the mutuality, 
the positive quality of the relationship as perceived by the caregiver, was shown 
to markedly decline in the advanced stages of the disease (64, 65). Many patients 
and their spouse caregivers experience stigma, feelings of shame or 
embarrassment about their conditions (66, 67) and fear about their future due to 
the increasing physical, emotional and financial burdens (10) coping with the 
disease (63, 68). In terms of social functioning, social isolation and degradation of 
social interactions were also found to be a common problem in people with 
Parkinson’s (69), which was found to be caused by speech (70, 71) and functional 
communication impairment (72), progressive physical disability, mood 
disturbances, shrinking of social activities and secluding oneself (73). Parkinson’s 
is a chronic progressive disease without a cure and as such the battle against 
Parkinson’s is a long tough journey, whereby interventions to improve a patients’ 
attitude towards the disease, their life, their general wellbeing, and even their 
carer’s quality of life should be considered with as great importance as direct 
symptom-relieving interventions.  
1.2.4 Management of Parkinson’s 
Without a cure, the goal of interventions in Parkinson’s is to control the various 
negative impacts of its symptoms on QoL. However, the wide spectrum of its 
symptoms necessitates complexity of treatment. A broad range of interventions 
have been developed addressing different areas of symptoms, e.g. deep brain 
stimulation (DBS) surgery, dopamine agonists, levodopa and MAO-B targeting at 
motor symptoms (74, 75), anti-depressants for depression problems, modafinil for 
daytime sleepiness,  physiotherapy to prevent falls, language and speech therapist 
to help patients who are experiencing problems with communications, swallowing 
or saliva (76). NICE recently updated its guidance on the management of 
Parkinson’s (July 2017), where fifteen ways of managing symptoms of Parkinson’s 
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are outlined, with each component focusing on a specific area of symptoms (76). 
Based on the type of intervention and the target type of symptoms, these are 
categorised as pharmacological management of motor symptoms, pharmacological 
management of non-motor symptoms, pharmacological neuroprotective therapy, 
non-pharmacological management of motor and non-motor symptoms, DBS and 
levodopa-carbidopa intestinal gel, and palliative care (76).  
1.2.4.1 Management of motor symptoms 
In the NICE guidance, Levodopa remains the preferred first line medicine for 
people with troublesome motor symptoms (76). Although many motor symptoms 
can be initially controlled by dopaminergic drugs, over time levodopa induced side 
effects will start to develop, adding more complexity to the management of the 
disease. The traditionally established side effects include motor fluctuations, 
dyskinesia (involuntary movement), hallucinations and delusions (77). Motor 
fluctuations oscillate between “off” times, a state of decreased mobility due to 
losing response to medications, and “on” times, periods when the medication is 
working and symptoms are well controlled (78). These complications are observed 
in 50% of patients after five years of treatment and in 80% of patients after ten 
years (79).  
Besides the traditional known side-effects, there has been a rising interest in the 
dopaminergic medication-related impulse control disorders in recent years (80) 
and it has been newly added to NICE’s updated guideline in 2017 as a recognised 
adverse effect of dopaminergic therapy (76). A large cross-sectional and case-
control multicentre study in 2010 showed that impulse control disorders were 
observed in 13.6% of its participants (problem and pathological gambling 5.0%, 
compulsive sexual behaviour 3.5%, compulsive buying in 5.7%, and binge eating 
disorder 4.3%) (81). Treated Parkinson’s patients were found to be 25 times more 
likely to have pathological gambling than general hospital controls (82) and this 
difference was not observed in untreated patients (83). In addition, the effect of 
medications can often ’wear off‘ as disease progresses, which means the effect of 
a given dose is not maintained as long as it is supposed to (84). Increasing daily 
dose would also deteriorate the medication related side effects, leading to 
additional negative impacts on patients’ life. Due to side effects and ‘wearing off’ 
of dopaminergic drugs, other drugs are recommended as adjuvant treatment for 
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motor symptoms. This includes dopamine agonists, monoamine oxidase B 
inhibitors, or catechol-O-methy transferase inhibitors.  
In people with advanced Parkinson’s, when symptoms are not controlled with best 
medical therapy, DBS (a type of surgical implant in brain) is recommended (76) to 
control the motor symptoms. DBS involves implanting a stimulation device in the 
patient’s brain which delivers high frequency electrical stimulation to the 
targeted area in the brain (85). This stimulation changes some of the electrical 
signals in the brain that are disrupted due to the lack of neurotransmitter, 
dopamine. Studies have shown that DBS led to significant reduction of dyskinesias 
and dopaminergic medication, improvement of all cardinal motor symptoms with 
sustained long-term benefits, and significant improvement of QoL when compared 
with best medical treatment (74, 86, 87). On the other hand, some patients had 
operation related or stimulation induced side effects including intracerebral 
haemorrhage (85), visual phosphenes, nausea, dyskinesia, and dystonia (86, 88-
90). As DBS targets the same mechanism as levodopa, its effectiveness is only clear 
in improving the dopaminergic induced motor symptoms while the impact on the 
non-motor symptoms remains to be elucidated (91). 
1.2.4.2 Management of non-motor symptoms 
Managing non-motor symptoms sometimes may be more complicated than the 
motor symptoms. This is not only due to the unclear pathology, the wide spectrum 
involved with multi organs and multi body systems, but also due to underreporting 
caused by the lack of awareness of the link with Parkinson’s (7). Since Parkinson’s 
has historically been recognised as a primary movement disorder, non-motor 
symptoms are frequently overlooked by clinicians and undertreated (7, 92). In 
2010, an international survey showed that up to 62% of patients with Parkinson’s 
do not declare symptoms such as apathy, sexual difficulty, bowel incontinence or 
sleep disorder, either due to embarrassment or lack of awareness of the link of 
these symptoms to their Parkinson’s, leaving their non-motor symptoms untreated 
(93). As a result, NICE recent updated guideline (2017) emphasised the importance 
of management of non-motor symptoms (76). An increased number of studies in 
recent years regarding the significant impact of non-motor symptoms on patients’ 
QoL has also been observed from the literature (7, 29, 42-44, 46, 94, 95).  
Chapter 1  10 
To manage non-motor symptoms, a variety of pharmacological and non-
pharmacological interventions are recommended depending on the specific non-
motor symptom. For example, modafinil is recommended to treat excessive 
daytime sleepiness, levodopa or oral dopamine agonists to treat nocturnal akinesia, 
quetiapine to treat hallucinations and delusions in patients who have no cognitive 
impairment, offering a cholinesterase inhibitor for people with mild or moderate 
Parkinson’s disease dementia, glycopyrronium bromide to manage drooling of 
saliva, and others. (76).  
1.2.4.3 Specialist care for motor and non-motor symptoms 
Interventions involving specialist care are also recommended to control motor as 
well as non-motor symptoms. These include: Parkinson’s nurse specialist 
interventions to enable a clinical monitoring, medicine adjustment and a 
continuing point of contact for support; physiotherapy and physical activity 
intervention for patients experiencing balance or motor function problems; 
considering occupational therapy for those having difficulties with ADL; and 
speech and language therapy for those experiencing problems with communication, 
swallowing or saliva.  
1.2.5 The economics of Parkinson’s 
Parkinson’s is a major cause of morbidity and has a substantial economic impact 
on patients, their caregivers, the health service, and broader social and 
community services. The burden of illness associated with Parkinson’s comes from 
two main categories of costs: (a) direct costs, where payment are directly related 
to the treatment of disease itself, and (b) indirect costs, for which resources are 
lost due to the decrease in productivity that patients experience performing their 
everyday life task as their disease progresses and the personal cost to patients and 
their carers (& for employing paid carers) due to the advancing disability (96). A 
recent systematic review summarized the cost of illness studies in Parkinson’s and 
the annual cost identified from the included studies varied by countries, methods 
and publication year, with the majority between £15,000 and £25,000 per year in 
the US and Europe (8). 
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Direct costs cover expenditures of the NHS, social care services and private 
expenditure that is directly related to the treatment of the disease (96, 97). A 
recent UK study (2016) (9) found that annual direct medical costs to the NHS, 
including both primary care and secondary care, were estimated to be £2,388 per 
patient, which is similar to a previous survey reporting a £2,277 direct cost to the 
NHS (10). The cost varies by disease severity; a previous study reported that the 
patients at lower severity cost £2,971 per patient per year and those at higher 
severity cost £18,358 per patient per year. The cost also varies by countries. An 
Australian study (2017) found that the mean annual cost per person to the health 
care system was $32,556 AUD (equivalent to £18,777) and a Chinese study 
estimated the direct health care related cost to be $2,503 USD (equivalent to 
£1,870) in China. In terms of the social care, the cost was estimated to be £2,097 
in the UK on average, with a marked increasing trend with age (10). Out-of-pocket 
private expenses towards travel and equipment for health care was reported to 
be £2,229 per patient, and additional living costs such as alterations in 
accommodation was reported to be £3,622 per household that had a person with 
Parkinson’s (9). 
Compared to the direct health and social care cost, the cost of work ability, 
productivity loss and informal care due to  disability in people with Parkinson’s is 
enormous, regardless of what approach chosen, and which country the survey is 
conducted. A recently completed study commissioned by Parkinson’s UK showed 
that the overall annual cost added up to £20,123 per person (Figure 1-1) (9), 
approximately half (£10,731) of which was arising from income loss and informal 
care. These contain direct salary lost from work days lost (£1,981), employment 
earnings forgone due to early retirement or unemployment due to Parkinson’s 
(£6,013), unpaid caring (earning loss) (£1,235), and state pension and benefit 
(£1,502). Another earlier study estimated the indirect cost was over £27,000 per 
patient per year when the care given by a family member was replaced with a 
professional carer (10). Similarly, the burden to society estimated in the 
Australian study also exceeded the health care cost, which amounted to $45,000 
(£25,954) per annum per person, including formal care with nurse and personal 
care assistance, and informal care and meals on wheels.  
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Figure 1-1: Cost of Parkinson’s.  
Source: Gumber A et al. Economic, social and financial cost of Parkinson’s on individuals, carers 
and their families in the UK. Final report. Available from Sheffield Hallam University Research 
Archive (SHURA)  2016 (9). Re-use permission is not required according to the copyright and re-
use permission information provided on SHURA website (Appendix G) 
 
The massive indirect cost arises from the great disability caused by the symptoms 
of the disease and their impact on QoL. Impairment in motor functions can lead 
to falls and injuries, not only adding to treatment cost, but also the disability to 
perform work and social activities. Non-motor symptoms such as depression, 
urinary incontinence and cognitive decline restrict patients’ independence, limit 
their ability to achieve their work and life roles, and lead to reliance on their 
carers, contributing to the psychological and economic burden of their carers and 
the society. As disease progresses, patients require increasing support emotionally, 
physically, and socially which all lead to the increasing burden on their carers (94). 
These demands are energy consuming, and also costly. 
Once diagnosed, Parkinson’s becomes a lifetime illness. As disease progresses, 
increasing annual cost will be cumulative until the patients’ end of life. The 
benefit and harms of interventions on patients’ symptoms and QoL may 
consequently translate to enormous economic impact on patients, their families 
and carers. Interventions that can relieve carers’ emotional and physical burden, 
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improve individual’s independence, working capability and self-care ability, and 
improve their ability to achieve their roles, may alleviate a high proportion of cost 
of illness and therefore may have great value in health care decision-making.  
1.3 Priority setting and economic evaluations 
“We never will have all we need. Expectation will always exceed capacity… This 
service must always be changing, growing and improving, it must always appear 
inadequate.” (98) 
Aneuryn Bevin, Minister of Health, 1948 
1.3.1 Priority setting 
Resources are scarce, but demands are growing. The total healthcare expenditure 
in the UK has increased every year, rising from £54.9 billion in 1997 to £185.0 
billion in 2015, with an annual growth rate of 8.1% between 1997 and 2009 and an 
average of 2.0% between 2009 and 2015 (99, 100). New health interventions (drugs, 
surgeries, devices, diagnostic test, preventative measures, etc.) are continually 
emerging which put considerable strain on the limited resources. Choices between 
health technologies have to be made and there is a need for healthcare decision-
making and priority setting.  
Making choices about allocation of health care resources implies trade-offs 
between the resources used to implement one intervention, and other potentially 
completing uses of those resources (101). The trade-offs have implications for the 
definition of the opportunity cost – “the opportunity cost of investing in a 
healthcare intervention is best measured by the health benefits (life years gained, 
quality-adjusted life-years (QALYs) gained) that could have been achieved had the 
money been spent on the next best alternative intervention or healthcare 
programme.” (Palmer 1999) (102) The concept of opportunity cost leads to a 
question of how health care resources can be distributed in the most efficient, 
and therefore health maximising, way. 
In a market system health care resources are distributed based on the choices and 
prevailing budget constraints of individual consumers and producers. If this is a 
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perfectly competitive market 4  these choices would jointly lead to the most 
efficient, i.e. welfare maximizing, distribution of resources in health care. The 
market is efficient as defined by the Italian economist, Vilfredo Pareto, that an 
allocation of resources is efficient if it is impossible to change that allocation to 
make one person better off without making someone else worse off (104). 
Two other types of efficiency are important when considering the distribution of 
resources in health care; technical/productive efficiency and allocative efficiency 
(105, 106). Technical / productive efficiency refers to the maximum output of 
production that can be generated by a given input of resources, which is close to 
the meaning of ‘efficiency’ in common English usage. Technical efficiency 
addresses the question of ‘how to do it’. In contrast, allocative efficiency is about 
‘whether to do it’ or ‘should something else to be done instead’ (107). It is 
achieved when it is not possible to increase the overall benefits produced by the 
health system by reallocating resources between interventions (107). Allocative 
and technical efficiency are achieved when the economy is producing exactly the 
quantity and type of health care that society wants and it is producing that health 
care for the lowest possible cost (108). 
1.3.2 Market failure 
In theory, a perfectly competitive market will automatically produce an 
equilibrium price and quantity. Whereas in reality, there are situations where a 
market fails. Market failure is a situation where there is an ‘inefficient’ allocation 
of resources; that is, when there exists another conceivable outcome where at 
least one individual may be made better-off without making someone else worse-
off (109). A health care system can be a market where the patients (consumers) 
buy the healthcare interventions and services from the healthcare provider. In 
practice however, this is an example of market failure due to the special features 
of health and health care (110). These special features are: risk and uncertainty 
associated with contracting a disease, asymmetrical information between the 
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 A perfectly competitive market is when without government interference, the ‘invisible hand’ of the 
market would allocate resources optimally leading to economic efficiency (Debreu 1955) (103). 
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healthcare providers and the consumers, supplier-induced demand and 
externalities (110-112).  
There is a great amount of uncertainty associated with the incidence of disease 
as well as progression or recovery from disease, and these uncertainties vary 
across individuals (110). In addition, patients may have more information about 
their risks and treatment than the health care providers whereas the health care 
providers may know more about the patient’s health conditions and available 
interventions than the patients. This imbalance in the level of information, or 
‘asymmetrical information’ may result in supplier-induced demand, in simpler 
words, over-treatment, that doctors may use a higher level of an intervention than 
would have been the case if the patients have had the necessary information (111).  
In a free insurance market, the considerable uncertainty and variability, as well 
as asymmetrical information, often lead to the problem of ‘moral hazard’ and 
‘adverse selection’, which cause significant market failure and allocative 
inefficiency. Moral hazard refers to that individuals covered by insurance tend to 
use more health care resources and they might not take necessary precautions to 
stay healthy as they do not bear the cost of disease (113). This leads to a higher 
level of service demanded than would have been the case without the insurance 
cover, and thus resource allocation is inefficient (111). Another problem is adverse 
selection in the health insurance market leading to market failure (113). 
Individuals with higher risk are more likely to purchase insurance than those with 
lower risk while high risk individuals use more health care resources than the low 
risk. To compensate for higher than expected costs the insurance provider might 
increase the premium, which further discourages the low risk individuals from 
purchasing the insurance while the higher risk individuals remain, leading to bigger 
losses and may drive the insurance company out of the market.  
Externalities are spill-over effects of consumption or production, which refers to 
the circumstances when the actions of one individual affects (positively or 
negatively) the wellbeing of another person (111) (113). In health care context, a 
commonly cited example is intervention such as vaccination programmes which 
may also protect other such as the family of the person getting immunised as they 
can no longer carry the infectious disease and thus there exist positive 
externalities. Externalities are usually not considered in decision-making in a free 
market since the producers of interventions are not incentivised to take into 
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account of the effect of their actions on others (do not receive or pay 
compensation for these effects) (111). Ignoring externalities leads to inefficiency 
of resource allocation overall and market failure; the vaccination program for 
infectious disease may be encouraged or implemented at a higher level when the 
spill-over effect is considered, and vice versa (the activities that have negative 
externalities may be less encouraged). 
Uncertainty associated with disease, asymmetry of information and externalities 
determine the failure of health care as a market. Market failure partly explains 
the emergence of non-market health care systems such as the UK NHS. In non-
market systems other mechanism has to be sought to achieve technical and 
allocative efficiency. Economic evaluation is one such mechanism.  
1.3.3 Economic evaluation 
“Choices must and will be made concerning their deployment, and methods such 
as ‘what we did last time’, ‘gut feelings’, and even ‘educated guesses’ are rarely 
better than organized considerations of the factors involved in a decision to 
commit resources to one use instead of another” (114) 
Michael F. Drummond, Professor of Health Economics, 2005 
 
In a publicly funded health care system with limited budget, decisions must be 
made regarding the choice of which health care technology to offer. The term 
‘health technology’ covers a range of health care interventions including devices, 
medicines, vaccines, procedures and systems developed to solve a health problem 
and improve QoL (115). In a non-market system, economic evaluation is a tool to 
aid prioritisation of health care technologies to make efficient and equitable 
decisions by comparing the costs and consequences of health technologies (97).  
The last two decades have seen a rising use of economic evaluations in supporting 
the allocation of resources in health care agencies at national and local level 
worldwide. In England and Wales, since 1999, the assessment of new health 
technologies are conducted by NICE, through providing guidance on the 
Chapter 1  17 
effectiveness and cost-effectiveness of new and existing drugs, treatments and 
procedures in the NHS (116). In other countries such as Australia, New Zealand, 
and Scotland, economic evaluation evidence is required for all new drugs to be 
listed on the national drug formulary for reimbursement (116). In addition, NICE 
clearly recognised the importance of incorporating cost-effectiveness in its 
‘Methods for the development of NICE public health guidance (2012)’, with the 
statement that ‘The Public Health Advisory Committee (PHAC) are required to 
make decisions informed by the best evidence of both effectiveness and cost 
effectiveness.’ (117) Choices have to be made, and economic evaluation offers a 
transparent process by systematically identifying, measuring, valuing and 
comparing the costs and benefits between different health care interventions for 
informing such choices.  
Economic evaluation compares the costs and consequences of health technologies 
to support decision-making (97). This definition explicitly describes its two 
features. First, economic evaluation concerns itself with choices; that is, it is 
concerned with the incremental difference between two or more alternatives, i.e. 
what additional health benefit can we get for what additional cost? Second, it 
must be involved with both the cost and outcomes, or the input and the output 
when carrying out the alternative interventions. It answers the question that ‘are 
we satisfied that the healthcare resources should be spent in this way rather than 
in any other way?’ (98). Outcomes of interventions can be direct health benefit 
such as reduction of the level of disability as well as indirect benefit such as 
productivity and income gain, reduction of carer burden, and improvement of 
social and emotional wellbeing. Similar to the cost categories in the cost of illness 
studies mentioned earlier in Section 1.2.5, costs considered in economic 
evaluations may include direct medical cost (cost to the NHS and social care), 
direct non-medical cost (e.g. family expenditure due to the disease) and indirect 
cost (e.g. cost of informal care) or productivity cost (e.g. early retirement). Whilst 
the methods for capturing the cost of health care interventions are relatively 
tangible, the outcomes of health interventions however are arguably less obvious 
and more controversial to assess (118). 
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1.4 Outcome measurement 
Economic evaluation aims to aid priority setting, which requires methods to 
facilitate comparison across different disease areas. This necessitates the need 
for standardisation of methods to capture the benefit of varied interventions or in 
populations with different conditions. As mentioned above, consequences of 
health care interventions can be within health (direct health benefit) and beyond 
health (indirect benefit), which may have considerable variations depending on 
the symptoms and impact of specific conditions. This raises a question as what 
should be ‘counted’ in the standardised measurement in economic evaluations, 
the keyword of this thesis.  
In the UK, NICE recommends the quality-adjusted life-years (QALY) framework as 
the standardized approach to quantify the benefit of interventions across disease 
areas. It combines a person’s length of life and the person’s QoL (12, 119, 120) 
into a single index. Measuring length of life is straightforward however the 
assessment of QoL is challenging. Debates have arisen from different perspectives 
surrounding its identification, measurement and valuation due to the complexity 
of the QoL concept (this will be discussed in Chapter 2, Section 2.3). Currently, 
NICE recommends a generic instrument, namely EQ-5D (121), as the standardised 
solution to measure and value the benefit of the intervention (122). Because of 
this, the EQ-5D measure is considered to be the cornerstone of the QALY 
framework. It assesses QoL with five simple questions addressing different 
functioning problems, i.e. mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression, each with three (EQ-5D-3L) or five levels (EQ-5D-5L). The EQ-
5D is a ‘preference-based’ QoL (PbQoL) measure, meaning that valuation of its 
attributes and levels (essentially a trade-off between its states) is conducted so 
that its valuation system incorporates people’s preferences.  The notion of QALY 
and ‘preference’ will be described in depth in Section 2.2.2 and 2.4. EQ-5D is 
preferred by NICE due to its generic nature, simplicity in its descriptive system, 
relevance to health-care decision makers, and the availability of large-scale 
validation and valuation studies (123).  
Using an EQ-5D based QALY allows for cross-sector comparison. This uniform 
approach, not surprisingly, brings sceptical voices claiming - ‘one size does not fit 
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all’ or ‘resulting in tortuous attempts to compare apples and oranges’ (Robinson 
1993) (124). Conditions are different, and interventions are varied in their aims, 
and thus the impact of different health care interventions on people’s life can be 
varied. EQ-5D focuses on health-related QoL so its adoption beyond health 
interventions is argued to be limited (125). It raises the question of whether such 
measure is sufficient to reflect the broader impact of disease beyond narrowly 
defined health alone. This will be further described in depth and critically 
discussed in Chapter 2, Section 2.4.4.2 and Section 2.5. 
The quote at the beginning of this chapter (i.e. “Not everything that can be 
counted counts, and not everything that counts can be counted.” (1) William 
Bruce Cameron) has implications in the health-care context where diseases and 
their impact on QoL can be diverse to a substantial degree. Firstly, the aspects 
that are measured may not be important to patients in all disease areas; secondly, 
the aspects that are important may not easily be captured. Consequently, 
questions should be raised in each specific disease area: is this ‘prescribed’ 
measure appropriate to be used in the population with a specific disease? Are 
there any limitations of this measure for capturing specific benefits of different 
interventions? In addition, what is the desired measure for the specific disease 
area and how does that compare to the ‘prescribed’ measure? If this measure does 
not fit, what is the consequence to the funding decisions regarding the 
intervention and population affected? These questions result in a myriad of 
different answers and have made measuring and valuing the outcomes a 
substantial focus of many theoretical and empirical explorations in economic 
evaluations. 
1.5 Rationale of this thesis 
1.5.1 Assessing the use of current measures 
“QALYs in their current form do not capture the positives of a treatment beyond 
direct health benefits. To measure the true value of a new treatment NICE must 
demonstrate….that it recognizes a treatment which makes somebody more 
independent and therefore less reliant on family or a carer. This may free up that 
person’s time to engage with an economy or in wider society and so we would 
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expect this is factored into any appraisal of the value of a treatment. …Parkinson’s 
UK therefore warns NICE against becoming too tied to measuring the value of a 
new treatment through the use of QALYs alone and urges NICE to take into account 
a more individual qualitative approach” (p279)(18) 
Parkinson’s UK, Parkinson's research and support charity in the UK, 2014 
Economic evaluation within the QALY framework relies on PbQoL measures. 
However, concerns are raised regarding the appropriateness of using the current 
PbQoL measure (i.e. the EQ-5D) in the Parkinson’s population. Researchers and 
patient groups have argued that the comprehensive impact of Parkinson’s on 
patients and the subsequent progressive disability (as shown in Section 1.2.2 and 
1.2.3) and impacts on QoL and wellbeing may not be sufficiently captured by EQ-
5D. Thus these are not given enough consideration in the decision-making process. 
EQ-5D focuses on HrQoL, notably physical functioning (14, 126), which, it has been 
argued, limits its ability to capture broader aspects of QoL (127, 128). As described 
in 1.2.4, there are various interventions for management of the motor and non-
motor symptoms of Parkinson’s, and the direct and indirect benefits of these 
interventions on the patients QoL are different. The potentially limited ability of 
EQ-5D to discriminate benefits, if there are any, may disincentivise some types of 
interventions when the intervention is targeting QoL aspects that are under-valued 
in its system. This may affect the assessment of cost-effectiveness and the 
ultimate allocation of resources in the Parkinson’s population. This highlights a 
need to review and critically appraise the performance of the existing PbQoL 
measures including EQ-5D, in the Parkinson’s population. 
1.5.2 Incorporating broader aspects 
The comprehensiveness of symptoms and the subsequent management raises a 
challenge to decision-makers regarding the comparison of the benefit between 
these interventions. Currently, NICE states  (‘developing NICE guidelines: the 
manual – 7 incorporating economic evaluation’) , although not in its methods for 
technology appraisal (119) that:  
“for some decision problems (such as for interventions with a social care focus) 
the intended outcomes of interventions are broader than improvements in health 
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status. Here broader, preference-weighted measures of outcomes, based on 
specific instruments, may be more appropriate….similarly, depending on the  
topic, and on the intended effects of the interventions and programmes, the 
economic analysis may also consider effects in terms of capability and wellbeing.” 
(NICE, 2014) (11)  
Typical cases of broader benefit usually exist in public health interventions, 
however, for a long-term progressive disabling disease such as Parkinson’s, 
wellbeing is important for the patients suffering from it as they have to ‘accept 
and live with it’. As the Actor Michael J Fox (diagnosed with Parkinson’s in 1992) 
said: “live in the moment, enjoy the day make the, most of what you have” (130). 
Parkinson’s specific QoL measures cannot be used in economic evaluations since 
none of them are preference-based and priority setting requires a generic measure. 
However, they were developed from the specific disease perspective and may be 
the best surrogate to reflect what matters to this group of people, i.e. ‘what 
counts’.  It is not hard to find that in addition to the health attributes such as 
mobility, broader attributes are highly prevalent in Parkinson’s specific QoL scales, 
for example: stigma, social support, cognition and communication in 39-Item 
Parkinson’s disease questionnaire (PDQ-39) (131); social/role function, self-image 
and outlook in Parkinson’s disease quality of life scale (PDQUALIF) (132); social 
functioning in Parkinson’s disease Quality of Life Questionnaire (PDQL) (133); and 
all of the attributes in Parkinson’s impact scale (PIMS) which include self-positive 
(self-worth, happiness, optimism), self-negative (level of stress, anxiety or 
depression), family relationships, community relationships, work, leisure, travel 
and safety, financial security and sexuality (134). Therefore, there is scope for 
use of a suitable preference-based measure to appropriately capture and value 
these broader attributes of wellbeing in Parkinson’s particularly for use within 
economic evaluations and priority setting. 
1.5.3 Capability wellbeing and the ICECAP-O instrument  
One potential approach that has been heralded for enabling such overall wellbeing 
evaluation in health economics is Amartya Sen’s ‘capability approach’ (135-138). 
Sen’s capability approach advocates the evaluation of programmes focusing on 
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capability (what a person is able to do) in addition to functioning (what a person 
does) (136, 139).  
Among the attempts to operationalise the capability approach, the ICECAP-O 
(Investigating Choice Experiments for the preferences of older people CAPability)  
instrument (140, 141) is the currently most well-known capability measure as an 
outcome for use in economic evaluation as shown in a previous study (125). It was 
developed with a view to expand the evaluative scope of current measures for 
economic evaluation and measure ‘capability’ wellbeing in older people (140). 
Research using ICECAP-O has the potential to provide rich and broad information 
regarding older populations’ wellbeing as its attributes are of direct relevance to 
the older population, including: attachment, security, role, enjoyment, and 
control (140, 141). It could potentially provide a complement to the existing 
measures by providing a full picture of the impact of Parkinson’s and enable a 
broader set of outcomes to be considered in economic evaluations across health 
and social care areas. ICECAP-O will be further introduced regarding its 
development, validation and use in economic evaluations in Section 2.7.2 and 
2.7.3. 
ICECAP-O is recommended by NICE’s economic evaluation methods for social care 
interventions for capturing capability when the intervention effects are beyond 
health (11, 142). In NICE’s manual for developing NICE guidelines, it says 
“depending on the topic, and on the intended effects of the interventions and 
programmes, the economic analysis may also consider effects in terms of 
capability and wellbeing. For capability effects, use of the ICECAP-O instruments 
may be considered by NICE when developing methodology in the future.” 
Furthermore, ICECAP-O has been found to be the most widely applied older person 
specific instrument in both community and residential aged care by a recent 
systematic review published in 2015 (20). Given its popularity and NICE’s 
recommendation, along with the fact that Parkinson’s primarily affects elderly 
people aged over 60, the ICECAP-O is deemed as a strong candidate for capturing 
the broad benefit of interventions that are beyond health in this population. 
ICECAP-O has not yet been reported in the population with Parkinson’s, therefore 
their level of capability is unknown. Also, the feasibility of using ICECAP-O in this 
disease area has not been previously investigated. Among the most crucial issues 
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for broadly defined wellbeing measures is their relevance and sensitivity to 
specific health and non-health aspects in the health care context (143) and 
therefore validation in specific populations is required.  
1.5.4 Construct validity and responsiveness 
Construct validity and responsiveness are two psychometric properties that can 
be quantitatively tested with data and are highly relevant to the use of PbQoL 
measures in economic evaluations (118). Construct of a measure relates to the 
hypothesized manifestations linking the underlying factors and a person’s 
behaviour (298). Construct validity requires a measure to be able to differentiate 
between states that are different in the aspects that are measured (i.e., 
discriminant validity), and correlated with measures that are built with similar 
purpose. It is an important property for a PbQoL measure to be reliable to 
generate a utility value which is a key parameter in decision-analytic modelling. 
For example, Hoehn & Yahr (H&Y) staging (i.e. a measure of motor complication 
of Parkinson’s) has been commonly used as a criteria to define the Markov states 
in cohort Markov models of disease progression (144-146). This is based on the 
assumption that utility weights should be able to differentiate between these H&Y 
staging defined health states; this assumption requires construct validity. In 
addition, previous modelling studies have identified that utility values were the 
top source of uncertainty in the studies comparing DBS and medications (144, 147). 
For example, Eggington et al. (2014) estimated the incremental cost effectiveness 
ratio (ICER)5 to be £20,678 in base case which was within the cost effectiveness 
threshold set by NICE, i.e. £20,000~£30,000 (144). In their univariate sensitivity 
analysis however, when a different study source was used for utilities, with which 
the utilities in each H&Y stage were very similar to each other, the ICER increased 
to £64,170. In contrast, when changing utility data source to another study which 
reported a larger difference across H&Y stages, the ICER decreased to £18,650, 
which fell remarkably to below the boundary. 
After construct validity has been established, responsiveness requires a measure 
to be sensitive to important changes in the aspects that it is designed to measure 
                                            
5
 ICER: estimated difference of cost divided by estimated difference of QALYs between the 
alternatives. Definition will be covered in Chapter 2, Section 2.2.2 Cost utility analysis. 
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(148). It is essential in economic evaluation alongside any longitudinal studies that 
use PbQoL measures as outcomes. In these studies, a utility profile which is 
comprised of utility values at each assessment point is mapped out over the time 
horizon of the study to generate QALYs. Ultimately, the QALY difference between 
alternatives is affected by the ability of the PbQoL measure to detect important 
changes that matter to the patients in QoL. The ability of each measure was found 
to vary significantly across instruments and populations (149, 150). Previous 
studies have found that the choice of PbQoL instruments matters to the estimate 
of the ICER (151, 152). For example, Sach et al. (2009) (152) compared the ICER 
of four options for the treatment of knee pain and found that EQ-5D and SF-6D 
would provide opposite recommendations of which option is cost-effective. The 
option ‘diet and strengthening exercise advice’ was the most cost-effective option 
(ICER=£10,815 per QALY gained) when EQ-5D was used whereas this option was 
dominated by another option ‘strengthening exercise advice only’ (ICER=£9,999 
per QALY gained) when SF-6D was used. The responsiveness of each instrument is 
different to different aspects of QoL, therefore the cost utility estimate may likely 
be different when an alternative instrument is used. 
1.6 Research questions 
The aim of this thesis is to examine the performance of the existing preference-
based outcome measures in people with Parkinson’s, and evaluate the potential 
of using a generic preference-based capability-wellbeing measure, the ICECAP-O, 
to incorporate broader aspects affected by Parkinson’s in economic evaluations. 
There are two overarching research questions for this thesis: 
1) Are the existing PbQoL measures appropriate to be used in the Parkinson’s 
population? In other words, do existing preference-based generic measures 
capture all important aspects of QoL in People with Parkinson’s?  
2) Is the ICECAP-O capability wellbeing measure appropriate to capture the 
wellbeing impact of interventions in Parkinson’s, and is it sensitive in this 
population? 
In answering these questions the use of existing PbQoL measures was critically 
assessed via a systematic review and the ICECAP-O measure was empirically 
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assessed using primary data, in the Parkinson’s population. The data were 
obtained from a large-scale long-term randomised controlled trial (RCT) in 
Parkinson’s in the UK, namely the PD MED study. The PD MED is the first study 
collecting ICECAP-O data in the Parkinson’s population and thus this thesis will, 
for the first time, provide the information regarding the capability wellbeing in 
this population, and how its validity compared with existing measures in this 
context. To my knowledge, up to the submission of this thesis (March 2018), the 
PD MED study is the only study that reported to have collected ICECAP data in the 
Parkinson’s population. Given its large scale nature which has recruited 1620 
patients with early Parkinson’s and 500 with advanced Parkinson’s, and a broad 
range of patient profiles representing the general Parkinson’s population, it is 
deemed to be more practical than collecting primary survey data. To answer the 
two overarching research questions, this thesis is split into three main empirical 
works. 
The first research question is addressed by a systematic review of studies which 
used PbQoL measures in people with Parkinson’s. This was conducted to identify 
and determine how PbQoL measures have been used in people with Parkinson’s. 
Construct validity and responsiveness of the identified measures were assessed 
with the secondary data provided in each included study. Given mapping is 
recommended by the NICE to generate EQ-5D-3L score when it is not directly 
measured, studies that mapped from non-preference based measures to EQ-5D-3L 
were included in the review. 
The second research question is addressed through two case studies, both using 
data from the PD MED RCT in Parkinson’s, each focusing on one of the two key 
psychometric properties important for PbQoL measures, construct validity, and 
responsiveness. 
The first case study explored, cross-sectionally, the impact of Parkinson’s on 
capability-wellbeing and assessed the construct validity of ICECAP-O in people 
with Parkinson’s in terms of its discriminant ability between groups and 
convergent validity with measures with similar construct. The second case study 
further explored the impact of progression of Parkinson’s over time on patients’ 
capability-wellbeing and assessed, longitudinally, responsiveness of the ICECAP-O 
in people with Parkinson’s to the change of patients’ overall and various aspects 
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of QoL, and clinical health status. To aid understanding of the results in the 
context of PbQoL measures and understand implications for decision-making, the 
psychometric properties of the existing measure recommended by NICE (122), the 
EQ-5D-3L, were also tested. In these measurement tests, the most widely 
validated Parkinson’s specific QoL measure, the PDQ-39, was assumed as the ‘gold 
standard’ to measure the QoL in this population.  
In each empirical chapter, specific objectives are also defined under the primary 
aim and addressed separately within each section. 
1.7 Structure of thesis 
Following this introduction to Parkinson’s, priority setting, use of economic 
evaluation, issues in preference-based outcome measurement, rationale for this 
thesis, and research questions, this chapter concludes with an overview of the 
thesis. This overview is visualised in Figure 1-2. This figure will be shown at the 
beginning of each chapter to highlight how it fits within the overall thesis structure. 
Chapter 2 overviews and critiques the essential theories and developments in 
measuring and valuing health outcomes for economic evaluations. It includes the 
three primary economic evaluation frameworks, the concept and measurement of 
health, QoL, HrQoL, utility and the QALY, a critique of the QALY method 
particularly in outcome measurement, followed by a critical description of 
alternative approaches, then finally focused on one of the proposed approaches, 
the capability approach, as operationalised using the ICECAP-O instrument. 
Drawing on this, chapter 2 provides an overview of the use of health outcomes in 
economic evaluation, serving as a foundation for the empirical work of this thesis. 
Chapter 3 introduces the methods used for assessment of measurement properties 
to determine whether an instrument is appropriate to be used in populations in 
given health states. In particular, this chapter focuses on the definition and 
assessment methods of construct validity and responsiveness, the two properties 
that are employed to address the overarching research questions of this thesis. 
Chapter 4 presents a systematic review which addresses the overarching research 
question 1, which is to identify PbQoL measures in people with Parkinson’s and 
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assess their appropriateness in terms of construct validity and responsiveness in 
this population. This chapter details the methodology of systematic review and 
the assessment methods for construct validity and responsiveness and provides 
the results of the research and assessment. The identified economic evaluations 
in Parkinson’s were reviewed and the challenges arising in relation to valuing 
outcomes were summarized. This chapter demonstrated a justification for further 
exploration of the construct validity and responsiveness of the PbQoL measures in 
the Parkinson’s population due to possible lack of considerations in the social and 
mental wellbeing attributes in the EQ-5D measure important to people with 
Parkinson’s. 
Chapter 5 provides a brief further justification based on the findings in Chapter 4 
for the next two chapters of the empirical case studies. In addition, given the data 
for the case studies both come from the PD MED trial, this chapter provides an 
overview of the trial and the key outcomes data collected. Since there are a 
number of challenges when applying the classic psychometric testing methods to 
answer the research question of the case studies, this chapter concludes by 
discussing the challenges related to the assessment of these properties, which 
have important implications in the methods chosen and interpretation of results 
in Chapter 6 and 7. 
Chapter 6 and 7 present two empirical works assessing the broadly defined 
measure, the ICECAP-O in terms of its construct validity and responsiveness, 
respectively. These two chapters directly address the second overarching research 
question by investigating the impact of Parkinson’s on capability-wellbeing and 
assessment of the appropriateness of ICECAP-O. Drawing on the methods reviewed 
in Chapter 3, Chapter 6 details the construct validation methods and results with 
hypotheses tested in regards to the ability of the ICECAP-O to differentiate 
between groups that are expected to differ, and its correlation with other 
measures with similar construct.  Similarly, Chapter 7 details the methods and 
results for the assessment of responsiveness to examine the extent to which the 
ICECAP-O is sensitive to the change of various health, QoL and wellbeing aspects. 
Chapter 7 also explores the impact of missing data handling strategies on the 
results of the responsiveness assessment result. To aid the interpretation of the 
results, the EQ-5D-3L was also tested and compared with the assessment results 
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of ICECAP-O in each chapter. Discussions surrounding the findings and the methods 
used are provided at the end of each chapter. 
Finally, Chapter 8 summarises the main findings and contributions of the thesis by 
revisiting the two overarching research questions. The challenges and 
recommendations arising from the practical application of the assessment 
methodologies in this thesis are discussed and summarized. This chapter also 
places the findings from this thesis within the context of wider literature in 
relation to incorporating broader aspects into consideration for healthcare policy 
making in Parkinson’s. Lastly, Chapter 8 provides the overall conclusions drawn 
from the research conducted and scope for future research.  
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2.1 Introduction 
As mentioned in last chapter (Section 1.4), whilst the cost of health care 
interventions is relatively straightforward for measurement and valuation, 
challenges arise regarding how to measure and value the benefits of healthcare 
interventions (118). 
This chapter describes and critiques the essential theories and developments in 
measuring and valuing health outcomes for economic evaluations. As described in 
Chapter 1 (Section 1.3.3), economic evaluation is the comparative assessment of 
the costs and consequences of alternative health care interventions (97). This 
chapter begins by introducing three main economic evaluation frameworks, cost-
effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis 
(CBA). The distinguishing feature of these analyses is the expression of outcomes 
and thus an in-depth description of relevant outcomes is further provided as well 
as their roles, and the limitations of use of each method in economic evaluations. 
This includes health, QoL, health utility and the QALY. The benefit of health care 
interventions is often classified into two key dimensions, life expectancy, and how 
well an individual lives, i.e. QoL. The most widely applied approach to generate 
health utility is through the use of PbQoL measures and thereby this chapter then 
introduces the preference-based measures, and one of the best-known examples 
among them, the EQ-5D-3L/5L instruments (153) as mentioned previously in 
Section 1.4. Accompanied by the growing recognition of the usefulness of the QALY 
in healthcare resource allocation, is the increasing debate regarding the relevance 
of the QALY, among which a well-known controversial issue is the recommendation 
of using EQ-5D as a cornerstone in the QALY framework. Therefore, this chapter 
discusses the issues in the PbQoL measures used in the QALY framework and 
reviews the alternatives to the use of current generic preference-based measures. 
This is followed by further examining the theoretical basis and role of wellbeing 
measures as alternatives to the current health-related preference-based measures, 
with a particular focus on the relatively new ICECAP-O instrument, a preference-
based capability-wellbeing measure for older people (141). 
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2.2 Economic evaluation in healthcare 
2.2.1 Cost effectiveness analysis 
CEA compares the costs and consequences of the alternative interventions and the 
consequences are quantified through a single natural unit, e.g. life years gained, 
number of falls reduced, number of cases avoided in preventative interventions 
etc. CEA results are presented in terms of incremental cost per unit of health gain, 
such as cost per additional HIV child prevented for a HIV screening program, or 
cost per hospitalisation avoided for people with Parkinson’s, cost per LDL 
cholesterol unit decreased, etc. The outcome measure is typically the primary 
outcome measure used in a study and this is assumed to appropriately capture the 
effect of interest and be specific to the condition (124). For example, a 
physiotherapy intervention to prevent falls in people with Parkinson’s may assess 
cost per fall averted, and a diagnostic technology intervention to increase the 
sensitivity and specificity of the detection of cases may assess cost per additional 
case found. 
However, while appropriate for the specific intervention or issue, the CEA 
framework is not useful for decision-making across different disease areas as the 
CEAs are incompatible. CEA is helpful to some extent for decision makers to rank 
interventions for the same condition (or symptom) using the same cost per natural 
unit improved. Nonetheless, it does not provide information on whether the 
intervention is value for money. This would require a valuation of the natural unit 
of the specific outcome and a further comparison to a societal consumption value 
of health benefit (154). 
In addition, when the intervention has an impact on more than one aspect in the 
population, CEA is unable to include the full impacts together as only one measure 
of outcome at a time can be used in any given CEA analysis (118). It is argued that 
CEA is only considered to be appropriate when that outcome is the major objective 
of therapy. However, this is unlikely the case in most circumstances as any specific 
health outcomes (e.g. falls, hospitalisation, LDL cholesterol) are usually linked 
with other aspects of life, either in life expectancy, or QoL, or both (97). Even 
when the clinical outcome is survival / mortality, it is likely that the intervention 
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affects QoL as well, or the reduction in mortality may be at the expense of 
reduction in QoL and hence the patients would be concerned with QoL. Therefore, 
only measuring a specific clinical outcome will probably leave some impact of the 
intervention overlooked in economic evaluation. 
2.2.2 Cost utility analysis 
CUA is the most frequently used form of economic evaluation for decisions making 
to aid health care resource allocation (97). It is often seen as a special case of 
CEA as the unit of effect is ‘one year in full health’. The most widely used outcome 
in CUA is QALYs and the result of CUA would be incremental cost per QALY gained. 
As previously mentioned in Chapter 1 Section 1.4, QALY combines length of life 
and QoL. One QALY means a person lives for one year in perfect health (i.e. full 
utility). It is generated by multiplying a person’s life expectancy by the health 
utilities in each period and summing the products from each period together (118). 
Health utilities represent the preferences (i.e. desirability) of individuals for a 
health state as valued against length of life or risk of death (155). Therefore, 
although much of the literature on economic evaluation does not differentiate 
between CEA and CUA, the outcomes used in CUA incorporate public preferences 
which distinguishes it from CEA and constitutes one of the necessary conditions 
accounting for its wide use in health care decision-making. 
Health utilities are typically between 1, corresponding to optimal health, and 0 
corresponding to a health state judged to be equivalent to death. Health utilities 
can be negative, indicating a health state worse than death. These values are 
often estimated through administering a standard questionnaire to get a 
description of an individual’s health state (i.e. health profile) and then typically 
‘off-the-shelf’ preference weights are attached to the described health state. 
Those preference weights for each standard questionnaire are elicited through 
specific valuation techniques from a sample of the general population. The 
standard questionnaires along with their preference weights form preference-
based measures. Health utilities, preference-based measures and the valuation 
techniques will be defined and discussed in greater depth in Section 2.4. 
The preference-based measures are intended to be general and relevant to all 
conditions in order to enable comparisons of cost-effectiveness across 
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interventions and disease areas (will be covered in Section 2.4.3). The composite 
outcome, incremental cost per QALY gained, also called ICER (incremental cost 
effectiveness ratio as briefly mentioned in Chapter 1, Section 1.5.4), regardless 
of interventions and disease areas, permits comparison across the wide range of 
healthcare programmes which makes CUA of particular use to aid resource 
allocation by decision-making agencies (12, 119). Despite the ideal intention to 
be relevant to all conditions, the QALY has been criticised for being insensitive or 
irrelevant to some specific conditions (156, 157) and therefore the use of typical 
CUA methods is not without sceptical critical voices in real clinical and patient 
decision-making setting (158). This will be further discussed in Section 2.5. 
In health care decision-making process, the ICER of a programme is compared 
against a threshold, which represents the maximum willingness to pay (WTP) of 
the health care system for an additional QALY gained. The threshold also reflects 
the opportunity cost in terms of the foregone benefits because other interventions 
cannot be provided (159). An intervention with an ICER below the threshold would 
be considered cost-effective in comparison to the alternative and would be likely 
to be funded, while one above the threshold would be considered not cost-
effective and less likely to be funded. This decision rule ensures that the total 
QALYs generated from a given budget is maximized (118).  
In the UK, the threshold value or national accepted ceiling ratio for the ICER 
established by NICE is considered to range between £20,000 - £30,000 per QALY 
gained (119). NICE Methods for Technology Appraisal (2013) states that when ICER 
is below £20,000/QALY, judgements about the use of a technology are based 
primarily on ‘the cost-effectiveness estimate and the acceptability of a 
technology as an effective use of NHS resources’. When the ICER is between 
£20,000 and £30,000 per QALY gained, the following factors are considered: the 
degree of uncertainty around the ICER calculation, whether the change in HrQoL 
has been adequately captured, the innovative nature of the technology especially 
when the benefits brought by the innovative nature cannot be adequately 
captured in the reference case QALY measure; and aspects that relate to non-
health objectives of the NHS including broader benefits beyond health and costs 
and benefits incurred outside the NHS and personal and social services. Notably, 
the 2013 guide for the first time explicitly recognizes the possible 
inappropriateness of the HrQoL measure in some conditions and populations (15, 
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160). This change in NICE’s guideline reflects the development of methodology in 
the last ten years as well as the increasingly important methodological issues and 
debate in outcome measurements.  
In 2015, Claxton et al. published a study which empirically estimated the NICE 
cost-effectiveness threshold based on routinely available data and suggested a 
much lower threshold practiced by NICE, which is estimated to be £12,936 per 
QALY surrounded by considerable uncertainty. This work has generated an uproar 
in the press (161, 162) as well as challenges from other researchers (e.g. Office 
of Health economics (OHE) (163, 164)) and NICE (165), as it will eventually mean 
there will be a great proportion of new interventions be rejected by NICE unless 
the price of new interventions are greatly reduced, as said by NICE’s chief 
executive Sir Andrew Dillon (165). Despite the methodological and 
implementation issues in debate surrounding this work, it is the first meaningful 
attempt at empirically estimating the threshold. If a lower threshold is adopted 
by NICE, it would lead to more fierce competition of interventions for NHS funding, 
and appropriately capturing the benefit of these interventions would become even 
more vital.  
2.2.3 Cost benefit analysis 
Cost-benefit analysis (CBA) requires programme consequences to be valued in 
monetary units, alongside the cost (114). The consequences not only include those 
financial consequences but also intangible outcomes such as survival and QoL. The 
use of monetary units as output measurements allows for comparisons between 
the return on investment in health and return from elsewhere in the economy 
(129). An intervention is considered worthwhile if the monetary valuation of all 
the benefits exceeds the costs (i.e. positive net benefit) (97).  
In CEA and CUA, the results indicate the price of achieving a particular health goal 
(e.g. incremental cost per QALY gained) while information is not given on whether 
the price is worth paying to achieve such a goal. For this reason, CEA and CUA 
must rely on an external criterion of value to determine whether or not an 
intervention is cost-effective, such as the aforementioned NICE threshold £20,000 
- £30,000 per QALY in the UK. CBA, on the other hand, incorporates the monetary 
valuation of the outcomes in the evaluation process and thus can inform us 
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whether a goal is worth achieving given the social opportunity costs (i.e. foregone 
benefits) of the programme that would be displaced (97).  
A number of techniques for obtaining monetary valuation of health benefits have 
been proposed, among which the ‘stated preference’ method or more specifically 
contingent valuation method is the most commonly used approach in applied 
microeconomics. The contingent valuation method asks respondents to determine 
how much they would be ‘willing to pay’ (WTP) for an intervention in a survey, 
through a variety of formats (e.g. closed ended, open-ended, payment scales 
(166) ), although they are not required to pay (which contrasts the ‘revealed 
preference’ approach) (167) . WTP has the potential to allow all the benefit (not 
just health) of an intervention to be considered by the respondent in the 
preference elicitation process and thus it would be suitable for use in the scenario 
where wider benefits beyond health are expected from the intervention (168). 
However, there are a number of concerns with the use of WTP methods. Firstly, 
in a publicly funded health care system, people may not have an accurate sense 
of the value as they do not pay for health care out of pocket (169). In a more 
practical way, this may lead the method being vulnerable as it is open to 
manipulation and hence NICE puts less weight to it when making decisions than 
other methods using patient self-reported preference-based outcomes (169). In 
addition, a strong relationship was found between income and WTP, whereby 
people with low income provide low valuations (170). This may lead to 
measurement bias and equality issues, affecting reliability of WTP method to be 
used in economic evaluations especially when effect of intervention is related to 
income (171). 
2.3 Health, Qol and HrQoL 
As mentioned in last section, the distinguishing feature of different economic 
evaluation frameworks is how the outcomes are measured (and valued). A 
prerequisite to critique these outcomes is the understanding of the concept that 
they are measuring. There are considerable confusions regarding the use of the 
terms health, QoL, and HrQoL and those terms can be used interchangeably in 
some situations but they may refer to different concepts in other situations.  
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2.3.1 Definition of Health 
What is health? The definition of health is evolving over the years with the 
development of health care and wellbeing but still under debate (172). One of the 
key controversial issues is its scope. The ‘Father of western philosophy’, Aristotle 
(384-322 BC) discussed that extremes in the bodily condition should be avoided 
and maintaining a proper balance is a virtue. He considers ‘endaimonia’ (wellbeing) 
the final goal and ‘final good for man’ (173, 174). This represents the typical 
historical view of health about the human potential to be in a state of balance 
and the aim of developing oneself to achieve wellbeing. This view remained highly 
influential in western medicine and thinking of what health is over 15 centuries 
(173) and its impact continues to this day. From the 16th century, a ‘microscopy’ 
way of interpreting human health and disease began with the invention of 
microscope, marked as the milestone for the development of modern medicine. 
Disease is no longer to be explained by misbalance of nature but a result of the 
changes in physical body detected by modern technology and correspondently 
(173), health is defined as the absence of disease (175).  
In the 20th century, the World Health Organisation (WHO) was founded after the 
Second World War in 1948 and the definition of health in its Constitution is perhaps 
the current most well-known and enduring one. It explicitly clarifies its broad 
scope as “a state of complete physical, mental and social wellbeing and not 
merely the absence of disease or infirmity.” The breadth and ambition of this 
definition was a ‘radical development in its day’ (173) from the dominant 
definition among physicians of the ‘absence of disease’ over the previous four 
centuries (176). In 1986, WHO elaborated its definition in the ‘Ottawa Charter for 
Health Promotion’ as “a state of complete physical, mental and social wellbeing, 
an individual or group must be able to identify and to realise aspirations, to satisfy 
needs, and to change or cope with the environment.” Health is regarded as a 
resource for everyday life, not the objective of living and health promotion goes 
beyond the healthy life-styles to wellbeing (177). 
This broad definition of health has been subject to criticisms. It is argued that 
health is one of the determinants of social wellbeing but social wellbeing is not 
part of health (178). One of most cited argument in the area of health economics 
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comes from the views by Evans and Wolfson (1980) (179). They argued that the 
WHO definition is indistinguishable from the concept of utility and that a public 
system ‘wishes you well, but not necessarily happy’ (180, 181). They suggested to 
“conceptualise health status for inclusion within the utility function in its narrow, 
negative, but more or less objectively measurable form” (180, 181). This narrow 
definition, on one hand, offers the advantage of easy measurement of health 
outcomes as a result of health care interventions. On the other hand, this narrow 
approach brings concerns over its limited ability to understand the underlying 
causes of disease (182, 183) and the impact of disease, the outcome measure 
developed under which is criticised for failing to capture the full spectrum of the 
impact of intervention (184).  
Related to the scope debate is the argument proposed by Alex Jadad and Laura 
O’Grady that the ‘absolute’ or ‘complete’ health state in the WHO definition 
makes it impracticable for what the health care systems can achieve, unattainable 
for people with chronic illness and disabilities, and lowering the threshold for 
unnecessary intervention (185). They argued that the requirement for complete 
health “would leave most of us unhealthy most of the time” (186). Therefore, 
they proposed a new definition of health in 2009 as “the ability to adapt and self-
manage” in the face of social, physical, and emotional challenges. This new 
concept has its advantage of emphasizing on human-beings more than their illness 
and its focus on their strength rather than their weakness, yet it requires 
substantial personal input, as not all people were believed capable of providing 
such input (173). 
2.3.2 QoL and HrQoL 
2.3.2.1 QoL 
The WHO broad definition of health, in particular, the term ‘wellbeing’, means 
that the measurement of health and the effects of health care must include not 
only an indication of changes in the frequency and severity of diseases but also an 
estimation of wellbeing (187). This is believed to be one of the most important 
traced root to the development of the concept of QoL and has been very 
influential in the development of QoL measures (188). Following the WHO’s 
definition of health, the majority concepts of QoL developed in health sciences 
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encompassed at least three dimensions, namely physical function, mental status, 
and the ability to interact with society and achieve roles. For example, in the 
dictionary of epidemiology, QoL is “the degree to which persons perceive 
themselves able to function physically, emotionally, mental, and socially.” 
(Hartge 2015 p234) (189) 
A discriminatory feature between the concept of QoL and health lies in the 
subjectivity of QoL. A person’s QoL is about how health is perceived by that 
individual. WHO defines QoL as “an individual’s perception of their position in life 
in the context of the culture and value systems in which they live and in relation 
to their goals, expectations, standards and concerns.” It is a broad ranging 
concept which encompasses “individual responses to physical, mental and social 
effects of illness on daily living which influence the extent to which personal 
satisfaction with life circumstances can be achieved” (Bowling 2005) (190).  
Therefore it can be seen that QoL is a subjective concept with a focus on people’s  
perception and reaction to their health status (191), which means it may vary 
substantially between individuals (192). Due to this subjectivity, the measurement 
of an individual’s QoL exhibits complexity and cannot be replaced by the 
perception of other people. A substantial body of evidence has demonstrated the 
significant differences in the perception between professionals on patients’ health 
status and the patients themselves (193-195). Consequently, the importance of 
measuring how patients perceive their health status themselves is becoming 
increasingly recognized in order to reflect the actual experience of the disease 
and the intervention (196).  
2.3.2.2 QoL vs. HrQoL 
In the literature, the use of QoL may refer to varied scope and there is overlap 
between QoL and health (16, 188, 197). Underlying the issue of the mixed use of 
terms is an important implication for policy in terms of what should be counted 
as a benefit and what could be given less weight in the decision-making process 
(118). Ware argues that the definition of the QoL in health science should be 
aligned with the aim of the health care system: “the goal of the health care system 
is to maximize the health component of quality of life, namely health status. 
Measures of health outcomes should be defined accordingly.“ (198) What echoed 
Ware’s argument is the development of the term “health-related quality of life 
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(HrQoL)” (Torrance 1987) as a pragmatic approach to QoL for the resource 
allocation purpose (Dolan & Olsen 2002). Torrance (1987) defined HrQoL as the 
subset of QoL, relating only to the health domain of that existence. Health is an 
important factor among the many that contribute to a person’s QoL (199). 
However, as a compound word derived from the multi-dimensional concept of 
health and QoL, the problem appears when defining HrQoL. Some of the 
definitions are more closely linked to health definition while others are closer to 
QoL (16). An example of the former is such as Torrance’s original definition which 
suggests that HrQoL includes only those factors that are part of an individual’s 
health (199). In contrast, some definitions resemble QoL: ‘those aspects of self-
perceived wellbeing that are related to or affected by the presence of disease or 
treatment’ (200). It brings the issue to discriminate between what aspects of QoL 
are affected or not affected by health, especially when the indirect influence is 
considered (e.g. health affects income and education) (16, 201). Guyatt et al. 
argued that although clinicians focus on HrQoL, ‘when a patient is ill or disabled, 
almost all aspects of life can become health related’ (202). Perhaps an 
explanation to this issue would be that all the aspects of QoL could be affected 
by health, but except for health, they may or may not be affected by other factors 
as well. As such, the term ‘health related’ in the HrQoL concept may not be the 
clearest description of what this term is intended to be. In health economics 
literature, HrQoL sometimes refers to the utility values assigned to different 
health states which are used to calculate QALYs (203). The values can be elicited 
from a range of preference-based measures, some of which are broad while some 
have a focus on health, and therefore it remains unclear if all of the measures 
that could produce values to be combined with length of life are eligible to be 
called HrQoL measures. 
Due to the complexity of the concept, there is considerable confusion regarding 
the use of the term QoL and HrQoL. It was recommended that researchers be as 
specific and clear as possible about the concept and operationalisation of QoL in 
the studies and the audience should inspect the context those terms are used 
(188). In summary, the essential concept of QoL is subjective, multi-dimentional 
and encompassing broad ranging aspects of wellbeing, whereas the HrQoL is also 
subjective but focuses on dimensions that are primarily determined by health and 
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is more related to the objectives of the health care system for resource allocation 
purposes. 
2.3.3 QoL outcome measures 
Due to the subjectivity of the QoL concept, QoL outcomes are subjective measures 
concerning with how patients perceive themselves about their health and 
wellbeing. The development of QoL measures can be traced back to the earliest 
stage of measuring function status as an extension beyond clinical outcomes (dates 
back to 1937) (204). An example is a single numerical scale developed by David 
Karnofsky in 1948, to measure the performance status of cancer patients (205). It 
gave scores between 0 and 100 for a combination of three factors: the ability to 
carry out normal activities, the need for custodial care, and the need for medical 
care. In the 1970s, several highly influential publications (206) showed that the 
subjective indicators could be measured, “enabling examination of the ‘soft data’ 
for QoL” (204). The earliest instruments specifically aiming at measuring QoL 
appeared in medical literature are the Vitagram Index (207) and Life Units (208) 
in the 1970s. The first QoL measurement to become popular was Priestman and 
Baum’s 1976 Linear Analogue Self Assessment Scale (204, 209) whereby the 
subjects were asked to place a mark corresponding to their feelings, on a visual 
analogue scale. Since the late 1970s, the researchers began to construct QoL 
measures with attributes. Examples are Index of Wellbeing, Index of Psychological 
Affect and Index of Overall Life Satisfaction, all developed by Campbel, Converse 
and Rodgers (206). The measurement of QoL became officially acknowledged with 
the requirement for QoL data as one of the ‘key efficacy parameters’ in clinical 
trials for new anti-cancer agents by the FDA in the US in 1985 (204), followed by 
the incorporation of QoL in outcome assessment for new health technologies by 
the UK Department of health in 1992 (210).  
Depending on the scope of the applicability of instrument, the QoL instruments 
can be categorised to either generic or specific. Generic measures are intended 
to be relevant to all conditions, many of which may be applicable for use within 
the general population, such as the EQ-5D-3L/5L (153) and Short Form -36 items 
(SF-36) (211). The specific measures are developed to measure QoL in people with 
a specific condition such as the Parkinson’ specific questionnaire, PDQ-39 (131) 
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(will be introduced in Chapter 5 Section 5.3.4) and the cancer specific 
questionnaire EORTC QLQ-C30 (212).  
The QoL measures that are not valued are not suitable for use in economic 
evaluation directly because they simply measure the amount of limitation a 
patient is experiencing compared to a perfect health; it does not contain weights 
corresponding to people’s preference for each amount (i.e. levels) of limitation 
for each attribute. The weights are elicited through valuation process. If the 
valuation of the QoL measure is completed, the measure becomes a preference-
based measure. The preference-based measures can be used in CUA. These will 
be discussed in depth in the next section.  
2.4 Health utility and preference-based QoL measures 
In the 50-year history of health economics, one of the most important innovations 
in economic evaluation has been the development of the QALY (213). It was 
initially introduced in 1968 by Herbert Klarman and colleagues in a study on 
chronic renal failure, where for the first time the life-year gained was calculated 
with the QoL adjustment in an economic evaluation (214). The Q in the QALY 
comes from utility values attached to the health state, which is usually measured 
indirectly with preference-based outcomes. This section will introduce the 
definition of health utility, how the utility values are elicited, the features of 
preference-based measures and the most widely used preference-based measure, 
the EQ-5D instrument. 
2.4.1 Health utility 
Health utility (also called health state preference values (215)) is used as a 
preference weight to adjust the length of life in the calculation of QALYs. In 
microeconomic theory, utility represents the degree of satisfaction experienced 
by the consumer through the consumption of a good or services. In Alfred 
Marshall’s book ‘Principle of Economics’, it states that ‘utility is taken to be 
correlative to Desire or Want.’ (p78) (216) Utility cannot be directly measured; 
however, economists suggest it can be indirectly revealed as “the price, which a 
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person is willing to pay for the fulfilment or satisfaction of his desire” (Marshall 
2013) (216).  
Adapted from the traditional economics theory, utility in health economics refers 
to the degree of desirability by the individuals or society for any particular set of 
health outcomes (e.g. for a given health state, or a profile of states through time) 
(97). The more desirable (i.e. more preferred) health outcomes will be attached 
with larger health utility values on the scale, while the less desirable health 
outcomes will be attached with smaller values on the scale. In simpler words, ‘a 
health state that is more desirable is more valuable’ (Weinstein 2009) (120) and 
vice versa. As such, health utility measures can be differentiated from the other 
measurement of health as it represents a valuation. Consequently, CUA allows 
health outcomes to be ‘valued according to their desirability’ (97). 
As mentioned in Section 2.2.2, utility values conventionally fall between 0 and 1, 
where 0 indicates the valuation of death and 1 indicates the valuation of a state 
of perfect health (215). In some scoring system a negative utility value is also 
possible (e.g. EQ-5D-3L (217)), which indicates that a health state that is less 
desirable than death (118). Utility values are on an interval scale, on which the 
same change means the same irrespective of the part of the scale being considered 
(e.g. a change in health from 0.2 to 0.3 is equivalent to a change from 0.8 to 0.9) 
(218). Utility can be compared but cannot be multiplied or divided (e.g. a utility 
value of 0.6 does not mean the desirability for this health state is twice as much 
as another health state with a utility value of 0.3).  
In the literature, utility is often used interchangeably with the term ‘value’ and 
‘preference’. Some consider the value is equated with preference or desirability 
(which is the core concept of utility as mentioned above) (120) while the others 
argue that there are differences between them (97). Preference is regarded as 
the umbrella term (97) describing trade-offs between outcomes. Whether it is 
‘value’ or ‘utility’ depends on how the question is framed in the preference 
measuring (or elicitation) process. It has been suggested that when the question 
is framed under uncertainty which is usually involved with probability or risk, 
‘utility’ is elicited, whereas ‘value’ is elicited when the question is framed under 
certainty (97). However, in practice, their meanings are usually not differentiated, 
for example, in the NICE glossary, utility is the ‘the measure of the preference or 
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value that an individual or society gives a particular health state’. In this thesis, 
‘utility’ or ‘utility values’ refers to the index score of a preference-based measure 
or the result score from direct preference elicitation, which to be combined with 
length of life in the QALY calculation. ‘Value sets’ refers to the readily used 
preference weights attached to each state defined by the preference-based 
measure. ‘Preference’ is used in more general circumstances, to refer to ordering 
of people’s desirability between health states, and used to describe a measure for 
which the health states have gone through the preference-elicitation process and 
have the value sets attached, i.e. preference-based measures.  
2.4.2 Preference elicitation 
The methods by which preferences are elicited vary, but fall into two main 
categories: scaling based methods such as the visual analogue scale (VAS) and 
choice-based methods such as the standard gamble (SG), time trade-off (TTO), 
the discrete choice experiment (DCE) and best worst scaling (BWS). The choice-
based methods are more commonly used and preferred by health economists 
compared to the scaling based method since the former incorporate ‘trade-off’ in 
the valuation (219). The choice-based method is also recommended by NICE in its 
guide to the methods of technology appraisals (122). 
2.4.2.1 The scaling based method 
The scaling based method is to ask participants first to rank health outcomes from 
most preferred to least preferred, and then, to place the outcomes on a scale 
such that the distance between placements corresponds to the differences in 
preference (97). Scores generated from the scaling based method provide the 
information of the ordering of health outcomes and the relative degree of 
preferences between these outcomes. The utility score for a health state is a 
proportion of its placement as relative to where death and full health is marked 
on the scale. However, rating scales do not satisfy the axioms of expected utility 
theory6, nor do they require ‘trade-off’ between length of life and QoL by the 
participants (221). In addition, this technique is associated with specific 
                                            
6
 The expected utility theory states that decision maker chooses between risky or uncertain 
prospects by comparing their expected utility values (220). 
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measurement biases, such as the end aversion bias (222), and context bias (223, 
224). The end aversion bias reflects the fact that participants are reluctant to 
place health states at the extreme ends of the scale (97). Context bias refers to 
the fact that the VAS score for a state depends on its relative place compared to 
the other states presented at the same time (222). A higher value will be given 
for a state if it is included along with many worse states, and a lower value will 
be given if the state is presented along with many better states. Despite models 
were invented to adjust the biases (225) to some degree, the scaling based method 
is less preferred by health economists compared to the choice-based method (97, 
120) due to aforementioned intrinsic limitations in valuation. It is more often 
replaced by the latter or only used as a ‘warming up’ exercise (218).  
2.4.2.2 The standard gamble 
The SG method is based directly on the third axiom of expected utility theory 
about continuity of preferences, first presented by von Neumann and Morgenstern 
(1944) (226, 227) and sometimes called ‘the von Neumann-Morgenstern standard 
gamble’ (228). It asks participants to trade-off between two alternatives. In 
alternative one the participant stays in a chronic state (i) for lifetime; alternative 
two is a treatment with two possible outcomes attached with different 
probabilities: for outcome one the participant returns to perfect health and lives 
for an additional set number (t) of years (probability p), or for outcome two the 
participant dies immediately (probability 1-p) (97). Probability p is varied in the 
exercise until the participant is indifferent between the two alternatives, at which 
point the required utility for state i for t years is equal to p. In simpler words, 
utility can be understood as the probability of full health in the gamble that makes 
the participant indifferent between the two choices, staying in chronic state, or 
going for the gamble. There are two disadvantages associated with SG. It was 
found that SG results could be affected by risk attitude – risk-seeking respondents 
tend to choose gamble while risk-averse respondents tend to choose staying in 
chronic state (229, 230). In addition, unlike the scaling-based method, it 
complicates the task by incorporating trade-off and uncertainty into the process 
(97). This leads to an issue that participants may find the concept of probability 
difficult to grasp. Despite the development of visual aids, an incorrect 
understanding may still exist to some degree, thereby causing measurement bias. 
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The process of administering the exercise may also being time-consuming for 
participants. 
2.4.2.3 The time trade-off 
The TTO technique is considered easier to understand than SG. The TTO was 
developed specifically to be used in health care (228, 231). It asks participants to 
choose between two alternatives, living in full health for a given period of time 
(x) followed by death, versus, living in a worse health state (i) than full health for 
a longer period of time (t) followed by death. Time x is varied in the task until 
the respondent is indifferent between the two alternatives, at which point the 
required preference score for state i is given as the ratio of x divided by t. It 
requires participants to choose between alternatives. The less complex 
alternatives in TTO overcomes the difficulty of explaining probabilities to 
respondents in SG. A key criticism of the TTO is the bias caused by time preference, 
as it is argued that TTO can be contaminated by the variation of time preference 
of each individual, i.e. individuals have higher preference for health now over 
future health all else being equal (232). It was also found some respondents were 
unwilling to sacrifice any of their life expectancy, leading to difficulty of 
administering the task (233). 
2.4.2.4 Discrete choice experiment and best worst scaling 
Besides the VAS, TTO and SG, two commonly used alternative preference-based 
approaches in health economics are DCEs and ranking methods such as BWS. These 
alternatives can establish the degree of preference for one alternative over 
another directly. They do not establish the indifference point of the individual 
respondent in a single question as the SG and TTO do. The DCE is a survey method 
asking respondents to choose between two or more alternatives which vary on 
level for each attribute or characteristics. In a typical BWS, respondents are asked 
to indicate the best and worst attributes with levels for one single profile at a 
time. Compared to the SG and the TTO methods, the DCE and BWS (or ordinal 
methods in general) require less abstract reasoning and are thus less cognitively 
demanding. Nonetheless, the ordinal techniques have an important limitation 
attributed to their ordinal nature that the elicited values require rescaling to be 
anchored to death so that the measure can be used for QALY calculation (118). 
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2.4.3 PbQoL measures 
Compared to the time/cost consuming direct preference measurements such as 
the SG or TTO for each time a CUA is conducted, the off-the-shelf preference-
based instruments are most widely used in health economic evaluations to obtain 
utility values for the calculation of QALYs due to its simplicity. Such measures 
usually comprise two components: a questionnaire formed by a number of 
descriptive attributes and levels regarding a person’s QoL status, and an algorithm 
to calculate the value attached to each health status described by the 
questionnaire (i.e. health profile). The algorithm contains weights for each 
attributes and levels, derived from health state valuation tasks (as introduced in 
Section 2.4.2) where a sample of the general public’s preferences for different 
combination of health states are elicited.  
After an instrument is developed, validation tests should be conducted to examine 
their measurement properties in order to determine their appropriateness to be 
used in future studies (118). Chapter 3 will introduce a range of important 
measurement properties, among which the construct validity and responsiveness 
will be discussed in depth and will be assessed in the case studies in Chapter 6 
and 7.   
The traditional PbQoL measures are generic to enable comparisons of CUA results 
across areas when making decisions. However, a growing body of evidence has 
been published expressing concerns on the degree of sensitivity of the generic 
PbQoL measures to some specific conditions (156, 234-236). A way to address this 
criticism is the research of developing condition-specific preference-based 
measures (CS-PBMs) in the last decade  and therefore the preference-based 
measures now can be either generic or specific (237). The advantages and 
limitations of CS-PBMs will be discussed in section 2.6.2. 
2.4.3.1 Examples of generic PbQoL measures 
Examples of generic PbQoL measures include the SF-6D, the Health Utilities Index 
(HUI) and the EQ-5D-3L/5L. The SF-6D is developed based on the longer SF-36 QoL 
instrument by reducing it to a six-dimension classification and the preference 
elicitation process transforms its scores to utility values (238). The six dimensions 
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are: physical functioning, role limitations, social functioning, pain, mental health 
and vitality. The UK scoring model for the SF-6D was developed using SG technique 
on a sample of 836 among general population. The scores are on a conventional 
dead-perfect health 0-1 scale, with the worst state with a score of 0.345. In the 
UK, it has been used as the primary health utility measure by NICE for CUA analysis 
of pharmacological treatments such as for Alzheimer’s, low platelet count, 
peripheral arterial disease, and gout (239). 
The HUI consists of two systems, HUI2 (240) and the newer HUI3 (241). Scoring 
algorithms are both based on SG measured in the general public. The two systems 
shared some attributes: emotion, cognition, and pain. Additionally, HUI2 contains 
sensation (as one dimension), mobility, and fertility. HUI3 removed ‘fertility’, 
spilt ‘mobility’ into ‘ambulation’ and ‘dexterity’ to increase the structural 
independence, and expanded the sensation into three attributes: vision, hearing, 
and speech. It is suggested HUI3 should be used as the primary analysis and HUI2 
in a secondary role with the exception of circumstances that focus on self-care, 
worry/anxiety, and fertility (97).   
The EQ-5D-3L is NICE’s preferred instrument for cost-utility evaluations in 
healthcare technology assessments. It will be introduced along with its newly 
developed variant, EQ-5D-5L, in the next part. 
2.4.4 The EQ-5D instrument 
2.4.4.1 Introduction 
The EQ-5D-3L is a generic preference-based health-related QoL measure that has 
been widely used worldwide (153, 217). It was developed by a multidisciplinary 
group of researchers from five western European countries, the EuroQol group, in 
the late 1980s. The EuroQol group selected the ‘core’ domains common to other 
generic PbQoL measures and which reflected the most important concerns of the 
patient based on the group’s expertise and evidence from literature (14, 118, 242). 
It was initially comprised of six dimensions: mobility, self-care, main activity, 
social relationships, pain, and mood (14). The instrument was further modified to 
a standard five-dimensional format which has since remained unchanged (153). 
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The five dimensions are: mobility, self-care, daily activities, pain and discomfort, 
anxiety and depression.  
EQ-5D has two forms: the classic EQ-5D-3L and the recently developed EQ-5D-5L. 
The EQ-5D-3L contains three levels for each dimension: ‘no problem’, ‘some 
problems’ and ‘a lot of problems’, which defines 243 possible health states. By 
March 2017, it has been translated into 172 languages (243). The country-specific 
value sets have been elicited in approximately 20 countries and regions using a 
mixture of TTO and VAS technique (118, 244). In the UK, the valuation work was 
undertaken by the UK Measurement and Valuation of Health (MVH) group at York 
who applied the TTO technique with a random sample of 2,997 members of 
general public selected using the national postcode address file from England, 
Scotland, and Wales (245). By applying the scoring values, the EQ-5D-3L health 
states can be converted into utility values. The UK EQ-5D-3L values ranged from  
- 0.59 to 1, with 0 representing death.  
2.4.4.2 Limitations 
As use of the EQ-5D-3L has become common, voices both criticising and endorsing 
its use have been heard in a growing body of literature over the last decade (234-
236, 246-248).  Whilst in many applications the EQ-5D-3L has been shown to be a 
valid and reliable measure of QoL (example such as (249), (250)), its limitations 
are raised to an increasing volume of literature which could be mainly summarized 
by two points. The first concern deals with the sensitivity of the EQ-5D-3L to small 
changes. It was found that in some contexts the EQ-5D-3L may lack responsiveness 
to small changes especially when people have milder conditions (251). Related to 
this is the exhibited ceiling effects (i.e. the proportion of respondents reporting 
the best possible health is high (typically >15%) who are therefore unable to record 
any improvement in health status (252)) in both general and disease-specific 
populations (127, 253-255), leaving less room for improvement over time in 
response to an intervention.  
Another concern is that the scope of EQ-5D dimensions may fail to capture 
important aspects of QoL in certain condition areas, for example mental health 
(234), schizophrenia (246), cancer (247), Alzheimer’s disease (236) and dementia 
(248). One suggestion is that the generic attributes making up these measures may 
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not be sufficiently relevant to the specific populations (256). Longworth et al. 
(235) valued three condition-specific ‘bolt-on’ attributes as extensions to the EQ-
5D related to hearing, tiredness and vision, and found that the ‘bolt-on’ attributes 
had a significant impact on the values of the health states.  
To address the limitation in sensitivity, in 2011 the EuroQoL group developed the 
EQ-5D-5L which contains five levels for each dimension (255). The two additional 
levels are ‘slight problems’ between the existing ‘no problems’ and ‘moderate 
problems’, and ‘severe problems’ between the existing ‘moderate problems’ and 
‘extreme problems’. This version now describes a total of 3,125 distinctive health 
states and thus should be more sensitive than the EQ-5D-3L version to detect minor 
changes. While valuation work for the EQ-5D-5L is underway, an interim value set 
was developed from 3,691 respondents with broad-ranging level of health in six 
countries by mapping (cross-walk) from the EQ-5D-3L (257). This is also relevant 
to those wishing to achieve consistency with previous studies using the EQ-5D-3L 
(118). The English value sets for EQ-5D-5L have been developed in 2016 using the 
TTO and the DCE techniques with data provided from 996 participants (258), 
although NICE recently chose not to recommend this new value set owing to the 
concerns on consistency with the 3L version (259). Value sets for other countries 
are under construction at the time of writing this thesis and not available yet. Up-
to-date information can be found from the Euroqol official website: 
www.euroqol.org. Although EQ-5D-5L has been shown in several studies with an 
improved sensitivity and reduced ceiling effect compared to EQ-5D-3L (260-263), 
the relevance of its dimensions and scope to some specific conditions still remains 
questionable. 
2.5 Critiques of the use of the QALY in outcome 
measurement 
2.5.1 Evaluative scope 
As mentioned in the example of the EQ-5D above, QALYs have been criticized for 
not encapsulating all the relevant attributes of health care and being too narrowly 
focused on health in its narrow meaning (97). Related to this, the concerns raised 
regarding the methods of the QALY, for being not sensitive enough to the health 
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change brought by an intervention. Empirical evidence regarding this ‘generic vs. 
specific’ debate can be traced back to the 1980s. Donaldson et al. showed that 
the one of the earliest generic PbQoL instrument, the Rosser disability and distress 
scales (264), is less responsive to the changes in elderly people’s health states 
compared to the specific measures in stress and life satisfaction, using data from 
a trial of long-term care for elderly people (184). 
A review in 2014 of the use of generic and condition-specific HrQoL measures in 
the context of NICE decision-making found that the EQ-5D-3L’s performance was 
poor in hearing impairments and varied in vision according to aetiology (235). 
Qualitative research suggested that the EQ-5D and the SF-36 (and subsequently, 
SF-6D) have limitations in capturing most of the concerns for patients with mental 
health problems (265). An overview of reviews published in 2017 assessed the 
appropriateness of five commonly used PbQoL measures, including EQ-5D, SF-6D, 
HUI3, 15D and AQoL (19). In this overview, the performance of these measures 
varied across conditions. The EQ-5D was found to perform poorly in hearing 
impairments, multiple sclerosis, personality disorders, schizophrenia and 
dementia. SF-6D showed poor performance in cardiovascular, respiratory disease, 
and neoplasms and HUI3 for some subpopulations of neoplasms.  
Furthermore, this limitation in evaluative scope may cause problems in evaluation 
of the public health and social care interventions where the social and medical 
considerations overlap, since the benefits of these interventions are often beyond 
health and may also fall in other sectors such as empowerment, education, and 
crime. Therefore, QALYs and their associated PbQoL measures like the EQ-5D or 
SF-6D are likely to underestimate or overlook the relative benefits of public health 
interventions when compared to health care interventions (171). 
As a response to this criticism, a two-and-a-half-year research project called 
‘extending the QALY’ led by University of Sheffield has begun in May 2017 to 
review the way QoL is measured across health and social care. It aims to assess if 
the current measures miss  the important benefits of treatments beyond HrQoL, 
such as independence, or improved relationships with family, friends and carers 
(266). If the results of the review demonstrate a gap, the research team said “NICE 
would consider whether and how to include any new QoL measure in its work.” 
(266) 
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2.5.2 Comparison of different preference-based measures 
Another issue of the QALY framework is the discrepancies in utility values when 
measured with different preference-based instruments in the same patients and 
this explains why NICE recommends specifically the use of EQ-5D as the 
preference-based outcome in economic evaluations.  The discrepancies have been 
shown by a substantial body of evidence across many different conditions (127, 
267-270). The discrepancies not just lie in the absolute magnitude on a scale but 
also the relative direction. Richardson et al. (2015) compared the utilities 
obtained by the EQ-5D, SF-6D, HUI 3, 15D, Quality of Wellbeing (QWB) and 
Assessment of Quality of Life (AQoL-8D) and it was found that the agreement 
between these measures was substantially varied with interclass correlation 
coefficient values ranging between 0.34 and 0.82 (271). For the head-to-head 
comparison, substantial differences between EQ-5D and SF-6D have been reported 
widely (118). For instance, Brazier noted that a full score in EQ-5D could have as 
low as 0.56 on SF-6D in the scatter plot of the pairs (127). The difference also has 
been shown to have an implication on the results of QALY gained and affect the 
cost-effectiveness results. Xie et al. found the difference between the utility 
values generated from the two measures is 0.14, which yielded a difference of 
$10,000/QALY in ICER estimation (272).  
The difference of these values may come from three aspects: differences in 
dimensions and items, the number of levels, and valuation methods (118). These 
measures differ in their coverage; e.g. EQ-5D, HUI3 and 15D are mainly concerned 
with physical aspects, SF-6D have special wide coverage of the sensations. 
Difference in the number of levels also cause the incompatibility of the measures. 
for instance, after adding two levels, the EQ-5D-5L was found to lead to smaller 
incremental QALY gain compared to EQ-5D-3L from effective health technologies 
and therefore interventions may appear less cost-effective (273). Furthermore, it 
has been suggested that SG would generate higher values than TTO due to risk 
aversion and positive time preference, and TTO values would exceed VAS in most 
of the studies due to measurement bias of VAS (118).  
These differences have implications in utility measurement and the result of 
economic evaluations, which may lead to the varied degree of sensitivity in 
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different population and for use with evaluating different interventions. This 
‘unfair’ treatment by different measures may cause concerns about their validity 
to measure true preferences. If the benefit of an intervention for a certain disease 
is relatively under-estimated this may cause it to be ‘unfairly’ assessed in NICE’s 
decision-making process.   
2.5.3 Whose preferences matter? 
Another debated issue is that of whose preference should be valued. The values 
from most of the preference-based instruments for estimating QALYs use samples 
of the general public (as recommended by NICE) rather than the specific 
population who are currently experiencing the health state of interest. This poses 
a question of whose preferences to elicit in health-state valuation (274). The 
general public may or may not be in the health state at the time of assessment 
and they have to try to imagine what the state would be if not.  The arguments 
for the use of general public are the insurance principle (i.e., the public are 
payers), the social contract principle (i.e., health system benefits all members of 
society), and the concern about bias associated with patient valuations, practical 
issues with obtaining patient samples, and to ensure comparability across 
different studies (203).  However, some suggest that the preferences should be 
elicited from the patients (275). It was argued that the general public does not 
have the same experience of the disease as patients and thus cannot reveal the 
true preference of the specific population being evaluated (276).  
The values can vary with the source. A number of empirical studies have shown 
that higher values tend to be placed on disease state by the patients who are 
experiencing the disease than the public (275, 277). However, this was not 
supported a review of studies which did not find consistent difference between 
the values from patients and general public (278). This review suggests that 
patients tend to give higher values on severe health state but lower values on 
milder health state than general public.   
There are three key factors leading to the differences: different understanding of 
the health state description, ‘adaptation’ to disease, and incorporation of self-
interest from different perspectives (279). It was suggested that health state 
description might not fully capture the patients’ experience of a specific health 
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state due to lack of scope, which may cause different understanding between the 
patients’ experience and what is intended to value (280). The fact of placing 
higher values can be explained by ‘adaptation effect’ where the patients have 
adjusted themselves to their limited health state physically and psychologically. 
On the contrary, when healthy people are asked to imagine the hypothetical 
impaired health state, they tend to ‘focus on the negatives’ and thus lack ability 
‘to look at the bigger picture of life’ (279). Another factor led to the difference 
comes from the different perspectives held by the patients and the general public. 
Kahnemann (281) previously described the general public as the ‘seller of health’ 
and patients as ‘buyer of health’ however this analogy may not be correct in the 
UK NHS context. General public is a ‘payer’ rather than ‘seller’ as they pay for 
the health care through the tax system, while patients are ‘consumer’ rather than 
‘buyer’ as they obtain the benefit from the health care services and product. 
Payer would assign a lower value to the services and products as they do not get 
the benefit of them, and on the contrary, the consumer would assign a higher 
value as they do not need to pay. 
2.6 Alternatives to health-related generic preference-
based measures 
Due to the limitations of generic preference-based measures which may be 
insensitive or irrelevant to some specific conditions or interventions, alternative 
methods have been proposed to ‘bypass’ this issue in CUA. The alternative 
methods can be classified to two types: a) condition-specific approaches which 
include mapping from a non-preference based (usually condition-specific) QoL 
measure to a preference-based measure, valuation of a condition-specific QoL 
measure, and adding ‘bolt-on’ items to EQ-5D; and b) incorporating broader 
aspects to preference-based measures.  
2.6.1 Mapping from non-preference based measures 
Preference-based measures are the key instruments to value the impact of the 
intervention in economic evaluations which enable the decision bodies such as 
NICE to judge whether an intervention is value for money, however, they are not 
always included in clinical studies. For example, studies of new interventions 
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sometimes only include the condition-specific measures to demonstrate if the 
intervention is working as what it claims to do, since those studies are mainly 
conducted to inform licensing decisions (118). Preference-based measures are less 
often seen in studies conducted in the countries where CUA is not used to inform 
decision-making. One practical solution to make use of these studies for decision-
making is to conduct mapping (also called cross-walking) to predict utilities from 
non-preference based measures. 
Mapping is the process of development and use of an algorithm, typically a 
regression equation, to predict the primary outputs of generic PbQoL instrument 
using data on other measures or indicators of health (282). The regression 
equation is then the mapping algorithm which can be used to predict the PbQoL 
value in a dataset which contains the source measure but not the PbQoL measure. 
There is a growing trend of exploring and applying mapping algorithms where the 
utilities are not directly measured in studies. Mapping is recommended by NICE to 
estimate EQ-5D utility data when EQ-5D data are unavailable in the study dataset 
(283). Around one quarter of the QALY estimations informing recent NICE 
appraisals in England and Wales involved the implementation of a mapping 
algorithm (284). A database of mapping studies has been developed by Health 
Economics Research Centre (HERC) at University of Oxford (current version 5.0) 
which provides a readily-accessible collection of all studies mapping to EQ-5D 
(285). 
As use of mapping algorithms becomes increasingly common, a growing number of 
researchers show their concerns regarding its development, reporting and 
application in practice. In 2015, the ‘MAPS’ (Mapping onto Preference-based 
measures reporting Standards) statement has been developed which is a checklist 
to promote transparent reporting of mapping studies. However, besides poor 
quality of reporting, there are many fundamental issues related to mapping that 
are not yet been addressed which can be summarized to three aspects: inaccuracy 
of utility predictions for poor health states, lack of instructions on the 
generalisability of the mapping algorithms from the authors, and failure to capture 
uncertainty around means and the variability across individuals (284, 286, 287). In 
addition, the mapping function relies on statistical association which is based upon 
the conceptual overlap between the source measure and the target measure. It 
was argued that mapping may not be appropriate for measures that have different 
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construct, such as between the HrQoL measures and the wellbeing measures. An 
example of this is to map the Adult Social Care Outcomes Toolkit (ASCOT) / ICECAP 
to EQ-5D, which may not be appropriate since EQ-5D would be unable to reflect 
many of the outcomes captured by the wellbeing measures (169). These issues are 
likely to introduce important biases when using those mapped utilities in economic 
evaluations to compare alternatives.    
2.6.2 Valuation of condition-specific QoL measures 
Besides the mapping, another attempt to overcome the limited sensitivity of the 
generic measures in some specific populations is to construct condition-specific 
PbQoL measures (CS-PBM) (237). These measures can be developed from existing 
QoL measures in a specific area or developed de novo. Examples include the AQL-
5D developed from the Asthma Quality of Life Questionnaire (AQLQ) for asthma 
(288) and the EORTC-8D developed from the European Organization for Research 
and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQC30) for 
cancer (212). 
Although such CS-PBMs are able to achieve great precision and sufficient coverage 
to reflect what is suffered by the patients in the specific condition, they also face 
criticism. Researchers are concerned that CS-PBMs are sometimes insensitive to 
measuring the side-effects which have different symptoms and impact on QoL 
from the condition, and lack of comprehensiveness in people with comorbidities 
due to the narrow scope (234, 289). These may cause issues leading to bias in the 
values elicited. One such issue is the preference interaction whereby other 
important aspects of QoL that are not included in the CS-PBM may interact with 
the included aspects thus causing the coefficient (weights for dimension and level) 
to change (290). This implies that a preference-based measure should contain all 
of the important aspects of QoL into its descriptive system, which might be 
unattainable for a CS-PBM. Another issue is focusing effect whereby respondents 
overemphasize the dimensions included and ignore other aspects of life (291). In 
addition, in the same way as the other solutions that go for a ‘condition-specific’ 
approach, CS-PBMs share the same criticism that they would lose comparability 
across disease areas (289). However, some argued that comparability should be 
achieved by the use of a common numeraire such as money or a year of full health 
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(118). This means the comparability is not affected as long as the valuation was 
conducted using the same technique with common anchors, and from the same 
type of respondents (118). Despite the criticisms, the development of CS-PBM is 
argued to be valuable as it enriches the database of utilities measured by different 
approaches in a disease area where there exist limitations with current methods 
(289) and may provide valuable supplements to existing generic measures (291).  
2.6.3 Bolt-on attributes 
Besides mapping and CS-PBM, another ‘specific’ approach is to add condition-
specific ‘bolt-on’ attributes to the generic measures (235). These ‘bolt-on’ 
attributes are designed to cover the dimensions missing from the generic measures 
such as EQ-5D-3L without compromising the comparability across disease areas. 
Cognition (292), sleep (22), vision (235), hearing (235) and tiredness (235) have 
been explored as bolt-on dimensions to the EQ-5D-3L in the literature.  
Longworth et al. (2014) developed three ‘bolt-on’ items related to hearing, 
tiredness and vision to the EQ-5D-3L and valued them along with three health 
states (i.e. mild, moderate and severe) defined by EQ-5D-3L using the TTO method 
(235). They found that each of the bolt-on items had a significant impact on at 
least one EQ-5D-3L health state. The magnitude and direction of the impact varied 
according to the relative level (i.e. severity) of the bolt-on item compared to the 
health state to which it was added. The addition of a relatively severe ‘bolt-on’ 
tends to lead to a decrease of the health state values and addition of a relatively 
milder ‘bolt-on’ would result in an increase of the health state values. 
For the comparability issues, the bolt-on approach is claimed to have a lower 
degree of inconsistency than the CS-PBM by retaining the EQ-5D as the core basis 
for measurement and by using a common valuation methodology. The research on 
bolt-ons is still at early stage and hence it is not yet clear what the valuation 
approaches should be the best, e.g. whether a full valuation of the EQ-5D plus 
bolt-on is required for each new bolt-on item (235), what the capacity of a 
valuation model is for the ‘bolt-on’ items if many items have to be added (169). 
Another issue is double counting as the bolt-on dimension may have already been 
captured to some extent by the existing generic dimensions of EQ-5D (169), e.g. 
vision can affect mobility, usual activities and self-care. A more fundamental 
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limitation is related to the evaluative scope of the EQ-5D which cannot be 
addressed by the addition of one or more missing dimensions (169). 
2.6.4 Wellbeing measures 
The specific approaches as alternatives to the generic preference-based measures 
should improve the sensitivity of the measure to the specific conditions, yet they 
cannot avoid the criticism on comparability issues across programmes. Another 
option is the use of generic wellbeing measures. The wellbeing measures broaden 
the scope of the measurement which can capture the full impact of health from 
an overarching level. Although it is argued that the impact of health on wellbeing 
has been considered in the valuation process, evidence has shown that the 
respondents have limited ability to predict the impact of the health state on 
wellbeing in the preference elicitation process (293, 294). As a result, some argue 
that a more direct measurement of wellbeing is required (294).  
Subjective wellbeing (SWB) has been described under three headings: hedonism 
(pleasure), fourishing theories (fulfilments) and life satisfaction (295). Although 
there are a number of wellbeing measures, only a limited amount of research has 
been done to explore how to use the wellbeing measures in economic evaluations. 
Very few of the wellbeing measures are preference-based, among which are the 
capability measure ICECAP (Investigating Choice Experiments Capability measure) 
(140) as mentioned previously in Section 1.5.3 and later in Section 2.7 and the 
Adult Social Care Outcomes Toolkit (ASCOT) (296).  
ICECAP capability measures are based upon Sen’s capability theory which focuses 
on what a person is able to do rather than what a person actually does (136). The 
ICECAP measures cover a broad range of psychological wellbeing along with 
enjoyment. The measures (ICECAP-O for older people, and ICECAP-A for adults) 
are valued using BWS (i.e. best worst scaling) method (141, 297). Section 2.7 will 
discuss in depth the capability approach and ICECAP. Also based on Sen’s 
capability approach, the ASCOT is a social care-related QoL measure which aims 
to assess the extent to which an individual’s social care needs and wants are being 
met. It contains eight domains: control over daily life, personal cleanliness and 
comfort, food and drink, personal safety, social participation and involvement, 
occupation, accommodation cleanliness and comfort, and dignity (296). Similar to 
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the ICECAP, ASCOT preference score is developed using the BWS method, which 
can be anchored onto the QALY scale with 0 representing being dead using the 
TTO technique, and thus ASCOT can be used in economic evaluations (296). 
The inclusion of wider aspects into economic evaluation depends on the debate 
about whether the NHS should be primarily concerned with promoting health, or 
some broader notion of wellbeing for the purpose of its resource allocation. On 
one hand, it has been argued in a substantial amount of literature that the QALY 
should not be health-only, since this will overlook the benefits of the interventions 
beyond health, such as freedom, strength of relationships, etc (298). On the other 
hand, some argue that SWB may suffer from memory bias or involving too much 
subjectivity, making it less useful to be used for health resource allocation (299). 
In addition, some evidence showed that SWB was not as responsive to the health 
status changes to the same extent as the generic HrQoL preference-based 
measures, leading to more doubts on the use of wellbeing measures for economic 
evaluations (299, 300). 
2.7 The ICECAP-O instrument 
As introduced in Section 1.5.3 and discussed in Section 2.6.4, a possible solution 
to the limitation in evaluative scope of the current generic PbQoL measures is the 
wellbeing measures that are developed based on Sen’s capability approach. An 
attempt to measure capability in health and social care is the ICECAP instrument, 
which is recommended by NICE’s latest guidelines on social care and public health 
interventions to measure broader benefit (117, 142). It expands the evaluation 
space to consider whether a programme enhances an individual’s capability and 
wellbeing. The next section will introduce Sen’s capability approach and one of 
the ICECAP measures, the ICECAP-O for older people. The application of the 
ICECAP-O in economic evaluations will be discussed at the end. 
2.7.1 Sen’s capability approach 
Sen’s capability approach advocates the evaluation of programmes focusing on 
capability (what a person is able to do) rather than functioning (what a person 
does) (136, 139). Sen has argued that actual achieved wellbeing can be assessed 
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by ‘functioning’ measures, which should be differentiated from a person’s ability 
to achieve. Bleichrodt and Quiggin (2013) (301) explained that the capability 
approach distinguished between ‘means’ and ‘ends’; that is, only ends are 
important and means are instrumental in reaching the ends. Good health therefore 
has two-fold meanings: it is a means to achieve other functionings, such as working 
and leisure, but it is also an end itself. This constitutes a key distinguishing feature 
between the expression form of the capability approach (e.g. ICECAP-O 
questionnaire) and the QALY approach (e.g. the EQ-5D-3L/5L). The former views 
health as a means to achieve, for example, the ICECAP-O include dimensions like 
attachment (love and support from family and friends) and role (doing things that 
make you feel valued), while the latter focuses on health as an end goal, for 
example, the EQ-5D -3L/5L include attributes such as mobility and 
pain/discomfort. 
Capability was defined by Sen as freedom of choice to achieve functionings, and 
can be viewed as the set of potential combinations of functionings from which an 
individual could choose to live (139, 302). Cookson (2005) (303) argued that the 
emphasis on the choice for functioning differentiates the capability approach from 
the conventional welfare approach as it relaxes the assumption of rational self-
interest. That means, in the capability approach, an individual does not 
necessarily choose the option with the best value. Wellbeing can be improved 
when additional choices are provided even if the option with the maximum value 
already exists, while in the welfare approach, the utility of a set of functioning is 
determined by its most valued element and thus in this case utility won’t change 
with the additional less-valued option (135, 304). A widely quoted example is the 
‘fasting-starving’ distinction (305, 306). Someone voluntarily fasting may have the 
same nutritional intake as someone who is starving, however, the person who is 
fasting has the freedom to choose to fast or eat whereas the starving person has 
no choice. The notion of capability considers the freedom of choice for achieving 
actual functioning rather than whether the functioning has been achieved.  
Although Sen’s capability approach has been criticised for being highly conceptual 
(307), it has contributed to several theoretical and practical development in 
health economics (125). It influenced the development of ‘extra welfarism’ (308) 
with enriched evaluative space. The main features of the extra welfarism are 
permitting outcomes other than utility and taking into account the sources of 
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valuation from other people other than the affected individuals (309). This is 
distinguished from the traditional ‘welfare’ which focuses on maximizing a social 
welfare utility function. In practice, it is argued that this complex and broad 
extra-welfarist approach has been narrowly implemented with utility replaced by 
health and function as the only outcome but losing other and broader outcomes 
(138, 310). The focus of CUA on health represented by the generic preference-
based HrQoL measures limits the broader outcomes of the health care and social 
care intervention to be incorporated into economic evaluations (171).  
Given that ‘extra-welfarism’ in practice has not incorporated broader benefit, 
Sen’s capability approach has been promoted in the last decade as an alternative 
to broaden evaluative space and several instruments have been developed, 
including the ICECAP and ASCOT (as mentioned in last section). In addition, 
criticisms are raised that beside ‘health’, the capability, i.e. the ability of 
achieving functioning, is also of importance to people. This concern was reflected 
with the empirical evidence shown by Grewal et al. (2006) that older people in 
the UK appeared to be concerned about their (lack of) ability to meet particular 
‘functionings’ (140). This has led to the theoretical and empirical development of 
ICECAP-O which draws directly on the capability approach (138) in contrast to the 
utility approach. 
2.7.2 ICECAP-O 
ICECAP-O considers wellbeing in a broader sense than health itself and therefore 
could potentially be used in economic evaluations across health and social areas 
in which a broader set of outcomes is considered (140, 311). It contains five 
capability attributes which are identified through qualitative in-depth interviews 
with older members of the British public (140). The attributes are:   
• Attachment which incorporates feelings of love, friendship, affection and 
companionship, sources of which appear to include partners, family, friends, 
and pets’  
• Security which ‘incorporates ideas of feeling safe and secure, not having to 
worry and not feeling vulnerable’  
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• Role which ‘incorporates the idea of having a purpose that is valued, either 
by the individual and /or others’ 
• Enjoyment which ‘pulls together notions of pleasure and joy, and a sense 
of satisfaction, sources of which include personal and communal activities’ 
• Control which ‘involves being independent and able to make one’s own 
decisions’.  
By asking respondents whether they ‘can have…’ or ‘are able to..’, the ICECAP-O 
is aligned with Sen’s capability approach of focusing on the freedom of choice. 
The breadth of the dimensions reflects its wellbeing theme. Each attribute 
contains one question with four levels (no, a little, some, and a lot of capability), 
thereby distinguishing 1,024 possible ‘capability states’ (140). The value set was 
developed using the BWS method from the UK older adults whereby the 
respondents were asked to choose the best and worse scenarios from a selection 
of methods. From these choices values for the capability were derived. The values 
were anchored between 0 (no capability) and 1 (full capability) and did not make 
assumptions about where death fell on this scale (141).  
A variety of studies have evaluated the psychometric properties of ICECAP-O in 
different populations. Its construct validity was tested and demonstrated among 
the general population in the UK (312), post-hospitalized older people in the 
Netherlands (313), in the general population (314) and the older post-acute 
patient population in Australia (315), in a falls prevention clinical setting in 
Canada (316), and among dementia patients at a nursing home in Germany (317). 
Its face validity was assessed and demonstrated in hip and knee arthroplasty 
patients (318). Recently, a study from the Netherlands assessed the ICECAP-O and 
demonstrated its test-retest reliability, construct validity and responsiveness in 
frail older adults (319).  
2.7.3 Use of the ICECAP-O in economic evaluation 
The ICECAP-O was developed to capture broader benefit for economic evaluations, 
however little guidance is provided on how such measure should be used to aid 
healthcare resource allocation decisions. A fundamental issue is how to combine 
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ICECAP-O with length of life (320). The reason why the preference-based measures 
such as the EQ-5D can be combined with length of life to calculate QALY is that 
the valuation of health states is against death which is given the value of 0. This 
allows the interpretation of QALY to be that ‘zero QALY means years of death’ 
since it is generally accepted that the absence of health is the same as the absence 
of life. However, the ICECAP-O is valued with zero representing ‘no capability’ 
rather than death, which means ICECAP-O adjusted length of life cannot generate 
the QALY with the same conventional meaning. Rather, it generates a new concept, 
called Years of Full Capability (YFC). Zero YFC means years of no capability rather 
than years of death. Some suggest that it could be assumed that those who die 
have no capability, or more conservatively, death is among the states that have 
no capability (320). With this assumption, a person who dies would have zero YFC.  
Another concept undergoing development is the Years of Sufficient Capability 
(YSC), whereby the length of life is adjusted by the amount of capability that 
deemed to be sufficient for the consideration of equity (321). Existing approaches 
to economic evaluation focus on maximising outcomes, irrespective of the 
distribution of outcomes within society. In contrast, the capability approach 
particularly has been concerned with equity as it focuses on what a person is able 
to do rather than what a person actually does (321). For example, a better-off 
person may not do a lot of leisure things but he/she has the ability to do it while 
a poor person does not have the ability to do them. Therefore, decision making 
using the capability approach might aim to provide a “decent minimum level of 
capability for as many people as possible, and thus focus on the distribution of 
capability not its maximisation” (Coast 2008) (125, 137).  Kinghorn conducted a 
qualitative study applying deliberative methods to establish a sufficient level for 
capability and found the sufficient capability to be 33333, i.e. level three (feel 
capable in many areas) for all attributes (322). This distinguishes the concept of 
‘sufficient capability’ from the ‘full capability’ (level four for all attributes) and 
established the basis for its use in decision-making in the contexts of public health 
and social care.  
Once the YFC or YSC is generated, it would require a decision threshold to judge 
if the intervention is value for money. For QALY, the cost-effectiveness threshold 
in the UK set by NICE is £20,000 to 30,000 per QALY gained. This threshold reflects 
the amount of willingness to pay by the society for each additional QALY provided 
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by a new intervention. Establishing societal willingness to pay for a year with 
sufficient capability would be more difficult due to the complex nature of the 
concept. This work is ongoing by Dr. Kinghorn at the University of Birmingham 
(320). 
2.8 Chapter summary 
This chapter provides an overview of outcome measurement for economic 
evaluations. Upon reviewing the forms of economic evaluations, concept of health, 
QoL and utility and existing approaches employing the generic preference-based 
HrQoL measures, limitations around their use are discussed and alternative 
methods including the capability approach are provided. The ICECAP-O instrument 
offers a broader evaluative space than the current HrQoL preference-based 
measure EQ-5D, which shows potential to be an alternative as a preference-based 
outcome in populations with diseases such as Parkinson’s that have a broad impact 
on people’s wellbeing or complex interventions such as those in public health and 
social care. The next chapter will introduce the criteria for assessing the 
appropriateness of outcome measures which will be applied in the empirical works 
of this thesis. 
 
 
   
Chapter 3 Construct validity and 
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3.1 Introduction 
Chapter 2 introduced a variety of outcome measures used within the different  
economic evaluation frameworks, along with their merits and limitations. There 
are varied opinions on the subjective concept of QoL and what should be included 
in PbQoL measures being considered for resource allocation purposes. 
Consequently, the choice of the measures to be used in the intervention studies 
has often become a point of debate. Are the PbQoL measures suited to capture 
the health, QoL and wellbeing aspects that are valued by people? In other words, 
are the PbQoL measures appropriate to be used in the population of interest? This 
echoes the overarching research questions of this thesis.  
Construct validity and responsiveness are important properties for preference-
based measures to exhibit (118, 148). A PbQoL measure with limited construct 
validity or responsiveness would generate unreliable utility values for different 
health states, which would eventually affect QALY calculations in economic 
evaluations. In particular, responsiveness of a PbQoL measure means that the 
utility profile is able to reflect the change in health state caused by the 
intervention that are deemed to be important for the patients. Lack of 
responsiveness of the PbQoL measure may lead to a false judgement of an 
effective intervention being not cost-effective, whereas the truth may be that the 
PbQoL measure could not fully capture the intended benefit of the intervention. 
Consequently, the rigor of the economic evaluations will be undermined and its 
role in health care decision-making will be weakened. NICE clearly emphasizes the 
importance of assessment of these two properties when there is a doubt on the 
use of EQ-5D in specific populations in its ‘Guide to the methods of technology 
appraisal’ (119). It states that construct validity and responsiveness in a particular 
patient population should be investigated through a synthesis of peer-reviewed 
literature to support the claim that the EQ-5D may not be the most appropriate 
in some circumstances (323).  
Cautions should be made when applying the classic psychometric testing methods 
to the PbQoL measures (148, 246). The purpose of a PbQoL instrument is to 
measure all differences or changes in health state that are important to patients 
and valued by public. As introduced in Chapter 2 (Section 2.4), for a PbQoL 
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instrument, an improvement in a defined state being ‘important’ means that 
public would like to trade their length of life for this positive change, or accept 
higher risk of death for this positive change. The PbQoL measures are developed 
and valued incorporating people’s preference and thus assumptions are made in 
the testing regarding the resulting values rather than simply aggregated scores 
(i.e. weighting attributes equally and equal difference between levels).  The 
interpretation of results should take account of all the required assumptions in 
the valuation process. Methodological considerations will be discussed in this 
chapter following the description of each method and will be further summarized 
in Chapter 5 (Section 5.4) before their applications in the case studies in Chapter 
6 and 7. 
This chapter will start with a brief introduction of psychometric properties in 
general and then focus on construct validity and responsiveness. Assessment 
methods for these two properties introduced in this chapter are used in Chapter 
4 as criteria for critically appraising the existing preference-based measures 
identified through the systematic review, and also Chapter 6 and 7 for empirically 
testing these two properties of the ICECAP-O capability measure. 
3.2 Overview: psychometric properties 
Whether a QoL measure is appropriate to be used in a given context depends on 
its psychometric properties. Psychometric validation tests whether a QoL 
instrument is performing in the way expected. These methods were initially 
developed in the field of psychology and used in areas such as behaviour testing, 
personality, and beliefs, and they now extend to measures of QoL. Their 
importance is increasingly emphasized by health economists to evaluate PbQoL 
measures (148). Measurement of PbQoL can be described as “the process of linking 
abstract concepts to empirical indicants” (Carmines 1979) (305, 324) given the 
intangible, patient self-reported nature of the concept of PbQoL. As a result, 
testing the psychometric properties of the instruments measuring such abstract 
concepts are important for PbQoL measures to be trusted when being used in 
economic evaluations for decision-making.  
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Psychometric validation is the “process by which an instrument is assessed for 
reliability and validity through the mounting of a series of defined tests on the 
population group for whom the instrument is intended.” (Bowling 2014) (325). 
Reliability and validity are the two basic domains for assessment, while there are 
additional domains proposed in the literature such as practicality (118), and 
responsiveness (326). 
3.2.1 Reliability 
Bowling (2014) defined reliability as meeting two criteria: ‘reproducibility’ (the 
degree to which it is free from random error) and ‘internal consistency’ (the 
homogeneity of the instrument) (325). Mokkink et al. (2012) also included these 
two criteria but defined reliability more generally as “the degree to which the 
measurement is free from measurement error” (327). Mokkink et al. further 
clarified the use of the criteria of ‘internal consistency’ that it is only relevant 
when the measure is constructed in a ‘reflective model’, but not when the 
measure is constructed in a ‘formative model’. 
3.2.1.1 Reflective model versus formative model 
 ‘Reflective model’ and ‘formative model’ are specific types of measurement 
models, which describe the relationship between a construct and its indicators / 
items (328). The terminology of formative and reflective models was introduced 
into the health sciences in the 2000s by Fayers and Hand for the measurement of 
QoL (329). In a reflective model, all items are a manifestation of the same 
underlying construct (330) and hence they are expected to be highly correlated 
and homogeneous (330, 331). In contrast, a formative model applies to the 
construct in which the items together form a construct and thus it is not necessary 
for the items to be highly correlated (327). A way to differentiate between the 
two types of framework is to judge whether the items would change when the 
overall construct changes (327). Change in overall construct is expected to lead 
to changes in all items in a reflective model but not in a formative model. It was 
suggested that instruments measuring perceived health or HrQoL are usually in 
the form of a formative model and hence the test of internal consistency would 
not be relevant (327).  
Chapter 3  69 
For example, to measure HrQoL, EQ-5D instrument contains mobility, 
pain/discomfort, anxiety/depression and so on, where these dimensions represent 
the multi-faceted nature of the HrQoL concept and are not interchangeable. The 
items are not highly correlated (e.g. a person with extreme anxiety and depression 
may have no physical discomfort or disability at all). This explains why the EQ-5D 
is constructed in a formative model rather than a reflective model and only 
‘reproducibility’ should be assessed but the ‘internal consistency’ is irrelevant. 
This is in line with Brazier et al’s (2017) definition of reliability for testing PbQoL 
measures, which states that “reliability is the ability of a measure to reproduce 
the same value on two separate administrations when there has been no change 
in health”. This definition eliminates the ‘internal consistency’ and keeps 
‘reproducibility’ only (118).  
3.2.1.2 Reproducibility 
Three aspects of reproducibility are usually assessed: test-retest, inter-rater, and 
intra-rater reproducibility. Test-retest assesses the stability of the measure over 
a period of time during which what is measured is not expected to change (332). 
It is examined by presenting the same data repeatedly within a period of time to 
a single rater. Good test-retest reliability is represented by the same or highly 
similar measurements. The key to this methodology is to ensure that there is no 
actual change over the period of time so that any discrepancy between the two 
measurements can only be attributed to error. 
Both Interrater and intra-rater reproducibility (commonly called interrater and 
intra-rater reliability) concern with raters: interrater examines the degree to 
which the results obtained from two or more raters agree with each other while 
intra-rater assesses the agreement between the repeatedly obtained results from 
the same rater (333). Interrater reliability investigates the (in)consistency among 
individuals since human observers may have variable individual experience and 
thus interpret the phenomena differently. Examples include scoring injuries by 
different observers using MRI grading and prognostic parameters (334), counting 
2-minute push-up repetitions that meet the push-up protocol by different raters 
(335), etc. Intra-rater reliability examines if an individual interprets and records 
the data the same when the exactly same data are presented. For example, the 
study of assessing the 2-minute push-up test examined the intra-rater reliability 
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by making a single rater counting video-taped push-up repetitions repeatedly with 
a minimum 1-week apart (335). The within-individual agreement in this study was 
found to be not ideal, ranging from 41.8% to 84.8%.  
3.2.2 Validity 
Validity is the extent to which an instrument measures what it purports to measure. 
The word ‘valid’ is derived from the Latin word ‘validus,’ meaning strong (336). 
In that sense, validity requires an instrument to reflect strongly what it claims to 
measure. Validity has been more complexly defined as “an overall assessment of 
the degree to which evidence and theory support the interpretation of the scores 
entailed by proposed uses of the instrument” (Krabbe 2016) (p113) (337). In some 
literature this conventional meaning is referred to as internal validity to 
distinguish from external validity which refers to the generalisability of the 
research findings to the wider population (338). Validity testing may not seem to 
be complicated for the measures of observable outcomes, e.g. temperature 
measured by a thermometer, however, for the unobserved concept, for instance, 
QoL, life stress, testing validity is a prerequisite to their use. This is because the 
measurement of these factors is dependent upon their definitions, which may vary 
according to individual’s perceptions or preferences and the way the perceptions 
or preferences are being measured (339). This may lead to different results 
yielded by different instrument although they may claim to measure the same 
concept, raising the question of which instrument is valid.  
3.2.2.1 Face validity and content validity 
Validity has many different components. Face validity and content validity both 
assess whether the descriptive system of the measure is relevant, logical and 
sensible for the population. Face validity is more ‘superficial’ which is, according 
to some, e.g. Bowling (2014), based on investigators’ subjective assessments (325) 
and to others, e.g. Holden (2011), based on the respondent’s perspective (340). 
In contrast, content validity assessment is usually conducted by an expert panel 
using a more systematic approach which also assesses the comprehensiveness of 
the instrument in addition to the relevance of the items (325).  
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3.2.2.2 Criterion validity 
Criterion validity assesses the correlation of a measure with another measure of 
the same trait under study, ideally, a ‘gold standard’ accepted in the field (339). 
Sometimes, the criterion may have drawbacks such as being expensive and 
invasive for a diagnostic measure, or time-consuming for a questionnaire, and as 
such a new measure is intended to reduce these burdens. Criterion validity has 
two types: concurrent validity and predictive validity; the distinguishing feature 
between the two is the timing of administering the criterion (339). To assess 
concurrent validity, the criterion and the new measure are given at the same time 
whereas for predictive validity, the criterion is given at a later time to examine 
how well the new measure can predict the criterion. Examples of application of 
criterion validation include medical diagnostic measures using concurrent 
validation to test if the new diagnostic procedure under scrutiny can provide the 
same diagnosis as the reference standard, and in school admission context to test 
if the criteria for admission can predict the performance in the school using 
predictive validity. However, in the field of QoL, criterion validation has limited 
application due to its requirement of an existing ‘gold-standard’ measure. The 
new ankle-brachial pressure index designed to detect arterial disease in the leg 
can be compared against the gold standard of venography (341). Similarly, 
students’ performance in school can be measured by their scores of standardised 
exam with the highest score representing the best performance for each subject. 
In contrast, due to the different views on the definition of QoL as mentioned in 
Section 2.3, individuals have varied perceptions of what representing the ideal 
status of QoL and thus there is no standardised criteria.  
3.2.2.3 Construct validity 
Another important component of validity is construct validity. It considers 
whether the instrument is measuring the underlying concept it purports to 
measure. Construct of a measure relates to the hypothesized manifestations 
linking the underlying factors and a person’s behaviour (339). The underlying 
factors are referred to as hypothetical constructs (339). In psychology, these 
hypothetical constructs are explanatory variables which are not directly 
observable. This is distinguished from other sciences where a construct is a real 
existence, for example, the natural sciences contain constructs such as gravity, 
Chapter 3  72 
temperature, and pressure whereas the behavioural science contain construct 
such as motivation, intelligence, self-esteem, etc (342). In QoL studies, construct 
refers to the unobservable / hypothetical factors that contribute to the concept 
of QoL (343).  
All the components mentioned in this section can be organized to ‘three Cs’ 
according to Landy’s ‘trinitarian’ point of view (1986), i.e. content validity, 
criterion validity and construct validity (339). The three Cs are seen as three 
relatively independent attributes of a measure. Among the three Cs, only 
construct validity can be empirically and quantitatively tested for a QoL measure. 
This will be described in-depth in section 3.3 and 3.4. 
3.2.3 Other properties 
Besides the above-mentioned components in validity and reliability, a number of 
other issues have also been purported to be important concerns for assessing the 
performance of any measurement instrument (339), and are deemed important 
for PbQoL measures (118). Practicability considers the acceptability of the 
descriptive system to the respondents and the cost of administration (118). 
Responsiveness refers to the ability of an instrument to be responsive to change. 
Some argue it is a special form of validity and should be covered under the 
umbrella term of validity since the ability to measuring change is essentially a 
discriminant validity between different states of what is being measured (327). 
Responsiveness will be primarily focused in Section 3.5 and 3.6 in this chapter. 
An issue related to responsiveness is floor and ceiling effects. Ceiling effect occurs 
with tests or scales “that are relatively easy, when a substantial proportions of 
individuals obtain either maximum or near-maximum scores” (Uttl 2005) (344). On 
the contrary, floor effect occurs when the test is difficult and as a result a 
substantial proportion of individuals produce the minimum possible score (345). 
The existence of ceiling or floor effect of a PbQoL measure will result in score 
distributions that are compressed at the upper or lower end of the scale and thus 
cannot reveal any differences among the individuals that scored the highest or 
lowest of their utility values. The EQ-5D-3L is an example which has been shown 
to exhibit ceiling effect (full score recording perfect health) in both general and 
disease-specific populations, leaving less space for improvement in response to an 
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intervention (346, 347). In contrast, SF-6D (introduced in Section 2.4.3.1) is often 
found to exhibit floor effect for patient groups in severe health where a significant 
number of patients report the lowest level of health possible for some dimensions 
(348-350). Ceiling effects can be also understood as “when one can be better than 
can be captured by the measure’ and floor effect is ‘when one can be worse than 
the lowest score in the range of the measure” (Feeny 2012) (351). When a measure 
has ceiling or floor effects, its responsiveness to change would be threatened since 
there is no space for the score to move up when the baseline value is the highest 
on the scale or vice versa. 
3.2.4 COSMIN checklist 
As shown above, the literature in psychometric properties contains varied opinions 
regarding what criteria are important when selecting an instrument. To address 
this, in 2010, a group of international experts reached consensus on the criteria 
to evaluate the performance of health related patient reported outcomes, and 
developed a critical appraisal checklist in a Delphi study, named the COSMIN 
checklist (352). COSMIN stands for Consensus-based Standards for the selection of 
health Measurement Instruments, which contains standards for evaluating the 
methodological quality of studies related to the measurement properties of health 
related patient reported outcomes (326, 327). Three assessment domains are 
distinguished in COSMIN checklist, i.e. reliability, validity, and responsiveness. 
Figure 3-1 presents the components under each domain. 
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Figure 3-1: Relationship between measurement properties. 
 
Source: Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HCW. 
International consensus on taxonomy, terminology, and definitions of measurement properties: results of 
the COSMIN study. J Clin Epidemiol 2010;63:737-745. 2012.(352) Permission to include this figure in this 
thesis has been granted from the publisher, Elsevier (Appendix G). 
 
The ‘reliability’ domain contains internal consistency, reliability, and 
measurement error. The ‘validity’ domain covers three measurement properties: 
content validity which also contains face validity, criterion validity and construct 
validity. The ‘responsiveness’ domain contains only one measurement property, 
which is also called responsiveness. Besides these measurement properties, 
interpretability is also listed as an important characteristic of a measurement 
instrument which considers the degree to which one can easily interpret the 
quantitative score by clinical or commonly understood connotations. The 
definition of ‘construct validity’ and ‘responsiveness’ defined by COSMIN checklist 
will be mentioned in Section 3.3 and 3.5. COSMIN checklist provides a detailed 
guidance on how these measurement properties should be evaluated in terms of 
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study design and statistical analysis and critically discussed the associated issues. 
It can be used when selecting a measurement instrument and designing or 
reporting a study on measurement properties.  
An important note from the authors is that this checklist is to evaluate the quality 
of studies on measurement properties of a HrQoL instrument, rather than 
determining what constitutes good measurement properties of instrument (326). 
The criteria for determining the adequacy of measurement properties were 
discussed in the Delphi discussion however consensus was not achieved. This 
relates to the limitation in the interpretation of the results of case studies of this 
thesis and the proposition of future research in that a clear guidance is needed to 
determine the degree of construct validity or responsiveness is adequate. The lack 
of consensus among the international experts indicates that determining what 
degree of the properties should be judged adequate is very challenging. This will 
be further discussed in Chapter 8 (Section 8.6.3). 
Among the many psychometric properties, content validity, construct validity and 
responsiveness are recommended by NICE to judge the appropriateness of the 
currently recommended EQ-5D for specific populations (323). Furthermore, 
construct validity and responsiveness can be empirically tested and are essential 
for economic evaluation which requires an instrument to be able to differentiate 
between different health states or responsive to the change of health states over 
time (118).The following sections, 3.3-3.6, will further discuss construct validity 
and responsiveness along with their testing methods. 
3.3 Construct validity 
As introduced in Section 3.2.2, in psychometrics, construct refers to the 
unobservable objects that are used to represent or explain a concept, and 
construct validity represents the ability of an instrument to measure the 
underlying concept it intends to measure (332, 353). Cronbach and Meehl (1955) 
stated that “construct validity is involved whenever a test is to be interpreted as 
a measure of some attribute or quality which is not operationally defined” (353). 
Consideration of construct validity is therefore necessary “whenever no criterion 
or universe of content is accepted as entirely adequate to define the quality to be 
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measured.” This section will introduce a brief history of the emergence of 
construct validity theory and the various views around the definition of construct 
validity. 
3.3.1 History of construct validity 
Construct validity is the last developed measurement test in history compared to 
criterion and content validity owing to the gap identified in psychometrics (339). 
Assessment of validity was dominated by criterion validity prior to 1950s however 
it cannot be used in an area without a criterion (354).  Content validity has 
limitations as it does not provide inferences quantitatively about the validity of 
test scores (355). Consequently, there was a gap in methods to assess the 
usefulness of a scale in clinical psychology where there is no criterion but uses 
quantitative scores. In health, scales for physical symptoms are objective as the 
symptoms are mostly directly observed in contrast to the scales for psychological 
aspects which are subjective as the aspects are invisible, such as attitudes, 
feelings, depression. To fill this gap, Cronbach and Meehl (1955) introduced the 
concept of construct validity as “a framework of hypothesis testing based on the 
knowledge of the underlying construct” (p230) (339). In other words, when there 
is no ‘gold standard’, criterion testing is replaced by hypothesis testing about the 
relationship between underlying construct and the observed outcomes, which 
constitutes the basis of construct validation. Since then, construct validity, 
together with content validity and criterion validity, gradually became the three 
key criteria for testing of an instrument. Zumbo and Chan (2014) conducted a 
systematic review to identify the trend in the number of publications of validation 
studies since 1960s. Figure 3-2 shows that a clear increasing trend was identified 
in both overall number and the number in life satisfaction, wellbeing and QoL area 
(356). 
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Construct validity of a measure is context-specific, i.e. a measure exhibiting 
construct validity in one population does not guarantee is construct validity in 
another population, but this was not seen until the late 1960s (339). Previously it 
was viewed as an intrinsic property of a scale rather than a varying property in 
different populations. In 1971, Cronbach (1971) shifted the focus of the 
Figure 3-2: Trend line of number of publications of 
validation studies.  
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interpretation of validity testing results from the measure’s property to the 
characteristics of the people who were being assessed (357). Landy (1986) 
interpreted this focus change led by Cronbach as “validation process are not so 
much directed toward the integrity of tests as they are directed toward the 
inferences that can be made about the attributes of people who have produced 
those test scores” (p1186) (358). In other words, validation process is about the 
inferences, claims, or decisions that one can make based on the scores rather than 
whether the measure is valid itself (356). Validation process provides information 
about how the measure performs in the population being assessed.  
3.3.2 Definition of construct validity 
In the psychometrics literature, there is no consensus regarding the scope of the 
definition of construct validity. Some support the traditional view of treating it as 
a component of validity in the three C model (along with content validity and 
criterion validity) as originally published by Cronbach and Meehl (1955) (326, 353). 
Others, sometimes called revolutionary theorists (including Cronbach himself in 
later years (337)), developed novel views whereby construct validity is the 
overarching concern of validity research, encompassing all the other types of 
validity evidence (359).  
Among the pioneers for modern views, Messick described construct validity as “an 
integrated evaluative judgement of the degree to which empirical evidence and 
theoretical rationales support the adequacy and appropriateness of inferences and 
actions based on instrument scores.” (355)  Following Messick, the American 
Psychological Association handbook of research methods in psychology, written by 
Grimm and Widaman (2012), also considers construct validity as a comprehensive 
concept which is formed by two major axes, internal validity and external validity 
(360). Internal validity represents the extent to which an instrument measures the 
intended construct. It includes content validity, dimensionality, reliability and 
discrimination. External validity focuses on the relations between test scores and 
external criteria. It consists of criterion-related validity, convergent and 
discriminant validity, change validity, score interpretation and consequences 
(360). Grimm and Widaman’s multi-faceted definition of construct validity 
reflects Messick’s view of the inclusiveness of construct validity in that all 
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measurement tests are based on hypothesis and construct interpretation underlies 
all score-based inferences (355, 361). From this sense, all the tests that claim to 
examine ‘validity’ are by nature testing the ‘construct’ of a measure and thus 
become construct validation and all the components, including content validity 
and criterion validity, can be seen as types of construct validity. Hypothesis 
testing is therefore a method for all validity testing regardless of the types.   
Others maintained the traditional narrower scope of construct validity as a 
component of three C under validity as this framework is considered to be 
sufficient and clear (337) and for the convenience of understanding the different 
testing methods (339). With the narrow scope, construct validity is usually defined 
as having two components, convergent validity which examines how well it 
correlates with another measure of the same construct, and discriminant validity 
which examines whether it is possible to differentiate between groups thought to 
differ in the characteristics that the new instrument is supposed to measure(p185) 
(118, 332).  
The COSMIN checklist is consistent with the three C model whereby construct 
validity is one of the three elements within validity. It defines construct validity 
as “the degree to which the scores of an HR-PRO (health related-patient reported 
outcome) instrument are consistent with hypotheses (for instance with regard to 
internal relationships, relationships to scores of other instruments, or differences 
between relevant groups) based on the assumption that the HR-PRO instrument 
validly measures the construct to be measured” (352).  Construct validity is 
considered to include three aspects: structural validity, hypotheses-testing and 
cross-cultural validity, as shown in Figure 3-1 (327). Structural validity examines 
“the degree to which the scores of an instrument are an adequate reflection of 
the dimensionality of the construct to be measured”. It is not considered to be 
relevant in a ‘formative model’ (as mentioned earlier in Section 3.2.1), in which 
the items together form the construct, such as the case of most QoL measures 
including ICECAP or EQ-5D-3L, in contrast to a ‘reflective model’ in which all items 
are a manifestation of the same underlying construct. Cross-cultural validity 
considers the external generalisability that “the degree to which the performance 
of the items on a translated or culturally adapted instrument are an adequate 
reflection of the performance of the items of the original version of the 
instrument”. It is only relevant to the translated or culturally adapted instrument. 
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Hypotheses testing is the basic spirit of construct validity which examines “the 
degree to which the scores of an instrument are consistent with hypotheses based 
on the assumption that the instrument validly measures the construct to be 
measured”. (327) The research question for hypothesis testing asks ‘does the 
hypothesis of this validation study make sense in light of what the scale is designed 
to measure? ’ (339) 
Regardless of the scope, as mentioned in the last section, validity is about the 
interpretation of the scores in context. From this sense, the validation process is 
an ongoing process in which various types of evidence are accumulated and 
synthesized to support the construct validity of interpretation of an instrument 
(356). It is further argued that any conclusion about a construct validity test is not 
dichotomous but is a question of degree (362). It is a question of how well or 
poorly the measure performs in the population rather than whether or not it 
performs.  
3.4 Methods to assess construct validity 
Assessment of construct validity is to test the hypotheses which are made in 
relation to the underlying construct. A key concern for Cronbach and Meehl (1955) 
was that theories concerning inferred constructs be tested with rigor (339). Rigor 
generally refers to soundness of method, design, and test construction. In this 
scenario, it refers to the quality of assessment methods, which contains the 
hypotheses one tests about a theory, the methodology for testing and the 
statistical methods to generate inferences (363, 364).  
3.4.1 A five-step model for construct validation 
Smith (2005) (365) proposed a five-step model for construct validation. This model 
is shown in Figure 3-3. In practice, the five-step model can be applied to any 
validation tests as they all require hypothesis testing (355). This model has been 
used in previous studies validating the ICECAP questionnaire (305). 
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Figure 3-3: A five-step model for construct validation. 
Source: Smith GT. On construct validity: issues of method and measurement. Psychol Assess. 
2005;17(4):396-408.(365) Permission to include this figure in this thesis has been granted from the 
publisher, American Psychological Association (Appendix G). 
 
The steps are: 
(1) Theory specification (T): careful specification of the theoretical constructs in 
question, 
(2) Hypothesis derivation (H): articulation of how the theory of the construct is 
translated into informative hypotheses, 
(3) Research design (D): specification of appropriate research designs to test one’s 
hypotheses, 
(4) Empirical observation (O): articulation of how observations from samples 
pertain to one’s prediction, and, 
(5) Revision (R) of the theory and the constructs. 
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First, theoretical background for the construct of a measure to be tested should 
be clearly specified. This can be informed by the past empirical and theoretical 
work. Second, underpinned by the theoretical basis in step 1, hypotheses should 
be stated clearly, well justified, and be able to provide informative evidence 
about the test measure’s ability. A good hypothesis should be able to “facilitate 
the ongoing process of critical evaluation that is the hallmark of science” (Weimer 
1979) (366). Third, designing an appropriate study is crucial, as they should reflect 
what the hypothesis is intended for test. Inappropriate design will cause deviation 
from the hypothesis and misinterpretation of the results.  
Fourth, empirical observations require the application of appropriate statistical 
methods to be able to make inferences about the test measure. The classic 
statistical method proposed in psychological testing for construct validity is the 
multitrait and multimethod matrix (MTMM) method firstly proposed by Campbell 
and Fiske (1959) (367), which is essentially correlation testing. In health 
economics, the primary approaches are the ‘known-group’ method and convergent 
validity test proposed by Brazier (1999) adapted from psychometric literature 
(148). All these methods will be described in depth in the next section. The 
statistical test should allow the evaluation of the degree to which empirical 
observations conform to hypotheses. 
In the end, revision of the theory reflects that the “construct validation process 
is an ongoing, iterative process in which new findings and new theories clarify and 
alter existing theories, thus requiring new measures and new theory tests” 
(Weimer 1979) (366) . Assessment of an instrument’s validity is gradually built up 
through accumulative evidence, contributing to people’s understanding of the 
actual construct that an instrument can truly measure. The revision process allows 
the interpretation of the test measure in the context and thus reflects the value 
of the construct validation process. 
3.4.2 Statistical methods for testing construct validity 
Step 3 and 4 in Smith’s five-step model is to design methods to empirically test 
the construct validity based on observed data. The classic method of testing 
construct validation in psychology is by examining discriminant validity and 
convergent validity (325, 353). Discriminant validity requires that a measure 
Chapter 3  83 
should not correlate with other dissimilar, unrelated measures  and convergent 
validity examines the extent to which a measure correlates with another measure 
with the similar construct (353, 368). To examine these, the classic statistical 
approach is the MTMM method as mentioned above and the factor analysis method 
(332, 337, 360, 369, 370). 
PbQoL measures are unique from non-preference based HrQoL instruments as 
discussed in depth in Chapter 2 (Section 2.4) since the former additionally contains 
a value set which is to be attached with the responses from people on the levels 
for each attribute in questionnaires. Owing to this, the index values of PbQoL 
measures are reflecting relative preferences that patients and others place on the 
dimensions and the items, rather than simply score aggregates from the ordinal 
responses of level to the dimensions. As such establishing the validity of 
preference-based measures was described by Williams as “chasing will o’ the wisp, 
and probably equally unproductive” (371). However, construct validity is all about 
hypothesis testing and thus construct validation should still be rigorous and 
meaningful providing the hypothesis is constructed in a certain way to incorporate 
assumptions about preferences (118).  
As mentioned earlier, two approaches are commonly used to empirically test 
PbQoL measures: ‘known-group’ and convergent validity (148). Both approaches 
begin with setting up hypotheses. The COSMIN checklist states that specific 
hypotheses to be tested should have been formulated a priori, which ‘concerns 
expected mean differences between groups or expected correlations between the 
scores on the instrument and other variables, such as scores on other instruments, 
or demographic or clinical variables.’ 
The classic methods along with the known-group method and convergent validity 
approaches are introduced below.  
3.4.2.1 Classic psychometric approach 
The MTMM assessment is based on four sets of correlation coefficients, which aims 
to show that measures of the same construct should yield similar results 
(convergent validity) while measures of different constructs should produce 
different results (discriminant validity) (337, 367). The first set assesses the 
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correlation of using the same method to measure the same construct (monotrait-
monomethod) at two separate occasions, which is essentially a correlation test for 
test-retest reliability. The second set of coefficients assesses the correlation of 
using the same method to measure different traits (heterotrait-monomethod). 
Discriminant validity is established if this set of correlation coefficients is low. 
The third set examines the correlation of using different methods to measure 
different constructs (heterotrait-heteromethod), and the last set examines the 
correlation of using different methods to measure the same construct (monotrait-
heteromethod). Convergent validity is established if the monotrait-heteromethod 
coefficient is high.  
However there are several limitations of the MTMM methods as summarized by 
O’Leary-Kelly and Vokurka (369). It was argued that there is no precise standard 
for determining the degree to which the correlation criteria are met and the 
original recommendation of visual inspection is subjective. Furthermore, there 
lacks assessment for the underlying assumption that the traits are all equally 
influenced by the different methods used to measure them. Related to this is that 
there is no way to separate out the variance that is attributable to the traits, vs. 
the methods, vs. random error (369). Also, finding a measure with similar 
construct is straightforward but finding a measure with a different construct is 
less pragmatic since theoretically there could be unlimited options. 
Besides the MTMM method, another classic method to test construct validity is 
factor analysis (325). Measurement of variance contains both shared and unique 
variance across variables. Factor analysis is concerned with the variance that each 
variable has in common with other variables. It is used to determine the number 
and nature of latent constructs within a set of observed variables and cluster 
highly interrelated variables into factors. Researchers can use it to group similar 
questions together from a lengthy questionnaire (337). In construct validation, it 
can be used to group the correlated attributes together from different measures 
to aid the understanding of the overall correlation between measures. Another 
related method, known as principal component analysis, extracts factors based on 
the total variance of the variables, aiming to find the fewest variables that explain 
the most variance. Principle component analysis decompose a set of data with 
correlated variables to independent (i.e. uncorrelated) components and thus it is 
sometimes used by researchers to reduce a large number of variables to a smaller, 
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more manageable number of components (337). Therefore, factor analysis and 
principle component analysis are different processes to understand the structure 
of the construct; the former looks for the shared factors while the latter looks for 
the independent components to form the whole construct, and as such they can 
be used for determining whether two measures can be substitute or complement 
for each other. 
3.4.2.2 The known-group method 
Another method to demonstrate construct validity is the known-group method. 
The relatively new measure is administered to two groups that are known to or 
logically should be different in the feature that is expected to be captured in the 
construct of the instrument (372). The hypothesis is that there is difference in the 
scores of the instrument between the two groups (368). Therefore the known-
group method is to determine the extent to which the instrument can differentiate 
between groups that are expected to differ in terms of the concepts of interest 
being measured. Good evidence of construct validity is demonstrated by a 
statistically significant difference of the scores of the instrument between the 
groups. Given that statistical significance is dependent on sample size, weak 
evidence of construct validity is also considered if a statistically significant 
difference is nearly shown.  
Known-group validity has been widely tested for validating PbQoL instruments (19, 
21, 373-379). Brazier et al. (2014) assessed the known-group construct validity of 
the EQ-5D and SF-6D in populations with mental health problems (380), Stavem et 
al. (2011) assessed known-group construct validity of the 15D and EQ-5D in a 
community sample of people with epilepsy (381), Maddigan et al. (2004) assessed 
known-group construct validity of the SF-12, HUI-2 and HUI-3 in type 2 diabetes 
(382). In particular, the known-group method has also been used in previous works 
of testing the construct validity of ICECAP-O and ICECAP-A (305, 383). For example, 
Makai et al. (2013) used it to test the ICECAP-O in a population of post-hospitalised 
older people in the Netherlands (313). Al-Janabi et al. (2013) used it to test the 
ICECAP-A and found that its responses and scores could differentiate between 
different health and socioeconomic groups but not across individuals with 
different levels of local deprivation (383).  
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One issue to be noted in the known-group method is the criteria for groupings. 
The choice of criteria can influence the results of the known-group tests; usually 
the higher correlation between the criteria and the test measure, the more 
favouring the known-group results will be to the test measure (118). When using 
measures that only have a weak relationship to QoL, the results of assessment 
should be interpreted carefully. For example, when grouping using clinical 
measures such as cholesterol level, in which case the known-group results may 
fail to show the difference in the mean score of the QoL measure between people 
who have a high and low cholesterol level, but this cannot conclude that the QoL 
measure has weak construct validity. Any negative results towards the QoL 
measure may likely be caused by the unsuccessful choice of criteria and hypothesis 
rather than weakness in validity with the measure. Similarly, any positive results 
could also be due to the choice of criteria and hypothesis, rather than the strength 
in validity with the measure. 
Another issue relates to the use of a non-preference based measure as criteria to 
test the construct validity of a preference-based measure. As mentioned earlier, 
hypothesis of the known-group difference has to be made relevant to the 
preference values (118). Using the example above, the hypothesis is not simply 
‘patients with low and high cholesterol level have differed QoL’, but would be 
‘patients would prefer having low cholesterol level than having high cholesterol 
level’. The ‘prefer’ here means that patients would like to trade some of their 
length of life for some decrease in their cholesterol level.  
Given the above issues, care must be taken to scrutinize the criteria being used 
to establish known-group differences, and difference in preferences must be 
assumed in the hypothesis if the test measure is a preference-based measure. 
3.4.2.3 Convergent validity 
Convergent validation is another test of construct validity defined as the extent 
to which one measure correlates with another measure of the same or similar 
construct (353). The direction and magnitude of the correlation are important for 
understanding the association between the measures. Convergent validity is 
demonstrated if the test measure is highly correlated (correlation coefficient (r) 
≥ 0.5) with a measure with similar construct (324). A perfect correlation or very 
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high correlation (r>0.8) would mean the test measure and the criteria measure 
are measuring the same construct.  
Like the known-group method, the choice of the criteria measure is important for 
interpretation of the result. A very high correlation is not expected if the test 
measure and criteria measure are essentially different but related, such as 
physical health and general wellbeing. Physical health is one determinant of 
general wellbeing but not equal to general wellbeing. A perfect correlation means 
the measure of physical health and the measure of wellbeing are measuring 
exactly same thing, which is incorrect. Therefore, the test of convergent validity 
is about whether the strength of the correlation meets expectation based on the 
assumed overlapping concept between the test measure and the criteria measure, 
rather than simply expecting a high correlation.  
Convergent validity is commonly assessed together with known-group validity or 
occasionally independently to provide evidence for construct validity of PbQoL 
measures (21, 246, 375-377, 379, 384). For example, Papaioannou et al. (2011) 
assessed convergent validity of EQ-5D and SF-6D in patients with schizophrenia. 
Ratcliffe et al. (2017) assessed convergent validity of EQ-5D-5L, and the 
preference-based dementia specific QoL measures, DEMQOL-U and DEMQOL-
Proxy-U, in a post-hospitalisation population of frail older people living in 
residential aged care (379). Lorgelly et al. (2015) assessed the convergent validity 
of the cancer-specific preference-based measure EORTC-8D in cancer patients 
(384). It also has been used in the recent validation work of ICECAP measures. For 
instance, Sarabia-Cobo et al. (2017) assessed convergent validity of the Spanish 
version of the ICECAP-O in nursing home residents with dementia (385) and 
Goranitis et al. (2016) assessed convergent validity by exploring the correlation 
between the ICECAP-A and the EQ-5D-5L (386). 
3.5 Responsiveness 
Responsiveness refers to the ability of an instrument to measure change. 
Responsiveness is a relatively new term that has been introduced to the field of 
psychometric evaluation in the past 20 years (339).  There is a debate on how it 
is related to the classic categories of psychometric properties, i.e., reliability and 
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validity (337). Theorists often regard it as a longitudinal construct validity (387, 
388) whereas there is new proposition that responsiveness should be considered 
as the third essential measurement property of an instrument, primarily in the 
area of HrQoL (389). The term responsiveness is also often used interchangeably 
as ‘sensitivity to change’ and there are mixed views of its definition. This section 
will introduce why responsiveness is an important property of a measure and why 
it is crucial for economic evaluations. This is followed by a summary of the various 
views towards how responsiveness should be defined. The definition of 
responsiveness is embedded with the concept of minimally important differences 
(MID) and thus MID will also be discussed. 
3.5.1 Why we measure change 
The ultimate goal of healthcare interventions is to induce positive change in the 
population’s health status (339). Therefore measuring whether the status of 
patients – physical and mental health, QoL and wellbeing - has changed over time 
(either due to effect of intervention, or natural health status change), and to what 
extent the change has happened is of great importance in clinical practice and 
health research. 
The measurement of change can be directed at three different goals (339, 390). 
The first goal is to measure the differences between individuals in the amount of 
change. This aids to differentiate between the individuals who have larger changes 
and those who have little change when receiving the same intervention. So the 
first goal is to identify individual variability in terms of the magnitude of change, 
which has received renewed attention in precision medicine (391). Because of the 
differences across individuals, an intervention that, on average, has been shown 
statistically significantly effective in a large group of sample may not lead to the 
same amount of change to every individual. The distribution of change is hoped 
to be deciphered by the research of precision medicine which analyses person’s 
genes, lifestyle and environment to investigate explanations of ‘what works for 
whom’ and tailor the treatment (392). 
The second goal is a logical follow-up objective after the first one. When the 
individual difference in change is identified, researchers may then be interested 
in identifying the factors that are associated with this change. This will help 
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understand the reasons leading to the difference and can subsequently take 
measures to adjust the change stimuli (e.g. health intervention) according to 
population characteristics. The third goal of measurement of change is to infer 
treatment effects from group differences. This goal is mostly relevant to any 
intervention study with two or more groups which differs in the intervention 
received. For example, in a RCT, a treatment effect is determined by comparing 
the average change from baseline until endpoint between the different groups.  
Simply put, the first goal is to identify if there are individual differences in their 
response to treatment, followed by a second goal to identify the factors that are 
contributing to the differences if the differences are identified. Then the last goal 
is to identify the treatment effect of intervention by comparing the change 
between treatment group and control group.  
3.5.2 How responsiveness should be defined 
PbQoL instruments are developed to measure change and to what degree the 
PbQoL measure is sensitive to change is what the ‘responsiveness’ property is 
about. The literature contains various definitions of responsiveness, and the 
differences between them are instructive, leading to a number of parameters 
proposed in the literature to assess responsiveness. The common basic framework 
to define responsiveness is ‘the ability to measure change’ or ‘sensitivity to 
change’ and the differences between definitions are usually surrounding the 
meaning of ‘change’. For example, the change could be defined as ‘clinically 
important changes’ (393-395) such as in  Guyatt et al’s original definition that the 
“instrument must detect clinically important changes over time, even if those 
changes are small” (396).  Alternatively, the change could be ‘in the construct to 
be measured’ such as in the definition by COSMIN checklist that responsiveness 
refers to “the ability of a health-related patient-reported outcome to detect 
change over time in the construct to be measured”(327). Terwee (2003) reviewed 
literature published between 1985 and 2002 and categorised the varying 
definitions for the concept of responsiveness to three groups (397). In the first 
group, responsiveness is defined as the ability to detect change in general while 
in the second group it is defined more specifically as the ability to detect clinically 
important change, such as the example of Guyatt’s definition above. The third 
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group expands the focus on clinical area in the second group to ‘the concept being 
measured’ (397). 
The many definitions are primarily distinguished upon two traits: whether the 
change is meaningful / important or not, and whether the change is specific to 
clinical or health in general or in the concept being measured. The first trait 
differentiates between the term ‘responsiveness’ and the term ‘sensitivity to 
change’.  Although literature sometimes uses ‘responsiveness’ and ‘sensitivity to 
change’ interchangeably, the meanings of the two terms differ according to Liang 
(2000); ‘sensitivity to change’ makes no judgement about whether the change is 
important or not but ‘responsiveness’ does, in some of its many definitions (394). 
Confusion upon the second trait can be traced back to the evolving process of the 
term ‘minimally clinical important difference’ (MCID) and MID (i.e. minimally 
important difference). MCID was introduced by Jaeschke and Guyatt in 1989 as a 
way to translate changes in instrument scores into clinically meaningful terms 
(398). The focus of MCID on clinical arena, however, limits its use in HrQoL 
instruments which emphasize on patients’ experience, and subsequently the ‘C’ 
is removed from the original MCID and MID was born (399). This will be further 
discussed in the next section. This broader scope of the definition of ‘change’ 
expands the meaning of responsiveness accordingly. 
This thesis considers responsiveness as a context-specific term and adopts the 
definition in the third group outlined by Terwee et al.’s review (397); 
responsiveness refers to the ability of an instrument to detect important change 
over time in the construct to be measured. A prerequisite of the test of 
responsiveness therefore lies in the interpretation of the change that occurs in its 
construct; a question of what is an important change in the context. This change 
may, for example, allow an individual to achieve walking without assistance, or 
live with a more manageable level of stress, or just simply is perceived by an the 
individual as important. The next section will continue from last paragraph on the 
discussion around MID and the question as to what degree a change is considered 
important. 
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3.5.3 Minimally important differences  
MID and its earlier form, MCID, were developed to aid the interpretation of a 
change score on an instrument. MID is defined as “the smallest difference in score 
in the outcome of interest that informed proxies perceive as important, either 
beneficial or harmful, and which would lead the patient or clinician to consider a 
change in the management” (Schünemann and Guyatt 2005) (399). This definition 
did not stress that the change must occur in one specific domain; rather, a general 
change could occur as long as it is the outcome of patients’ interest and perceived 
important by the patients.  
In clinical trials, where QoL instruments are being used increasingly as the primary 
outcome measure, determining if the change is statistically significant is easy, but 
this does not, however, inform clinicians whether the change is meaningful to 
patients or not. Also, any change, no matter how small, can be statistically 
significant with a large enough sample size. However, statistical significance will 
not inform if those small changes are meaningful to patients or, from a health 
economist’s perspective, can lead to any difference in preferences. To fill this 
gap, MID (or MCID) was introduced to place the magnitude of change in a measure 
in a context which can be detected and is valued by a patient (398). 
Criticisms have been raised regarding the research on obtaining MID for the PbQoL 
measures, such as the EQ-5D. Walters and Brazier established the MID for the SF-
6D and EQ-5D-3L to be 0.041 and 0.074, respectively (400). They defined the MID 
in this context as “the smallest change in utility scores that can be regarded as 
important”. However, it can be argued that utility scores have their own meaning 
since they are ‘preference-based’ and as such they represent the trade-offs 
between health states and length of life. Owing to this, any difference in utility 
scores could be quantitatively translated to a difference in length of life. In 
simpler words, because of the valuation process, the utility values represent for 
how much length of life an individual would trade for, or how much higher/lower 
risk of death an individual could accept. For example, despite being small, a 0.01 
absolute difference of utility value for one year means a difference of living for 
3.65 days with full health. This forms the fundamental basis for the utility values 
to be able to combine with length of life to generate QALYs. On the contrary, MID 
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is only relevant to the instruments with a score that does not have a meaning. The 
preference elicitation process (the valuation stage, as introduced in Chapter 2 
Section 2.4.2) has already incorporated the concept of ‘importance’, as the larger 
coefficient of the health state defined by the dimension and level, means more 
importance, which is related to the degree of how it is preferred by the public. 
Therefore, any difference in utility value could be considered to be important and 
the remaining issue is whether the difference is statistically significant to guard 
against a chance finding. Besides, the PbQoL measures are developed for the 
purpose of economic evaluations, where what is important is not whether there is 
a meaningful change in the preferences but whether there is a difference in the 
combined cost-effectiveness, or the ICER (401) and therefore eliciting a MID for a 
PbQoL measure may not be relevant for economic evaluations.   
3.5.4 Why responsiveness is important for PbQoL instruments 
Responsiveness is an important property for PbQoL measures, given their role in 
economic evaluations. As covered in Section 1.4, 2.2.2, and 2.4.3, PbQoL 
measures are used to obtain utility values which are to be combined with length 
of life to calculate QALYs in economic evaluations and the magnitude of 
incremental cost per QALY (or, ICER) will affect the funding decisions of new 
interventions. Therefore, responsiveness is an essential property of an instrument 
for comparing the outcomes of health care interventions as well as measuring 
longitudinal change over time (396, 402). For example, in clinical trials where the 
effectiveness of an intervention is demonstrated by the condition-specific QoL 
measures with the assumptions that these changes are deemed important to both 
patients and public, if this is not appropriately reflected on the change of the 
PbQoL measures, the treatment effect may be underestimated or overestimated 
in the QALY calculation for the intervention arm. In the case of the former, i.e. 
the underestimated QALY, the aspects where benefit shows cannot be fully 
captured and valued by the PbQoL measure, while for the latter case, those 
aspects may have been over-emphasized by the PbQoL measure at the cost of 
compromising the value of other domains to overall QoL. In both cases, low 
responsiveness of the PbQoL measures may cause error to the ICER estimation of 
the alternative interventions, which may affect health care decision-making. 
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3.6 Methods to assess responsiveness 
The definition of responsiveness suggests its assessment would require another 
measure to identify the happening of the important ‘change’, i.e. whether the 
patients have improved or worsened over time, regardless of whether the change 
is meaningful clinically or on the concept of interest over time (403). This is 
commonly known as the ‘anchor-based’ method (403). It explores the relationship 
between the change in scores of a measure and the same or similar concept 
measured by an independent anchor. 
Another method that is commonly seen in literature is the ‘distribution method’ 
which uses statistical parameter such as effect sizes of a sample to estimate 
change (404). It is considered as an alternative to anchor-based methods when an 
appropriate anchor is not available. However, the application of ‘distribution-
based’ method in the assessment of responsiveness should be treated with caution. 
The effect size statistics is concerned with both the size of the real change and 
the ability of detecting change of the test measure (327). In the absence of an 
external reference point to confirm the magnitude and direction of the change in 
the population, it is unknown whether the small effect size is the consequence of 
ineffective treatment / small real change, or due to the poor responsiveness of 
the measure (327, 404). Examples of such misuse of the distribution-based method 
are, unfortunately, not hard to find in previous literature (405, 406). Given the 
limitations, distribution based approaches are not recommended by FDA guidance 
to play a primary role for patient reported outcome measures (404). A solution to 
this limitation is that the distribution-based method could be applied in 
conjunction with the anchor-based method, in which the effect size statistics are 
calculated for each of the anchor group, rather than the whole population.  
In the anchor-based approach, anchors are used as an external surrogate ‘criterion’ 
to identify the change. It is hypothetical because there is no real criterion in QoL 
area. This indicates that testing responsiveness also follows the five-step model 
introduced in 3.4.1 which starts from setting up hypothesis and testing the 
hypothesis (118). For testing a PbQoL measure, in the same way as for a hypothesis 
set for construct validity, the researcher must assume the change of preferences. 
The hypothesis could be, for example, the preferences captured by the new 
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measure should be responsive to the change of the degree of pain, or in other 
words, when the patients feel less pain over time, it is expected to see a higher 
utility value (measured by the test measure) towards the later state with less pain. 
Once an anchor is selected, either clinical or QoL-centred, the anchor is then used 
to assign participants into groups reflecting some degree of change according to 
the size and direction of the change between baseline and follow-up in the anchor 
measure (403). The groups could be no change, improvement, worsened, or if 
sample sizes allow further stratification, such as no change, small or large 
improvement, small or large worsened. After the grouping is completed, 
statistical methods are then used to determine the direction and magnitude of 
the change in the test measure in relation to the variance of the change for groups 
of patients with a confirmed experience of change.  
The most commonly used statistical parameter to assess responsiveness is the 
‘effect size’, where the mean change in score is divided by either the standard 
deviation at the baseline or the standard deviation of the change (402). The effect 
size statistics indicate the relative size of the ‘signal’ in comparison to the 
underlying ‘noise’ in the data (148). Good responsiveness of a test measure to the 
concept measured by an anchor is demonstrated if the change in the scores of the 
test measure in each group of participants is in the expected direction as indicated 
by the change in the scores of the anchor measure (403, 404). In other words, it 
is expected to see the improvement of the score on the test measure in the 
‘improvement’ group defined by the anchor measure, no change of the test 
measure in the ‘no change’ group, and worsening of the test measure in the 
‘progressed’ group.  
This section will introduce how the anchors are selected and how the change 
groups are formed, followed by the effect size statistics and other statistical 
methods to aid the understanding of responsiveness. 
3.6.1 Anchor selection 
The anchor should be a validated measure with the same or related concept as 
the test measure. It is widely recommended to use multiple anchors (403, 404, 
407, 408). The anchor(s) may be a clinical objective measure, or a subjective 
Chapter 3  95 
measure reported by patients (409). Condition-specific scales, being more focused 
and tailored towards problems of particular importance to the target patient 
groups, are generally more sensitive in the specific context than generic health-
status measures (410) and thus more commonly chosen as anchor measures. 
In general, the choice of anchor is a function of the strength of correlation 
between the anchor and the test instrument, and the degree to which it would 
increase understanding and is of interest to the researchers (403, 404). Anchors 
can be justified when it is shown to have a theoretical or proven association with 
the test measure. The association can be informed by initial assessment of the 
correlation of change scores of the anchor and the test measure. An acceptable 
correlation threshold is taken to be 0.3 (403, 404), while a lower correlation 
thresholds may still be acceptable in some situations (403). Cross-sectional 
correlations at baseline and follow-up between the measures can also be 
considered. Besides, anchors can also be chosen if any theoretical or 
methodological reasons can be provided, or when analysis using the anchor would 
be of interest to investigators and researchers.  
Two cautions should be noted for the selection of anchor. First, before testing the 
correlations, the measurement properties of the anchor measure or the 
comparator instruments should be adequate (403). Otherwise, it is difficult to 
decide afterwards whether negative results are due to lack of responsiveness of 
the instrument under study or poor quality of the anchor. Second, where multiple 
anchors are selected, differences in their constructs are expected (403). The 
benefit of choosing multiple anchors is to enable testing the construct of the new 
measure from different angle, e.g. whether the new measure is responsive to pain, 
or whether it is responsive to change in QoL. Therefore, it is important to choose 
a series of anchors with different correlated constructs with the test measure. 
3.6.2 Anchor group formation 
Once anchors are selected, they are then used to assign participants into ‘change 
groups’. As mentioned earlier, the groups could be no change, improvement, 
worsened, or in more detailed stratification. Depending the type of anchor, four 
methods to form change groups are identified from literature. The first method is 
the global rating method where groups could be formed by directly asking patients 
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whether or not they feel some degree of change. The second method is used where 
there is an intervention with proven effectiveness. Groups can be formed naturally 
by patients receiving intervention vs. not receiving intervention. Groups can also 
be formed using anchors such as clinical measures or QoL measures; the former 
would require clinician’s opinions on the interpretation while the latter would 
need MID to infer how many points of change on the score would translate into a 
meaningful change experienced by the patient. These methods are described 
below. 
3.6.2.1 Global rating of change scales 
In a classic anchor-based approach, the change groups are formed naturally by 
using Global rating of change scales, or simply put, Global rating scales (GRS), as 
the external anchor (411). GRSs are designed to quantify the magnitude of the 
improvement or deterioration of a person’s health status over time (411).  It asks 
a person to rate his or her current health status compared to a previous time-point 
on a multi-point GRS. For example, to assess responsiveness of the Anterior 
Cruiciate Ligament Quality of Life Measure, Lafave et al. (412) reported that 
patients were asked to select one of seven categories of change on the 7-point 
GRS and were grouped accordingly: 7, significantly better; 6 much better; 5, 
somewhat better; 4, no change; 3, somewhat worse; 2, much worse; 1, 
significantly worse. Similarly, Greco et al. (413) created three change groups 
based on the 7-point GRS with slightly different description, including: the ‘the 
improved’ group consisted of individuals who rated themselves on GRS as ‘much 
better’ or ‘somewhat better’, ‘unchanged group’ consisted of ‘slightly better’, 
‘not changed’ or ‘slightly worse’, and ‘worse’ group for GRS rating of ‘somewhat 
worse’ or ‘much worse’. Although GRS provides a convenient path for forming the 
anchor groups, it is acknowledged that GRS should not be considered as gold 
standard as its reliability and validity is not established (327, 409). A prominent 
criticism is the potential for recall bias. Studies have found that people tend to 
link to their current status when asked to recall a prior state, leading to 
retrospective judgements of change vulnerable to bias (414). On the other hand, 
reliable and accurate information from the GRS scale places considerable 
cognitive demand on the patient (411).  
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3.6.2.2 Intervention group with proven effectiveness 
The second approach is to divide the groups according to the different 
interventions assigned, where the effectiveness of the interventions has been 
proven to be distinctive (415). For example, to assess the responsiveness of the 
EQ-5D-3L and SF-6D to the change of inflammatory arthritis, Harrison et al. (416) 
grouped the patients according to their treatment arms in clinical trials based on 
the expectations on the effectiveness of the intervention, and the natural 
progression/deterioration of the control arm, e.g. the patients receiving 
treatments which inhibit the action of TNFα were assigned to the ‘improvement 
group’ as the treatment was expected to dramatically improve the outcomes.  
However, this method is subject to limitations in the ‘proven effectiveness’ of the 
intervention since response to an intervention may be varied across individuals. It 
also neglects the fact that responsiveness is about ‘degree’ rather than ‘yes’ or 
no’ since ‘proven effectiveness’ alone would provide no information on how much 
change one should expect on both the health status of the patients and the test 
measure. 
3.6.2.3 Distinct health stages defined by objective clinical measures 
The third approach is to use objective clinical measures as external criteria, which 
sometimes are combined with the global rating scale to substantiate the patients’ 
subjective assessment (409). For instance, due to the lack of a gold standard to 
assess patients with heart failure, two clinical objective assessments and one 
cardiologist completed GRS were used instead as external indicators of heart 
failure status change in Eurich et al’s study (417), which  evaluated the relative 
responsiveness of several QoL measures to the clinical change of heart failure. 
One clinical objective measure used in this study was cardiologist’s assessment of 
the patients’ New York Heart Association (NYHA) classification at baseline and at 
endpoint. This is an ordinal measure which produced easily defined groups and 
therefore subjects were classified to five change groups: improved/deteriorated 
two classes of NYHA, improved/deteriorated one classes of NYHA and no change. 
Another objective measure was the six-minute walk test (6 MW) which produces 
the travelled distance within six minutes as a continuous number. The authors 
classified the change of the travelled distance between baseline and endpoint to 
seven mutually exclusive categories, on the basis of previous research which used 
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physician-assessed global rating of change as criterion to quantify the number of 
minutes between each category of change. 
3.6.2.4 Minimally important difference 
The last approach is to use the MID of the condition-specific anchor measure to 
define the groups providing the MID information is available (418). People who 
experienced a change equal to or greater than the MID are categorised into the 
change groups, i.e. improved or deteriorated group. For example, Keeley et al. 
(418) assessed the responsiveness of ICECAP-A and one of the anchors used was 
the EQ-5D-3L. By using the MID value of EQ-5D-3L from one previous research (400), 
0.074, three subgroups were formed: improved/deteriorated group (patients who 
had improved/worsed by larger or equal to 0.074), or no change group (patients 
who had a change with a smaller size than 0.074). Although the meaningfulness of 
MID for preference-based measures is controversial as mentioned in 3.5.3, this is 
a useful example of grouping by MID when the anchor is a PbQoL measure.  
The approach of using MID to defining groups has its own limitations in application 
in addition to the issue of interpretation of MID for PbQoL measures. First, it relies 
on the robustness of the previous study of testing the MID and the generalisability 
to the current study. Second, using a universal MID to generate both improved and 
worsened groups may not be appropriate in some clinical areas. It was found that 
the MID generated from the ‘somewhat better’ group and ‘somewhat worse’ group 
were different for SF-6D (mean difference: 0.079, p=0.02) in people with back 
pain and EQ-5D-3L (mean difference: 0.275, p=0.001) in people with osteoarthritis 
in knee (400). Therefore, care should be taken before generalizing the results of 
MID to another study. Lastly, it does not provide any inferences on the threshold 
between the ‘a little change’ and ‘a lot of change’, since MID by its definition only 
concerns with the difference of the measure between ‘minimal change’ and ‘no 
change’.  
Nevertheless, using MID as criteria may be a more robust approach to assessing 
the responsiveness of a ‘preference-based’ measure compared to the other 
approaches. As mentioned earlier, Brazier and Deverill (148) are concerned that 
the common approach of using the non-preference-related instrument to confirm 
the change (such as using clinical measures), cannot reflect the changes in 
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‘preferences’, or the degree of importance of a change to patients. The MID 
method incorporates ‘importance’ to some extent into the measurement of 
change.  To test MID, typically, studies would ask patients whether there is no 
change, a little change or a lot of change in their overall health. In this process, 
when a patient is considering whether what happened over the study period could 
be called a ‘change’, the aspects that are related to a patient’s QoL are being 
weighted with importance to some degree in his/her mind.  
3.6.3 Statistical methods for testing responsiveness 
After grouping is completed, statistical methods are then conducted to determine 
the degree of responsiveness of the test measure to the change of the anchor. 
Terwee et al. reported there were as many as 31 different responsiveness 
statistics (397). Methods that are relevant to the testing of PbQoL measures within 
the anchor-based approach are described below.  
3.6.3.1 Effect size statistics 
Effect size statistics are recommended as the primary method for assessing 
responsiveness of patient-reported outcome measures (148, 397, 404, 415). They 
quantify the magnitude of change based on variation in the scores of the measure. 
The standard effect size (ES) is also called Cohen’s effect size, which was invented 
by Cohen in 1988 (419). It is calculated by dividing the mean change between 
baseline and endpoint by the standard deviation (SD) of the baseline scores 
(Formula 1) (415) . 
ES = Meanchange / SDBaseline  (Formula 1) 
The standardised response mean (SRM) is a variant of ES, which was suggested by 
McHorney and Tarlov in 1995 (420). It is calculated by dividing the change between 
baseline and endpoint with the SD of this change (415).  
SRM = Meanchange)/ SDChange  (Formula 2) 
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Compared to the ES, the SRM is more closely linked to the paired t-test. In a paired 
t-test, T is calculated by dividing the mean change by standard error. Standard 
error is calculated by dividing standard deviation by the root square of sample size 
(√n). And therefore, SRM is simply the T divided by √n (339). (Formula 3) 
T= Meanchange/ SEChange= Meanchange / (SDChange/√n) = Meanchange/SDChange*√n=SRM*√n 
(Formular 3) 
And therefore, SRM=T/√n 
Both of the methods are based upon means and SDs, which implies an underlying 
assumption that the data distribution of the outcome measure follows a normal 
distribution. Many QoL scales have a non-normal distribution, in which case 
unfortunately little work has been carried out into how to test the responsiveness 
when the assumption is not met. 
Cohen (419) provided a rule of thumb for the cut-off values to interpret the 
magnitude of the ES. A score below 0.2 represents very small ES, 0.2 to 0.5 – small, 
0.5 to 0.8 – medium ES, larger than 0.8 - large ES (421). These cut-offs, however, 
are argued to be problematic when being applied to interpret SRM (422). The main 
reason is due to the different SD used for ES and SRM, SD of baseline value is used 
for ES but that of the change value is used for SRM and thus using Cohen’s 
threshold to determine the magnitude of the effect size may not be accurate. 
Middel et al. have shown some estimates based on Cohen’s threshold applied to 
SRM values being either over- or underestimation of an intervention-related effect 
(423). Sivan suggested to use the method proposed by Middel & Sonderen, which 
applies the correlation coefficient between the repeated measurements (i.e. 
baseline and endpoint) to Cohen’s threshold (424).  
However, all the rules above are aiming for the situation where effect size is used 
as a measure for treatment effect, rather than a measure for testing the 
responsiveness to a change. Therefore focus should not be put on finding measures 
with the largest responsiveness statistics or determining if a measure can produce 
a ‘large’ effect size statistics when the aim is to test the responsiveness of a test 
measure to a hypothetical anchor (327). Within the anchor-based approach, the 
expected size of the effect size statistics is conditional on the relationship 
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between the test measure and the anchor. As mentioned earlier, when the anchor 
and the test measure are designed for different purposes, expecting a large ES is 
inappropriate. Therefore, hypothesis should be carefully set describing what the 
expected ES/SRM based on the relationship between the anchor and the new 
measure or relative size of ES/SRM if multiple new measures are compared. 
3.6.3.2 Paired t-test 
The paired t-test tests the null-hypothesis that there has been no change in the 
mean response of the new measure. In the anchor-based approach, the paired t-
test is conducted within each change groups, e.g. no change, small improved, 
small deteriorated, etc (415, 425). A weakness of the t-test is that it is highly 
dependent on the sample size included in the measure and thus its result only 
plays a supportive role in determining responsiveness. 
3.6.3.3 Correlation method 
The correlation between change scores is the preferred method of the COSMIN 
group for comparing changes in the test measure with changes in an anchor if the 
scores on the test measure and the anchor are both continuous (327). The 
correlation method provides a useful indication of the extent to which the change 
score of the anchor and test measure are associated; a stronger correlation 
typically means a stronger responsiveness of the test measure to the anchor (415). 
The correlation coefficient describes both the strength and direction of the 
relationship.  
There are two types of correlations: Pearson product moment correlation, and 
Spearman rank-order correlation, the choice of which is dependent on whether 
there is a linear relationship between the scores of the two measures. Pearson’s 
correlation coefficient is used when a linear relationship is demonstrated, 
typically by visual inspection in a scatter plot of the two variables or a more 
sophisticated regression method. In a regression between the two variables 
(regardless which one is the dependent or independent variable), a linear 
relationship is shown if the regression residuals (fitted value – observed value) are 
normally distributed and do not show skew (426). Two approaches are proposed 
to judge if the residuals are normally distributed: the kernel density plot, and the 
Chapter 3  102 
Shapiro-Wilk W test. The kernel density plot is plotted to allow a visual comparison 
of the distribution of the residuals against an overlaid normal distribution (427, 
428). The Shapiro-Wilk W test is performed for significance testing of the 
assumption that the distribution is normal (427, 429). When this linear relationship 
assumption does not meet, Spearman’s rank correlation coefficient should be used 
instead (430). Spearman’s rank correlation is a nonparametric measure of rank 
correlation, which is similar to the Pearson correlation but using the rank values 
of the scores of the measures. 
3.6.3.4 Regression methods 
Regression methods can be used to explore the relationship between the change 
of the anchor and the change of the test instrument after adjusting for potential 
confounders (415). It can identify the key determinants for the change in the test 
measure. When multiple anchors are used as independent variables to predict the 
test measure, the regression result should be able to aid the interpretation of the 
results from other aforementioned tests, such as why the test measure is more 
responsive to some anchors than the others. 
3.7 Chapter summary 
Both construct validity and responsiveness are crucially important for any 
measurement. This chapter provides an overview of psychometric properties of 
validity, reliability and responsiveness, discussed the definition and features of 
construct validity and responsiveness, summarized the methods through which 
they can be assessed, and critically discussed the challenges when applying classic 
psychometric testing methods to the assessment of PbQoL measures. These 
assessment methods will be used in Chapter 6 and 7 for the testing of construct 
validity and responsiveness of ICECAP-O in people with Parkinson’s. Prior to the 
case studies, the practical challenges and special considerations that were 
discussed in this chapter will be summarized in Chapter 5 Section 5.4, which 
provides justifications for the methods chosen and assumptions for the case 
studies. 
   
Chapter 4 A systematic review of the use of 
preference-based measures in Parkinson’s and 
assessment of their construct validity and 
responsiveness 
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4.1 Introduction 
Economic evaluation using the QALY framework relies on PbQoL measures. 
However, as described in Chapter 2 (Section 2.5), current PbQoL measures are 
often criticised for being insensitive or failing to capture important aspects of QoL 
in specific populations. In people with Parkinson’s, the patient group Parkinson’s 
UK have expressed their concerns on the use of EQ-5D as it may not be sufficient 
to capture the impact on QoL from all motor and over 40 types of non-motor 
symptoms of Parkinson’s (see quote on p19). These symptoms have a broad 
influence on patients’ physical, emotional and social wellbeing, and there is some 
evidence as summarized in Chapter 2 (Section 2.4) that generic PbQoL measures 
like EQ-5D with its five generic health-related dimensions may have limited ability 
to fully measure the broad impact of diseases on QoL and wellbeing (128, 431, 
432). For example, in schizophrenia, Mulhern et al. (2014) found that the 
responsiveness of EQ-5D and SF-6D was weak, as shown by a smaller than 0.2 SRM 
(below the clinically significant range) while the clinical measure of schizophrenia 
has large SRM (128). Jenkinson et al. (1997) compared SF-36 and EQ-5D-3L with 
condition specific measures in a RCT of transurethral resection of the prostate 
with laser vaporization prostatectomy for benign disease and found that although 
the condition specific measures showed statistically significant difference 
between the arms (which indicating the effectiveness of the intervention), the 
PbQoL measure, EQ-5D-3L failed to show any difference (431). The insensitivity of 
PbQoL measures often found in other disease areas raised a concern about 
whether they are sensitive enough to capture the broad impact of Parkinson’s. 
Imagine a situation when people with Parkinson’s are unable to control their limbs 
due to the involuntary movement, suffer from social isolation because of stigma 
and face the fact that their symptoms can only slowly get worse without a cure in 
the future. When there are new interventions available to improve these 
situations, is the population willing to trade some length of life for these 
improvements? If so, to what degree is the population willing to trade for each of 
these improvements? These questions require systematic valuation of the health 
aspects against risk of death or length of life, which have not been conducted yet 
(further discussion in Chapter 8 Section 8.6.2). However, an intuitive answer to 
these questions is yes, and yes to all of the three aspects of improvement because 
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the health aspects as well as wellbeing aspects are all highly prevalent in all 
Parkinson’s QoL questionnaires as shown in Chapter 1 (Section 1.5.2) indicating 
their importance to patients, clinicians and researchers.  
After determining the importance of those aspects, the next question is whether 
such important improvements in health and wellbeing are being adequately 
reflected in the PbQoL measures? In other words, to what degree can the existing 
generic PbQoL measures capture the comprehensive impact of Parkinson’s on 
people’s life? As discussed in Chapter 1, the consequence of underestimation of 
any important QoL aspects in the PbQoL measures is that the benefit of 
interventions targeting on such aspects would not be captured by the PbQoL 
measures and thereby the interventions may appear ineffective and have smaller 
QALY gains than they should have. This will result in the intervention appearing 
less cost-effective and impacting on funding decisions. This highlights a need to 
review and critically appraise the performance of the existing PbQoL measures 
including EQ-5D, in the Parkinson’s population. 
A brief scoping search of the literature identified two published reviews of QoL 
measures in Parkinson’s which assessed the use of several PBQoL measures (433, 
434), however both reviews are not specific to PBQoL measures hence insufficient 
to provide an overall critical assessment of the PBQoL measures. Martinez-Martin 
et al. (433) classified the generic and specific HrQoL scales to three groups 
(‘recommended,’ ‘suggested,’ or ‘listed’) by summarizing the existing evidence 
of psychometric properties from other studies. EQ-5D-3L and 15D were the only 
two PbQoL measures in their assessments; the former was assessed to be 
‘recommended’ and the latter was grouped to the ‘suggested’ category due to 
lack of validation studies. This study, however, did not assess the properties using 
a pre-defined methodology, instead, the recommendation was established upon 
reviewing the reported conclusions from the existing validation studies. Another 
study from Dodel et al. (434) reviewed approaches to evaluate cost of illness, cost 
effectiveness, and discussed the utility instruments in Parkinson’s. In this study, 
EQ-5D-3L, SF-6D, 15D, and HUI were compared upon six criteria of psychometric 
properties, which were adapted from two previous studies published in 2001 (435) 
and 2005 (436). Although the authors recommended the use of EQ-5D-3L and HUI 
over 15D and SF-6D along with the direct valuation method, a gap was identified 
in this study which necessities the assessment of psychometric testing of these 
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measures in Parkinson’s. In particular, it pointed out that the responsiveness of 
EQ-5D-3L required further validation and there was inadequate amount of 
validation evidence for HUI, SF-6D and 15D in Parkinson’s (434).  
As discussed in Chapter 3, psychometric properties are context-specific and 
psychometric testing is an iterative process, whereby evidence is gradually 
accumulated to lead to an increasing understanding of to what degree a measure 
is suitable for use in a certain population. The above reviews point towards a need 
to conduct a systematic review by collecting all existing evidence regarding the 
use of PbQoL measures in Parkinson’s and critically analysing the identified 
evidence to assess their psychometric properties. 
In addition to directly using a PbQoL instrument to measure preferences for 
economic evaluation, there is a growing trend of applying mapping algorithms to 
predict EQ-5D-3L utilities where a PbQoL measure is not used, as recommended 
by NICE. These mapping algorithms are generated through applying statistical 
methods to explore the relationships between a non-preference based measure 
and EQ-5D-3L using cross-sectional measurements of both. Accompanied with the 
increasing number of mapping studies are the growing voices to strengthen the 
methodological quality of these studies (see Section 2.6.1 for details). One factor 
affecting quality is the conceptual relationship between the measures on the two 
ends of the mapping algorithm. When mapping from dimensions of a non-
preference based measure to EQ-5D-3L, whether or not each of the dimensions 
was included or to what extent the inclusion of the individual dimensions is in the 
mapping algorithms can affect the weight of the individual dimensions in the EQ-
5D-3L. The answers to these questions are closely linked to the construct validity 
of a measure. Given this, there is a need to conduct an overview of the existing 
mapping studies to EQ-5D-3L in the Parkinson’s, critique their study quality and 
compare their results. 
This chapter will start by introducing the objectives of the systematic review and 
assessment methods of the PbQoL measures. The theoretical basis, definitions, 
assessment methods of the measurement criteria have been introduced in Chapter 
3. This is followed by describing how the search was conducted, eligibility criteria 
and data extraction for the methodological systematic review. Following this is 
the result section which contains search results, assessment results, a summary of 
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the identified economic evaluation studies and the mapping algorithms. A 
summary of results, discussion, and a summary of this chapter are provided at the 
end. Notably, given the methodologies used in this chapter and the case studies 
in Chapter 6 and 7 are similar, the strength and limitations are summarized 
altogether in Chapter 8. 
4.2 Objectives 
This systematic review has four objectives. They are: 
1) To describe the use of PbQoL measures in studies in the Parkinson’s 
population; 
2) To critically assess the construct validity and responsiveness of the 
identified PbQoL measures in Parkinson’s; 
3) To critique the use of PbQoL measures in the included economic evaluations 
of interventions in Parkinson’s; and 
4) To summarize the mapping studies from condition specific QoL measures to 
EQ-5D-3L in people with Parkinson’s identified in the literature search in 
terms of their data, methods, and the generated mapping algorithms. 
The first objective is to investigate how frequently each PbQoL measure was used 
in the literature in the Parkinson’s population, and summarize the purposes (study 
design, country, patient characteristics) that these measures were used for. 
Meanwhile, except for PbQoL measures, this study will also summarize the use of 
each Parkinson’s specific measure used in the included studies, to facilitate the 
second objective below (i.e. the assessment of the generic PbQoL measures).  
Through analysing the summary statistics provided in the included studies for both 
the PbQoL and another QoL measure, this chapter will also critically assess the 
construct validity and responsiveness of the identified PbQoL instruments in 
Parkinson’s. As mentioned in Chapter 3, these two properties are essential for 
PbQoL measures to provide accurate utility values associated with the benefit of 
interventions. As mentioned previously (Section 1.5.4, 3.1), NICE in its current 
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guideline for technology appraisal recommends investigating these two properties 
when determining the appropriateness of PbQoL measures (119). In particular, 
this chapter will assess (1) to what degree the PbQoL measures are able to 
differentiate between groups that are expected to differ, i.e. known-group 
construct validity (see 3.4.2.2 for details), (2) to what degree they are correlated 
with a measure with similar construct, i.e. convergent validity (see 3.4.2.3 for 
details) and (3) to what extent they are responsive to the ‘known’ changes that 
they are expected to detect, i.e. responsiveness (see 3.5 and 3.6 for details).  
The third objective is related to the assessment of responsiveness as above but 
putting this assessment in a real economic evaluation context. It will contrast the 
results from the Parkinson’s specific measures and the PbQoL measures, and 
discuss the implications of consistency or inconsistency between them.  
The last objective is to compare the mapping algorithms. As outlined in the 
introduction section above, mapping is a NICE recognised avenue to generate EQ-
5D-3L values. However the quality of these mapping studies varies, the original 
patient population where the mapping formula generated varies, and their 
resulting algorithms can vary accordingly, which necessities an overview of them.  
4.3 Methods 
4.3.1 Assessment criteria 
Construct validity and responsiveness of the PbQoL measures used in the included 
studies were assessed. Methods for this assessment through the format of 
systematic review were adapted from the empirical assessment methods 
introduced in depth in Chapter 3 (Section 3.4 and 3.6). These methods have also 
been commonly used in previous similar reviews that aiming to assess the 
appropriateness of PbQoL measures (21, 235, 246).  
For example, Longworth et al. (2014) conducted a systematic review of 
psychometric properties of three commonly used generic PbQoL measures, EQ-5D, 
SF-6D and HUI-3 in four broadly defined conditions: visual impairment, hearing 
impairment, cancer and skin conditions (235). They assessed the (a) known-group 
construct validity, i.e. the extent to which the measure can differentiate between 
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groups defined according to severity or between people with or without the 
condition, (b) convergent validity, i.e. the strength of correlation, and (c) 
responsiveness, i.e. the extent to which the change (size and statistical 
significance) shown on other measures has been observed in PbQoL measures, and 
vice versa, i.e. the extent to which the PbQoL measure shows no change when no 
change was shown on other measures (although they called this as ‘reliability’ in 
the original text). Similarly, an earlier study conducted by Papaioannou et al. 
(2011) (246) and a more recent study conducted by Yang et al. (2015) (21) also 
assessed known-group construct validity, convergent validity and responsiveness 
of PbQoL measures through systematic reviews; the former assessed EQ-5D and 
SF-6D in people with schizophrenia, and the latter assessed EQ-5D, HUI-3 and SF-
6D in patients with skin conditions. 
4.3.1.1 Reference measures 
Assessment of convergent validity and responsiveness requires at least one 
reference measure, or anchor measure. As introduced in Chapter 3, convergent 
validity was based on the expectations on the relationships between the PbQoL 
measure and the reference measure. When the reference measure has a very 
similar construct with the test measure, the relationship is expected to be highly 
correlated; when the reference measure is related but not with similar construct, 
then a high correlation is not expected. In addition, a reference measure is 
required in the examination of responsiveness to confirm the happening of change 
over time. In this context, the reference measure has to be condition specific 
which is assumed to be sensitive to the change in Parkinson’s patients. It could be 
another PbQoL measure (although in the Parkinson’s population, no CS-PBM is 
available), non-preference based QoL measure, or commonly used clinical 
measures in Parkinson’s.  
For the clinical measures, The UPDRS and H&Y are commonly used clinical 
measures in Parkinson’s to assess disease severity. The UPDRS assesses clinical 
status of Parkinson’s in four domains including, mood and cognition, ADL, motor 
symptoms severity, and complications of treatment (437). The H&Y describes 
progression of motor function in Parkinson’s population, ranging from stage I 
(mildest) to stage V (most severe) (438).  
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4.3.1.2 Construct validity 
As described in Chapter 3, construct validity represents the ability that an 
instrument measures the construct it is intended to measure (353, 439), and is 
typically assessed by the known-group method (Section 3.4.2.2)  and convergent 
validity (Section 3.4.2.3) (235, 260, 353, 440-442).  
The known-group method tests the extent to which a measure can discriminate 
between groups that are theoretically known to differ (353, 368). This review 
examined to what extent the index scores distinguished between patients with 
different characteristics of Parkinson’s, with the premise that the mean utilities 
of the different patient groups were expected to differ. The characteristics that 
were used to define the groups were examined prior to the performance of PbQoL 
measures to determine the expectations on the mean difference of the PbQoL 
scores. Good evidence of construct validity deemed to be demonstrated by a 
statistically significant difference (e.g., t test) of the mean utility values between 
the ‘known’ groups that were expected to differ.  
However, simply relying on statistical significance may bias the results given that 
sample size may have a great influence on the statistical significance; a large 
sample size may give statistical significance to very small effect, and a small 
sample size may fail to achieve statistical significance to a large effect. Therefore, 
when sample size is relatively small, appropriate size of difference with near 
significance was also considered as evidence for ‘known-group’ validity. In 
addition, as mentioned in Chapter 3 (Section 3.4.2.2), another issue is regarding 
the use of a non-preference based measure as reference measure to test the 
construct validity of a preference-based measure (118). Assumptions have to be 
made when assessing the PbQoL measures regarding people’s preferences in the 
groups defined by the reference measures in that their preference for the two 
state has to be different, i.e. patients would trade different amount of their 
length of life for the two states. This assumption regarding people’s preferences 
have to be made for the assessment of convergent validity and responsiveness as 
well. 
Convergent validation examines the extent to which one measure correlates with 
another measure of the same or similar construct (see Section 3.4.2.3 for details) 
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(324, 353, 368, 440). If the PbQoL measure is highly correlated (correlation 
coefficient (r) ≥0.5) with a reference measure of similar concept then convergent 
validity is determined to be adequate. A moderate correlation (0.3 < r < 0.5) is 
expected if the PbQoL and the reference measure are convergent to some degree 
but not strongly. As mentioned in the ‘reference measure’ section, when the 
reference measure is not a similar concept as the test measure, a high correlation 
(r ≥ 0.5) is not expected as the PbQoL and the reference measure are designed to 
measure different concepts and this would not treat as negative evidence for the 
performance of PbQoL measures. 
4.3.1.3 Responsiveness 
Responsiveness is the ability of an instrument to accurately detect a ‘known’ 
change on its construct over a longitudinal time period (443, 444). This study 
examined the extent to which PbQoL measures were able to detect changes in 
some characteristics over time as confirmed by clinical measures or Parkinson’s-
specific QoL measures, i.e. reference measures. The change could be due to the 
health intervention or natural progression of Parkinson’s.  
As with the known-group method, responsiveness is determined to be adequate 
when the change/difference between the baseline and follow-up time point is 
statistically significant different or nearly statistically significant, if the happening 
of the change is confirmed by a reference measure of similar construct, or when 
the change on the reference measure is expected to associate with a change in 
the test measure. Similarly, when the reference measure shows no change, and 
no change led by other factors is expected to happen on the test measure, 
responsiveness of the PbQoL measure is determined adequate if no change 
happening on the PbQoL measure as well.  
In addition, correlations between the change scores of the PbQoL instrument and 
the reference measures were also examined when they were reported in the study. 
The correlation method was another recognised method to assess responsiveness 
(327, 415), which was introduced in Chapter 3 Section 3.6.3.3. As with convergent 
validity, a moderate to high correlation coefficient was expected when the 
reference measure was with similar construct with the PbQoL measure (e.g. both 
are HrQoL measures, or both are wellbeing measures). When the PbQoL and the 
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reference measure were with dissimilar construct, e.g. a clinical measure and a 
QoL measure, a small correlation was acceptable. 
It is worth noting that although the assessment methods of responsiveness used in 
this systematic review were adapted from the methods introduced in Chapter 3 
(Section 3.6), there are some differences between them. Firstly, the methods in 
Chapter 3 are for empirical validation studies which are applied on actual 
individual patient data, while the method used in this chapter using secondary 
summary statistics reported from the literature. Secondly, the main statistics for 
testing responsiveness are the effect size statistics which may not be reported in 
every study included in this review; it may be that only studies that are designed 
for the purpose of assessment of responsiveness would report these statistics. 
Therefore, this review did not use this as the main method for the assessment 
based on the secondary data.  
4.3.2 Databases and search strategy 
PbQoL measure is the outcome of health economic research as an interdisciplinary 
science that is established on both the theory of economics and health 
measurement. Therefore, use of multiple databases across social science and 
health science to search for literatures relevant to PbQoL measures would benefit 
maximizing the number of relevant results. Due to the differences in coverage of 
journals and search systems, more than one database was searched for literature 
in the area of biomedical science and social science.  
In total, nine databases were searched to identify studies that used at least one 
PbQoL instrument to measure preferences in people with Parkinson’s. The 
databases were: biomedical databases including MEDLINE (Ovid and Pubmed)) and 
EMBASE (Ovid), nursing database CINAHL, behavioural and psychology database 
PsycINFO, Social science databases including Applied social sciences Index and 
Abstracts (ASSIA) and Social service abstracts (SSA) (ProQuest), AgeInfo, Database 
of Abstracts of Reviews of Effects (DARE), and NHS Economic Evaluation database 
(NHS EED). These databases are briefly introduced in the following paragraphs. In 
addition, the aforementioned (Section 2.6.1) database of mapping studies 
developed by the Health Economics Research Centre at University of Oxford 
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(Database version 5.0, based on search conducted in April 2016) (285) was also 
checked for mapping studies that were not identified in the primary search. 
Pubmed and MEDLINE (Ovid) both provide access to the database MEDLINE. 
MEDLINE (1946 – present) provides more than 15 million articles published in more 
than 5600 biomedical periodicals (445). EMBASE (1947 – present) covers the same 
subjects as MEDLINE with an additional focus on drugs and pharmacology, medical 
devices, clinical medicine, and basic science relevant to clinical medicine (446). 
EMBASE includes all of MEDLINE’s citations plus 2,500 journals not currently 
indexed in MEDLINE (446). CINAHL (1937 – present) contains 5400 journals which 
covers health science in a broader sense including nursing science, paramedical 
science, education, behavioural science, and health administration (445). Search 
in MEDLINE, EMBASE and CINAHL was expected to identify original intervention 
studies or health determinant studies that used PbQoL measures. 
PsycINFO (1967 – present) specializes in behavioural science and social science, 
produced by the American Psychological Association (447). ASSIA (1987 – present) 
contains records from over 500 journals in social science and health from the 
practical and academic perspective (448) and SSA focuses on social work, social 
welfare, social and health policy and community development (449). Through 
PsycINFO, ASSIA, and SSA, it was expected to identify the additional psychometric 
literature regarding the PbQoL measures and the use of PbQoL measures in social 
care interventions that were not covered by the above major biomedical 
databases. Parkinson’s mostly affects elderly people and hence Ageinfo was 
searched which focuses on social gerontology. In addition, two HTA focused 
databases produced by the NIHR center for Reviews and Dissemination (CRD) at 
the University of YORK, DARE (1994- March 2015) and NHS EED (1968 - March 2015), 
were searched to identify relevant systematic reviews and economic evaluations 
(450).  
A search strategy was developed together with an expert information scientist 
from University of Glasgow library to maximize the chance of retrieving potential 
relevant studies. Search filters (pre-tested strategies) for economic study 
developed by the Scottish Intercollegiate Guidelines Network (SIGN) were 
reviewed and discreetly selected to aid the development of search strategies for 
the aim of this study (451). It was developed initially in MEDLINE (Ovid) and 
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adapted for other databases (Appendix A). Databases were searched from 
inception until November 2013 and the search was updated in July 2015. The 
database of mapping studies was checked in March 2017. 
4.3.3 Eligibility criteria and data extraction 
Studies were included when meeting the following criteria: 
• a PbQoL instrument was used to measure preferences in people with 
Parkinson’s; and 
• sufficient data were provided to allow the assessment of construct validity 
and/or responsiveness (the details are provided as follows).  
Studies that were eligible for the assessment of convergent validity and 
responsiveness must also contain a reference measure. Besides, for the 
assessment of ‘known-group’ validity, at least two groups of patients that were 
differed in their characteristics had to be available, divided based on the score of 
the reference measure. PbQoL measure index scores had to be available for those 
groups. For convergent validity, correlation coefficients should be reported 
between the PbQoL measure and the reference measure. For responsiveness, at 
least two measurements or difference over a period of time (e.g., baseline and 
primary end point) of both PbQoL measure and the reference measure should be 
reported.  
There was no limit on study types so both RCTs and observational studies were 
included. Conference abstracts were excluded as they are usually not peer-
reviewed and thus difficult to judge validity of the results. All results were limited 
to English. In addition, mapping studies from non-preference based measures to 
preference-based measures in Parkinson’s were also included. 
Studies were excluded if the population being measured were patients without a 
confirmed diagnosis of Parkinson’s; the utilities of patients were not measured, 
measured but not reported, not appropriately presented (e.g., EQ-5D index value 
not on a ‘0 (death) -1 (full health)’ scale), or not adequately presented for the 
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assessment purpose; or a full result published later covering the shorter time 
period result in earlier papers.  
After two-step screening based on title & abstract and full-text, included studies 
were reviewed and study characteristics were extracted. They contained: first 
author and publication year, country, study type, number of participants, clinical 
characteristics, and length of follow-up (when applicable). For the purpose of 
assessing psychometric properties, study objectives, methods, the measures used, 
and their scores were also extracted. The characteristics of the mapping studies 
were also extracted to enable the critique, including: author, year, country, the 
QoL instruments involved (i.e., the condition specific measure to map from and 
the generic PbQoL measure to map to), sample size for the estimation of the 
algorithm and validation of the algorithm, the mapping model(s) used, measure 
of model performance, and the final mapping algorithm. 
4.4 Results 
4.4.1 Search results 
A total of 2,758 records were retrieved after removing duplicates. The number of 
records identified from each database is presented in Appendix A. Titles and 
abstracts were initially screened based on eligibility criteria and 2,536 records 
were excluded. Full text of the remaining 222 studies was further screened from 
which 22 studies were included in this review for the assessment of construct 
validity and responsiveness, and five studies were included for the review of 
mapping.  A flowchart of the screening process with the reasons for exclusion in 
the full-text screening stage is shown in Figure 4-1.  
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Figure 4-1: Flowchart of study screening process 
 
Included studies were classified into three groups based on their study type for 
the assessment: Group A: cross-sectional studies (250, 452-459) for assessing 
‘known-group’ and convergent validity (n = 9); Group B: longitudinal studies (251, 
460-471) for assessing responsiveness (n = 13); Group C: mapping studies (472-476) 
(n = 5). 
Among the included studies, one focused on people with early Parkinson’s (465), 
three focused on advanced Parkinson’s (466, 468, 471), and the remaining studies 
covered a wide range of severity levels. Among the cross-sectional studies, five 
explored the relationship between QoL and specific symptoms of Parkinson’s, 
including apathy (452), depression (454, 458), life stress (454), presence of 
Database search after 
removing duplicates 
n = 2,758 
Full text screened 
n = 222 
Studies excluded (n = 195): 
Reasons: 
• Economic modelling with utility data from other sources 
(n=48) 
• Reviews, methodology, protocol (n = 43) 
• Cost study (n=16) 
• Measured QoL but did not value (n=23) 
• Updated paper existed (n=13) 
• Measured utilities but did not report (n=13) 
• Measured utilities of carers of PwP rather than PwP (n=5) 
• Diagnosis of Parkinson’s was not confirmed in the patient 
group (n=3) 
• Insufficient data to assess psychometric properties 
(n=31) 
Studies excluded  
(title and abstract screening)  
n = 2,536 
Included (n=27): 
• Cross-sectional studies (n=9) 
• Longitudinal studies (n = 13) 
• Mapping studies (n=5) 
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dyskinesia (250), presence of ‘wearing off’ period of drugs (250), sweating 
dysfunction (459). The remaining studies examined the association between QoL 
and more general Parkinson’s status, as measured by H&Y stages (453), MDS-
UPDRS domains (455), SCOPA-AUT for automatic dysfunction (457), and the 
presence of Parkinson’s in general (456). 
Among the longitudinal studies, there were seven RCTs (460, 462, 463, 465, 466, 
468, 470), five prospective self-comparison studies (251, 461, 464, 469), and one 
cohort study (467). Two studies measured patients’ natural progression over a 
period (251, 464) and the remaining eleven studies evaluated the effect of an 
intervention. The interventions included: drugs (461, 465, 466, 468), provision of 
community-based nurse specialists (462), provision of instructions of clinical 
guidelines to neurologists (463), standardised pharmaceutical care (467), 
adherent therapy (460), deep brain stimulation surgery (471), and 
multidisciplinary rehabilitation (469, 470). Among the intervention studies, three 
studies conducted CUA (465, 466, 471) and one study conducted cost-consequence 
analysis (470). 
EQ-5D (3L & 5L) was the most commonly used PbQoL instrument, which was 
reported in 19 studies (250, 251, 434, 452, 453, 457-465, 467-471). Meanwhile, 
HUI-3 was reported in two studies (454, 456), HUI-2 in one (458), 15D in two (453, 
466), and the Disability and distress index (DDI) (often referred to as the Rosser 
Index) in one (458). EQ-5D, HUI-3 and HUI-2 have been introduced in 2.4.3.2 in 
Chapter 2. The DDI, developed by Rosser and colleagues in 1970s, is comprised of 
eight levels of disability (loss of function and mobility) and four levels of 
subjective distress, describing 29 disability/distress states (264, 477). One single 
index score is available for each state, which is generated through a valuation 
process using ranking and relative magnitude of severity exercise (478). The 15D 
is a less commonly used instrument developed in Finland (60). It was chosen in the 
Norwegian and Swedish studies due to its wider spectrum aspects of QoL, higher 
sensitivity with five levels on each attribute and availability of value sets in the 
specific country where the study was conducted (479, 480).  
Among the non-preference based QoL measures identified as reference measures 
for the assessment of psychometric properties, the PDQ-39 was the most widely 
used Parkinson’s-specific QoL measure, reported in 9 studies (251, 458-460, 462, 
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463, 466, 470, 471), followed by the short version of the PDQ-39, the PDQ-8 in 5 
studies (250, 453, 455, 464, 467), the PDQUALIF in one study (465), the PDQL (251) 
in one, and the generic QoL instrument, the SF-36 in one (470). The measures used 
in each of the included studies are presented in Table 4-1. The characteristics of 
all the identified QoL (including both Parkinson’s specific and generic PbQoL 
measures) in the included studies are summarized in Table 4-2.  
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Table 4-1: Measures used in the included studies 
Study PbQoL instruments  Non-preference based QoL instruments   Common clinical measures  
EQ-5Dc EQ-VAS HUI-3 HUI-2 15D DDI  PDQ-39 PDQ-8 PDQUALIF SF-36 PDQL  UPDRS H&Y 
Studies for assessment of ‘known-group’ and convergent validity (n=9)          
Benito-Leon et al. 2012 (452)   
           
  
Garcia-Gordillo et al. 2013 
(453) b               
Jones et al. 2009 (454)                
Luo et al. 2009 (250)                
Martinez-Martin et al. 2014 
(455)              a  
Pohar et al. 2009 (456)                
Rodriguez-Blazquez et al. 
2010 (457)                
Siderowf et al. 2002 (458)                
Swinn et al. 2003 (459)                
Studies for assessment of responsiveness (n=13)            
Daley et al. 2014 (460)                
Ebersbach et al. 2010 (461)                
Jarman et al. 2002 (462)                
Larisch et al. 2011(463)                
Luo et al. 2010 (464)                
Noyes et al. 2006 (465, 481)                
Nyholm et al. 2005 (466)                
Reuther et al. 2007 (251)                
Schröder et al. 2012 (467)                
Stocchi et al. 2011 (468)                
Trend et al. (469)                
Wade et al. 2003 (470)                
Zhu et al. 2014 (471)                
EQ-VAS EuroQol Visual Analogue Scale, HUI-3 Health Utilities Index – Mark 3, HUI-2 Health Utilities Index – Mark 2,  15D 15 Dimensions, DDI Disability and Distress Index, PDQ-39 
Parkinson’s Disease Questionnaire-39-item, PDQ-8 Parkinson’s Disease Questionnaire-8-item, PDQUALIF Parkinson’s Disease QUAlity of LIFe scale, SF-36 Short-Form 36-item, PDQL 
Parkinson’s Disease Quality of Life questionnaire, H&Y Hoehn and Yahr scale, UPDRS Unified Parkinson's Disease Rating Scale 
a
 Movement disorder society - UPDRS 
b
 EQ-5D-5L 
c refers to EQ-5D-3L if no other notation. 
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Table 4-2: Characteristics of the health-related QoL instruments in the 
included studies 
Name 
Generic or 
Parkinson
’s specific 
Possible score range (UK 
value) Dimensions (D) / attributes 
PbQoL measures  
EuroQoL EQ-
5D-3L (14) Generic 
-0.594 (worst) ~ 1 (full 
health) 
5D: mobility, self-care, usual activities, 
pain/discomfort, and 
anxiety/depression 
HUI-2 
(Health Utilities 
Index – Mark 2) 
(482) 
Generic -0.03 (worst) ~ 1 (full health) 6D: sensation, mobility, emotion, 
cognition, self-care, and pain 
HUI-3 
(Health Utilities 
index – Mark 3) 
(483) 
Generic -0.36 (worst) ~ 1 (full health) 
8D: vision, hearing, speech, 
ambulation, dexterity, emotion, 
cognition, and pain 
15D (15 
Dimensions) 
(60) 
Generic 0 (being dead) ~ 1 (full health) 
15D: mobility, vision, hearing, 
breathing, sleeping, eating, speech, 
elimination (bladder and bowel 
function), usual activities, mental 
function, discomfort and symptoms, 
depression, distress, vitality, and 
sexual activity. 
DDI (Disability 
and distress 
index, or Rosser 
Index) (477) 
Generic −1.486 (worst) ~ 1.0 (full health) 2D: disability and distress 
Non-preference based QoL measures 
SF-36 (Short-
Form 36-item) 
(211) 
Generic 
Physical summary: 0 (worst) 
~ 400 (full health) 
Mental summary: 0 (worst) ~ 
400 (full health) 
8D: physical functioning, role physical, 
bodily pain, general health 
perceptions, vitality, role emotional, 
social role functioning, and mental 
health 
PDQ-39/8 
(Parkinson’s 
Disease 
Questionnaire -
39/8-item) (131) 
Specific 0 (best) -100 (worst) 
8D: mobility, ADL, emotions, stigma, 
social support, cognition, 
communication, and bodily discomfort 
PDQUALIF 
(Parkinson’s 
Disease QUAlity 
of LIFe scale) 
(132) 
Specific 0 (best) -100 (worst) 
7D: social/ role function, self-image/ 
sexuality/sleep, outlook, physical 
function, independence, urinary 
function and one global health-related 
quality of life item 
PDQL  
(Parkinson’s 
Disease Quality 
of Life 
questionnaire) 
(133) 
Specific 37 (worst) -185 (best) 
4D: Parkinsonian symptoms, systemic 
symptoms, emotional functioning, and 
social functioning 
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4.4.2 Assessment of the construct validity and responsiveness 
The assessment relied on the expectations of the relationship between the PbQoL 
instrument and the group defining criteria, or between the PbQoL instrument and 
the reference measure. Given this, in addition to describe what was reported in 
each of the included studies for each assessment, the results section also provides 
the explanations of the expectations and whether the results of PbQoL instrument 
met the expectations. The degree to which the result of PbQoL measure met the 
expectations are marked in the tables as ‘assessment result’. 
4.4.2.1 Known-group validity 
Four studies provided sufficient evidence (i.e. reference measure available, 
groups that differed in characteristics are defined, PbQoL scores for each group 
available, see Section 4.3.3 for details) for the assessment of the known-group 
validity of the EQ-5D-3L (250, 452, 458, 459), two studies for the HUI-3 (454, 456), 
one study for the EQ-5D-5L and 15D (453), and one study for the DDI and HUI-II 
(458). The characteristics of these studies are shown in Table 4-3 along with the 
assessment results.  
EQ-5D-3L index scores achieved statistically significant differences between the 
groups defined by the presence of apathy ('with' vs. 'without': 0.64 (0.26) vs. 0.83 
(SD 0.17), p=0.001) (452), and in a case-control design comparing people with 
Parkinson’s with sweating disturbances’ and healthy controls (459). These results 
were expected given there were large differences between the groups shown in 
the reference measure. The study investigating apathy showed that there were 
large differences between the groups ('with' vs. 'without') in terms of the UPDRS 
motor score (p<0.001), disability and disease severity, as such the EQ-5D-3L was 
expected to be distinguishing between the groups. The other study was a case-
healthy control design, which determined that there must be large difference in 
utilities between the groups given the large impact on QoL by the disease of 
Parkinson’s as introduced in Chapter 1 (Section 1.2.3). 
Inconsistent results were found for groups defined by the presence of dyskinesia 
(‘with’ or ‘without’) and the presence of 'wearing off' periods (‘with’ or ‘without’) 
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(250, 458). Statistically significant differences for both were shown in one study 
which reported a 0.28 difference of EQ-5D-3L between groups defined by 
dyskinesia (p=0.009), and 0.18 difference between groups defined by ‘wearing off’ 
(p<0.0001) (250). In contrast, the differences detected in the study by Siderowf 
et al. were not statistically significant: 0.09 (p= 0.43) for dyskinesia  and 0.14 (p= 
0.29) for the ‘wearing off’ period (458). The Siderowf study did not identify any 
difference in HUI-2 and DDI for the above groups either. The inconsistent result 
may be due to the smaller sample size in Siderowf study, but a closer investigation 
of the literature lowered the expectations on the strength of the relationship as 
well. Other literature also failed to reach consistent conclusions regarding the QoL 
and these two characteristics: Pechevis et al. (2005) found dyskinesia substantially 
affect patients’ QoL measured by SF-36 and PDQL (484), while Schrage and Quinn 
did not find any difference between patients with / without motor fluctuations, 
or with/without dyskinesias, measured by PDQ-39 (79).   
Moreover, Siderowf et al. (458) found a limitation in EQ-5D-3L and HUI-2’s ability 
but not DDI to differentiate groups with mild Parkinson’s defined by total UPDRS 
score. It showed that all of the three measures could differentiate between groups 
with upper (severe) and lower (mild) halves of UPDRS score (p < 0.001) and 
between first (mildest) and fourth (most severe) quartiles (p < 0.001); however, 
no difference was found in the EQ-5D-3L and HUI-2 between groups with first and 
second quartiles of UPDRS scores (mean difference = -0.009, p = 0.88 for EQ-5D-
3L; mean difference=-0.008, p = 0.85 for HUI-2) whereas a statistically significant 
difference was shown in the DDI (p = 0.03). This should be considered as negative 
evidence for the ‘known-group’ validity of EQ-5D-3L and HUI-2 since the UPDRS 
were with high correlations with EQ-5D-3L (r=-0.61) and HUI-2 (-0.59), therefore 
their relationship was expected to be strong (this is reported in the Section 4.4.2.2 
result of convergent validity). 
In the same study, all three measures were found to be sensitive to symptoms 
including falling, freezing, visual hallucinations and depression with a statistically 
significant unadjusted mean difference between groups divided based on these 
symptoms (p < 0.05), although HUI-2 did not show difference between groups with 
and without swallowing difficulty (p = 0.20) (458).  
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For the HUI-3, both studies showed a statistical significant difference between the 
groups, with relative large magnitude of difference (454, 456). This was as 
expected given the known groups in these two studies were characterised by the 
aspects that have been known to affect QoL in a large way. The first study was a 
case-control study, which demonstrated a large difference between people with 
Parkinson’s and the general population, with the HUI-3 score being 0.56 (95% CI 
0.48, 0.63) and 0.87 (95% CI 0.87, 0.88) respectively (456). Besides the presence 
of Parkinson’s, their QoL was expected to differ given there was a 20 years age 
difference between the groups as well as the difference in their number of 
medical conditions. The other study, by Jones et al. (2009), divided the 
Parkinson’s patients by whether or not they had depression, and they reported 
that the HUI-3 values for those who had depression was 0.20 (95% CI 0.03, 0.37) 
and those who did not have depression was 0.49 (95% CI 0.39, 0.59); the difference 
was statistically significant after adjusting for several confounders such as age, 
sex, duration of Parkinson’s etc (454). This study also evaluated the impact of life 
stress on HUI-3 utility values and identified statistically significant adjusted mean 
difference between not at all/not very stressful and quite a bit/extremely 
stressful (adjusted mean difference 0.19 (p < 0.05)), but no difference found 
between a bit stressful and quite a bit/extremely stressful groups (0.14, p < 0.05) 
(454). 
One study reported EQ-5D-5L and 15D values for groups with varied severity of 
Parkinson’s stratified with H&Y (stage 1&2 vs. stage 3&4) and found the mean 
values were statistically significantly different between the defined groups for 
both groups (453). This was also as expected given numerous evidence has shown 
that patients with advanced Parkinson’s (usually H&Y stage equal or larger than 
2.5) had substantially decreased QoL compared with the patients with early stages 
of Parkinson’s (H&Y stage equal of less than 2). 
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Table 4-3: Characteristics of included studies – assessment of ‘known-group’ validity (n=7) 
Study  Year Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study 
type 
Group define 
criteria(C) and 
groups (G) 
Evidence for ‘known-group’ validity: mean (standard 
deviation) 
Asses
sment 
resultb 
Stage of 
Parkinson
’s (Early 
or 
Advanced 
Other 
characteristic
s 
Reference measurea Preference-based measure 
Benito-
Leon  et al. 
(452) 
2012 Spain 557 Both 
Recently 
diagnosed with 
Parkinson’s, 
duration <2 
yrs, age ≥ 30 
Cross-
sectional 
C: presence of apathy 
defined as Lille 
Apathy Rating Scale. 
G1: Noapathetic; 
G2: Apathetic 
UPDRS motor; 
G1: 17.1 (8.5); 
G2: 24.8 (11.3); 
p < 0.001. 
H&Y; 
Higher proportion of early 
stages in G1; p < 0.001 
EQ-5D-3L; 
G1: 0.83 (0.17); 
G2: 0.64 (0.26); p < 0.001. 
All attributes of EQ-5D-3L 
showed sig 
 
Garcia-
Gordillo et 
al. (453) 
2013 Spain 133 Both 
Able to answer 
questions 
independently, 
age > 18 
Cross-
sectional 
C: H&Y. 
G1: H&Y stages 1-2; 
G2: H&Y stages 3-4 
PDQ-8; 
G1: 18.30 (11.83); 
G2: 31.58 (19.56); 
p < 0.001 
EQ-5D-5L; 
G1: 0.70 (0.18); 
G2: 0.53 (0.28); 
p < 0.001. 
15D; 
G1: 0.81 (0.10); 
G2: 0.70 (0.17); 
p = 0.001 
 
Jones et 
al. (454) 2009 Canada 259 Both 
Self-reported 
Parkinson’s in 
a Canadian 
Community 
Health Survey 
Cross-
sectional 
C: depression. 
G1/G2: without/with 
depression. 
C: life stress. 
G1’/G2’/G3’: not at 
all/ a bit/extremely 
stressful 
NA 
HUI-3; 
G1: 0.49 (95% CI 0.39, 0.59); 
G2: 0.20 (95% CI 0.03, 0.37); 
p (G1 vs. G2) < 0.05. 
G1’: 0.42 (95% CI 0.29, 0.55); 
G2’: 0.38 (95% CI 0.24, 0.51); 
G3’: 0.23 (95% CI 0.10, 0.36); 
p (G1’ vs. G3’) <0.05; 
p (G2’ vs. G3’) >0.05 
o 
Luo et al. 
(250) 2009 
Singapor
e 
135 Both 
Without severe 
disabilities, 
Chinese 
MMSE score > 
20 
Cross-
sectional 
C: presence of 
dyskinesia. 
G1: no dyskinesia; 
G2: with dyskinesia. 
C: presence of 
‘wearing off’ periods. 
G1’: no ‘wearing off’; 
G2’: with ‘wearing off’ 
NA 
EQ-5D-3L; 
G1C: 0.80 (0.65, 1.0) 
G2C: 0.52 (0.52, 0.73) 
p (G1 vs. G2) < 0.01. 
G1’C: 0.80 (0.71, 1.0); 
G2’C: 0.62 (0.52, 0.78); 
 
p (G1’ vs. G2’) < 0.0001 
 
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Study  Year Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study 
type 
Group define 
criteria(C) and 
groups (G) 
Evidence for ‘known-group’ validity: mean (standard 
deviation) 
Asses
sment 
resultb 
Stage of 
Parkinson
’s (Early 
or 
Advanced 
Other 
characteristic
s 
Reference measurea Preference-based measure 
Pohar et 
al. (456) 2009 Canada 261 Both 
- Data from 
Canadian 
Community 
Health Survey 
Cross-
sectional, 
case-
control 
 
C: presence of 
Parkinson’s. 
G1: With Parkinson’s; 
G2: general 
population 
Age; 
G1: 68.9 (95% CI 66.6, 
71.2); 
G2: 44.8 (95% CI 44.8, 
44.9); 
p < 0.05. 
No. of  
medical conditions; 
G1: 3.0 (95% CI 2.5, 3.4); 
G2: 1.5 (95% CI 1.5, 1.5); 
p < 0.05 
HUI3; 
G1: 0.56 (95% CI 0.48, 0.63); 
G2: 0.87 (95% CI 0.87, 0.88); 
p < 0.05 
 
Siderowf et 
al. (458) 2002 US 97 Both 
Without 
cognitive 
impairment 
Cross-
sectional 
C: total UPDRS 
score. 
G1 and G1’: upper 
and lower halves; 
G2 and G2’: 1st and 
2nd quartiles; 
G3 and G3’: 1st and 
4th quartiles. 
C: depression. 
G4 and G4’: with and 
without depression; 
and a various motor & 
non-motor symptoms 
NA 
EQ-5D-3L; 
Diff (G1vs.G1’):0.24; p < 0.001; 
Diff (G2vs.G2’):-0.009;p = 0.88; 
Diff (G3vs.G3’):0.40;p < 0.001; 
Diff (G4vs.G4’):0.26;p < 0.001. 
DDI; 
Diff (G1vs.G1’):0.09;p = 0.007; 
Diff (G2vs.G2’):0.01;p = 0.03; 
Diff (G3vs.G3’):0.17;p = 0.02; 
Diff (G4vs.G4’):0.17;p < 0.001. 
HUI-II; 
Diff (G1vs.G1’): 0.15;p = 0.001; 
Diff (G2vs.G2’):-0.008;p = 0.85; 
Diff (G3vs.G3’):0.25;p = 0.001; 
Diff (G4vs.G4’):0.17;p < 0.001. 
o 
Swinn et 
al. (459) 2003 UK 77 Both 
Patients with 
sweating 
disturbances, 
without 
marked 
cognitive 
impairment or 
confusion 
Cross-
sectional, 
case-
control 
Case-control. 
G1: PwP with 
sweating 
disturbances; 
G2: healthy controls 
PDQ-39; 
G1: 41.7 (19.5); 
G2: NA 
EQ-5D-3L; 
G1: 0.47; 
G2: 0.85; 
p < 0.005 
 
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a. Reference measure could be either another PbQoL measure, Parkinson’s-specific QoL measure, or (if the former two not available) clinical measures. 
b. Assessment result for discriminant validity: ‘’ evidence available to demonstrate that the PbQoL measure was able to show statistically significant difference between the known 
groups that were expected to differ as shown by the reference measure; ‘o’ some evidence available but still uncertain whether PbQoL measure can show statistically significant 
difference between the known groups that were expected to differ; ‘’ – evidence showing the PbQoL measure failed to differentiate between the known groups. 
c. median (inter-quantile). 
Abbreviations: MMSE - Mini-Mental State Examination, H&Y Hoehn & Yahr scale, HAD Hospital Anxiety and Depression Scale, SCOPA-Motor Scales for Outcomes in Parkinson’s 
disease – Motor examination, UPDRS Unified Parkinson's Disease Rating Scale, Diff mean difference between groups, sig statistically significance, C criteria, G group, NA not available, 
PwP people with Parkinson’s. 
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4.4.2.2 Convergent validity 
Five studies reported correlation coefficients between a PbQoL measure and a 
reference measure for the assessment of convergent validity (250, 453, 455, 457, 
458). Among them, three studies examined the correlation between EQ-5D-3L and 
other measures (250, 455, 457), whereas two studies examined multiple PbQoL 
measures (one for EQ-5D-3L and 15D (453), another for EQ-5D-3L, DDI and HUI-II 
(458)) in regards to their correlation with other measures. The characteristics of 
these studies are shown in Table 4-4 accompanied by the evidence for assessment 
and the assessment result. 
The EQ-5D-3L score showed strong correlation with (in the order of correlation 
coefficient from strongest to weakest) the PDQ-8 summary score (r = -0.75) (250), 
Movement disorder society – UPDRS (MDS-UPDRS) motor score (r = -0.72) (455), 
MDS-UPDRS non-motor score (r = -0.63) (455), UPDRS total score (r = -0.61) (458), 
and Non-Motor Symptoms Scale (NMSS) score (r=-0.57). It showed moderate to 
strong correlation with H&Y staging (r = -0.32 (250), r = -0.53 (455)), and moderate 
correlation with the Scales for Outcomes in Parkinson’s disease – Autonomic 
(SCOPA-AUT) (r = -0.49) (457) and UPDRS motor score (r = -0.39) (250).  
The above results met expectations to some degree. EQ-5D-3L was expected to 
show the strongest correlation with the Parkinson’s disease QoL measure, PDQ-8. 
However, the correlation with the UPDRS motor score was unstable: 0.72 with 
MDS-UPDRS motor score, which was halved in another study with UPDRS motor 
score, given the similarity between the UPDRS and MDS-UPDRS scale (which was 
adapted from UPDRS scale). 
Two studies compared multiple PbQoL measures in terms of their correlations with 
Parkinson’s-specific QoL measures, and the results were mixed (453, 458). Garcia-
Gordillo et al. (453) found that the correlation between the 15D and the PDQ-8 
summary score were stronger than that between the EQ-5D-5L and PDQ-8 summary 
score, with coefficients being -0.710 and -0.679, respectively. The authors 
explained that this could be due to the broad attributes of 15D such as leisure 
activities, housework, communication, worries about the future, which were 
likely to be substantially affected by Parkinson’s (453). As with the authors, this 
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result was expected given both 15D and the PDQ questionnaire contains broadly 
scoped dimensions (Table 4-2) (60) (131). Siderowf et al. (458) compared DDI, EQ-
5D-3L, and HUI-II and found that the utility score from EQ-5D-3L correlated most 
strongly with PDQ-39 while DDI showed the weakest correlation. Regarding the 
specific PDQ-39 dimensions, they found that the EQ-5D-3L correlated most 
strongly with the ADL attribute (r = -0.69) and weakly with social support (r = -
0.27), HUI-II correlated most strongly with mobility (r = -0.62) and weakest with 
stigma (r = -0.12), and DDI correlated most strongly with mobility and ADL (r = -
0.42 for both) and weakest with stigma (r = 0.067) (458). These results also met 
expectations given the three PbQoL measures all have a focus on daily functioning, 
rather than psychological and social wellbeing, as shown in the coverage of their 
dimensions summarized in Table 4-2. 
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Table 4-4: Characteristics of included studies – assessment of convergent validity (n=5) 
Study 
Pub
licat
ion 
year 
Country 
 
No. of 
particip
ants 
Study eligibility criteria 
Study type 
PbQoL 
measure
(s) 
Evidence for convergent validity 
Assessment 
resultb 
Stage of 
Parkinson’
s (Early or 
Advanced 
Other clinical 
characteristics 
Reference 
measure a 
Correlation coefficients (r) 
Garci-
Gordillo et 
al. (453) 
201
3 Spain 133 Both 
Be able to answer 
questions 
independently, 
age > 18 
Cross-sectional 
EQ-5D-
5L, 
15D 
PDQ-8 15D/PDQ-8: -0.710. EQ-5D-5L/PDQ-8: -0.679  
Luo et al. 
(250) 
200
9 Singapore 31 Both 
Well enough to 
complete surveys 
Before and after 
self-comparison, 
4 yrs 
EQ-5D-
3L 
PDQ-8 SI, 
H&Y, 
UPDRS motor 
EQ-5D-3L/PDQ-8: -0.75. 
EQ-5D-3L/H&Y: -0.32. 
EQ-5D-3L/UPDRS motor:-0.39 
 
Martinez-
Martin et 
al. (455) 
201
4 
Argentina, 
Cuba, 
Mexico, 
US, and 
Spain 
435 Both 
Spanish native 
speakers, at any 
age and severity 
of Parkinson’s 
Cross-sectional EQ-5D-3L 
H&Y, 
NMSS, 
MDS-UPDRS-non 
motor, 
MDS-UPDRS-
motor 
EQ-5D-3L/H&Y: -0.53. 
EQ-5D-3L/NMSS: -0.57. 
EQ-5D-3L/MDS-UPDRS-non 
motor: -0.63. 
EQ-5D-3L/MDS-UPDRS-
motor: -0.72. 
 
Rodriguez-
Blazquez 
et al. (457) 
201
0 Spain 387 Both 
Age ≥ 30 at 
disease onset, 
with a main carer 
Cross-sectional EQ-5D-3L SCOPA-AUT EQ-5D-3L/SCOPA-AUT:-0.49  
Siderowf et 
al. (458) 
200
2 US 97 Both 
Without cognitive 
impairment Cross-sectional 
EQ-5D-
3L, 
DDI, 
HUI-II 
PDQ-39 all sub-
attributes, 
UPDRS 
EQ-5D-3L/PDQ-39 all 
attributes: from -0.27 (social 
support) to -0.69 (ADL). 
EQ-5D-3L/UPDRS total: -0.61. 
HUI/ PDQ-39 all attributes: 
from -0.12 (stigma) to -0.62 
(mobility). 
HUI/UPDRS total: -0.59. 
DDI/PDQ-39 all attributes: from 
0.067 (stigma) to -0.42 
(mobility/ADL). 
DDI/UPDRS total: -0.40 
o 
a. Reference measure could be either another PbQoL measure, Parkinson’s-specific QoL measure, or (if the former two not available) clinical measures. 
b. Assessment result for convergent validity: ‘’ evidence available to demonstrate that PbQoL measure and the reference measure were highly related (r ≥ 0.5); ‘o’ the PbQoL measure 
and the reference measure were moderately correlated (0.3 ≤ r < 0.5); ‘’ the PbQoL measure and the reference measure were weakly correlated (r < 0.3). 
Abbreviations: NMSS Non-Motor Symptoms Scale, SCOPA-AUT SCales for Outcomes in PArkinson’s disease – AUTonomic, ADL Activities of Daily Living, H&Y Hoehn & Yahr stage, , r 
correlation coefficient 
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4.4.2.3 Responsiveness 
Thirteen studies provided required information according to the eligibility criteria 
(Section 4.3.3) to allow an assessment of responsiveness of the PbQoL measures, 
including twelve studies for the EQ-5D-3L (251, 460-465, 467-471)  and one study 
for the 15D (466). The evidence for the assessment of responsiveness is provided 
in Table 4-5. The expectations on the mean change and direction of PbQoL score 
were established based on the mean change and direction of the reference 
measure, as well as the relationship between the PbQoL and the reference 
measure.  
Overall, there is some evidence supporting the responsiveness of the PbQoL 
measures. The one 15D study, by Nyholm et al. (466), demonstrated improved QoL 
in the duodenal levodopa infusion arm compared to conventional oral 
polypharmacy arm on both PDQ-39 and 15D (both p < 0.01); agreement between 
the Parkinson’s specific QoL measure PDQ-39 and the 15D supported the 
responsiveness of the 15D. Among the twelve EQ-5D-3L studies, half (n=6) showed 
consistency between the EQ-5D-3L and the reference measures in terms of the 
evidence for whether there was a statistically significant change over time; the 
reference measures included UPDRS part II ADL (461), PDQ-39 (462, 463, 471), 
PDQ-8 and H&Y (464), and the Hospital Anxiety and Depression scale (469).  
Concerns are raised to various degrees regarding the agreement between the EQ-
5D-3L and reference measures in the remaining six studies (251, 460, 465, 467, 
468, 470). Among them, four (251, 460, 467, 468) studies (Group A as below) 
showed a change in the reference measures but not in EQ-5D-3L whereas in the 
other two studies (Group B as below) (465, 470), change was not found in the 
reference measure but in EQ-5D-3L.  
Group A: change shown in reference measures but not in EQ-5D-3L (n=4) 
Among the four studies, Daley et al. (460) reported statistically significant higher 
QoL as shown on PDQ-39 summary score, mobility, ADL, emotional wellbeing, 
cognition, communication and bodily discomfort after adherence therapy as 
compared to routine care in a RCT, but the change in EQ-5D-3L was small and not 
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statistically significant (mean difference 0.07, 95% CI -0.1, 0.2). Nevertheless, 
given the sample size of this study is small (n=76), the assessment result was 
determined to be ‘uncertain’. Similarly, Schroder et al. (467) detected an 
improvement (difference = -3.3, p = 0.034) in PDQ-8 score in the group with 
standardised community pharmaceutical care for eight months and deterioration 
(difference = 4.4, p = 0.019) in the group with usual care. However, this treatment 
benefit was not only not replicated in EQ-5D-3L score for either group, but the 
direction of change was the opposite, although the change was not statistically 
significant (difference for intervention = 0.02, p=0.29; difference for control = -
0.03, p=0.13; sample size: n=161).  In both of the above cases, given the change 
detected in the specific QoL measures, it was expected that change was also 
shown in the PbQoL measure, which was not the case. 
In addition to the PDQ, the inconsistency was also found when using the UPDRS 
clinical measure as reference measure. Stocchi et al. (468) compared adjunctive 
ropinirole prolonged release and immediate release in a RCT and reported an 
improved UPDRS total motor score (p = 0.022), but a non-significant improved 
UPDRS ADL score (p = 0.270) and EQ-5D-3L score (difference = 0.03, p = 0.165). 
Although the difference was not statistically significant, given the unstable 
correlation between the UPDRS and the PbQoL measures as identified in the result 
of convergent validity (see Section 4.4.2.2), the non-significant result for EQ-5D-
3L score was not considered as evidence rejecting the responsiveness of EQ-5D-
3L.  
One study (251) reported a counterintuitive result between the clinical measures 
and the QoL measures. Reuther et al. (251) evaluated the change in QoL and 
clinical measures over one year without any study intervention (i.e. before – after 
comparison) in 145 patients. They found that clinical scores deteriorated (H&Y, p 
= 0.000, and UPDRS, p = 0.019); however the scores of PDQ-39 and PDQL improved 
(PDQ-39, difference = -3.8, p = 0.000, and PDQL, difference = 4.2, p = 0.030), and 
there was no difference in the EQ-5D-3L (difference = 0.01, p = 0.488). In addition, 
all of the PDQ-39 sub-dimensions in their study showed an improvement, including 
the dimensions that may have an overlapped concept with EQ-5D-3L dimensions 
such as mobility, ADL, emotional wellbeing, and bodily discomfort. The authors 
briefly explained that this could be due to the bias in repetitive measurement or 
other factors but did not provide any details. Although the result was inconsistent, 
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the Parkinson’s QoL measures were judged to be a more suitable measure 
assessing PbQoL instruments given they both measure the concept of QoL, 
compared to the clinical measures which do not. As such the EQ-5D-3L was 
expected to show a larger difference given all the dimensions of PDQ-39 showed 
an improvement. This expectation was not met based on the above results. 
Group B: change not shown in reference measures but shown in EQ-5D-3L (n=2) 
In contrast to the above results (Group A) where EQ-5D-3L was not responsive to 
a confirmed change, two studies showed statistically significant change over time 
in the EQ-5D-3L but not in the reference measures (465, 470). Noyes et al. (465) 
compared pramipexole and levodopa in a RCT with 301 patients over four years. 
Although a difference in PDQUALIF was detected it was not statistically significant, 
whereas EQ-5D-3L showed a difference between the arms from year 2 to 3 
(difference = 0.048, p = 0.03) and year 3 to 4 (difference = 0.071, p = 0.04). Wade 
et al. (470) compared multidisciplinary rehabilitation program versus usual care 
in 94 patients, in which difference was shown between the arms in the SF-36 
physical score and EQ-5D-3L score, albeit the difference was small (0.026 for EQ-
5D-3L, p=0.026),  while no difference found for PDQ-39 (0.5 on a 0-100 scale, 
p=0.687) and SF-36 mental score (0.5 on a 0-400 scale, p=0.655). Given that the 
reference measures (SF-36 and PDQ-39) were not consistent in term of confirming 
the happening of the change, and the fact that the difference shown in EQ-5D-3L 
was small in size, albeit statistical significant, this study was considered as 
‘uncertain’ evidence for the assessment of responsiveness.
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Table 4-5: Characteristics of included studies – assessment of responsiveness (n=13) 
Study Publicati
on year Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and 
after (A) 
Evidence for responsiveness – change from 
baseline to primary endpoint: 
Mean change (standard deviation) Assess
mentc Stage of Parkinson’s 
(Early or 
Advanced 
Other clinical 
characteristics Reference measure
a
 PbQoL measure 
Daley et 
al. (460) 2014 UK 76 Both 
On anti-
parkinsonian 
drug(s), no 
dementia 
RCT, 12 wks 
I: adherence 
therapy; 
C: routine care 
PDQ-39; 
I : -6.8 (6.4); 
C: 2.3 (7.4); 
Diff: -9.0 (95% CI -12.2, -
5.8); 
p < 0.001 
EQ-5D-3L; 
I: 0.04 (0.3); 
C: -0.03 (0.3); 
Diff: 0.07 (95% CI -
0.1, 0.2);  
p = 0.055 
o 
Ebersbac
h et al. 
(461) 
2010 Germany 61 Both 
Responsive to 
levodopa, had not 
responded to or did 
not tolerate 
entacapone, age 
30-80, H&Y 2-4, on 
stable medication 
for ≥ 4 wks 
Before and 
after self-
comparison, 
4 wks 
B and A: tolcapone 
targeting sleep 
quality 
UPDRS part II (ADL); 
Be: 15.1 (7.1); 
Ae: 10.8 (7.0); 
p < 0.0001 
EQ-5D-3L; 
Be: 0.562 (0.234); 
Ae: 0.678 (0.206); 
p = 0.0001 
 
Jarman 
et al. 
(462) 
2002 UK 1859 Both 
On anti-
parkinsonian 
drug(s) 
RCT, 
2 yrs 
I: provision of 
community based 
nurses specialists; 
C: no provision. 
B and A: Also 
analysed 
deterioration over 2 
yrs’ of all 
participants 
PDQ-39; 
B and A: all sub-attributes: p 
<  0.05; 
Diffb: 0.47 (95% CI -2.72, 
3.66); p = 0.77 
EQ-5D-3L; 
B and A: -0.10 (-
0.12, -0.08); p < 
0.001; 
Diffb:-0.02 (95% CI -
0.06, 0.02); p = 0.30 
 
Larisch 
et al. 
(463) 
2011 Germany 386 Both Not reported Cluster RCT, 9 mths 
I: providing 
instructions of 
clinical practice 
guidelines to 
neurologists; 
C: without 
instructions  
PDQ-39; 
I: 1.8 (11.2); 
C: 1.1 (11.5); 
pd=0.7591 
EQ-5D-3L; 
I: -0.001 (0.195); 
C: 0.007 (0.209); 
pd=0.5148 
 
Luo et al. 
(464) 2010 
Singapor
e 
31 Both Well enough to 
complete surveys 
Before and 
after self- No intervention 
PDQ-8 SI; 
Be: 17.74 (14.17); 
Ae: 35.08 (17.43); 
EQ-5D-3L; 
Be: 0.76 (0.23); 
Ae: 0.52 (0.33); 
 
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Study Publicati
on year Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and 
after (A) 
Evidence for responsiveness – change from 
baseline to primary endpoint: 
Mean change (standard deviation) Assess
mentc Stage of Parkinson’s 
(Early or 
Advanced 
Other clinical 
characteristics Reference measure
a
 PbQoL measure 
comparison, 4 
yrs 
p < 0.0001. 
H&Y； 
Be: 2.09 (0.38); 
Ae: 2.40 (0.70); 
p = 0.0133  
p = 0.0014 
Noyes et 
al.(465, 
481)  
2006 US 301 Early 
Age  ≥  30, 
duration with 
Parkinson’s ≤ 7 
yrs, H&Y 1-3, 
required 
dopaminergic anti-
Parkinson’s 
therapy 
RCT, 4 yrs; 
cost-utility 
analysis 
I: pramipexole; 
C: levodopa 
PDQUALIF; 
Diff over 4 yrs:0.040; 
P = 0.45. 
Diff from yr 2 ~3: 0.015; 
P = 0.36. 
Diff from yr 3~4: 0.036; 
P = 0.25 
EQ-5D-3L; 
Diff over 4 yrs: 
0.149; 
p=0.11. 
Diff from yr 2 ~3: 
0.048; 
P = 0.03. 
Diff from yr 3~4: 
0.071 
p=0.04 
o 
Nyholm 
et 
al.(466, 
481) 
2005 Sweden 24 Advanced 
Experiencing motor 
fluctuations and 
dyskinesia 
Crossover 
RCT, 2 three 
wks trial plus 6 
mths follow up; 
cost-utility 
analysis 
I: duodenal 
levodopa infusion 
(DLI) as 
monotherapy; 
C: conventional oral 
polypharmacy 
PDQ-39; 
Ie: median 25 (range 10-42); 
Ce: median 35 (range 16-
55); 
p < 0.01 
15D; 
Ie: median 0.78 
(range 0.64-0.95); 
Ce: median 0.72 
(range 0.58-0.88); 
p < 0.01 
 
Reuther 
et al. 
(251) 
2007 Germany 145 Both Not reported 
Prospective 
self-
comparison 
non-
intervention, 
12 mths 
No intervention 
PDQ-39; 
Be: 29.4 (17.5); 
Ae: 25.6 (16.2); 
P = 0.000. 
PDQL; 
Be: 118.6 (27.5); 
Ae: 122.8 (26.1); 
P = 0.030. 
H&Y; 
Be: 2.81 (1.16); 
Ae: 3.13 (1.04); 
P = 0.000. 
UPDRS; 
Be= 48.1 (33.3); 
EQ-5D-3L; 
Be: 0.61 (0.30); 
Ae: 0.60 (0.28); 
P = 0.488 
 
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Study Publicati
on year Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and 
after (A) 
Evidence for responsiveness – change from 
baseline to primary endpoint: 
Mean change (standard deviation) Assess
mentc Stage of Parkinson’s 
(Early or 
Advanced 
Other clinical 
characteristics Reference measure
a
 PbQoL measure 
Ae= 53.1 (34.0); 
P = 0.019 
Schröder 
et al. 
(467) 
2012 Germany 161 Both 
On anti-
parkinsonian 
medication(s), 
age > 35, sufficient 
physical and 
cognitive ability to 
complete 
questionnaires 
without assistance 
Cohort study, 
8 mths 
I: standardised 
community 
pharmaceutical 
care; 
C: usual care 
PDQ-8; 
I: -3.3 (95% CI -6.3, -0.3); 
pf=0.034. 
C: 4.4 (95% CI 0.8, 8.1); 
pf=0.019 
EQ-5D-3L; 
I:0.02 (95% CI -0.02, 
0.06); 
pf=0.29. 
C:-0.03 (95% CI -
0.08,0.01); 
pf=0.13 
 
Stocchi 
et al. 
(468) 
2011 
Bulgaria, 
Canada, 
Czech 
Republic, 
France, 
Hungary, 
Poland, 
Romania, 
Spain, 
UK. 
177 Advanced 
Age ≥30, H&Y 2-4, 
not adequately 
controlled on L-
dopa (3-12 hrs of 
daily awake time 
spent as ‘off’ time) 
RCT, 24 wks 
I: adjunctive 
ropinirole prolonged 
release; 
C: immediate 
release 
UPDRS total motor; 
Diff: -2.30 (95% CI -4.27, -
0.33); P = 0.022. 
UPDRS ADL in ‘off’ state; 
Diff: -0.77 (95% CI -2.13, 
0.60); P = 0.270. 
UPDRS ADL in ‘on’ state; 
Diff: -0.69 (95% CI -1.51, 
0.13); 
P = 0.100 
EQ-5D-3L; 
Diff: 0.03 (95% CI -
0.01, 0.08); 
P = 0.165 
o 
Trend et 
al. (469) 2002 UK 118 Both 
Score of at least 
7/10 on 
Hodkinson’s mini-
mental test, no 
cognitive 
impairment 
Before and 
after self-
comparison 
B and A: intensive 
multidisciplinary 
rehabilitation 
HAD anxiety: 
Be: 5.51 (3.31); 
Ae: 5.19 (3.43); 
p value not sig. 
HAD depression: 
Be: 6.06 (2.88); 
Ae: 5.57 (2.80); 
P = 0.029. 
p value of all of the other 
motor and non-motor scales 
achieved sig. 
EQ-5D-3L; 
Be: 0.55 (0.24); 
Ae: 0.63 (0.22); 
P = 0.001 
 
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Study Publicati
on year Country 
 
No. of 
partici
pants 
Study eligibility criteria 
Study type 
and time 
horizon 
Intervention (I) and 
comparator (C) or; 
before (B) and 
after (A) 
Evidence for responsiveness – change from 
baseline to primary endpoint: 
Mean change (standard deviation) Assess
mentc Stage of Parkinson’s 
(Early or 
Advanced 
Other clinical 
characteristics Reference measure
a
 PbQoL measure 
Wade et 
al. (470) 2003 UK 94 Both 
Without severe 
cognitive losses 
Crossover 
RCT, 24 wks; 
vost-
consequence 
analysis 
I: multidisciplinary 
rehabilitation 
program; 
C:usual care 
PDQ-39; 
B: 25.5 (10.7); 
A: 26.0 (12.7); 
P = 0.687. 
SF-36 physical; 
B: 29.5 (11.1); 
A: 27.28 (10.9); 
P = 0.046. 
SF-36 mental; 
B: 51.0 (8.4); 
A: 50.5 (10.3); 
P = 0.655  
EQ-5D-3L; 
B: 0.72 (0.22); 
A: 0.66 (0.21); 
P = 0.026 
o 
Zhu et al. 
(471) 2014 
HK 
(China) 13 Advanced 
Disabling or 
troubling motor 
symptoms, dopa 
responsive, clear 
understanding risk 
of and realistic 
about surgery 
outcomes, age<70 
Prospective 
before and 
after self-
comparison, 2 
yrs; 
cost utility 
analysis 
(before-after) 
B and A: deep brain 
stimulation surgery 
PDQ-39; 
Be=39 (13); 
Ae=27 (14); 
P = 0.019. 
EQ-5D-3L; 
Be=0.504(0.24); 
Ae=0.662(0.13); 
P = 0.033. 
 
ADL activities of daily living, H&Y Hoehn & Yahr scale, HAD Hospital Anxiety and Depression scale, UPDRS Unified Parkinson's Disease Rating Scale, I intervention group, C control 
group, B before, A after, Diff difference of scores between the changes of the two comparative groups over the trial period, yrs years, mths months, hrs hours, sig significant 
a
 Reference measure could be either another PbQoL measure, Parkinson’s-specific QoL measure, or (if the former two not available) clinical measures. 
b
 Difference between the intervention group and the control group at endpoint (no difference was found between two groups at baseline.) 
c Assessment result for responsiveness: ‘’ evidence available to demonstrate that PbQoL measure and the reference measure were consistent; ‘o’ weak evidence available but 
uncertain; or the PbQoL measure and the reference measure were not always consistent; ‘’ the PbQoL measure and the reference measure were inconsistent. 
d Hypothesis testing if the difference in change over time between the intervention and the control group equals to zero 
e
 Score at either baseline or endpoint, instead of change over time 
f
 Hypothesis testing if the change within group over time equals to zero
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4.4.3 Performance of PbQoL measures in economic evaluations 
Since the results of PbQoL measures are usually reported alone in a separate CUA 
study while the results of Parkinson’s specific QoL measures and clinical measures 
are usually reported in the main clinical study report, the number of CUA studies 
that met our eligibility criteria (which required a reference measure together with 
a PbQoL measure) for the assessment purpose was limited. Three studies 
conducted CUAs of health interventions (465, 466, 471, 481). 
The first CUA was one of the two studies in the Group B described in the last 
section 4.4.2.3, where there was statistically significant change over time in the 
EQ-5D-3L but not in the reference measures (465, 481) 7. The CUA used the 
identified EQ-5D difference in a four-year economic evaluation model and 
determined that the probability that the intervention of pramipexole compared 
with levodopa was cost effective was 0.57 when the WTP threshold was USD 50,000. 
However, the sensitivity analysis on the QALY gained revealed great uncertainty, 
which is expected given no difference was identified in the Parkinson’s specific 
QoL measure. The authors varied the QALY profiles following drop-out of 
participants and found that the ICER could be varied up to USD 233,025 per QALY 
with the probability for the intervention to be cost effective decreasing to 0.14, 
and down to USD 29,759 per QALY with the probability increasing to 0.88. 
The other two CUAs both come from the studies that supported the responsiveness 
of PbQoL measures, one with 15D evaluating the effect of duodenal levodopa 
infusion for advanced Parkinson’s in Sweden (466), the other with EQ-5D-3L 
evaluating the DBS for advanced Parkinson’s in Hong Kong (471). Despite this, the 
15D study reported that the change in 15D was among the parameters that had 
the greatest impact on the cost per QALY, although no detail regarding the amount 
of impact from varying 15D was provided. The EQ-5D-3L study did not report any 
sensitivity analysis so the uncertainty around the EQ-5D-3L estimate on the ICER 
was not determined, although the size of improvement of PDQ-39 and EQ-5D-3L 
                                            
7
 The CUA was reported in a separate paper from the other outcomes. 
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were both relatively large (mean difference 0.203, p=0.013 for the first year; 
mean difference 0.158, p=0.033 for the second year)  (471). 
4.4.4 Mapping algorithms 
Five mapping studies were identified from the literature search which used 
mapping from the non-preference based measure to the preference-based 
measures (472-476). This includes two studies mapping from the PDQ-8 to the EQ-
5D-3L (473, 474) and three studies mapping from the PDQ-39 to the EQ-5D-3L (472, 
475, 476). Their characteristics and the resulting mapping algorithms are 
presented in Table 4-6 and Table 4-7, respectively.   
Table 4-6 showed that four out of the five studies estimated a prediction model 
using regression approaches in an original dataset and then validated their derived 
algorithm in one or more validation dataset(s) (473-476). They compared different 
regression models based on model fit informed by statistical indicators. The 
remaining one study used a Markov blanket-based approach, which is a method 
for learning multi-dimensional Bayesian network classifiers to identify the 
relationships within multi-dimensional classification systems (472).  
Sample size varies in the original datasets for deriving the different models. The 
largest dataset comes from Kent and colleagues (2015) (475) which contains 9,123 
pairs of observations for estimation of the algorithm and 719 pairs of observations 
for validation. Linear regression, beta regression, mixtures of linear and beta 
regressions, and multinomial logistic regression were compared based on model 
fit indicators including mean error, mean absolute error, and mean square error. 
The estimated regression model incorporated adjustment for age and sex (Table 
4-7). 
For the mapping results shown in Table 4-7, mobility, ADL and bodily discomfort 
were included in all mapping algorithms, and emotional wellbeing was included in 
all but one (474) algorithms. However, four of the five mapping algorithms did not 
include half of the PDQ dimensions which are related to mental health and overall 
wellbeing aspects of QoL, i.e. stigma, social support, cognition and 
communication (472-475). Especially, stigma was not included in any of the 
algorithms. 
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Table 4-6: Characteristics of studies mapping PDQ-39/PDQ-8 scores to EQ-5D-3L utility values 
Author, 
year Year Country 
Sample size for Mapping 
Mapping models used 
Measure of 
model 
performancea 
Estimation of 
the algorithm 
Validation 
of the 
algorithm 
From 
PDQ-39 / 8 
To 
EQ-5D-3L 
Borchani 
et al. 
(472) 
2012 Spain 448 - 
PDQ-39 
each 
question 
Each 
dimension 
Markov blanket-based approach using Multi-dimensional Bayesian 
network classifiers (MBC), class-bridge decomposable MBC, 
independent Marokov blankets, and independent PC Bayesian 
networks, back propagation for multi-label learning (BP-MLL), 
multi-label k-nearest neighbor (ML-kNN), multinomial logistic 
regression (MNL), ordinary least squares (OLS), and censored 
least absolute deviations (CLAD) 
MSE, MAE, R 
square, AbsDiff 
Cheung et 
al. (473) 2008 Singapore 162 162 
PDQ-8 
each 
question 
Overall 
score 
OLS, censored least absolute deviations method R square, MAE 
Dams et 
al. (474) 2013 Germany 121 
Overall 
number not 
reportedb 
PDQ-8 
each 
question 
Overall 
score 
OLS, fractional polynomial regression; logarithmic function 
R square, RMSE, 
Pregibon link test, 
BIC 
Kent et al. 
(475) 2015 UK 
9,123 pairs 
from 2043 
patients 
719 pairs 
from 352 
patients 
PDQ-39 
each 
dimension 
a. each 
dimension 
b. overall 
score 
OLS, 2-part Beta Regression, Finite Mixture Models, Mixtures of 
linear regressions, mixture of beta regressions, multinomial logistic 
regression 
ME, MAE, MSE. 
Young et 
al. (476) 2013 Austria 80 16 
PDQ-39 
Each 
dimension 
Each 
dimension Ordinal regression with the Cauchit link function,  MAE,RMSE. 
Abbreviations: OLS – ordinary least square 
a ME - Mean error, calculated as the average difference between observed and predicted utilities;  MAE – mean absolute error, calculated as the average of the absolute differences 
between observed and predicted utilities; MSE – mean square error, calculated as the average of squared differences between observed and predicted utilities; RMSE – root mean 
square error, calculated as the root square of MSE; AbsDiff – the absolute difference,  calculated as the absolute difference between the true and predicted EQ-5D utility mean scores; 
BIC – Bayesian information criterion; PwP – people with Parkinson’s. 
b. Data come from three datasets: 1). authors’ own unpublished data; 2).Siderowf et al.(Germany, 97PwP) (458); 3). Schrag et al. (124 PwP, UK) (485) 
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Table 4-7: Summary of PDQ dimensions included in each mapping algorithm 
Author, 
year 
PDQ1-
Mobility 
PDQ2-
Activities 
of daily 
living 
PDQ3- 
Emotion
al 
wellbein
g 
PDQ4- 
Stigma 
PDQ5- 
Social 
support 
PDQ6- 
Cognition 
PDQ7- 
Commun
ication 
PDQ8-
Bodily 
discomfort 
Other 
variables 
in the 
model 
Algorithm of EQ-5D utility 
Borchani et 
al. (472)    - - - -  None Not reported. 
Cheung et 
al. (473)    - - - -  None 
Utility=1 if at least seven responses are 
“never”, otherwise 
Utility=1-0.135-0.052*PDQ1-0.0034*PDQ2-
0.031*PDQ3-0.030*PDQ7 
R2=52.1%. 
Dams et al. 
(474)   - - - - -  None 
Utility=0.9298-0.00004*PDQ12-
0.00002*PDQ22-0.00004*PDQ82 
R2=60.34%. 
Kent et al. 
(475)    - - - -  Age, sex Not reported. 
Young et al. 
(476)    -     None 
Overall EQ-5D utility function is not reported, 
utility function to each EQ-5D dimension is 
available. 
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4.5 Summary of results 
This chapter systematically reviewed the use of the PbQoL measures in people 
with Parkinson’s, assessed the construct validity and responsiveness of PbQoL 
measures, and summarized the mapping algorithms from non-preference based 
measures to EQ-5D-3L. The EQ-5D-3L was found to be predominantly used as the 
PbQoL measure in Parkinson’s while the PDQ-39 was the most widely used 
Parkinson’s-specific QoL measure among included studies.  
EQ-5D-3L did achieve statistically significant differences between the known 
groups divided based on clinical characteristics in most studies, but it may have 
limited sensitivity to detect differences in QoL among patients with mild 
Parkinson’s as evidenced by the subgroup analysis in an included study (458). Good 
evidence of known-group validity has also been demonstrated in the HUI-3, EQ-
5D-5L, 15D, HUI-2, and DDI despite limited evidence being available to allow the 
assessment. HUI-2 may be less sensitive among patients with mild Parkinson’s as 
there is no difference in the mean utility score between patient groups with first 
and second quartile UPDRS scores (458).  
In terms of convergent validity, overall moderate to strong correlations were 
shown between the PbQoL measures (EQ-5D-3L, EQ-5D-5L, 15D, DDI, and HUI-II) 
and Parkinson’s-specific QoL measures/clinical measures. It was found that the 
EQ-5D-3L, DDI, and HUI-II all correlated most strongly with the physical attributes 
(i.e., mobility and ADL) of PDQ-39 and least strongly with mental and wellbeing 
attributes (i.e., social support and stigma).  
For responsiveness, most evidence was found for the EQ-5D-3L. The agreement 
between EQ-5D-3L and the Parkinson’s-specific QoL/clinical measures in regards 
to the change over time varied across studies. Half of the studies showed that EQ-
5D-3L scores reflected changes in clinical status over time as shown on the 
reference measures, while the other half failed to reach consistent conclusions 
between the measures. Concerns are raised in the responsiveness of the PbQoL 
measures especially the EQ-5D-3L to the changes over time that are specific to 
disease progression in the Parkinson’s population. 
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Through a summary of the identified mapping algorithms, it is found that four of 
the five mapping algorithms did not include half of the PDQ dimensions, i.e. stigma, 
social support, cognition and communication (472-475). Using these mapping 
algorithms to generate EQ-5D-3L values may be problematic as these algorithms 
neglected to some extent the impact on mental and overall wellbeing aspects of 
Parkinson’s.  
4.6 Discussion 
There is evidence from this review that the mental/wellbeing attributes of PDQ-
39 may not be fully captured by the EQ-5D instrument. Parkinson’s is a chronic, 
progressive condition which has been shown to affect mental/wellbeing aspects 
of QoL and as such it is important to include appropriate valuations for 
improvements in such attributes within priority setting decisions. The importance 
of these mental/wellbeing aspects is demonstrated by consistent presence of such 
attributes within Parkinson’s-specific QoL measures and by previous literature 
examining the effect of the mental and wellbeing aspects on Parkinson’s patients’ 
QoL (95, 486). With approximately half of the domains in PDQ-39/PDQ-8, 
PDQUALIF, and PDQL relating to aspects other than physical health, such domains, 
e.g., social communication, stigma/self-image, emotional functioning, cognition, 
and outlook, are highly likely to have a substantial impact on patients’ QoL. A 
recent systematic review found that depression was the most frequently identified 
determinant of HrQoL in people with Parkinson’s among all the demographic and 
clinical factors (487). Therefore, sufficient incorporation of valuations for these 
broader attributes is crucial when measuring PbQoL in Parkinson’s.  
The utilities from the PbQoL measures generally discriminated well between 
groups and correlated well with Parkinson’s clinical and QoL measures. However, 
the inconsistency in findings of responsiveness between those measures cautioned 
that the change shown on clinical measures may not necessarily lead to the same 
change in QoL scores. Reuther et al. (251) assumed that there might be other 
undetected factors leading to the opposite change of QoL scores to the clinical 
measures. One reason might be the fact that clinical measures such as H&Y and 
UPDRS focus mostly on the physical symptoms of Parkinson's while QoL measures 
are subjective to individuals and based on overall experience of health and 
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wellbeing. This may also help explain our finding that the PbQoL measures that 
focused on physical health should be theoretically able to discriminate between 
groups defined by clinical factors. Besides this, as clinical status or objective 
health status is usually one of the primary predictors of QoL, it is reasonable to 
expect that PbQoL measures would display discriminant and convergent validity.  
Responsiveness of PbQoL measures is crucial to economic evaluations. In a bid to 
measure resource use and QALYs, economic evaluations often need to be carried 
out longitudinally over an appropriate and meaningful time horizon depending 
upon the intervention being assessed. Previous studies have suggested that the 
results of economic evaluations are sensitive to the change of utility values when 
chronic conditions or long-term sequelae are involved (488); Parkinson’s is one of 
those conditions. Therefore, lack of definite evidence of responsiveness may 
critically undermine the results of CUA analysis in Parkinson’s and thus decision-
making as QALY gains may differ depending on the derivation of utility values. 
4.7 Chapter summary 
This chapter reported the objectives, search methods and eligibility criteria of a 
systematic review of the use of PbQoL measures in Parkinson’s, as well as the 
methods for an assessment of their construct validity and responsiveness in the 
included studies. In addition, this chapter also summarized the published mapping 
algorithms identified from the search that could be used to map from the non-
preference based measures in Parkinson’s to EQ-5D-3L. Results from the search, 
assessment and the summary of mapping algorithms were reported. The evidence 
for construct validity of the PbQoL measures identified in this review was generally 
positive except for in people with milder Parkinson’s, nevertheless, there were 
concerns regarding their responsiveness to the change in QoL over time. The 
substantial lack of mental and social wellbeing dimensions in the mapping 
algorithms revealed a concern in EQ-5D-3L’s inability to reflect these impact in 
the Parkinson’s population.  
Psychometric validation is an iterative process especially when the existing 
evidence is inconsistent. This chapter demonstrates a need to further explore the 
construct validity and responsiveness of the PbQoL measures in this population. In 
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particular, exploring the ability of other PbQoL measures to capture wider 
benefits that are underestimated by the NICE recommended EQ-5D-3L may 
represent a valuable research development in this area. Therefore, Chapter 6 and 
7 will empirically explore the construct validity and responsiveness of the broadly 
defined preference-based measure, ICECAP-O, in comparison to the EQ-5D-3L 
using a large longitudinal dataset in Parkinson’s. Prior to this, Chapter 5 will 
provide the information on the data used and discuss the methodological 
challenges that are to be explored for the case studies in Chapter 6 and 7. 
   
   
Chapter 5 Case studies: justification, data 
source and methodological challenges  
 
Chapter 5  146 
5.1 Introduction 
Following the results of the systematic review reported in Chapter 4, which 
revealed a clear need to further explore the construct validity and responsiveness 
of the PbQoL measures in the Parkinson’s population this chapter will provide a 
brief digest of rationale for the following two empirical chapters. In addition, as 
discussed earlier in Section 3.3.1 and 3.5.2 respectively, construct validity and 
responsiveness are context-specific. This is especially important in the assessment 
of generic measures as those measures are designed to be generic whereas in 
practice applied to specific populations with varied characteristics. Tests of 
measurement properties of generic measures usually requires assessment in 
different populations to demonstrate its usefulness in each of the specific contexts, 
thereby a full understanding of where the data come from is essential. Both 
Chapter 6 and 7 used data from one of the largest trials of medication in 
Parkinson’s (the PD MED RCT), this chapter will provide an overview of the trial 
and the key outcomes data collected. Given the importance of PDQ-39 in the case 
studies, a detailed introduction of the PDQ-39 will be provided. 
Chapter 3 discussed a number of challenges when applying the classic 
psychometric testing methods to answer the research question of the case studies. 
This chapter will provide a summary of these conceptual and practical challenges. 
They include: (a) How to validate a measure of QoL and wellbeing concept when 
there is no gold standard measure and no consensus on the concept? (b) Is it 
appropriate to validate a ‘preference-based’ measure using non-preference based 
measures as gold standard? (c) How to set up hypotheses and expectations when 
there is no prior information regarding capabilities measured by ICECAP-O in 
Parkinson’s?  (d) How the variability within the sample would affect the validation 
of construct validity and responsiveness? These challenges have important 
implications for the methods chosen and interpretation of results in Chapter 6 and 
7. 
5.2 Justification for the case studies 
In Chapter 1, Section 1.2 described the breadth of Parkinson’s motor and non-
symptoms, their broad impact on people’s health and wellbeing, and the 
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corresponding wide scope of interventions to manage Parkinson’s. Chapter 4 
revealed evidence that this wide impact, however, was not found to be 
sufficiently captured by the EQ-5D-3L measure. In particular, concern was raised 
in EQ-5D-3L’s ability to measure and value the mental and social wellbeing 
dimensions associated with Parkinson’s. This raises concerns about whether the 
EQ-5D captures the full benefit of interventions, especially the interventions that 
are substantially associated with patients’ broader wellbeing. Examples of such 
interventions may include speech and language therapy (mentioned in 1.2.4.3) 
that improves patients’ communication, and glycopyrronium bromide (a drug) that 
manages drooling of saliva, both of which may have wide impact on their family 
relationship, social wellbeing and stigma.  
The results from Chapter 4 point to a valuable research direction which is to 
explore the ability of other PbQoL measures to capture the wider benefits of 
interventions in Parkinson’s. As mentioned in Section 2.7, the ICECAP-O was 
developed with a view to expand the evaluative space and measure ‘capability’ 
wellbeing in older people in response to the need for a broader PbQoL measure 
(489). It could potentially be used in economic evaluations in older people across 
health and social areas in which a broader set of outcomes is considered (311, 
489). Indeed, NICE recommends the use of ICECAP-O where outcomes in terms of 
capabilities are considered relevant to the intended effects of social care 
interventions and programmes. In addition, despite having  been developed for 
only less than 10 years, the ICECAP-O has been found to be the most widely applied 
older people specific instrument in both community and residential aged care 
among all the generic preference-based instrument in a recent (2015) systematic 
review in aged care (20). This review further recommended the use of the EQ-5D 
to obtain QALYs in combination with a broader QoL measure such as ICECAP-O to 
facilitate the measurement and valuation of broader QoL benefits as defined by 
older people (20). 
Parkinson’s mainly affects elderly people aged over 60 (490) and its impact on 
people’s QoL and social wellbeing is extensive, as demonstrated in Chapter 1 
(Section 1.2.3). The validity of the ICECAP-O instrument has not been tested in a 
Parkinson’s population yet and therefore the next two chapters will endeavour to 
answer the second research question, namely: is the ICECAP-O appropriate to 
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capture the wellbeing impact of interventions in Parkinson’s, and is it sufficiently 
sensitive in this population? 
5.3 Case studies: data source  
Psychometric assessment relies on the assumption surrounding the relationship 
between the test measure and the distinguishing characteristics of the population 
and as such the assessment result is specific to these characteristics. Accordingly, 
a full understanding of where the data come from and the characteristics of the 
underlying population is therefore essential to inform the psychometric validation 
in terms of the design of methods, and interpretation and generalisation of the 
results (491, 492). 
Data for the empirical psychometric testing works in Chapter 6 and 7 were 
collected from the participants in the PD MED RCT. The PD MED is a large-scale, 
simple, long-term and ‘real-life’ study that aims to compare different classes of 
drugs in terms of their effectiveness, safety and cost-effectiveness, for patients 
with both early and later stages of Parkinson’s (Registration number: 
ISRCTN69812316). The primary objective was to compare QoL between the 
different classes of drugs. The PD MED trials included up to three QoL measures – 
the two most commonly used QoL and wellbeing measures in Parkinson’s, EQ-5D-
3L and PDQ-39, and a new measure, ICECAP-O. This lays a rich data foundation for 
this thesis. The development, valuation, and validation of ICECAP-O and EQ-5D-3L 
have been reviewed and critiqued in Section 2.7.2 and 2.4.4, respectively. This 
section describes the design, inclusion and exclusion criteria, and the key outcome 
measures collected from the trial, and introduce in depth the PDQ-39 measure.  
5.3.1 Trial design 
The PD MED (75, 493) study contains two RCTs, the Early trial and the Later trial. 
The Early trial is for patients diagnosed with early stages of idiopathic Parkinson’s 
– those just initiated on treatment, while the Later trial is in patients with later 
stage of idiopathic Parkinson’s whose symptoms can no longer be controlled well 
by the initial therapy. All the drugs in each arm are available in clinical practice 
and had been tested previously, nevertheless, there is uncertainty around their 
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relative effectiveness and cost-effectiveness due to the small sample size, short-
term follow-up and lack of proper QoL measures in previous studies (494, 495). 
The trials are co-ordinated by the University of Birmingham Clinical Trials Unit. 
The recruitment started from 2001 until 2009 and participants are being followed 
up for ten years until 2019. 
Whilst maintaining its robustness as a RCT through the randomisation process, PD 
MED is designed in a pragmatic and more ethically acceptable way to reach the 
recruitment target number and maximize the relevance of trial finding to clinical 
practice. The eligibility is not based on rigid entry criteria but on a real-life 
approach, which is, the ‘uncertainty principle’. It allows the clinicians to consider 
if there is a definite indication for, or a definite contraindication against, a class 
of drug. In the former case, the patient is not eligible for randomisation; in the 
latter case, the patients could still be randomised to any of the other two arms. 
A patient is eligible for the three-arm randomisation only when there is 
uncertainty regarding which class of drugs should be offered. In addition, to 
reflect the normal clinical practice, the clinicians could decide the specific drug 
within each class that they prefer, and vary the dose as they see fit within the 
bounds of the manufacturer instructions. If patients’ symptoms are not adequately 
controlled by the assigned class of drugs, or adverse effects are observed, adding 
or switching to a new drug from another drug class is permissible. This pragmatic 
approach should make the trial participants representative sample of the overall 
Parkinson’s population, and subsequently enhances the generalisability of the 
results produced from the data to the wider Parkinson’s population.  
5.3.2 Inclusion/exclusion criteria and recruitment 
Patients who met the eligibility criteria were recruited from over 80 neurology & 
care of the elderly units throughout the UK. The eligibility criteria for the Early 
trial were: 1) recently diagnosed with idiopathic Parkinson’s by movement 
disorder specialists using UK Brain Bank diagnostic criteria and; 2) previously 
untreated for Parkinson’s and therapeutic intervention was considered 
appropriate, or the patient had previously been treated with dopaminergic 
medication for less than 6 months, and there was uncertainty as to which class of 
drug to use. For the Later trial, the patients were eligible if they developed motor 
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complications that were uncontrolled by levodopa (LD) (alone or in combination 
with either dopamine agonists (DA) or monoamine oxidase type B inhibitors 
(MAOBI)), and hence required the addition of another class of drug. For both Early 
and Later trial, patients were not eligible for the randomisation if they had 
dementia or unable to give informed consent. If the patient developed dementia 
during the trial, they can stay in the trial. Patients who had been randomised into 
the Early trial were re-randomised into the later disease randomisation if motor 
complications developed that were uncontrolled by the classes of drugs offered in 
the Early trial. 
5.3.3 Outcome measures 
The primary outcomes of the PD MED trials were the patient self-reported 
functional status on the mobility subscale of the PDQ-39 questionnaire and the 
CUA outcomes (i.e. the EQ-5D-3L, and the QALYs). The secondary outcomes 
included the other subscales of PDQ-39 questionnaire and the overall score, 
cognitive function assessed by Mini-Mental State Examination (MMSE), wellbeing 
of the carers assessed by SF-36 and Carer Experience Scale (CES), resource usage, 
toxicity and side-effects including mortality rates. In addition, time to onset of 
motor complications was assessed in the Early trial, and the time to surgical 
intervention or start of apomorphine was assessed in the Later trial. 
To reach the recruitment target and keep the patients in the trial, the extra 
workload of assessment for the patients was kept to a minimum. The QoL, side-
effects and resource usage questionnaires were completed by the patients via 
postal questionnaires. Meanwhile, MMSE and annual follow-up forms were 
completed by clinicians and the carer wellbeing forms were completed by carers. 
All assessments were completed annually after the first year until the end of the 
ten-year follow-up apart from MMSE, which is measured at baseline and at every 
subsequent five years. Table 5-1 illustrates the assessment of each of the 
questionnaires. The ICECAP-O capability measure (140, 141), which was developed 
in 2006 (140) and valued in 2008 (141), was added to the trial follow-up in 2010 
and has since been being collected annually until the end of trial, December 2019.  
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Table 5-1: Baseline and follow-up assessments of the PD MED trial outcomes  
Note: This table is adapted from PD MED trial protocol (493). 
* ICECAP-O was added to the trial since November 2010. 
Abbreviation: MMSE – Mini Mental State Examination;  CES – Carer Experience Scale; H&Y – Hoehn & Yahr 
staging scale 
 
5.3.4 The PDQ-39 instrument 
The PDQ-39 (131) is the most commonly used condition-specific QoL measure in 
Parkinson’s and is judged to be the most thoroughly tested questionnaire in 
Parkinson’s (433, 496-499). It assesses the effect of Parkinson’s on QoL, and is 
sensitive to changes regarded as important to patients, but not identified by 
clinical rating scales (62, 131).  The PDQ-39 was developed by Crispin Jenkinson, 
Ray Fitzpatrick and Viv Peto and published in 1997 (131). Aspects of health status 
were identified through in-depth interviews with 20 people with Parkinson’s 
attending a neurology outpatient clinic, which generated a large number of 
possible items (500). After scrutinizing, a 65-item questionnaire was developed 
and piloted to test acceptability and comprehension in 359 individuals. The 
number of items was further reduced to 39-items with eight dimensions through 
factor analyses.  
The PDQ-39’s test-retest reliability was assessed by using Cronbach’s alpha 
statistics with data from two time-point postal surveys with 3-6 days apart. A 
correlation coefficient value above 0.5 is judged to be acceptable and higher than 
0.7 is good. The Cronbach’s alpha was found to be good (above 0.7) for all 
Domains Outcome 
measure 
Completed 
by At Entry 
6 
months 
1st - 10th 
years, 
annually  
5th, 
and 
10th  
Functional 
status / 
Quality of 
Life 
PDQ-39, 
EQ-5D, 
ICECAP-O* 
Patient     
Side effects Side effect form Patient     
Health 
Economics Resource usage Patient     
Carer 
wellbeing SF-36, CES Carer     
Cognitive 
function MMSE Clinician     
Disease 
status 
Follow-up form, 
including current 
H&Y, and 
complications 
Clinician Rand, 
notepad    
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dimensions (500), except for the social support dimension which is 0.66 at time 1 
(62, 500). Its construct validity was tested by correlating scale scores with 
relevant SF-36 scores (62) and UPDRS score in a Spanish study (501). 
As seen previously in Chapter 4 Table 4-2, PDQ-39 has 39 questions in total 
addressing eight domains of functioning and wellbeing in Parkinson's: mobility, 
ADL, emotional wellbeing, stigma, social support, cognition, communication and 
bodily discomfort. There are five levels for each attribute: never, occasionally, 
sometimes, often, always, with scoring being 0, 1, 2, 3 and 4 respectively. The 
score is calculated by averaging the levels for all the questions within each 
attribute and then standardizing the ‘averaged level’ to a scale of 0-100. The 
summary index (SI) of the PDQ-39, PDQ-39-SI, is the average of the eight attribute 
scores.  The PDQ-39 has a short form version, the PDQ-8, comprising eight of the 
original 39 items of PDQ-39, with one item selected from each of the eight 
attributes, and thus the response level for each of the questions in PDQ-8 
represents the score for each attribute after standardization (502).  
Despite accurately measuring the key condition attributes in Parkinson’s, its 
unweighted scoring system brings limitations for use in CUA. With the summary 
score being formed without weighting across dimensions and items within each 
dimension, it is unclear what the combined scores represent and thus hampers 
their interpretation (503). This instrument cannot be used directly in CUA due to 
the lack of valuation of attributes. Without valuation of the health states against 
length of life, or using monetary vehicles, no information is obtained on how its 
score could be interacted with length of life and how much society would be 
willing to pay for improvements in scores.  
5.4 Methodological challenges of the assessment of the 
construct validity and responsiveness of ICECAP-O 
in Parkinson’s 
5.4.1 No criterion  
No ‘criterion’ exists for a QoL measure. Due to the mixed views on the definition 
of health and QoL as discussed in Section 2.3, measures are established on 
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different theoretical basis leading to different sets of descriptive system. This 
creates challenges in identifying the most appropriate anchor for testing 
responsiveness and the criteria for known-group validity. Using clinical measures 
it is possible to test whether the test measure is responsive to the change in a 
particular clinical aspect, however it requires an implicit assumption that the 
change in the clinical aspects will lead to the change in the test measure. Using 
another QoL instrument could also be problematic as any negative result can be 
attributed to the fact that the other QoL measure does not have the same 
construct as the test measure. As a result, choice of anchor or criteria would 
affect the interpretation of the validation results.  
Chapter 6 and 7 will test the appropriateness of the ICECAP-O capability measure. 
Then what should be the proper anchor? The optimum anchor for a capability 
measure is another capability measure with the same construct - a ‘duplicate’ 
that is almost impossible to have in a trial setting for ethical considerations (i.e. 
not adding patients’ burden). Using instruments that are not measuring capability 
as anchors cannot provide evidence regarding how the ICECAP-O capability 
instrument measures true capability. The HrQoL measures are expected to be 
correlated with the health measures but this may not be the same for a capability 
measure with a much broader construct. Some aspects of capability, such as the 
attachment attribute in ICECAP-O about family and friendship may be affected by 
health like mobility issues, but not as strongly as other attributes such as control 
or fulfilment of role.  
Although the limitation of no gold standard is not likely to be completely solved, 
consideration on this can be reflected in the hypotheses drawn through properly 
specifying the expected strength and correlation between the anchor measure and 
the test measure. The expectations are on the basis of theoretical understanding 
and other evidence prior to the testing and thus interpretation of the results 
should be treated with caution. 
5.4.2 How to validate ‘preferences’? 
The next challenge is related to the validation of the value set of a preference-
based measure since none of psychometric validation approaches are developed 
considering for the assessment of the PbQoL measures. The essential part of 
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preference-based measures is the value set which incorporates people’s 
preference. As introduced in Section 2.4, preference represents individual’s or 
group’s relative desirability of the different outcomes, and hence the more 
desirable (more preferred) health states receive greater weight or utility score 
(97). Only by incorporating the preferences against 0 (death) and 1 (full health), 
the score of a measure can be viewed as weight for length of life in the QALY 
calculation. This is because the preferences are elicited using ‘trade-off’ exercises 
involving risk of death as a gamble or length of life as a trade. Details of this have 
been provided earlier in Chapter 2 Section 2.4.  
Owing to the special purpose of preference-based measures with their score to be 
combined with length of life, interpretation of the instrument should be based on 
the overall index value as a whole, which is about the values of a state rather than 
the state itself (148, 504, 505). Accordingly, lack of construct validity or 
responsiveness may be due to the inappropriateness in the descriptive system, or 
could also because of the inappropriate values attached to the states. When it is 
unknown to what degree the change on the anchored measure is preferred by the 
patients, the testing methods have to depend on the arbitrary assumptions of 
people’s preferences towards the change on each health state.  
Potential ways to validate stated preferences are perhaps by examining revealed 
preferences or direct elicitation using TTO or SG (118). However these cannot be 
achieved because it is impractical to measure revealed preference of health state 
given there is no direct choice of health states. Also, it will be problematic if 
validating the preference from a generic valued measure by comparing with the 
preferences from direct elicitation, since studies have shown that the values 
elicited from direct methods are not interchangeable with that from the indirect 
methods (118, 506). Arnold et al. (2009) systematically reviewed the studies that 
compared utilities obtained directly (TTO or SG) (Section 2.4.2 for details) or 
indirectly (EQ-5D, SF-6D and HUI) (Section 2.4.3 for details) from the same 
patients (506). They found that direct methods of obtaining utilities yielded 
systematically higher scores than the indirect methods; mean utility values were 
0.81 (SG) and 0.77 (TTO), in comparison to the indirect instruments, 0.59 (EQ-5D), 
0.63 (SF-6D), 0.75 (HUI-2) and 0.68 (HUI-3). This means on average the 
respondents would accept a 19% reduction in lifespan to avoid the condition based 
on results of SG, and the amount of reduction increased to 41% in lifespan when 
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considering the result from EQ-5D. This massive difference demonstrates that it is 
not feasible to validate preferences obtained from the off-the-shelf instruments 
using direct methods. What is also worth mentioning here is that this difference 
has significant implications for resource allocation decisions as when using a 
mixture of methods for different decisions is allowed, a motivated choice of 
method may distort the outcome in a preferred direction (506). This also highlights 
the importance of carefully scrutinizing the source of how the preferences were 
elicited before applying it in economic evaluations. 
5.4.3 No prior information 
Another challenge encountered in the design of the case studies in next two 
chapters is that there is often a lack of prior information for setting up hypotheses. 
Capability is an under-defined theory with many unsolved questions (305) when 
applying it to health economics research and there is no previous information on 
the possible magnitude of ICECAP-O change in the Parkinson’s population. 
However, hypotheses testing requires forming reasonable hypotheses based on 
theoretical understanding of the test measure and the other measures and 
previous evidence. To my knowledge, this is the first study to test the ICECAP-O 
in people with Parkinson’s, and thus no evidence is available to serve as a basis 
for us to speculate an ‘expected effect size’ or ‘expected correlation coefficients’ 
with which to benchmark the degree of responsiveness and construct validity of 
this measure in this population. For example, it is difficult to stipulate how much 
change is expected to happen on ICECAP-O for each degree of clinical 
improvement on the H&Y clinical scale. A compromise solution is to use another 
commonly used measure, for instance, EQ-5D-3L, if data are available, as a 
reference point to set up the hypotheses based on previous studies on their 
relationships. This partly explains why our case studies employed EQ-5D-3L as a 
reference measure in addition to aiding the interpretation of the results of the 
validity of ICECAP-O and add the relevance of the results to current practice. 
5.4.4 Heterogeneity within the sample 
The last challenge comes from the complex nature of Parkinson’s which leads to 
extensive heterogeneity across individuals. Given the large number of influences 
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on QoL that may vary across and within patients, large variability of QoL 
trajectories over time with disease progression were found in previous studies (507, 
508). As Parkinson’s UK stated: “each person will have a completely different 
experience of the condition and their Parkinson’s will progress at different rates.” 
(18) The large heterogeneity within the sample may increase the ‘noise’ in the 
validation test. For example, in the responsiveness analysis, even the patients are 
assigned to the ‘improved’ group based on one certain anchor, it does not mean 
that all the aspects of Parkinson’s are improved. In other words, getting worse in 
one aspect does not necessarily suggest overall deterioration of the health and 
QoL. Likewise, getting better in one aspect does not necessarily translate into the 
overall improvement of the health or QoL. This also affects the assessment of the 
known-group validity if the grouping criteria predict the test measure in varied 
ways across the population. In addition, Parkinson’s is a chronic progressive 
disorder and most patient symptoms are in the trend of deterioration. The 
improvement in one dimension may not suggest the overall health status has not 
progressed over time and therefore the effect size and the standard response 
mean for the ‘improved’ group may be quite small if the anchor is a weak 
determinant of the test instrument. Acknowledging these issues would help avoid 
miss-interpretation of the validation results. 
5.5 Chapter summary 
This chapter started with providing a further justification for the two case studies 
of exploring the broadly defined measure ICECAP-O in people with Parkinson’s by 
reflecting on the results from last chapter. This is followed by a description of the 
data source for the case studies, detailed introduction of PDQ-39 instrument and 
the conceptual and practical challenges related to the assessment of these 
properties in the case studies presented in Chapter 6 and 7. The next chapter will 
report the first case study, a cross-sectional assessment of the construct validity 
of ICECAP-O, in comparison with the EQ-5D-3L and the PDQ-39 in the Parkinson’s 
population.  
 
   
   
Chapter 6 Testing the construct validity of the 
ICECAP-O instrument and exploring its 
relationship with the EQ-5D-3L and the PDQ-39 
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6.1 Introduction 
Following the justification provided in last chapter for exploring the performance 
of ICECAP-O instrument in Parkinson’s, this chapter and the next chapter will 
empirically explore the construct validity and responsiveness of the ICECAP-O and 
how it compares with the EQ-5D-3L in people with Parkinson’s, using data 
collected from the PD MED trials. As introduced in last chapter Section 5.3, the 
PD MED is the first study to collect the ICECAP-O data in the Parkinson’s population 
hence this thesis will, for the first time provide evidence on the suitability of 
capability wellbeing as measured by the ICECAP-O in this population, and how its 
validity compares with existing measures in this context. 
As described in Chapter 3 Section 3.3, construct validity represents the ability of 
an instrument to measure the underlying concept it intends to measure (332, 353). 
This chapter will start by introducing the objectives of the construct validation. 
Definition of construct validity and methods of construct validation have been 
reviewed and discussed in greater depth in Chapter 3 (Section 3.3, 3.4). Specific 
hypotheses are described regarding the group comparison and convergent validity, 
and rationale for each of the hypotheses as well as the specific statistical methods 
are provided. Results of the assessment of each hypothesis are then provided, 
followed by a summary of results and discussion. 
6.2 Aims and objectives 
This chapter aims to explore the construct validity of the ICECAP-O instrument in 
a large-scale RCT of different classes of drugs in Parkinson’s (75). Specifically, 
there are three objectives for this chapter: 
1) To explore the impact of Parkinson’s on capability-wellbeing; 
2) To assess the construct validity of ICECAP-O in people with Parkinson’s in 
terms of its ‘known-group’ validity and convergent validity with measures 
with similar construct, i.e., the EQ-5D-3L, and the Parkinson’s specific QoL 
measure, the PDQ-39; and 
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3) To contrast the construct validity of ICECAP-O versus EQ-5D-3L in this 
population. 
In Chapter 1, Section 1.2.3 detailed the comprehensive impact of Parkinson’s on 
health, QoL and social wellbeing. Therefore, the first objective of this chapter is 
to use ICECAP-O to provide a broad picture of the capability-wellbeing impact in 
the population affected by Parkinson’s. 
As discussed in depth in Chapter 3 (Section 3.3), construct validity is a key 
property for a newly-developed measure to have established before it can be put 
into routine use in clinical or research settings. The second objective is to test the 
construct validity of the ICECAP-O in people with Parkinson’s. Establishing ‘known-
group’ validity is a prerequisite for the ICECAP-O to be used in health and 
wellbeing assessment studies to compare the impact from different interventions. 
In health economics, the ability of a measure to differentiate between varied 
health states is the premise for its application In economic evaluations. For 
example, the index score for the varied health states are directly used as 
parameters in economic models to generate QALYs. Testing convergent validity 
would aid the understanding of the underlying construct of ICECAP-O regarding its 
relationship with the validated measures, especially the existing commonly used 
measures. 
The third objective of this chapter is to test the construct validity of the current 
recommended measure by NICE, the EQ-5D-3L, as a reference point to help the 
interpretation of the ICECAP-O results. As discovered in Chapter 4, the EQ-5D-3L 
was generally able to distinguish between the groups defined by the clinical 
symptoms of Parkinson’s, such as apathy, falling, freezing, visual hallucinations 
and depression, although evidence was not consistent when distinguishing 
between groups with or without dyskinesia, and the presence of ‘wearing out’. By 
contrasting with the EQ-5D-3L, this research would be able to relate the results 
of construct validation of ICECAP-O to current decision-making and generate 
valuable insights which would help inform the choice of outcome measures in 
future research.  
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6.3 Data for this chapter 
Data for this chapter were collected from the PD MED RCTs. Details regarding the 
PD MED RCTs have been provided in last chapter Section 5.3. Cross-sectional data 
extracted from the overall RCT panel data were used for the analyses in this 
chapter. For the socio-demographic (i.e., age, sex, presence of a regular carer) 
and clinical characteristics (i.e., H&Y stages, duration with Parkinson’s) variables, 
they were extracted from the baseline assessment after each participant was 
recruited into the trial. For the QoL and wellbeing measures, including PDQ-39, 
ICECAP-O and EQ-5D-3L, responses were extracted only for the year when the 
participants completed their first ICECAP-O assessment. This analysis did not take 
the wave data (i.e., equal length of time staying in the RCT for each participant) 
from the RCT since the recruitment takes 10 years between 2001 and 2009 and 
thus by the year (2009/10) that the ICECAP-O added into the trial the participants 
were at varied wave of the trial. This ensures maximisation of sample size for this 
analysis, as well as generating a broad distribution of participants’ characteristics 
in the dataset, which improves the generalisability of the result.  
6.4 Methods 
As described in Chapter 3 Section 3.4.1, a five-step hypothesis testing model was 
used for construct validation. These steps are: theory specification, hypothesis 
derivation, research design, empirical observation, and revision of the theory and 
constructs. This study will follow this five-step model by applying data from the 
PD MED trials to conduct a construct validation of the ICECAP-O in people with 
Parkinson’s. This methods section will start by describing the hypotheses and 
justifications, followed by describing the statistical methods used to test these 
hypotheses. Missing data handling strategies are described at the end. 
6.4.1 Hypotheses 
In Chapter 3, Section 3.4.2 introduced two commonly used approaches to 
empirically test the construct validity of PbQoL measures: ‘known group’ method 
and convergent validity (440). Specific hypotheses were proposed a priori 
regarding the group differences in ICECAP-O responses (Early versus. Later) and 
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correlations between the three measures, as recommended by Brazier’s and 
COSMIN guideline (326, 327, 440). The detailed description, rationale and 
statistical methods for each of the hypotheses are presented in Table 6-1. They 
are summarised as below. 
Hypothesis 1: Early versus Later group comparison. This hypothesis contains two 
sub-hypotheses: 
(a) It was expected that the mean ICECAP-O index score in the Early group would 
be greater than that in the Later group (i.e. greater QoL/capability in the Early 
group).  
(b) It was expected that three ICECAP-O attributes, security, role and 
independence would be scored more highly (i.e. more capable) in the Early group 
than in the Later group. 
As mentioned previously in Section 3.4.2.2, the choice of criteria is important to 
the interpretation of the results in that the stronger correlation between the 
criteria and the test measure, the more favourable the ‘known-group’ results will 
be to the test measure. The criteria should be relevant to the use of the measure 
in practice. The criteria of Early versus Later group was chosen here because there 
was a clear difference regarding clinical management as distinguished by the PD 
MED trials. The patients were recruited to the Later trial or progressed from the 
Early to the Later groups when they developed motor complications or when their 
symptoms were not controlled by the drugs used in the Early trial. Therefore, as 
the first study with no previous information regarding the ICECAP-O capability-
wellbeing in this population, grouping by the most pragmatic criteria for making 
decisions about clinical management should provide valuable implications on the 
validity of ICECAP-O and its relevance to clinical practice in Parkinson’s.  
As a reference point to aid the interpretation of the result of the ICECAP-O, the 
responses for the EQ-5D-3L and PDQ-39 were also analysed and compared between 
the patient group in the Early and Later trial. 
Hypothesis 2:  convergent validity between instruments. It was expected that 
there would exist moderate correlation between the ICECAP-O and EQ-5D-3L and 
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between the ICECAP-O and PDQ-39. The correlation coefficient for the ICECAP-O 
and PDQ-39 was expected to be larger than that of the ICECAP-O and EQ-5D-3L.  
This latter hypothesis was developed based on the differing ‘constructs’ between 
the two ‘criterion’ measures; the construct of the PDQ-39 includes broader 
aspects (e.g. social support, communication) than the EQ-5D-3L whose construct 
focuses on health-related QoL especially physical aspects. An important 
terminology note here is that ‘criterion’ does not refer to the gold standard 
construct that ICECAP-O must conform to, or must only show high correlation to 
demonstrate its construct validity. Rather, the term ‘criterion’ here refers to a 
widely validated measure whose construct comprises a shared related theory with 
ICECAP-O in its design to some degree such that a correlation between them is 
expected (418). In this case, the shared related theory is that health is one of the 
key determinants of QoL and wellbeing. In addition, more specific hypotheses 
regarding the correlations between individual attributes of ICECAP-O and PDQ-
39/EQ-5D-3L were also proposed, which are presented in Table 6-1.  
 
Table 6-1: Hypotheses, rationale and testing methods 
1. Group comparison: groups classified by severity of Parkinson’s (Early vs. Later) 
Dependent 
variable(s) 
Independent 
variable(s) 
Hypotheses No. - 
Expected relationship(s) 
Testing 
method 
ICECAP-O 
total score 
Early - Later 1. The Early group was expected to have lower capability 
than the Later group. 
OLS 
univariabl
e 
regressio
n 
ICECAP-O 
total score 
Early - Later 
Age 
Sex 
2. The mean difference of ICECAP-O total score between 
the Early and Later group was expected to attenuate 
after adjusting for sex and age. 
Age is a potential confounding factor which was found 
previously to be negatively correlated with capability 
(312, 313), and those in the advanced group are older on 
average than those in the Early group. No relationships 
between capability and sex were found in both of above 
studies.  
OLS 
multivaria
ble 
regressio
n 
ICECAP-O 
security 
Early - Later 
Age 
Sex 
3. The Later group was expected to respond lower level in 
the ‘security’ attribute (i.e. more concerns towards future) 
than the Early group.  
Parkinson’s is a neurodegenerative disease with no cure 
and hence concerns towards future are common. 
Depression affects between 20-45% PwP(509) and has 
been found to be the most frequently identified 
determinant of HrQoL in PwP(487). 
Proportio
nal odds 
model 
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ICECAP-O 
Role 
Early - Later 
Age 
Sex 
4. The Later group was expected to report lower level in the 
‘role’ attribute (i.e. doing things making them feel valued) 
than the Early group.  
PwP’s productivity and performance towards their role 
can be affected by Parkinson’s symptoms. PwP have 
been found much higher chance to fall than general 
elderly population; e.g. a meta-analysis has shown 46% 
of PwP’s experience falls within a three month 
period(510). Furthermore, the hospital admission rate 
and length of stay has been found1.44 times more and 
1.19 times longer than the age-matched controls(511). 
Proportio
nal odds 
model 
ICECAP-O 
Control 
Early - Later 
Age 
Sex 
5. The Later group was expected to report lower level in 
‘control’ (i.e. be able to be independent) attribute than the 
Early group. 
Around 60% PwP have a regular carer in the PD MED 
trial(75), which suggests that their ability of self-care is 
limited. In addition, numerous studies have found 
Parkinson’s affect PwP’s ability of daily living. 
Proportio
nal odds 
model 
2. Convergent validity: relationship between ICECAP-O, EQ-5D-3L and PDQ-39 
Variables involved 
Hypotheses - 
Expected relationship(s) 
Testing 
method 
ICECAP-O 
total score 
EQ-5D-3L 
total score, 
PDQ-39 total 
score 
6. Medium correlation was expected to show between 
ICECAP-O and EQ-5D-3L and between ICECAP-O and 
PDQ-39 as they are measures with related construct but 
not same.  
 
7. It was also expected that ICECAP-O correlated more 
strongly with PDQ-39 than EQ-5D-3L because PDQ-39 
contains wellbeing attributes as well as HrQoL attributes.  
 
Davis et al. analysed the data from the seniors attending 
fall clinic in Vancouver and found the EQ-5D-3L values in 
the middle range were consistently lower than the 
ICECAP-O values but the two measures were consistent 
in the higher and lower range values (512). 
Pearson 
correlatio
n if the 
relations
hip is 
linear, 
otherwise 
Spearma
n 
correlatio
n 
Cocor R 
package 
is applied 
to test 
the 
significan
ce of the 
comparis
on 
 
ICECAP-O 
Attachment 
PDQ-39 
social 
support 
8. Strong correlation was expected between ICECAP-O 
attachment attribute and PDQ-39 social support attribute.  
 
ICECAP-O attachment attribute asks people how often 
they feel the love and friendship. This is very similar to 
the items in the ‘social support’ attribute in the PDQ-39, 
which asks: “Had problems with your close personal 
relationships?”, “Lacked support in the ways you need 
from your spouse or partner?” and “Lacked support in the 
ways you need from your family or close friends?” 
Pearson 
correlatio
n if the 
relations
hip is 
linear, 
otherwise 
Spearma
n 
correlatio
n 
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ICECAP-O 
Security 
PDQ-39 
emotional 
wellbeing, 
EQ-5D-3L 
anxiety/depre
ssion 
9. Strong correlation was expected between ICECAP-O 
security attribute and PDQ-39 emotional wellbeing 
attribute. 
  
ICECAP-O security attribute asks people to what degree 
they feel concern about future. Similarly, item 22 under 
the emotional wellbeing attribute in PDQ-39 asks: “felt 
worried about your future?” 
 
10. Strong correlation was expected between the security in 
ICECAP-O and the anxiety in EQ-5D-3L.  
 
‘Feel concerns about future’ and ‘feel anxious and/or 
depressed’ are associated. This association was found in 
Coast et al. in the general UK older population (312). 
Pearson 
correlatio
n if the 
relations
hip is 
linear, 
otherwise 
Spearma
n 
correlatio
n 
 
ICECAP-O 
role 
PDQ-39 
stigma 
EQ-5D-3L 
usual 
activities 
11. Medium correlation was expected between ICECAP-O 
role attribute and PDQ-39 stigma attribute. 
  
PDQ-39 item36 (stigma) asks “felt ignored by people?” 
which should be related to the role attribute in ICECAP-
O, “doing things make you feel valued”.  
 
12. Medium correlation was expected between the ICECAP-
O role attribute and EQ-5D-3L usual activities attribute. 
 
Makal et al. found there was medium association 
between ICECAP-O role and EQ-5D-3L usual activities 
(r=-0.47), the strongest correlation coefficient in their 
matrix of ICECAP-O attributes and EQ-5D-3L attributes 
(313). This was also tested in Davis et al.’s study using 
contingency table and Wilcoxon test, which, however, 
showed a few discrepancies between the two attributes 
(512). 
Pearson 
correlatio
n if the 
relations
hip is 
linear, 
otherwise 
Spearma
n 
correlatio
n 
 
ICECAP-O 
enjoyment 
PDQ-39 
Cognition 
and 
communicati
on 
13. Medium correlation was expected between ICECAP-O 
enjoyment attribute and PDQ-39 cognition and 
communication attributes. 
 
The items under these two attributes in PDQ-39 are very 
similar to the question of ‘enjoyment’ in ICECAP-O: PDQ-
39 item-31 (cognition): “had problems with your 
concentration. E.g. when reading or watching TV?” and 
PDQ-39 Item-35: “felt unable to communicate with people 
properly?” 
Pearson 
correlatio
n if the 
relations
hip is 
linear, 
otherwise 
Spearma
n 
correlatio
n 
 
ICECAP-O  
control 
EQ-5D-3L 
self-care 
14. Medium correlation was expected between ICECAP-O 
control attribute and EQ-5D-3L self-care attribute. 
  
Davis et al. hypothesized there were agreement between 
EQ-5D-3L self-care and ICECAP-O control in the 
Vancouver post fall senior population however their 
Wilcoxon test showed there were significant differences 
between the two attributes (512). 
Pearson 
correlatio
n if the 
relations
hip is 
linear, 
otherwise 
Spearma
n 
correlatio
n 
 
Abbreviation: PwP – people with Parkinson’s 
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6.4.2 Statistical analysis 
The statistical method used for each of the hypothesis is summarized in Table 6-1 
(Column: ‘testing method’).  
6.4.2.1 ‘Known-group’ analysis 
To test if the index scores of measures could differentiate between the Early and 
Later group (Hypothesis 1a), univariable regression was conducted to obtain the 
unadjusted mean difference between the groups, followed by multivariable 
regression which provided an adjusted mean difference after controlling for age 
and sex. Good evidence of construct validity was demonstrated by statistically 
significant difference between the groups. Given that statistical significance is 
dependent on sample size, weak evidence of construct validity was also 
considered if a statistically significant difference was nearly shown (p<0.1). 
For hypothesis 1b, the responses for each of the five attributes of ICECAP-O 
between the Early and Later groups were compared in five ordinal logistic 
regression models, adjusting for age and sex. Proportional odds model (POM) is a 
widely used ordinal logistic regression model but the POM’s validity relies on its 
underlying assumption, named the proportional odds assumption or parallel 
regression assumption (513). POM assumes that the coefficients which describe 
the relationship between the levels are the same (514). This is reflected in the 
output of POM that only one coefficient is reported for each variable. This 
assumption should be tested as it is unknown if the coefficient could be assumed 
to be the same between levels of ICECAP-O responses. The intervals of preference 
values between each level are varied, in other words, the increased preference 
for capability from level 1 (being unable) to 2 (being able in a little area) is 
different from the increase from level 2 to level 3 (being able in a lot of area). 
Therefore, the Brant test was conducted to test the proportional odds assumption 
(515). It allows testing the assumption for each independent variable separately, 
which is useful since only the variable that indicating the group assignment (Early 
vs. Later) was the interest of this study. If the assumption was violated for the 
group indicator variable, a partial proportional odds model would be fitted. This 
partial proportional odds model could provide a fixed coefficient for the 
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independent variables that meet the assumption and a series of varied coefficients 
for the independent variables that violate the assumption. 
In the proportional odds models, the reference group was the Early group for the 
models predicting the ICECAP-O attributes and Later group for the models 
predicting EQ-5D-3L attributes. This is because in EQ-5D-3L, level 1 is the best 
state (no problem) and level 3 (extreme problems) is the worst state, which is 
opposite to ICECAP-O in which level 1 is the worst state (least capable level) and 
level 4 is the best state (most capable level). This discrepancy led to the 
interpretation of the OR inversely if both of them use Early group as reference 
group. For ICECAP-O attributes, OR indicates the likelihood of responding to an 
increased level (more capability) in the Later group compared to Early group, 
which was expected to be less than 1 due to worsened health state of the Later 
group, whereas for EQ-5D-3L OR indicates the likelihood of responding to an 
increased level (worse health state) in the Later group compared to the Early 
group, which is expected to be larger than 1. Therefore, the reference group was 
switched to make the OR comparable between EQ-5D-3L and ICECAP-O. 
6.4.2.2 Convergent validity 
To test the convergent validity between instruments (Hypothesis 2), scatter plots 
were produced to enable visual examination of the relationship between the three 
sets of measures in the comparison, i.e. ICECAP-O & EQ-5D-3L, ICECAP-O & PDQ-
39, EQ-5D-3L & PDQ-39. Pearson correlations were then conducted to test when a 
linear relationship was observed; otherwise, Spearman’s rank correlation was used. 
Correlations above 0.6 are determined as strong, between 0.4 and 0.6 as moderate, 
and below 0.4 as weak. Where the magnitude of two correlations were compared, 
the web interface of the R statistical package cocor was implemented which offers 
ten statistical tests including Pearson and Filon’s z (1898) test and Zou’s 
confidence interval (2007) for testing the significance of the difference between 
correlations (516).  
6.4.2.3 Missing data and imputation 
Data were missing or incomplete if patients failed to return a questionnaire, 
provided an incomplete questionnaire or were lost to follow-up. Depending on the 
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pattern and reason, the missingness mechanism could be missing completely at 
random (MCAR), missing at random (MAR) and missing not at random (MNAR). The 
data are MCAR only if the missing values are like a random sample of all values so 
that missingness is not correlated with any variable, observed or unobserved (517, 
518). Only under MCAR, which is very rare, a complete-case analysis is unbiased; 
otherwise, a complete-case analysis may be biased as it omits every observation 
(row of data) that has a missing value for any of the model variables (i.e. observed 
data from patients for variables other than the one that is missing, is discarded). 
In addition, complete-case analysis shrinks the sample size substantially, 
increasing the uncertainty of the estimates. 
In contrast to MCAR, the data can be MAR or MNAR; the difference lies in whether 
the missingness depends only on information that are already observed. The data 
are MAR when the missingness is only correlated with observed variables and 
remains independent of the unobserved variables, so the observed variables are 
sufficient for predicting missingness (518). When there are unobserved factors 
that may strongly predict the missingness, the data are MNAR. Notably, it is 
unlikely to differentiate firmly between MAR or MNAR since proving MNAR requires 
us to observe, paradoxically, the ‘unobserved’ information. Nevertheless, it has 
been argued that the MAR assumption is more likely to be acceptable when adding 
more relevant variables in the imputation model (519).  
Multiple imputation with chained equations (MICE) was conducted which allows 
the imputation of multiple variables simultaneously. Missing responses for each 
question of EQ-5D-3L and ICECAP-O and missing subscores of PDQ-39 attributes 
were imputed. Ologit model was specified for the ordinal EQ-5D-3L and ICECAP-O 
responses and OLS regression model was specified for the PDQ-39 subscores. 
Besides the outcomes, Age, sex, duration with Parkinson’s and the baseline H&Y 
scale indicating severity of Parkinson’s were also included in the imputation 
models. Ten imputation datasets were generated and the results were combined 
using Rubin’s rule (520). The statistical analyses were conducted in STATA® 14 
(StataCorp. 2015) (521). The imputation code in STATA is shown in Appendix B. 
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6.5 Results 
The results section begins with a description of participant characteristics. 
Comparison between the Early and Later group are provided in terms of the 
summary scores of the ICECAP-O, EQ-5D-3L and the PDQ-39 measure, and each of 
the dimensions for these measures. This is followed by the scatter plot and 
correlation coefficients between the index scores of the three measures. The 
correlation coefficients between each dimension of the three measures are 
provided in the end. 
6.5.1 Sample description 
Responses from 1,010 participants in the Early group and 227 participants in the 
Later group were included in the analyses. Sample characteristics and percentage 
of missing values are presented in Table 6-2. Proportions of missing data were less 
than 5% for ICECAP-O index score and EQ-5D-3L index score, and around 20% for 
PDQ-39-SI. The difference in mean age of participants between the Early and later 
group was approximately two years (73.56 vs. 75.22), whereas the mean duration 
since diagnosis of Parkinson’s differed by four years (5.48 vs. 9.60). Consistent 
with the longer duration with Parkinson’s in the Later group was the increased 
H&Y stage in this group, which had a median of 2.5 compared to 1.5 in the Early 
group. The two groups were similar in the gender distribution with around 65% 
male participants, and approximately 65% participants in both groups had a 
regular carer.  
Besides age, duration with Parkinson’s, Parkinson’s severity (baseline H&Y scale), 
expected differences were observed between the Early and Later groups for the 
ICECAP-O score, EQ-5D-3L score, and PDQ-39-SI (Table 6-2). Distributions for the 
three measures are presented in Figure 1. The distribution for the Early and Later 
group are overlaid to enable contrasting between the groups. It shows that the 
Later group distribution (hollow bins) for all the three measures are consistently 
shifting to the lower QoL from the Early group distribution (filled with colour), i.e. 
ICECAP-O to the lower value on the left representing lower capability, EQ-5D-3L 
to the lower value on the left representing lower health-related QoL, and PDQ-39 
to the higher value on the right representing lower QoL and wellbeing. The mean 
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ICECAP-O score was 0.76 (SD 0.17) for the Early group and 0.69 (SD 0.18) for the 
Later group, EQ-5D-3L score 0.54 (SD 0.29) for the Early and 0.45 (SD 0.29) for the 
Later, and PDQ-39-SI 29.99 (SD 17.14) for the Early and 37.87 (SD 17.75) for the 
Later group.  
Table 6-2: Sample characteristics (complete case) 
 Early group  Later group 
 Mean SD N Missing (%)  Mean SD N 
Missing 
(%) 
Age 73.56 8.37 1010 0  75.22 8.36 227 0 
Duration with Parkinson’s 5.48 2.67 1010 0  9.60 4.48 227 0 
 Median IQR N   Median IQR N  
Baseline H&Y 1.5 1-2 1010 0  2.5 2-3 227 0 
          
 Freq. %    Freq. %   
Sex    0.4     0 
Male 653 64.65    147 64.76   
Female 353 34.95    80 35.24   
with Regular carer    0     0 
Yes 671 66.44    149 65.64   
No 339 33.56    78 34.36   
          
 Mean SD N   Mean SD N  
ICECAP-O index score 0.76 0.17 994 1.6  0.69 0.18 225 0.9 
EQ-5D-3L index score 0.54 0.29 998 1.2  0.45 0.29 218 4.0 
PDQ-39-SI 29.99 17.14 864 14.5  37.87 17.75 178 21.6 
Note: score range: H&Y (Hoehn and Yahr scale: a Parkinson’s severity measure): 1 (mildest) – 5 (most 
severe). ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 (worse than death) ~0(death) ~ 
1(full health). PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 (most severe).  
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Figure 6-1: Distribution of ICECAP-O, EQ-5D-3L and PDQ-39 in the Early group 
and the Later group.  
Note: score range: ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 
(worse than death) ~0 (death) ~ 1(full health). PDQ-39: 0 (least severe) ~ 100 (most 
severe). 
 
6.5.2 Known-group comparison 
6.5.2.1 Summary scores of three measures 
Table 6-3 shows the unadjusted and adjusted mean difference of ICECAP-O score, 
as well as EQ-5D-3L score and PDQ-39-SI. The Later group had a statistically 
significant lower (p<0.001) health-related QoL and wellbeing as shown by all  three 
measures, in both unadjusted and adjusted analysis. The unadjusted mean 
difference in the ICECAP-O value between the Early and Later participants (Early 
– Later) was 0.070 (95%CI 0.044, 0.096), which was slightly attenuated to 0.067 
(95%CI 0.041, 0.093) after adjusting for age and sex. The unadjusted and adjusted 
mean difference in the EQ-5D-3L value had a larger magnitude than the ICECAP-
O. This could be due to larger difference in HrQoL between the groups than in 
capability, or due to the larger possible score range of EQ-5D-3L which is 
approximately 1.5 times larger than ICECAP-O. Another reference measure, PDQ-
39, also showed a statistically significant difference between the two groups with 
8.30 (95%CI 5.72, 10.88) points difference after adjusting for age and sex. 
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Table 6-3: Early versus Later group: mean differences of ICECAP-O, EQ-5D-3L 
and the PDQ-39 
 Unadjusted  Adjusted for age and sex 
Measures Mean 
estimate 95% CI p value  
Mean 
estimat
e 
95% CI p value 
ICECAP-O -0.070 -0.096, -0.044 0.000  -0.067 -0.093, -0.041 0.000 
EQ-5D-3L -0.095 -0.137, -0.052 0.000  -0.091 -0.133, -0.049 0.000 
PDQ-39 8.39 5.81, 10.97 0.000  8.30 5.72, 10.88 0.000 
Note: score range: H&Y (Hoehn and Yahr scale: a Parkinson’s severity measure): 1 (mildest) – 5 
(most severe). ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 (worse than 
death) ~0(death) ~ 1(full health). PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 
(most severe).    
 
6.5.2.2 ICECAP-O dimension responses 
The distribution of responses for the ICECAP-O’s five attributes are shown in Table 
6-4 and Figure 6-2. For attachment, 55.5% and 47.6% of the participants in the 
Early and Later groups, respectively, reported the highest level of capability (level 
4) - “I can have all of the love and friendship that I want”. For the other four 
attributes, security, role, enjoyment and control, the most frequently reported 
level in the Early group was level 3 (capable in many things), compared to the 
Later group which was level 2 (capable in a few things). The proportion of 
participants reporting the least capable level of security was the largest as 
compared to that of other attributes:  20% of Later participants and 14% of Early 
participants reported the least capable level (level 1) - ‘I can only think about 
future with a lot of concern’. 
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Table 6-4: Responsesa on ICECAP-O for the Early group and Later group 
ICECAP-Ob 
Freq. %  Freq. %  Freq. %  Freq. %  Freq. % 
Attachment  Security  Role  Enjoyment  Control 
Early group               
Levels               
1 23 2.28  141 13.96  75 7.43  42 4.16  74 7.33 
2 123 12.18  379 37.52  366 36.24  320 31.68  285 28.22 
3 291 28.81  380 37.62  407 40.3  489 48.42  465 46.04 
4 561 55.54  105 10.4  159 15.74  156 15.45  184 18.22 
Missing 12 1.19  5 0.5  3 0.3  3 0.3  2 0.2 
Total 1,010 100  1,010 100  1,010 100  1,010 100  1,010 100 
Later group               
Levels               
1 4 1.76  46 20.26  26 11.45  15 6.61  32 14.1 
2 41 18.06  107 47.14  113 49.78  107 47.14  89 39.21 
3 73 32.16  58 25.55  67 29.52  88 38.77  91 40.09 
4 108 47.58  15 6.61  21 9.25  17 7.49  15 6.61 
Missing 1 0.44  1 0.44  0 0  0 0  0 0 
Total 227 100  227 100  227 100  227 100  227 100 
Note: a. The responses are the original observed data from the 1010 participants in this analysis at their first 
ICECAP-O assessments, including missing values, before multiple imputation. 
b. For ICECAP-O, level 1 is the least capable level while level 4 is the most capable level.  
 
 
 
 
Figure 6-2: Response on ICECAP-O for the Early group and Later group. 
Note: For ICECAP-O, level 1 is the least capable level while level 4 is the most capable level 
 
 
The results of the proportional odds models are presented in Table 6-5. The 
variable which indicates the group (Later/Early) met the proportional odds 
assumption for all models, hence, only one odds ratio (OR) was reported for each 
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attribute. The unadjusted ORs between the two groups (Later/Early) were 0.71 
(95%CI 0.54, 0.93) for attachment, 0.56 (95%CI 0.43, 0.73) for security, 0.52 (95%CI 
0.40, 0.69) for role, 0.49 (95%CI 0.38, 0.65) for enjoyment, and 0.46 (95%CI 0.35, 
0.59) for control. The ORs became smaller after adjusting for age and sex for 
attachment and security attribute, and larger after adjustment for role, 
enjoyment, and control; but the difference was minimal in both direction. As was 
theorised, all the ORs are less than one, indicating that participants in the Later 
group have reduced odds of reporting an increased level of capability in 
comparison to the participants in the Early group. For example, for the ‘role’ 
attribute, the odds that a participant in the Later group answers an increased 
level (more capability), is approximately half (0.52) the corresponding odds for a 
participant in the Early group, which means that the later stage group was 
approximately twice as more likely to respond with a lower level of capability 
than the early group for the ‘role’ attribute.  
Table 6-5: Odds ratio (OR) between the levels of ICECAP-O attributes (Later 
group / Early group) 
ICECAP-O 
Attribute 
Unadjusted  Adjusted for age and sex 
OR (95%CI) P value  OR (95%CI) P value 
Attachment 0.711 (0.541, 0.934) 0.014  0.706 (0.537, 0.928) 0.012 
Security 0.558 (0.428, 0.728)  0.000  0.533 (0.408, 0.697) 0.000 
Role 0.524 (0.400, 0.686) 0.000  0.548 (0.418, 0.718) 0.000 
Enjoyment 0.493 (0.376, 0.647) 0.000  0.506 (0.385, 0.665) 0.000 
Control 0.456 (0.349, 0.595) 0.000  0.484 (0.370, 0.633) 0.000 
Note for 2b: For ICECAP-O, level 1 is the least capable level while level 4 is the most capable 
level. For EQ-5D-3L, Level 1 is “no problem”, level 2 “some problems”, and level 3 “extreme 
problems”. 
 
6.5.2.3 EQ-5D-3L dimension responses 
Responses obtained for the EQ-5D-3L are presented in Table 6-6 and visualized in 
Figure 6-3. For the EQ-5D-3L, the most frequently reported level in both Early and 
Later group for all attributes was level 2, ‘some problems’. There was an obvious 
proportion shifting from level 1 ‘no problem’ to level 2 ‘some problems’ for 
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mobility and anxiety, and from level 1 ‘no problem’ to level 2 and 3 ‘some and a 
lot of problems’ for self-care, usual activities and pain/discomfort.  
Table 6-6: Responsesa on EQ-5D-3L for the Early group and Later group 
  EQ-5D-3Lb 
Freq. %  Freq. %  Freq. %  Freq. %  Freq. % 
Mobility  Self-care  Usual activities  Pain/ discomfort 
 
 
Anxiety/ 
depression 
Early group               
Levels               
1 234 23.17  429 42.48  202 20.00  238 23.56  435 43.07 
2 754 74.65  521 51.58  675 66.83  666 65.94  518 51.29 
3 14 1.39  51 5.05  124 12.28  98 9.70  47 4.65 
Missing 8 0.79  9 0.89  9 0.89  8 0.79  10 0.99 
Total 1010 100  1010 100  1010 100  1010 100  1010 100 
Later group               
Levels               
1 22 9.69  62 26.87  21 9.25  34 14.98  76 33.48 
2 194 85.46  136 59.91  155 68.28  160 70.48  135 59.47 
3 4 1.76  24 10.57  44 19.38  26 11.45  10 4.41 
Missing 7 3.08  6 2.64  7 3.08  7 3.08  6 2.64 
Total 227 100  227 100  227 100  227 100  227 100 
Note: a. The responses are the original observed data from the 1010 participants in this analysis at their first 
ICECAP-O assessments, including missing values, before multiple imputation. 
b. For EQ-5D-3L, Level 1 is “no problem”, level 2 “some problems”, and level 3 “extreme problems”. 
 
 
 
Figure 6-3: Response on EQ-5D-3L for the Early group and Later group.   
Note: For EQ-5D-3L, Level 1 is “no problem”, level 2 “some problems”, and level 3 “extreme problems”.  
 
The results of the proportional odds models for the EQ-5D-3L attributes are shown 
in Table 6-7. Similar to the ICECAP-O attributes, the group variable (Later/Early) 
met the proportional odds assumption for all five regressions. The ORs were all 
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less than one as expected, indicating that participants in the Early group have 
reduced odds of reporting an increasing level (a worse health state) compared to 
the Later group. The group difference can be ranked from the largest to smallest 
based on the adjusted OR (Early/Later) as mobility (0.43, 95%CI 0.29 - 0.65, the 
furthest OR from 1), self-care (0.50, 95%CI 0.37 - 0.67), usual activities (0.52, 
95%CI 0.38 - 0.71), pain and discomfort (0.67 (95%CI 0.49 - 0.90), and lastly, 
anxiety and depression (0.70, 95%CI 0.52 - 0.93).  
 
Table 6-7: Odds ratio (OR) between the levels of EQ-5D-3L attributes (Early 
group / Later group) 
EQ-5D-3L attributea 
Unadjusted  Adjusted for age and sex 
OR (95%CI) P value  OR (95%CI) P value 
Mobility 0.417 (0.277, 0.627) 0.000  0.434 (0.288, 0.653) 0.000 
Self-care 0.480 (0.357, 0.645)  0.000  0.497 (0.369, 0.669) 0.000 
Usual activities 0.492 (0.362, 0.670) 0.000  0.519 (0.380, 0.707) 0.000 
Pain and discomfort 0.668 (0.490, 0.910) 0.000  0.663 (0.486, 0.904) 0.000 
Anxiety and depression 0.710 (0.533, 0.945) 0.019  0.698 (0.523, 0.931) 0.014 
Note: a. For EQ-5D-3L, level 1 is “no problem”, level 2 “some problems”, and level 3 “extreme problems”. This 
is opposite to ICECAP-O in which level 1 is the least capable level and level 4 is the most capable level. To 
make the OR comparable between EQ-5D-3L and ICECAP-O, the comparison was reversed to ‘Early/Later’ 
with Later group as reference group. 
  
6.5.2.4 PDQ-39 dimensions 
Mean scores of the PDQ-39 eight dimensions for the Early and Later groups  are 
presented in Table 6-8 and visualised in Figure 6-4. Based on the magnitude of the 
score, the aspects that Parkinson’s affected most were mobility, ADL, bodily 
discomfort, and cognition.  Table 6-9 shows the unadjusted and adjusted mean 
difference (Later – Early) of the PDQ-39 attributes. For all of the eight attributes, 
the scores in the Later group were statistically significantly higher than the Early 
group. The magnitude of the mean difference between the Early and the Later 
group was largest in mobility (15.45, 95%CI 11.14 – 19.76), ADL (12.33, 8.49 – 
16.17), and communication (8.82, 95%CI 5.39 – 12.25), which indicates these 
attributes deteriorated most with the progression of Parkinson’s. These were 
followed by stigma (7.12, 95%CI 3.58 – 10.65), bodily discomfort (6.56, 95%CI 2.84 
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- 10.29), emotional wellbeing (6.46, 95%CI 3.19 – 9.72), cognition (5.53, 95%CI 
2.33 - 8.74), and social support (4.14, 95%CI 1.54 - 6.74). 
 
Table 6-8: Mean score of PDQ-39 eight dimensions for the Early group and 
Later group (complete casea) 
PDQ-39 attributesb 
Early group  Later group 
Mean SD N Missing (%)  Mean SD N Missing (%) 
Mobility 45.84 30.98 969 4.1  63.54 29.70 212 6.6 
ADL 39.57 25.77 958 5.1  51.46 25.35 206 9.3 
Emotional 27.82 22.33 936 7.3  33.77 22.37 200 11.9 
Stigma 21.56 23.13 965 4.5  27.51 26.13 207 8.8 
Social support 11.16 17.15 944 6.5  14.20 18.44 203 10.6 
Cognition 34.81 21.52 962 4.6  40.15 22.59 205 9.7 
Communication 24.17 22.85 965 4.5  32.61 24.92 208 8.4 
Bodily discomfort 39.75 25.20 959 5.0  45.73 26.78 207 8.8 
Note: a. The data are the original observed data from the 1010 participants in this analysis at their first 
ICECAP-O assessments, including missing values, before multiple imputation. 
b. score range: PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 (most severe).    
 
 
Figure 6-4: Responses on PDQ-39 eight attributes for the Early group and 
Later group.  
Note: score range: PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 (most severe).    
 
Chapter 6  177 
Table 6-9: Mean difference (Later – Early) of the PDQ-39 attributes 
PDQ-39 attributes 
Unadjusted  Adjusted for age and sex 
Mean 
difference 95%CI 
P 
value  
Mean 
difference 95%CI p value 
Mobility 16.81 12.33, 21.29 0.000  15.45 11.14, 19.76 0.000 
ADL 12.96 9.10, 16.81 0.000  12.33 8.49, 16.17 0.000 
Emotional 6.18 2.90, 9.47 0.000  6.46 3.19, 9.72 0.000 
Stigma 6.52 2.96, 10.07 0.000  7.12 3.58, 10.65 0.000 
Social support 3.64 1.02, 6.26 0.006  4.14 1.54, 6.74 0.002 
Cognition 6.21 2.98, 9.43 0.000  5.53 2.33, 8.74 0.001 
Communication 8.80 5.35, 12.25 0.000  8.82 5.39, 12.25 0.000 
Bodily 
discomfort 6.00 2.24, 9.77 0.002  6.56 2.84, 10.29 0.001 
Note: score range: PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 (most severe). 
 
6.5.3 Convergent validity 
Figure 6-5 shows a linear relationship between the ICECAP-O value and the PDQ-
39 summary score, the EQ-5D-3L utility values and the PDQ-39 summary score, and 
the ICECAP-O score and EQ-5D-3L utility values. The ICECAP-O index score was 
found to be highly correlated with the EQ-5D-3L index value (r = 0.65; p<0.001) 
and PDQ-39-SI (r = 0.73; p<0.001) ( 
Table 6-10). The null hypothesis that these two correlation coefficients are equal 
was rejected for all of the statistical tests (one-sided p value < 0.0001 for all) 
(Please see Appendix C for the full results). The confidence interval for the 
‘additional’ correlation coefficients for the ICECAP-O - PDQ-39 compared to 
ICECAP-O - EQ-5D was tested to be 0.0481 and 0.1109. Therefore, it shows that 
the ICECAP-O index score was more strongly correlated with PDQ-39 score than 
with the EQ-5D-3L index score (hypothesis 7 in Table 6-1). 
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Figure 6-5: Scatter plots of ICECAP-O - PDQ-39, EQ-5D-3L – PDQ-39 and 
ICECAP-O – EQ-5D-3L.  
Note: score range: ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 (worse than death) 
~0(death) ~ 1(full health). PDQ-39: 0 (least severe) ~ 100 (most severe). 
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Table 6-10: Pearson correlations between overall score of ICECAP-O, EQ-5D-
3L and PDQ-39 
 
ICECAP-O index 
score 
EQ-5D-3L index 
score 
PDQ-39-SI 
ICECAP-O index score 1   
EQ-5D-3L index score 0.654 1  
PDQ-39-SI 0.733 0.724 1 
Note: score range: ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 (worse than death) 
~0(death) ~ 1(full health). PDQ-39: 0 (least severe) ~ 100 (most severe). 
 
A correlation matrix between all the attributes of ICECAP-O, PDQ-39 and EQ-5D-
3L is presented in Table 6-11.  For each of the ICECAP-O attributes, the most 
correlated attributes from PDQ-39 and EQ-5D-3L respectively were: ICECAP-O 
‘attachment’ -  PDQ-39 ‘social support’ (r=0.50) and EQ-5D-3L ‘anxiety’ (r=0.26); 
ICECAP-O ‘security’ - PDQ-39 ‘emotional wellbeing’ (r=0.58) and EQ-5D-3L 
‘anxiety’ (r=0.50); ICECAP-O ‘role’ – PDQ-39 ‘mobility’ (r=0.63) and EQ-5D-3L 
‘usual activities’ (r=0.56); ICECAP-O ‘enjoyment’ – PDQ-39 ‘mobility’ (r=0.55) and 
EQ-5D-3L ‘usual activities’ (r=0.51); and ICECAP-O ‘control’ – PDQ-39 ‘mobility’ 
(r=0.72) and EQ-5D-3L ‘usual activities’ (r=0.62). In addition, the ICECAP-O 
attributes ‘role’ and ‘enjoyment’ correlated most strongly with each other 
(r=0.64), as well as ‘role’ and ‘control’ (r=0.63). 
 
 
 
   
Chapter 6  180 
Table 6-11: Pearson correlation coefficients matrix – attributes of ICECAP-O, PDQ-39 and EQ-5D-3L 
Attributes 
ICECAP-O EQ-5D-3L PDQ-39 
Attach
ment Security Role 
Enjoyme
nt Control Mobility 
Self-
care 
Usual 
activitie
s 
Pain Anxiety Mobility ADL 
Emotion
al 
Wellbei
ng 
Stigma Social 
support 
Cognitio
n 
Commu
nication 
Bodily 
discomfo
rt 
ICECAP-
O 
Attachmen
t 1 
                 
 Security 0.302 1                 
 Role 0.333 0.469 1                
 Enjoyment 0.458 0.457 0.638 1               
 Control 0.255 0.382 0.627 0.588 1              
EQ-5D-3L Mobility 0.142 0.253 0.402 0.365 0.484 1             
 Self-care 0.191 0.294 0.511 0.464 0.613 0.432 1            
 
Usual 
activities 0.222 0.322 0.562 0.513 0.624 0.510 0.574 1 
          
 Pain 0.146 0.239 0.282 0.304 0.333 0.341 0.243 0.313 1          
 Anxiety 0.261 0.495 0.412 0.413 0.389 0.264 0.299 0.330 0.309 1         
PDQ-39 Mobility 0.226 0.369 0.629 0.554 0.724 0.601 0.604 0.651 0.395 0.411 1        
 ADL 0.221 0.331 0.581 0.496 0.681 0.477 0.737 0.609 0.298 0.367 0.745 1       
 
Emotional 
Wellbeing 0.330 0.580 0.522 0.503 0.524 0.340 0.440 0.422 0.348 0.710 0.577 0.552 1 
     
 Stigma 0.265 0.393 0.399 0.392 0.394 0.224 0.317 0.320 0.244 0.429 0.409 0.465 0.598 1     
 
Social 
support 0.503 0.395 0.352 0.411 0.352 0.198 0.284 0.263 0.237 0.408 0.326 0.360 0.558 0.499 1 
   
 Cognition 0.194 0.285 0.459 0.429 0.497 0.333 0.444 0.390 0.285 0.390 0.493 0.578 0.534 0.369 0.348 1   
 
Communic
ation 0.278 0.337 0.462 0.422 0.486 0.353 0.428 0.408 0.202 0.366 0.436 0.569 0.526 0.465 0.492 0.549 1 
 
 
Bodily 
discomfort 0.150 0.340 0.364 0.352 0.383 0.362 0.330 0.324 0.565 0.387 0.453 0.452 0.519 0.384 0.335 0.476 0.365 1 
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6.5.4 Hypotheses tests 
The hypotheses (Section 6.4.1) testing results are summarized in Table 6-12. 
Table 6-12 Results of hypotheses testing 
Known-group hypotheses Testing 
result 
1. The Early group was expected to have lower capability than the Later group. Yes 
2. The mean difference of ICECAP-O total score between the Early and Later group 
was expected to attenuate after adjusting for sex and age. 
Yes 
3. The Later group was expected to respond lower level in the ‘security’ attribute (i.e. 
more concerns towards future) than the Early group.  
Yes 
4. The Later group was expected to report lower level in the ‘role’ attribute (i.e. doing 
things making them feel valued) than the Early group.  
Yes 
5. The Later group was expected to report lower level in ‘control’ (i.e. be able to be 
independent) attribute than the Early group. 
Yes 
Correlation hypotheses  
6. Medium correlation was expected to show between ICECAP-O and EQ-5D-3L and 
between ICECAP-O and PDQ-39  
Yes 
7. It was also expected that ICECAP-O correlated more strongly with PDQ-39 than EQ-
5D-3L. 
Yes 
8. Strong correlation was expected between ICECAP-O attachment attribute and PDQ-
39 social support attribute.  
No, 
r=0.503 
9. Strong correlation was expected between ICECAP-O security attribute and PDQ-39 
emotional wellbeing attribute. 
No, 
r=0.580 
10. Strong correlation was expected between the security in ICECAP-O and the anxiety 
in EQ-5D-3L. 
No,  
r=0.495 
11. Medium correlation was expected between ICECAP-O role attribute and PDQ-39 
stigma attribute 
Yes 
12. Medium correlation was expected between the ICECAP-O role attribute and EQ-5D-
3L usual activities attribute. 
Yes 
13. Medium correlation was expected between ICECAP-O enjoyment attribute and PDQ-
39 cognition and communication attributes. 
Yes 
14. Medium correlation was expected between ICECAP-O control attribute and EQ-5D-
3L self-care attribute. 
No, 
r=0.613 
 
 
6.6 Summary of results 
This study is the first to test the construct validity of the ICECAP-O in the 
Parkinson’s population. Groups with Early and Later stages of Parkinson’s in the 
PD MED trials were compared in terms of the ICECAP-O index score and the 
responses for each attribute. The EQ-5D-3L and PDQ-39 were also compared 
Chapter 6  182 
between groups as a reference. The Later group was found to have statistically 
significant lower capability wellbeing in comparison to the Early group.  
Specifically, for the ICECAP-O attributes ‘security’, ‘role’, ‘enjoyment’ and 
‘control’, the Later group was approximately twice as likely to respond with a 
lower level of capability than the Early group. This demonstrates the substantial 
impact on those aspects of QoL and wellbeing with the progression of Parkinson’s 
from the Early stage when symptoms can be controlled by drugs to the Later stage 
with motor complications developed. 
In addition, the ICECAP-O value was found to be highly correlated with the EQ-5D-
3L score and PDQ-39-SI, both of which are commonly used and widely validated 
QoL measures in Parkinson’s. PDQ-39 attributes, ‘social support’, ‘emotional 
wellbeing’ and ‘mobility’, and EQ-5D-3L attributes, ‘anxiety’ and ‘usual activities’, 
were found to correlate most strongly with ICECAP-O attributes. In summary, the 
ICECAP-O’s construct validity was established in terms of discriminating between 
groups with Early and Later stages of Parkinson’s and association with EQ-5D-3L 
and the Parkinson’s specific QoL and wellbeing measure PDQ-39. The ICECAP-O 
shows potential as a preference-based approach to the measurement of capability 
wellbeing in the Parkinson’s population.  
6.7 Results in the context of existing evidence 
This study found that the mean ICECAP-O value in the Early Parkinson’s group was 
lower than that in the Later group, both of which (0.76 for the Early group and 
0.69 for the Later group) were lower than the reported mean ICECAP-O score (0.83 
(SD 0.12)) in the UK general population aged ≥ 65 years assessed  by  Flynn et al 
(522). It was also lower than the population in previous validation studies, 
including in frail older adults (mean 0.78, SD 0.16) (319), post-hospitalized older 
people overall (mean 0.84, SD 0.14) (313), osteoarthritis patients requiring joint 
replacement (mean 0.772, SD 0.17) (523), and in older adults with mobility 
impairment (mean 0.815, SD 0.177) (316). In the study among the post-
hospitalized older people, the groups that had an ICECAP-O score lower than 0.8 
were the subgroup that were divorced (mean 0.76), or in a nursing home (mean 
0.78), limited social activity (mean 0.77) and depressed (mean 0.73) (SD not 
provided for the subgroups). The above comparisons indicate that the capability 
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impact of Parkinson’s in the affected population is substantial compared to people 
with other conditions. 
It was found that PDQ-39 ‘mobility’ and EQ-5D-3L ‘usual activities’ were the most 
highly correlated attributes to the ICECAP-O’s attributes ‘role’, ‘enjoyment’ and 
‘control’. This finding agrees with a study by Coast et al. which assessed the 
ICECAP-O in individuals aged 65 and over in the general population of the UK and 
reported strong relationships between physical measures of health and the above 
three attributes of ICECAP-O (312). Moreover, PDQ-39’s attributes ‘social support’ 
and ‘emotional wellbeing’ and EQ-5D-3L’s ‘anxiety’ were the highest correlated 
attributes with ICECAP-O’s ‘attachment’ and ‘enjoyment’ attributes, which also 
agrees with findings by Coast et al that mental health measures strongly relates 
to those two attributes (312). Both being generic preference-based measures, 
notwithstanding the moderate to strong correlation between the EQ-5D-3L and 
ICECAP-O, Davis et al. suggested that the EQ-5D-3L and ICECAP-O are 
complementary measures rather than substitutes as there are several differences 
between them (512). They conducted exploratory factor analysis on the responses 
of the two measures among the population that attended a fall clinic and found 
that the EQ-5D-3L attributes appear to represent a single factor, ‘physical 
functioning’ and in contrast, ICECAP-O attributes represent an “overall reflection 
of participants perceived capacity for QoL and wellbeing – ‘psychosocial 
wellbeing’”. 
6.8 Chapter summary 
This chapter explored the capability wellbeing in people with Parkinson’s using 
the PD MED data, and tested the ‘known-group’ validity and convergent validity 
of the ICECAP-O capability measure in this population. In conclusion, this  
demonstrated the construct validity of the ICECAP-O in Parkinson’s. Besides 
construct validity, another measurement property that is important to be tested 
for ICECAP-O is responsiveness, which will be reported in the next chapter.
   
   
Chapter 7 Testing the responsiveness of the 
ICECAP-O and comparison with the EQ-5D-3L 
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7.1 Introduction 
Chapter 6 demonstrated the construct validity of the ICECAP-O instrument, cross-
sectionally, revealing there are important, measurable differences in the ICECAP-
O score in patients with varied severity of Parkinson’s. Built on the findings in 
Chapter 6, this chapter will continue addressing the second research question (is 
the ICECAP-O appropriate to capture the wellbeing impact in Parkinson’s, and is 
it sensitive in this population? (Chapter 1, Section 1.6)) by assessing the ICECAP-O 
capability measure in a longitudinal way, i.e.  responsiveness; that is, the ability 
to measure a meaningful or clinically important change in various aspects of 
Parkinson’s patients’ QoL and wellbeing over time. This is the first time that the 
responsiveness of ICECAP-O has been assessed and compared with the EQ-5D-3L in 
this population. 
As discussed in Chapter 3 Section 3.5.2, responsiveness refers to the ability of an 
instrument to detect important change over time in the construct to be measured 
(322). Responsiveness of PbQoL measures to patients’ preference is critical, as it 
will affect the magnitude of the QALY. The impact is especially fundamental when 
QALY gain is small, which may result in dramatic change of funding 
recommendations of new interventions. In other words, the new intervention 
appearing to be not cost effective may be attributed to the non-responsiveness of 
the instrument to its intended benefit, rather than lack of benefit. Limited 
instrument responsiveness will hinder the use of preference-based measures to 
accurately measure the change in health utilities and jeopardize the rigor and 
usefulness of the cost-effectiveness result. 
This chapter starts with the aims and specific objectives for this assessment of 
responsiveness, followed by the methods, results and discussion. Definition of 
responsiveness, along with theoretical basis and statistical methods (e.g. anchor 
based methods, choice of anchor, group formation, effect size, correlations) to 
assess the responsiveness have been reviewed and discussed in greater depth in 
Chapter 3, Section 3.5 and 3.6. This chapter describes the methods in this specific 
context of Parkinson’s population with data from the PD MED trials in terms of the 
choice of anchors, the grouping information, the statistical methods for the 
assessment and the approach to handling missing data.  
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7.2 Aims and objectives 
This chapter aims to explore the responsiveness of the ICECAP-O in people with 
Parkinson’s and compare this with the current most commonly used measure in 
economic evaluations in Parkinson’s, the EQ-5D-3L.  
Specifically, there are five objectives for this chapter. They are: 
1) To explore the impact of Parkinson’s progression on individual’s capability-
wellbeing; 
2) To assess the responsiveness of ICECAP-O in people with Parkinson’s to the 
change of patients’ overall and eight specific aspects of QoL (i.e. mobility, 
ADL, emotional wellbeing, stigma, social support, cognitions, 
communication, and pain, as measured by PDQ-39), and clinical health 
status (as measured by H&Y); 
3) To assess the responsiveness of the EQ-5D-3L and compare with that of the 
ICECAP-O to the change of the various health and wellbeing aspects as 
outlined in the second objective above;  
4) To explore how to adapt the psychometric methods for the assessment of 
responsiveness to the assessment of PbQoL measures; and 
5) To investigate the impact of missing data on the result of assessment of 
responsiveness. 
The last chapter has demonstrated cross-sectionally that there was statistically 
significant and large difference in capability wellbeing between the groups with 
Early and Later stage of Parkinson’s. There is no doubt this finding could be 
interpreted as the substantial impact of Parkinson’s progression on people’s 
capability since all the patients will progress from Early to Later stage. 
Nevertheless, the nature of analysis in last chapter is a cross-sectional group 
comparison in that it compares between groups that formed by different 
individuals. This chapter will therefore assess the impact of progression from 
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another perspective, by examining the actual progression of each individual 
patient over time. This is the first objective of this chapter. 
The second objective is to jointly address the overall research question of this 
thesis with the assessment of construct validity in last chapter. The feature of 
‘being broad’ for a QoL measure brings positive voices but also doubts. The 
ICECAP-O measure is comprised of five broad dimensions of wellbeing: attachment, 
security, role, enjoyment and control, each with four levels. It was developed 
based on Sen’s capability approach and in response to the criticism over the 
application of extra-welfarism (Section 2.7) to broaden the evaluative scope. 
ICECAP-O is designed to capture the change of QoL in a broader sense and as such 
the full picture of a Parkinson’s patients’ life could be incorporated into decision-
making. Nonetheless, health-care interventions in many circumstances focus on 
health aspects of QoL (as opposed to the spill-over broader influence), with a core 
goal to treat diseases. The broad scope of the ICECAP-O instrument and deliberate 
divergence from ‘health-specific’ attributes to ‘capability wellbeing’ attributes 
could arguably generate concerns over its sensitivity to capture specific health 
changes in a narrower context focused on health. This may affect its use in 
evaluating typical health-care interventions and as such necessitates the 
comprehensive assessment of the tool’s responsiveness to change in health status. 
This leads to the second objective of this chapter. 
The review in Chapter 4 showed that there are some concerns regarding the 
responsiveness of the EQ-5D-3L as the agreement over the longitudinal change 
between the EQ-5D-3L and the Parkinson’s-specific QoL/clinical measures varied 
across studies. Half of the included studies showed that the EQ-5D-3L scores 
reflected changes in clinical status over time as shown on the reference measures, 
while the other half failed to reach consistent conclusions between the measures. 
The third objective is thus to test the responsiveness of the EQ-5D-3L in the PD 
MED data and compare with the ICECAP-O results to illustrate which measure is 
more responsive to the change of which aspects. 
A series of approaches are proposed in the literature to assess responsiveness (397, 
403) (please see section 3.6). However, none of them was developed specifically 
for the assessment of the ‘preference-based’ measures. As discussed in Chapter 5 
(Section 5.4), there raised methodological challenges in the methods and 
Chapter 7  188 
 
interpretation of the results - the testing methods may have to depend on the 
arbitrary assumptions of people’s preferences towards the change on each aspect 
of health. Therefore, the fourth objective of this chapter is to describe how these 
challenges are tackled in the methods when applying the traditional psychometric 
approaches to the test of the PbQoL measures in the PD MED context. 
In Chapter 6, the imputation strategy was straight-forward as the data structure 
was cross-sectional and contained low percentage of missing data (<5%). In 
contrast, repeated measurements are used in this chapter, which contains up to 
70% of missing data for some waves, creating much tougher challenges for the 
imputation. Simply dropping the whole observation that contains missing data may 
lead to biased result. Little information about how to address the missing data 
issue was provided in previous studies of assessment of responsiveness. Therefore, 
the last objective of this chapter is to fill this gap by examining how different 
missing data handling strategies would affect the result of assessment of 
responsiveness. 
7.3 Methods 
This section will introduce the data used for this analysis, choice of anchor 
measures, criteria for grouping the participants to different ‘change groups’ for 
each type of anchor, how to address missing data, and statistical methods for 
assessing responsiveness. 
7.3.1 Data 
The data for these analyses were obtained from the PD MED trials (75, 493). Details 
for the PD MED trial has been provided in Section 5.3. The data used for this 
chapter include: socio-demographic characteristics collected at randomisation 
and the annually collected PDQ-39, ICECAP-O, EQ-5D-3L, and follow-up 
questionnaires collected since 2010 when the ICECAP-O was added to the trial. 
The time horizon for this analysis was originally chosen to be four years between 
2011 and 2015 but changed to two years given the large amount of missing data 
after the trial has been running for more than ten years since 2001. However, the 
four-year analysis was conducted as part of sensitivity analysis.  
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7.3.2 The anchor based method 
As discussed in greater depth in Chapter 3 (Section 3.6), anchor-based approaches 
examine the relationship between the change in scores of the test measure and 
the independent anchor or external criterion (404, 409). The anchor(s) may be a 
clinical objective measure, or a subjective measure such as patient self-reported 
QoL measures (16), the selection of which depends on the correlations between 
the anchor and the test instrument, and whether it would increase understanding 
and of importance to the researchers (14, 15). 
The literature strongly recommends the use of multiple anchors, each of which is 
deliberately constructed with different focus, to examine responsiveness of a 
multi-dimensional measure from different aspects (403, 408, 524). This is 
especially of importance in this case of assessing the ICECAP-O capability measure 
and EQ-5D-3L, the QoL measures. As described in Chapter 2 Section 2.3, QoL has 
been defined as a concept encompassing a broad range of physical and 
psychological characteristics and limitations, which describe an individual’s ability 
to function and derive satisfaction from doing so (525). Similarly, capability 
focuses on the freedom of choosing among a combination of functionings which 
allows for measuring an even broader set of dimensions of wellbeing (135, 526, 
527). This wide definition of QoL and capability wellbeing requires that the choice 
of anchors for this assessment of responsiveness should cover a wide range of 
related concepts.  
Ten anchors were therefore identified as most appropriate allowing a 
comprehensive assessment of the impact of Parkinson’s. They measure health and 
QoL aspects that could be specifically affected by Parkinson’s to make this 
assessment context-specific and result relevant to Parkinson’s population. The ten 
anchors are: the most commonly used clinical measure in Parkinson’s, the Hoehn 
and Yahr staging scale (H&Y), and the most commonly used QoL measure in 
Parkinson’s, PDQ-39-SI (SI: summary index) along with its eight dimensions. The 
justifications for the choice of anchors are provided in the following section.  
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7.3.2.1 The modified Hoehn and Yahr staging scale 
The modified H&Y staging scale consists of seven stages (1.0, 2.0, 2.5, 3.0, 3.5, 
4.0, 5.0) of the typical progression of motor function from the mildest stage 1.0 
‘unilateral involvement only’ to the most severe, stage 5.0 ‘wheelchair bound or 
bedridden unless aided’ (528). It is objectively assessed by clinicians. Using H&Y 
as an anchor will inform whether the QoL measures are responsive to the clinical 
change in motor symptoms over time. However, it is not comprehensive in its 
component for impairment and disability by Parkinson’s, and there is no 
information concerning non-motor and mental aspects impaired by Parkinson’s. In 
line with aforementioned methodological considerations concerning the 
responsiveness test in Chapter 5 (Section 5.4), the result of responsiveness when 
using H&Y as an anchor should be interpreted with caution since H&Y and the 
ICECAP-O capability measure are essentially measuring different albeit related 
concept. Moreover, the broad definition of the staging may cause the insensitivity 
of H&Y to the slow progression of Parkinson’s, thereby bringing the concern that 
the anchor itself cannot act perfectly as a criterion for the test measure in terms 
of responsiveness to the change. Finally, the non-linear relationship between each 
H&Y stage creates challenges in the anchor group formation by H&Y staging which 
will be discussed later in the section 7.3.3.1. 
7.3.2.2 The PDQ-39 QoL measure 
In light of the above limitations with the use of a clinical measure as an anchor, 
choosing a condition-specific QoL instrument appears to be an optimal addition. 
The summary score of PDQ-39 QoL measure and its eight dimension scores were 
identified as relevant anchors to assess the responsiveness of the ICECAP-O. As 
discussed in greater depth in Section 5.3.4, the PDQ-39 is designed to measure 
QoL specifically in people with Parkinson’s (62, 131). It assesses impact of 
Parkinson’s on eight aspects of patients’ QoL, including mobility, ADL, emotional 
wellbeing, stigma, social support, cognitions, communication and bodily 
discomfort. Its validity, responsiveness and reliability have been well 
demonstrated in previous studies (503, 529, 530). Theoretically, all eight 
dimensions should influence patients’ overall wellbeing and therefore the change 
(improvement/deterioration) on any of the eight dimensions is expected to affect 
the overall perception of capability wellbeing as measured by ICECAP-O 
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accordingly. The choice of the eight dimensions also has the benefit of covering a 
wide scope of physical, mental and social wellbeing domains, which will broaden 
the understanding of the ICECAP-O capability measure in terms of its relationships 
with the wide range of aspects affected in Parkinson’s patients lives. 
It is recommended to use correlations to aid the justification for the choice of the 
anchor (403, 404) when data are available. A change correlation of 0.3 between 
the test measure and the anchor is regarded as the minimum threshold to warrant 
the choice of the anchor (403, 404). Chapter 6 found the correlations between the 
five dimensions of ICECAP-O and the eight dimensions of PDQ-39 to be ‘moderate 
to strong’ (Section 6.5.3, Table 6-10). The cross-sectional summary scores of the 
ICECAP-O and PDQ-39 were found to be highly correlated with the correlation 
coefficient larger than 0.7. Therefore, PDQ-39-SI and its eight dimensions were 
sufficiently correlated with ICECAP-O to be selected as anchors. 
7.3.3 Change group formation 
7.3.3.1 The modified Hoehn and Yahn scale 
Five change groups were defined according to the change of the staging on the 
modified H&Y scale (Table 7-1). The modified H&Y scale is an ordinal measure 
with each of the stages presenting distinct classification/clinical states from each 
other, which facilitates the group stratification. Every change to the next up 
staging of H&Y is associated with some extent of decreased level of quality of life 
according to previous studies (458, 531). This has also served as basis for previous 
decision-analytic modelling studies which constructed the health states based on 
H&Y staging (144, 145, 532) and thus this was used as grouping criteria for this 
study. Based on the H&Y, the ‘largely improved’ (or ‘largely deteriorated’) group 
is comprised of the participants with a decrease (or increase) in H&Y by more than 
one stage (e.g. ‘largely deteriorated’ if changing from stage 1 to 2.5). The ‘slightly 
improved’ (or ‘slightly deteriorated’) group is comprised of participants who had 
a change equal or less than one (e.g. ‘slight improved’ if changing from stage 2.5 
to 2 or 1.5). The ‘no change’ group if the H&Y stage kept the same between the 
two assessment points. 
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Table 7-1: Criteria for forming change groups in the base case analysis: H&Y 
and PDQ-39-SI and eight dimension scores 
Anchor 
measure 
From baseline to Follow-up 
Score range 
largely Improved/ 
Deteriorated 
A little improved/ 
Deteriorated No change group 
H&Y |change|  > 1 0 < |change| ≤ 1 |change| = 0 
1 (mildest) ~  
5 (confined to 
bed) 
PDQ-39-SI 
and 
dimensions 
|change| ≥ 5 *MID MID  ≤ |change|< 5*MID |change| < MID 0 (best) ~  100 (worst) 
Note: MID – minimally important difference 
7.3.3.2 The PDQ-39 QoL measure 
MID in the PDQ-39-SI and its eight dimensions were used as the threshold to classify 
the participants to the change groups (Table 7-1). As described in Section 3.6.2.4, 
grouping based on MID is the preferred method for continuous measures to assess 
preference-based measures as it implicitly incorporates the ‘importance’ in its 
survey question when asking the participants to determine if they had experienced 
a little better or worse in their health states.  
Understanding the process of how the MID was obtained for the anchor measure is 
essential for judging its appropriateness and identifying limitations of its use. The 
MID for PDQ-39 were investigated and reported in Peto, Jenkinson and 
Fitzpatrick’s study (533). They conducted a postal survey by sending PDQ-39 
questionnaires to randomly selected members of Parkinson’s Disease Society 
members on two occasions, six-month apart. Additional transition questions were 
asked at the second time to indicate how much change (‘a lot better’, ‘a little 
better’, ‘the same’, ‘a little worse’ or ‘a lot worse’) the participants had 
experienced since baseline in overall health and in each of the eight domains of 
the questionnaire. 728 participants completed the questionnaires at both time 
points. The mean change in scores for the summary index and each dimension of 
the PDQ-39 were calculated and compared with the responses to the relevant 
transition question. The authors argued that the MID could be the mean change in 
either the ‘a little better’ group, or the ‘a little worse’ group, as supported by 
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previous evidence (45) that small positive or negative change from baseline can 
be treated as equivalent for measuring MID. Although this assumption of equal MID 
in the better and worse groups was not always supported by literature (46), given 
the proportion of the sample who reported ‘a little better’ (between 3.7-13.0%) 
was much less than that who reported ‘a little worse’ (> 25%) for most of the 
dimensions, it is reasonable that the authors decided to use the mean change 
score in the ‘a little worse’ sample to calculate MIDs for each dimension and 
summary score.  The limitation of this assumption will be discussed later in this 
Chapter (Section 7.6.3.2). 
Peto et al.’s study (533) showed that the MID (with SD) varies among dimensions: 
3.2 (13.26) for mobility, 4.4 (16.56) for ADL, 4.2 (17.09) for emotional wellbeing, 
5.6 (22.98) for stigma, 11.4 (23.28) for social support, 1.8 (15.56) for cognition, 
4.2 (18.74) for communication, 2.1 (18.68) for pain, and 1.6 (8.89) for overall 
score. Statistically significant differences on the change scores were found for all 
except for the cognition and pain dimension. Among those, the sample size for 
the social support dimension was small as only 33 participants reported ‘a little 
worse’ while the majority of participants (n=547) reported ‘about the same’. The 
varied size of MID for each of the PDQ-39 dimensions is a reflection of the different 
weights that patients put on each dimension when generating their overall 
perception about their health and wellbeing. This addresses to some extent the 
issue of lacking a preference-based measure as anchor in this study. 
Based on MID, the ‘improved’ (or ‘deteriorated’) group is comprised of the 
participants with positive (or ‘negative’) change equal or larger than the size of 
MID; and the no change group is defined as the change is smaller than the size of 
MID. However, as mentioned in section 3.6.2.4, a limitation of this MID approach 
is that it does not provide guidance on the plausible cut-offs between the ‘a little 
change’ and ‘a lot of change’. Peto et al.’s study (533) did not report the average 
mean change in the ‘a lot better’ and ‘a lot worse’ groups providing its dedicated 
objective to determine the MID. Given no information is available from previous 
literature on this issue, sensitivity analysis was conducted to explore the impact 
of the varied threshold on the result – 5 * (multiplied by) MID was used in the base 
case analysis and 3 * (multiplied by) MID in sensitivity analysis. 5*MID was preferred 
over 3*MID as it is a more conservative estimate which is expected to overcome 
the ‘noise’ brought by the large SD of the MID estimates from Peto et al.’s study. 
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In addition, sensitivity analysis was also conducted by collapsing the ‘a little’ and 
‘a lot’ categories so that the five categories were reduced to three. This method 
has been used in a previous study (534). 
7.3.4 Missing data and multiple imputation 
7.3.4.1 Missingness diagnostics 
In Chapter 6, Section 6.4.2.3 has detailed the patterns of missing data (MCAR, MAR 
and MNAR) and the importance of imputation. Therefore prior to evaluating 
responsiveness, patterns of missing data were explored and logistic regression was 
conducted to investigate whether the probability of missing was associated with 
any patient characteristics. A binary variable was created which representing the 
missingness status (0: missing; 1: non-missing) of PDQ-39-SI. The MCAR assumption 
could be easily rejected as long as any link between the variable of interest and 
the probability of missing is identified. The variables of interest were selected 
from the pool of outcome measures and patient characteristics which may 
influence the missingness, including age, sex, duration with Parkinson’s, H&Y 
staging, EQ-5D-3L five dimensions, ICECAP-O five dimensions, number of 
hospitalisation days for treatment, whether or not having dementia, and whether 
or not the patient has a caregiver.  
If the logistic regression provides the evidence against the MCAR assumption, 
multiple imputation (MI) should be conducted to impute the missing data (535). 
MI has to meet a less restrictive assumption, the ‘missing at random’ (MAR). MAR 
allows missingness to be correlated with observed variables so long as it remains 
conditionally independent of the unobserved values (518), so the observed 
variables must suffice for predicting missingness.  
7.3.4.2 Imputation strategy 
The optimal imputation model should incorporate the correlation between the 
repeated assessments and allow the maximum inclusion of the variables which can 
predict missingness. However, it could not be executed successfully after many 
attempts of adjustment which might be because of the huge imputation burden 
from the multiplied number of the variables and covariates in the imputation 
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model and the large proportion of missing data. The details will be further 
discussed later in this Chapter (Section 7.6.3.4). 
Compromising imputation strategy was then applied. The time horizon was 
adjusted to two years (wave 2 to wave 4) from the original four years (wave 1 to 
wave 5) due to the lower proportion of missing data at wave 2-4. The scores of 
ICECAP-O, EQ-5D-3L and PDQ-39 were imputed along with the status of dementia 
and the H&Y scale indicating severity of Parkinson’s (19). Predictive mean 
matching was specified for the continuous ICECAP-O, EQ-5D-3L and PDQ-39 scores, 
ologit model was specified for the H&Y scale and the logit model was specified for 
the status of dementia. Age, sex, duration with Parkinson’s and the baseline H&Y 
status were included in the imputation models. Thirty imputed datasets were 
generated as the overall missing percentage is around 10-30% for each variable 
(shown in the result section, Table 7-7). The results were combined using Rubin’s 
rule (35). The STATA code for this imputation is provided in Appendix B. 
In addition, another two strategies were conducted as sensitivity analysis to the 
current method. The first used a multi-variate latent normal model with the 
Realcom Impute software (536), which could handle the two-level (multiple waves 
within each patient) data structure. However, a weakness was revealed in its 
formula in that it only used the variables that did not contain any missing data to 
predict the value of missing variables. This limits its prediction ability as the 
missingness may be most accurately predicted by the non-missing values of the 
same variable at other waves.  
Another imputation strategy in the sensitivity analysis which treated each wave 
from the same patient as independent. This was technically practical as it did not 
multiply the number of variables in the imputation model, and also enabled the 
missing values to be predicted by both the non-missing values from other waves 
and the non-missing variables. However, this method neglects the multi-level 
structure of the data.  
After the completion of imputation, the statistical analyses were conducted based 
on Rubin’s rules (520). The missing whole-waves were, despite being imputed, 
excluded from the analysis (537). The performance of the different imputation 
strategies was compared with imputation diagnostics strategies. The effect size 
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statistics were calculated in the dataset without imputation and with each method 
of imputation. 
7.3.5 Statistical analysis 
The statistical analyses conducted included: 1) a scatter plot using the change of 
the ICECAP-O index scores / EQ-5D-3L index scores against the change of the PDQ-
39-SI, and the correlations between them; 2) effect size and the standardized 
response mean of the change of ICECAP-O index scores /EQ-5D-3L index scores in 
each of the change groups formed based on the selected anchors; 3) regression 
analyses to explore the factors associated with the changes of ICECAP-O index 
score / EQ-5D-3L index score. These statistical methods have been described in 
depth in Chapter 3 (please see section 3.6.3). This section will describe the 
application of these methods with the PD MED data and the modified statistical 
approaches with the imputed datasets. The statistical analyses were conducted in 
STATA® 14 (StataCorp. 2015) (521). 
7.3.5.1 Scatter plot 
To visualize the relationship between the test measure and the anchor, two 
scatter plots were produced using 1) the change of ICECAP-O score 2) the EQ-5D-
3L score, against the change of the PDQ-39-SI for each patient. Fitted linear 
regression lines predicting the ICECAP-O/EQ-5D-3L change score using PDQ-39-SI 
change score were added to the plots with 95% confidence intervals. The change 
was averaged over the imputed datasets. Given the different scales for the three 
QoL measures, the change scores were standardized using the following formula 
before plotting to facilitate visual comparisons of the distributions:  
standardized change = (change - mean (change)) / SD (change). 
7.3.5.2 Correlation  
Correlations of the change of ICECAP-O / EQ-5D-3L index value against the change 
of PDQ-39-SI score were examined. This provides an indication of the extent to 
which the change score of the anchor and test measure (ICECAP/EQ-5D-3L) are 
associated; a stronger correlation typically means a stronger responsiveness of the 
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test measure to the anchor (415). The correlation coefficient describes both the 
strength and direction of the relationship.  
Linear regressions of the ICECAP-O / EQ-5D-3L against PDQ-39 were conducted and 
the normality of the residuals were tested to choose between the Pearson’s 
correlation coefficient and a Spearman’s rank correlation coefficient. To enable 
the normality testing in the multiply imputed datasets, the approach proposed by 
White et al. (538) was adopted. It recommends calculating fitted values and 
residuals for each imputed dataset first, and then, for each imputed dataset, plot 
these residuals against the fitted values. Following White’s recommendation, the 
kernel density plot was conducted to allow a visual comparison of the distribution 
of the residuals against an overlaid normal distribution (427, 428). The Shapiro-
Wilk W test was then performed for significance testing of the assumption that 
the distribution was normal (427, 429). Given the number of imputed datasets was 
relatively large (n=30) in this study, five out of the 30 datasets were randomly 
selected for the normality checking, i.e., the 1st, 3rd, 10th, 20th and 30th 
imputed dataset. Pearson’s correlation coefficient was used when the linear 
relationship was demonstrated and when it was not met, Spearman’s rank 
correlation coefficient was used (430). As with the correlation comparison in 
Chapter 6 (please see Section 6.4.2.2), the correlation coefficients of the change 
scores of ICECAP-O and PDQ-39 were compared with EQ-5D and PDQ-39 using the 
R statistical package cocor which examines the significance of the difference of 
correlation coefficients using a range of statistical tests.  
The Pearson correlation coefficient of the imputed datasets was calculated with 
Harel’s Fisher’s r to z transformation utilizing the normal distribution of z (539). 
This was realized with the user-written STATA command ‘mibeta’ with the option 
‘fisherz’ (539). Detail of this transformation is provided in Appendix D. Compared 
to the Pearson correlation coefficient, Herel’s transformation method cannot be 
applied to Spearman rank correlation since the linear relationship assumption does 
not meet. Neither does a user-written command exist to calculate Spearman rank 
correlation in imputed datasets and hence a compromise approach was adopted. 
The average of the standardized score change among the 30 imputed datasets was 
calculated (i.e. not combined using Rubin’s rule) and then the routine procedure 
(STATA command spearman) for Spearsman’s rank correlation was performed. 
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7.3.5.3 Effect sizes and standardised response means 
Effect size (ES) (i.e. mean change divided by the standard deviation (SD) of the 
baseline score) and the standardised response mean (SRM) (i.e. mean change 
divided by the SD of the change score) as introduced in Chapter 3 (Section 3.6.3.1) 
were calculated for each of the groups classified by the ten anchors. The standard 
error and confidence intervals for the estimates of SRM and ES were generated 
through bootstrap with 1000 replicates.   
Without imputation, SD is calculated by multiplying SE with square root of the 
sample size, whereas after the imputation, the sample size of each change groups 
varies across the imputed datasets depending on the imputed values. To address 
this, a transformation was performed. The ES/SRM was calculated individually for 
each patient using the SD for each imputed dataset. Then the means of the 
individual ES/SRM in each imputed dataset were combined using Rubin’s rule. This 
process can be summarized with the formula below: 
For each of the five change groups defined within imputed dataset (i=1,2,…30)), 
let the change of the measure (i.e. ICECAP-O or EQ-5D-3L) be noted as xic (x1c, 
x2c, x3c…x30c), and the baseline measurement be noted as xib (x1b, x2b, 
x3b…x30b). 
ES =
	()	
			(
)
 = μ	(
	
	()
 ) (i=1,2,...30) 
SRM =
	()	
			()
 = μ	(
	
	()
 ) (i=1,2,…30) 
This transformation bypasses the difficulty with calculating SD, and allowed the 
pooled estimates of ES/SRM applying Rubin’s rule.  
According to Cohen’s rule of thumb (419), an ES below 0.2 represents ‘very small’ 
effect, 0.2 to 0.5 – ‘small’, 0.5 to 0.8 – ‘medium’, and a ES score higher than 0.8 
represents a ‘large’ ES (421). It was inconsistent in the literature how to interpret 
the SRM with some suggesting SRM may be interpreted with the same rule (540) 
while other suggested it cannot be directly interpreted (422). However, as 
mentioned in Chapter 3, the COSMIN checklist manual gave a warning on using this 
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rule to assess the responsiveness of a measure. Cohen’s rule applies in situation 
where effect size is used as an indicator for treatment effect, rather than for 
testing the responsiveness of an instrument to a change (327), and therefore 
simply examining the size of ES/SRM is inappropriate. They proposed that the 
judgement on the responsiveness should be established on whether the magnitude 
of ES/SRM meet the expectations on the relationship between the test measure 
and the anchors. This has been discussed in more detail in Chapter 3 (Section 
3.6.3.1).  
In addition, this study used EQ-5D-3L as reference, which facilitates the 
interpretation of the ES/SRM statistics through the comparison between ICECAP-
O and EQ-5D-3L. In this study, the expectations of the magnitude of ES/SRM are 
indicated by the change (direction and magnitude) of the anchor measure in each 
of the five change groups. For example, the participants in the ‘largely improved 
group’ anchored by PDQ-39 are expected to have medium to large ES/SRM in 
ICECAP-O.  In this way, a measure is judged to be more responsive when it meets 
the expectation of each of the change group to a larger degree than the other 
measure. 
7.3.5.4 Paired t-test 
The paired t-test (415, 425) was used to assess change of the ICECAP-O / EQ-5D-
3L between baseline and follow-up in each of the four change groups (i.e. except 
for the ‘no change’ groups). Due to its high dependence on the sample size, the 
result from the paired t-test only plays a supportive role in the interpretation of 
the responsiveness.  
7.3.5.5 Regression 
Two multivariate linear regressions were conducted to further examine the extent 
to which the difference in the change of the ICECAP-O / EQ-5D-3L index score was 
influenced / explained by the change of eight QoL aspects as measured by the 
PDQ-39 eight dimensions. This method has been commonly used in previous 
validation of preference-based instrument (384, 541, 542). For example, in 
addition to assessing validity and responsiveness of the EORTC-8D relative to the 
EQ-5D-3L, Lorgelly (2017) employed regression analysis to understand the 
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determinants of the difference in QALYs generated independently by EORTC-8D 
and EQ-5D-3L (384). This aids the understanding of the interaction between the 
test measure and the anchors, and interpretation of the effect size results. A small 
effect size is due to the relative magnitude of ‘noise’ and in this context, the 
‘noise’ could come from the fact that patients value the change in other aspects 
of life more than the aspects that is being examined. A multivariate regression 
analysis will help the understanding of to what degree the change of Parkinson’s 
specific QoL aspects would lead to the change of the ICECAP-O after adjusting for 
each other. It would also inform which of these QoL aspects are deemed most 
relevant for a patient’s capability wellbeing. 
7.3.5.6 Sensitivity analysis 
Three sensitivity analyses were carried out to explore the impact of different 
methodologies on the responsiveness result. These sensitivity analysis have been 
mentioned in the methods above while describing the main analysis and this 
section provides a brief summary of them.  First, a two-level imputation model 
provided by the Realcom Impute software and imputation in long-form were 
carried out using the four year data as well as the two year data in addition to the 
imputation strategy used for the main analysis. Second, 3 * MID (in contrast to 5 * 
MID in the main analysis) was used as the cut-off for PDQ-39-SI between a small 
change group and a large change group given it represents the midpoint between 
1 and 5. Lastly, the number of change groups reduced from five to three by 
collapsing the ‘a little’ and ‘a lot’ categories to become ‘worse’, ‘no change’ and 
‘improved’. For all the sensitivity analyses, effect size results with PDQ-39-SI as 
anchor were estimated and compared with the main analysis results. 
7.4 Results 
The results section begins with a description of participant characteristics. Two 
scatter plots are provided to illustrate the relationships between the change on 
the ICECAP-O/EQ-5D-3L and the change on PDQ-39, which are explained by the 
correlations between the summary scores of the three measures. The grouping is 
summarized, followed by the effect size statistics of each group for each chosen 
anchor. The result of the regression analysis is presented at the end. 
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7.4.1 Patient characteristics 
Characteristics of the PD MED study participants used for this responsiveness 
analysis are presented in Table 7-2. A total of 1,238 participants were included 
for this analysis. Among them, 1,023 participants were eligible for the assessment 
of responsiveness who did not have unit-nonresponse (i.e. provided some 
responses to the assessment) at the two assessment points8. The mean age of 
participants at baseline for this analysis is approximately 74 years, with the mean 
duration since diagnosis of Parkinson’s 6.5 years. 65 % of the participants are male, 
which is in line with a previous finding that the relative risk of the incident rate 
of Parkinson’s in men is 1.5 times greater than women (543). 
                                            
8
 We included the participants that only had one ICECAP-O assessment to maximize information 
for the multiple imputation. However, they were excluded for analysis after imputation 
completed as change score requires two waves however in these participants another wave 
was purely imputed which may introduce overfitting of the estimation model (537). 
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Table 7-2: Participant characteristics, at baseline and two-year follow-up (complete case) 
Characteristics 
Baseline  Two years later 
Mean SD Median IQR Sample 
size 
Missing 
(%)  Mean SD Median IQR 
Sample 
size 
Missing 
(%) 
Age 74.15 8.25 75.34 69.42, 79.78 1238 0        
Duration with PD 6.54 3.44 6.03 4.07,8.31 1238 0        
H&Y   2.5 2, 3 1060 14.38    3 2, 3 806 34.89 
ICECAP-O index1 0.75 0.18 0.79 0.67, 0.89 1056 14.70  0.72 0.19 0.77 0.63, 0.87 879 29.00 
EQ-5D-3L index1 0.52 0.29 0.59 0.62, 0.69 1128 8.89  0.46 0.32 0.52 0.19, 0.66 882 28.76 
PDQ-39-SI1 31.72 17.41 29.87 19.09, 42.97 972 21.49  34.30 17.83 32.86 21.38, 45.16 704 56.87 
 Freq % of the 
observed 
Missing
%     Freq 
% of the 
observed 
Missing 
%    
Sex (male) 805 65.02 0           
Dementia   13.65       33.52    
With 82 7.67      126 15.31     
without 987 92.33      697 84.69     
Motor complication2 
  49.60       46.20    
With 364 58.33      283 42.49     
Without 260 41.67      383 57.51     
1 Note: score range: ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 (worse than death) ~0 (death) ~ 1(full health). PDQ-39: 0 (least severe) ~ 100 
(most severe). 
2 Motor complication includes motor fluctuation and dyskinesia. Motor fluctuation refers to the situation that patients oscillate between ‘on’, during which the patient 
experiences a positive response to medication and ‘off’ state, during which the symptoms cannot be controlled by the medication (544). Dyskinesia are involuntary 
movements in the muscles, often include twitches, jerks, twisting or writhing movements (545). 
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An overall trend of deterioration in clinical scores, health related quality of life 
and capability wellbeing over the two years was observed. The median H&Y stage 
increased (i.e a deterioration in health) from 2.5 (IQR: 2-3) to 3 (IQR: 2-3). Table 
7-3 shows specifically the distribution of the H&Y staging at baseline and two-year 
follow-up. There is a decrease in the percentage of the patients at the milder 
stages, i.e., stage 1-2.5, and an increase in the percentage of the patients at the 
more severe stages, stage 3-5. In terms of having dementia, 6.6% of the 
participants reported having dementia at baseline, which increased to 10.2% at 
endpoint, although the percentage of missing data also increased from 13.65% to 
33.52% (Table 7-2). 29.4% patients reported they had motor complication at 
baseline, which, unexpectedly, decreased to 22.86% two years later. This might 
be due to the very large proportion of missing data presented for this variable, 
i.e. patients that developed motor complications might take other treatment 
options such as deep brain stimulation surgery and thus may be more likely to drop 
out from the trial. 
Table 7-3: Distribution of H&Y scores, at baseline and two-year follow-up 
(complete case) 
Charact
eristic 
Baseline  Two years later 
Freq % of the 
observed 
Missing 
(%)  Freq 
% of the 
observed Missing (%) 
H&Y 
staging   14.38    34.89 
1 67 6.32   15 1.86  
1.5 90 8.49   36 4.47  
2 276 26.04   167 20.72  
2.5 199 18.77   123 15.26  
3 301 28.4   293 36.35  
4 96 9.06   122 15.14  
5 31 2.92   50 6.2  
 
All three QoL measures showed overall deterioration in QoL (Table 7-2, Figure 7-1). 
Figure 7-1 shows the distribution of the change score of the three measures with 
the imputed data. A change score being 0 indicates that there was no change over 
the two years. For EQ-5D-3L and ICECAP-O, a positive change score (>0) indicates 
the improvement of health status while a negative change score (<0) indicates 
deterioration. This trend is the opposite for PDQ-39 where a positive change score 
indicates a worse health status and negative indicates a better health. Figure 7-1 
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shows that larger area of distribution is on the worsened health status side for all 
the three measures. In particular, a spike at 0 was observed for EQ-5D-3L, which 
was partly attributed to the high percentage of no change in score for 
approximately 23.3% (238/1023) of patients. The mean change for ICECAP-O, EQ-
5D-3L and PDQ-39 were -0.057 (95%CI -0.066, -0.046), -0.095 (95%CI -0.11, -0.077), 
and 6.36 (95%CI 5.36, 7.36) respectively.  
 
Figure 7-1: The distribution of the change of ICECAP-O, EQ-5D-3L and PDQ-39 
Note: score range: ICECAP-O: 0 (no capability) ~ 1 (full capability). EQ-5D-3L: -0.59 (worse than 
death) ~0 (death) ~ 1(full health). PDQ-39: 0 (least severe) ~ 100 (most severe). 
 
In terms of the responses to each dimension of ICECAP-O, Table 7-4 and Figure 7-2 
shows that there was a higher proportion of lower levels (Level 1 and 2) of 
capability at two years later compared to baseline and decreased percentages of 
responses for all of the more capable levels (level 3 and 4) over time. Specifically, 
the proportion of level 1 (lowest level of capability) increased and other levels 
dropped for security dimension, level 1 & 2 increased and 3 & 4 dropped for role, 
enjoyment and control, and level 1 & 2 & 3 increased and 4 dropped for 
attachment. This suggests that the main deteriorating aspects were control, 
followed by security, role, enjoyment, and lastly, attachment. 
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Figure 7-2: Change of the distribution of responses for each of the ICECAP-O 
attributes over the two years (complete case) 
Note: For ICECAP-O, level 1 is the least capable level while level 4 is the most capable 
level.  
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Table 7-4: Responses (percentages) for each of the ICECAP-O attributes, at baseline and two-year follow-up (complete case) 
ICECAP-O 
attributes 
a,b(%) 
Baseline   Two years later  
Level 1 Level 2 Level 3 Level 4 
Missing 
 Level 1 Level 2 Level 3 Level 4 
Missing No 
capability 
A little 
capability 
Some 
capability 
A lot of 
capability  
No 
capability 
A little 
capability 
Some 
capability 
A lot of 
capability 
Attachment 2.07 13.37 30.32 54.24 14.22  2.83 14.16 33.97 49.04 28.68 
Security 14.33 40.44 35.86 9.37 13.73  18.25 39.3 33.67 8.78 28.27 
Role 8.61 38.01 37.73 15.64 13.73  11.6 41.45 33.67 13.29 28.27 
Enjoyment 4.88 33.58 46.06 15.48 13.89  6.18 37.2 42.47 14.16 28.11 
Control 8.06 29.14 47.6 15.19 13.81  12.6 31.95 43.75 11.7 28.19 
Note: a. the proportion for level 1-4 did not account for missing values (i.e. with total observed as denominator). b. For ICECAP-O, level 1 is the least capable level while 
level 4 is the most capable level. 
 
 
 
Table 7-5: Responses (percentages) for each of the EQ-5D-3L attributes, at baseline and two-year follow-up (complete case) 
EQ-5D-3L 
Attributes a,b (%) 
Baselinea  Two years latera 
Level 1 
No problem 
Level 2 
Some problems 
Level 3 
A lot of problems Missing  
Level 1 
No problem 
Level 2 
Some problems 
Level 3 
A lot of problems  Missing 
Mobility 19.63 78.88 1.49 8.24  15.99 80.75 3.26 28.27 
Self-care 37.97 56.21 5.81 8.32  30.10 59.64 10.26 28.35 
Usual activities 17.02 69.49 13.49 8.40  15.45 64.82 19.73 28.35 
Pain/discomfort 20.56 68.58 10.86 8.48  19.41 68.17 12.42 28.43 
Anxiety/depression 42.33 53.88 3.79 8.41  34.08 60.27 5.65 28.44 
Note: a. the proportion for level 1-3 did not account for missing values (i.e. with total observed as denominator). b. For EQ-5D-3L, Level 1 is “no problem”, level 2 “some 
problems”, and level 3 “extreme problems”.
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The proportion of responses for each level of EQ-5D-3L five dimensions at baseline 
and two years later are shown in Table 7-5 and Figure 7-3. Approximately 8% of 
the data were missing at baseline and this increased to around 28% two years later. 
Despite the missing data, the deterioration trend appears clear for all the five 
dimensions. This trend is particularly noticeable for self-care, depression/anxiety 
dimension and usual activities; 20% less in level 1 (no problem) and a 
corresponding increase in level 2 and 3 were observed for the former two, and a 
decrease in level 1 (no problem) & 2 and 30% more in 3 (a lot of problems) for the 
latter. 
 
Figure 7-3: Change of the distribution of responses for each of the EQ-5D-3L 
attributes over the two years (complete case) 
Note: For EQ-5D-3L, Level 1 is “no problem”, level 2 “some problems”, and level 3 
“extreme problems”. 
 
This deterioration trend was also demonstrated in the Parkinson’s specific QoL 
measure PDQ-39 with the increased overall score (Table 7-2) and the increased 
score for all the eight dimensions (Table 7-6 and Figure 7-4) over time.  
Deterioration of the dimensions over the two years can be ranked according to the 
size of the mean change (largest to smallest), as mobility (mean 10.54 (SD 18.25)), 
ADL (7.84 (17.60)), communication (5.54 (16.60), cognition (5.14 (15.90)), 
emotional wellbeing (4.47 (17.07)), bodily discomfort (3.79 (20.14)), social 
support (3.21 (14.47), and stigma (1.78 (17.40)). 
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Table 7-6: PDQ-39 eight dimension scores, at baseline and two-year follow-up (complete case) 
PDQ-39 eight 
dimensions 
Baseline Two years later Difference over the two years 
Mean SD Sample size Missing (%) Mean SD Sample size Missing (%) Mean SD Sample size Missing (%) 
Mobility 49.53 30.77 1102 10.99 56.06 30.65 863 30.29 10.54 18.25 801 35.30 
ADL 41.90 25.83 1080 12.76 46.19 26.25 799 35.46 7.84 17.60 755 39.01 
Emotional wellbeing 28.79 22.41 1062 14.22 31.16 23.19 785 36.59 4.47 17.07 733 40.79 
Stigma 22.15 23.56 1082 12.60 22.68 22.87 807 34.81 1.78 17.40 762 38.45 
Social support 11.98 17.73 1055 14.78 13.89 18.65 783 36.75 3.21 14.67 731 40.95 
Cognition 35.77 21.86 1082 12.60 37.70 22.02 801 35.30 5.14 15.90 758 38.77 
Communication 26.08 22.80 1087 12.20 29.23 23.62 802 35.22 5.54 16.60 760 38.61 
Bodily discomfort 41.00 24.98 1080 12.76 43.73 25.39 798 35.54 3.79 20.14 756 38.93 
Note: score range: PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 (most severe).    
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Figure 7-4 : PDQ-39 eight dimension scores, at baseline and two-year follow-
up (complete case) 
Note: score range: PDQ-39-SI and each of the attributes: 0 (least severe) ~ 100 (most 
severe).    
 
7.4.2 Missingness prediction 
The result for the logistic regression for explaining missingness is shown in Table 
7-7. Four independent variables were found to be associated with missingness of 
PDQ-39: age, ICECAP-O attachment, number of days treated in hospital, and lastly, 
whether the patient has dementia. Among them, the presence of dementia 
strongly predicted the missing observations – the odds of missing when patients 
have dementia is around ten times than the patients do not have dementia 
(OR=0.109, p<0.0001). The pseudo R square of the logistic regression was tested 
to be 0.153 and the p value for the whole model was <0.0001.  The C-statistic 
(area under the ROC curve) was 0.728. This demonstrated that the MCAR 
assumption was not met and provided justification for the multiple imputation 
approach. 
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Table 7-7: Predictors for the probability of missing values (0: missing, 1: non-
missing) for PDQ-39-SI 
Independent variables Odds Ratio 
Standar
d error P value 
Lower 
95% 
CI 
Upper 
95% CI Note for coding 
Age (years) 0.978 0.008 0.0080 0.963 0.994 Continuous 
Sex 0.895 0.112 0.3760 0.701 1.144 Binary: 1- male; 2-
female 
Duration with 
Parkinson’s (years) 
0.972 0.017 0.1060 0.940 1.006 Continuous 
H&Y stage (1-5) 1.011 0.084 0.8980 0.858 1.190 Ordinal, 1-mildest, 
5-most severe 
EQ-5D-3L       
Mobility 0.859 0.155 0.4020 0.603 1.225 Ordinal (1,2,3), 
Level 1: ‘no 
problem’; level 3: 
‘quite a lot 
problems’ 
Self-care 1.148 0.158 0.3150 0.877 1.504 
Usual activities 0.856 0.129 0.3010 0.637 1.149 
Pain/discomfort 1.078 0.129 0.5280 0.853 1.364 
Anxiety/depression 1.014 0.132 0.9170 0.786 1.308 
ICECAP-O       
Attachment 1.211 0.102 0.0230 1.027 1.427 Ordinal (1,2,3,4), 
Level 1: ‘no 
capability’; level 4: 
‘full capability’ 
Security 1.030 0.085 0.7250 0.875 1.211 
Role 1.053 0.109 0.6180 0.859 1.291 
Enjoyment 0.971 0.111 0.7940 0.776 1.214 
Control 1.178 0.129 0.1350 0.950 1.460 
Days treated in Hospital 0.984 0.008 0.0470 0.969 1.000 Continuous 
Dementia 0.109 0.018 0.0000 0.079 0.151 Binary, 0-no 
dementia;1-have 
dementia,  
Carer 0.902 0.131 0.4800 0.678 1.200 Binary: 0–no 
carer; 1- has carer 
Constant 20.213 19.847 0.0020 2.950 138.494  
 
 
7.4.3 Scatter plot of the change in ICECAP-O/EQ-5D-3L 
Figure 7-5 and Figure 7-6 shows the scatter plot of the standardized change of 
ICECAP-O / EQ-5D-3L against the standardized change of PDQ-39-SI. The fitted red 
lines in the plots are the predicted ICECAP-O/EQ-5D-3L change score from a linear 
regression of ICECAP-O/EQ-5D-3L change score on PDQ-39-SI change score, with 
95% confidence interval highlighted in the grey area. In the plots, each matched 
dyad (pairing of change score on ICECAP-O and change score on PDQ-39-SI or 
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pairing of change score on EQ-5D-3L and change score on PDQ-39-SI) represents 
one patient. A dyad on x-axis (y=0) indicates there was no change of ICECAP-O/EQ-
5D-3L over the two years, and similarly a dyad on y-axis (x=0) means no change of 
PDQ-39-SI happened over the two years. A dyad on the origin means there was no 
change for both measures over the two years.  
There is no substantial difference in terms of the pattern shown in the two plots. 
The dyads in Figure 7-5 appear more concentrated around the predicted linear 
regression line compared to the dyad in Figure 7-6, indicating a slightly stronger 
correlation between ICECAP-O change score and PDQ-39-SI change score. The size 
of the standardized EQ-5D-3L change score is larger than that of the ICECAP-O 
change score which indicated a larger mean of EQ-5D-3L change score and larger 
SD.  
 
Figure 7-5: Scatter plot of the change of ICECAP-O and PDQ-39-SI 
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Figure 7-6: Scatter plot of the change of EQ-5D-3L and PDQ-39SI 
 
 
7.4.4 Correlation 
Two regressions were conducted predicting ICECAP-O / EQ-5D-3L index value with 
PDQ-39-SI respectively and the normality of the residual of the regression were 
checked. For both of the regressions, the Shapiro-Wilk W test rejected the 
assumption that the residuals have a normal distribution with a p value <0.00001 
for all of the randomly selected imputed datasets (n=1, 3, 10, 20 and 30). The 
kernel density graphs of the residuals had a sharp bulge shape above the normal 
density reference line. Figure 7-7 shows an example of the kernel density graph. 
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Figure 7-7: An example for checking the normality of the regression residual 
to choose between Pearson correlation and Spearman correlation: ICECAP-O 
change score vs. PDQ-39 change score (m=10) 
 
Therefore, a linear relationship between the ICECAP-O/EQ-5D-3L and PDQ-39 
cannot be met and accordingly Spearman correlation coefficient was determined 
to be more appropriate than Pearson correlation coefficient. The detailed result 
of the residuals normality checking is shown in the Appendix E. 
Table 7-8 shows the correlation coefficients between the change of the three 
measures. The Pearson correlation coefficients are also presented here in addition 
to Spearman correlation coefficients as additional information. The correlation 
coefficients agreed with the scatter plot that the change of ICECAP-O index value 
was more strongly correlated with the change of the PDQ-39-SI (r = -0.526) than 
the change of EQ-5D-3L index value (r=-0.483) (one sided p value = 0.07 based on 
Pearson and Filon’s z statistics, 95% confidence interval: -0.0145, 0.1006). Full 
results of the statistical tests of the difference of correlations are provided in 
Appendix C. 
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Table 7-8: Correlation coefficients between the change scores of the ICECAP-
O, EQ-5D-3L and PDQ-39 
Change of the summary scores 
/ index scores 
ICECAP-O 
vs. 
PDQ-39 
EQ-5D-3L 
vs. 
PDQ-39 
ICECAP-O 
vs. 
EQ-5D-3L 
Spearman correlation 
coefficient 
-0.526 -0.483 0.401 
Pearson correlation coefficient -0.536 -0.482 0.425 
 
7.4.5 Effect size statistics 
7.4.5.1 Anchor by PDQ-39-SI 
A total of 933 patients were eligible for this analysis after excluding the patients 
that had missing whole-wave assessments for either baseline or follow-up 
assessment at two-years later for this analysis. Table 7-9 shows the grouping by 
PDQ-39-SI using the MID information. The sample size column depicts the median 
and average number of patients in each group across the 30 imputations. Nearly 
half of the participants are in the ‘largely deteriorated group’ for PDQ-39-SI. This 
may be because the MID for PDQ-39-SI is 1.6, and thus the 5*MID threshold (=8) 
between the slight and large change is still relatively small compared to the 
overall score range (0-100). This also explains the relatively small number of 
participants in the ‘no change group’. Despite the low threshold, a large overall 
deterioration is still observed in this ‘largely deteriorated group’ with a mean 
change score of PDQ-39-SI being 17.09 (95%CI 15.82, 18.36). From the ‘largely 
improved group’ to the ‘largely deteriorated group’, the mean change of the PDQ-
39-SI increased from -13.58 (95%CI -15.11, -12.05) to 17.26 (95%CI 16.22, 18.29). 
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Table 7-9: Change group formation: PDQ-39-SI in each change group 
anchored by PDQ-39-SI 
Stata wide form (yr2, yr4) 
Anchor: PDQ-39-SI 
Sample size* Change of the anchor measure 
Median Average Mean SE 95% CI 
Largely Improved group 85 86.5 -13.577 0.771 -15.106, -12.049 
Slightly improved group 144 144.3 -4.734 0.192 -5.113,-4.356 
No change group 128.5 128.3 0.050 0.093 -0.134,0.233 
Slightly deteriorated 277.5 277.1 4.412 0.120 4.177,4.648 
Largely deteriorated group 387 386.8 17.257 0.525 16.222,18.292 
* The sample size column depicts the median and average number of patients in each group across the 30 
imputations 
 
Table 7-10 shows the change of ICECAP-O and EQ-5D-3L in each change group 
defined by the change of PDQ-39-SI. In line with the trend of the PDQ-39-SI, from 
the ‘largely improved group’ to the ‘largely deteriorated group’, the mean change 
of ICECAP-O index value in each group decreased from the best 0.050 (95%CI 0.011, 
0.088) (p=0.011) to the worst -0.125 (95%CI -0.144, -0.105) (p<0.0001), and the 
mean change of the EQ-5D-3L index value decreased from the best 0.059 (95%CI -
0.009, 0.126) (p=0.086) to the worst -0.210 (95%CI -0.244, -0.176) (p<0.0001). 
The ES and SRM results of ICECAP-O and EQ-5D-3L with the anchor PDQ-39-SI are 
described in Table 7-11 and visualised in Figure 7-8. For the change groups, the 
larger ES or SRM means the more responsiveness of the measure to the change of 
PDQ-39-SI. Although EQ-5D-3L had a larger mean change than ICECAP-O in each 
group, it also had a larger size of SD for its means, leading to a smaller ES and SRM 
of EQ-5D-3L compared to ICECAP-O. The confidence intervals for the SRM 
presented as error bars in Figure 7-8 were overlapping, indicating that there was 
no statistically significantly difference between the responsiveness of EQ-5D-3L 
and ICECAP-O to the change of the PDQ-39-SI. 
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Table 7-10: Change score of the ICECAP-O and EQ-5D-3L over the two years for each of the five change groups (anchored by PDQ-
39-SI) 
Stata wide form (yr2,yr4) 
Anchor: PDQ-39-SI 
Change in ICECAP-O score  Change in EQ-5D-3L score 
Mean SE 95% CI p value 
 
Mean SE 95% CI p value 
Largely Improved group 0.050 0.019 0.011,0.088 0.0107  0.059 0.034 -0.009,0.126 0.0858 
Slightly improved group 0.009 0.012 -0.015,0.032 0.4835  0.002 0.024 -0.044,0.049 0.9326 
No change group -0.016 0.012 -0.04,0.009 0.2095  -0.016 0.023 -0.061,0.029 0.4901 
Slightly deteriorated -0.043 0.008 -0.059,-0.028 0.0000  -0.067 0.015 -0.095,-0.038 0.0000 
Largely deteriorated group -0.125 0.010 -0.144,-0.105 0.0000  -0.210 0.017 -0.244,-0.176 0.0000 
 
Table 7-11: ES and SRM statistics of ICECAP-O and EQ-5D-3L with the anchor PDQ-39-SI 
Stata wide form (yr2,yr4) 
Anchor: PDQ-39-SI 
Effect size (ES) Standardised response mean (SRM) 
ICECAP-O  EQ-5D  ICECAP-O EQ-5D 
Mean SE 95% CI  Mean SE 95% CI  Mean SE 95% CI  Mean SE 95% CI 
Largely Improved group 0.256 0.062 0.130,0.375  0.194 0.072 0.046,0.328  0.353 0.090 0.160,0.513  0.228 0.085 0.047,0.380 
Slightly improved group 0.052 0.048 -0.034,0.155  0.006 0.053 -0.101,0.107  0.073 0.068 -0.050,0.215  0.007 0.068 -0.131,0.134 
No change group -0.105 0.048 -0.223,-0.037  -0.057 0.051 -0.160,0.042  -0.145 0.065 -0.311,-0.056  -0.080 0.072 -0.223,0.059 
Slightly deteriorated -0.277 0.042 -0.353,-0.189  -0.261 0.039 -0.332,-0.180  -0.388 0.052 -0.486,-0.281  -0.331 0.048 -0.419,-0.232 
Largely deteriorated group -0.778 0.070 -0.910,-0.637  -0.791 0.065 -0.913,-0.660  -0.754 0.044 -0.837,-0.663  -0.700 0.049 -0.796,-0.605 
Note: an effective size statistic below 0.2 represents ‘very small’ effect, 0.2 to 0.5 – ‘small’, 0.5 to 0.8 – ‘medium’, and a ES score higher than 0.8 represents a ‘large’ ES (377). But this 
should be interpreted together with the expected ES/SRM as categorised in each of the change group. A measure is judged to be more responsive when it meets the expectation of the 
assignment of the change group to a larger degree than the other measure. Please see Section 7.3.5.3 for details. 
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Figure 7-8: SRM (SE) of ICECAP-O and EQ-5D-3L in the five change groups 
anchored by PDQ-39-SI 
Note: an effective size statistic below 0.2 represents ‘very small’ effect, 0.2 to 0.5 – ‘small’, 0.5 to 0.8 – ‘medium’, 
and a ES score higher than 0.8 represents a ‘large’ ES (377). But this should be interpreted together with the 
expected ES/SRM as categorised in each of the change group. A measure is judged to be more responsive 
when it meets the expectation of the assignment of the change group to a larger degree than the other measure. 
Please see Section 7.3.5.3 for details.  
 
7.4.5.2 Anchor by H&Y 
Five change groups were formed based on the change of H&Y over the two years 
(Table 7-12). There were large numbers of patients assigned to ‘no change’ group 
(median of sample size = 407) or the ‘slightly deteriorated’ group (median of 
sample size = 400), while only roughly9 five patients were in the ‘largely improved’ 
group.  
 
 
 
                                            
9
 ‘roughly’ is because sample size may be different for each imputed dataset. 
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Table 7-12: Change group formation: H&Y in each change group anchored by 
H&Y 
Stata wide form,(yr2,yr4) 
Anchor H&Y 
Sample size H&Y at year 2 H&Y at year 4 
Median Average Mean SE Mean SE 
Largely Improved group 5 5.3 3.174 0.406 1.593 0.325 
Slightly improved group 109.5 110.9 2.828 0.085 2.149 0.074 
No change group 407 406.9 2.725 0.042 2.725 0.042 
Slightly deteriorated 399 399.9 2.222 0.040 2.985 0.045 
Largely deteriorated group 100.5 100.0 2.043 0.079 3.908 0.095 
 
Table 7-13 shows the change score of the ICECAP-O and EQ-5D-3L over two years 
in the five change groups. In contrast to anchoring by PDQ-39-SI, with which the 
two test measures were changing in the same direction as the anchor, the ICECAP-
O and EQ-5D-3L both showed a decreased QoL in the improved groups defined by 
H&Y, being -0.085 (-0.268, 0.098) and -0.146 (-0.377, 0.085) respectively for the 
‘largely improved’ group, and -0.026 (-0.056, 0.004) and -0.025 (0.078, 0.029) 
respectively for the ‘slightly improved’ group. For the ‘no change’ and 
‘deteriorated’ groups, both the EQ-5D-3L and the ICECAP-O showed a statistically 
significant deterioration with an expected increasing size of mean change from 
‘no change’ group to the ‘largely deteriorated’ group.  
Table 7-13 shows the ES and SRM of the ICECAP-O and EQ-5D-3L in the five change 
groups. The mean SRM of EQ-5D-3L was larger than that of the ICECAP-O (-0.857 
and -0.800) in the largely deteriorated group but overall the mean of the ES and 
SRM for the two measures were comparable with an overlapping confidence 
intervals (Figure 7-9).  
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Table 7-13: Change score of the ICECAP-O and EQ-5D-3L over two years (anchored by H&Y) 
Stata wide form,(yr2,yr4) 
Anchor H&Y 
Change of ICECAP-O  Change of EQ-5D-3L score 
Mean SE 95% CI p value  Mean SE 95% CI p value 
Largely Improved group -0.085 0.093 -0.268,0.098 0.3666  -0.146 0.117 -0.377,0.085 0.2139 
Slightly improved group -0.026 0.015 -0.056,0.004 0.0845  -0.025 0.027 -0.078,0.029 0.3727 
No change group -0.038 0.008 -0.053,-0.022 0.0000  -0.052 0.013 -0.078,-0.025 0.0001 
Slightly deteriorated -0.064 0.009 -0.082,-0.045 0.0000  -0.114 0.016 -0.145,-0.083 0.0000 
Largely deteriorated group -0.125 0.026 -0.177,-0.072 0.0000  -0.264 0.040 -0.343,-0.184 0.0000 
 
Table 7-14: ES and SRM statistics of ICECAP-O and EQ-5D-3L with the anchor H&Y 
Stata wide form (yr2,yr4) 
Anchor: PDQ-39-SI 
Effect size (ES) Standardise response mean (SRM) 
ICECAP-O EQ-5D-3L  ICECAP-O EQ-5D-3L 
Mean SE 95% CI Mean SE 95% CI  Mean SE 95% CI  Mean SE 95% CI 
Largely Improved group -1.007 1.644 -4.327,2.118  -0.733 0.313 -1.332,-0.104  -0.549 0.272 -1.025,0.042  -1.149 0.483 -2.107,-0.215 
Slightly improved group -0.168 0.071 -0.299,-0.021  -0.113 0.078 -0.239,0.067  -0.183 0.077 -0.34,-0.038  -0.125 0.083 -0.258,0.067 
No change group -0.222 0.037 -0.300,-0.156  -0.166 0.042 -0.254,-0.09  -0.262 0.041 -0.376,-0.214  -0.203 0.047 -0.304,-0.121 
Slightly deteriorated -0.403 0.049 -0.469,-0.275  -0.421 0.050 -0.513,-0.317  -0.418 0.040 -0.474,-0.315  -0.415 0.044 -0.498,-0.325 
Largely deteriorated group -0.686 0.147 -1.034,-0.457  -0.992 0.147 -1.317,-0.739  -0.800 0.093 -0.883,-0.518  -0.857 0.084 -1.04,-0.712 
Note: an effective size statistic below 0.2 represents ‘very small’ effect, 0.2 to 0.5 – ‘small’, 0.5 to 0.8 – ‘medium’, and a ES score higher than 0.8 represents a ‘large’ ES (377). But this 
should be interpreted together with the expected ES/SRM as categorised in each of the change group. A measure is judged to be more responsive when it meets the expectation of the 
assignment of the change group to a larger degree than the other measure. Please see Section 7.3.5.3 for details.  
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Figure 7-9: SRM (SE) of ICECAP-O and EQ-5D-3L in the five change groups 
anchored by H&Y 
Note: an effective size statistic below 0.2 represents ‘very small’ effect, 0.2 to 0.5 – ‘small’, 0.5 to 0.8 – ‘medium’, 
and a ES score higher than 0.8 represents a ‘large’ ES (377). But this should be interpreted together with the 
expected ES/SRM as categorised in each of the change group. A measure is judged to be more responsive 
when it meets the expectation of the assignment of the change group to a larger degree than the other measure. 
Please see Section 7.3.5.3 for details.  
 
7.4.5.3 Anchor by PDQ-39 sub-dimensions 
Five change groups were formed based on the change score of each of the PDQ-
39 eight dimensions with the complete data at year 2 and year 4 (Table 7-15). The 
distribution of the sample size and the mean change in the five change groups 
varied across the sub-dimensions due to the different sizes of the MID. The larger 
size of the MID, the more likely that a patient was grouped into a no change or 
small change group but not a large change group. Among all the dimensions, the 
sample size for ‘no change’ group anchored by the social support dimension was 
the largest (n=459) since it has the largest MID, i.e., 11.4 points (533). For the 
dimension cognition and bodily discomfort, there were no observations / patients 
in the small change groups due to the small MID and the relatively small number 
of questions within the dimension. The possible scores for dimensions are discrete 
due to the limited number of questions and levels and there may be few scores 
that falls between one MID and 5 * MID, resulting in no observations in the small 
change group.  
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Table 7-15: Change groups formed by PDQ-39 dimensions: PDQ-39 dimension 
score in each change group anchored by that dimension 
Groups defined by the 
change of anchor measure 
(in bold) (MID in bracket) 
Sample size Change of the anchor measure 
ICECAP-O EQ-5D-3L Mean SE 95% CI 
Mobility (3.2)      
Largely Improved group 82 88 -16.733 0.764 -18.232, -15.234 
Slightly improved group 44 43 -5.795 0.178 -6.144, -5.447 
No change group 167 183 0.189 0.133 -0.073, 0.451 
Slightly deteriorated 96 98 6.262 0.125 6.017, 6.508 
Largely deteriorated group 339 375 24.804 0.760 23.313, 26.295 
Activities of daily living (4.4)      
Largely Improved group 62 67 -22.699 0.818 -24.305, -21.093 
Slightly improved group 63 66 -10.075 0.253 -10.571, -9.578 
No change group 231 248 0.753 0.209 0.343, 1.163 
Slightly deteriorated 131 134 10.205 0.177 9.858, 10.553 
Largely deteriorated group 205 231 27.849 0.813 26.253, 29.445 
Emotional wellbeing (4.2)      
Largely Improved group 66 70 -21.488 0.876 -23.207, -19.769 
Slightly improved group 92 98 -10.333 0.209 -10.744, -9.923 
No change group 268 286 0.345 0.185 -0.019, 0.709 
Slightly deteriorated 111 119 10.434 0.190 10.061, 10.807 
Largely deteriorated group 132 149 29.276 1.214 26.892, 31.661 
Stigma (5.6)      
Largely Improved group 82 85 -28.338 1.138 -30.572, -26.104 
Slightly improved group 124 136 -8.560 0.258 -9.066, -8.054 
No change group 231 240 0.000 0.000 -- 
Slightly deteriorated 161 179 8.924 0.231 8.47, 9.377 
Largely deteriorated group 97 111 30.580 1.274 28.079, 33.082 
Social support (11.4)      
Largely Improved group 5 7 -46.429 3.454 -53.209, -39.648 
Slightly improved group 70 69 -18.403 0.599 -19.578, -17.228 
No change group 459 493 0.434 0.182 0.076, 0.792 
Slightly deteriorated 118 127 20.410 0.554 19.322, 21.498 
Largely deteriorated group 20 24 46.833 1.527 43.836, 49.831 
Cognition (1.8)      
Largely Improved group 214 222 -12.416 0.516 -13.43, -11.403 
Slightly improved group 0 0 -- -- -- 
No change group 114 125 0.000 0.000 -- 
Slightly deteriorated 0 0 -- -- -- 
Largely deteriorated group 368 400 16.441 0.571 15.319, 17.563 
Communication (4.2)      
Largely Improved group 71 75 -22.478 0.987 -24.417, -20.54 
Slightly improved group 87 95 -8.333 0.000 -8.333, -8.333 
No change group 226 236 0.000 0.000 -- 
Slightly deteriorated 121 131 8.333 0.000 8.333, 8.333 
Largely deteriorated group 189 212 25.845 0.768 24.338, 27.352 
Bodily discomfort (2.1)      
Largely Improved group 213 229 -18.678 0.762 -20.175, -17.182 
Slightly improved group 0 0 -- -- -- 
No change group 152 165 0 0 - 
Slightly deteriorated 0 0 -- -- -- 
Largely deteriorated group 327 351 20.282 0.686 18.935, 21.628 
Note: complete case analysis. Change was from year 2 to year 4. 3*MID is used as the cut-off 
between slight change and large change. 
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Overall, the responsiveness of the ICECAP-O and EQ-5D-3L to the eight dimensions 
were similar, nonetheless, there were some differences to a small degree in 
responsiveness between the two measures to all the dimensions except for 
cognition and communication (Table 7-16). The trend of the SRM and ES were 
similar to that when anchored by other measures - the statistics decreased from 
the largely improved group to the largely deteriorated group.  
For mobility, stigma and social support, the ICECAP-O met the expectations of the 
assignment of the change group to a slightly larger degree than the EQ-5D-3L, 
indicated by a larger size of SRM in the change groups with an expected sign 
(positive mean change in the improved groups, and negative mean change in the 
deteriorated groups). Likewise, EQ-5D-3L met the expectations to a slightly larger 
degree with the dimension ADL, emotional wellbeing, and bodily discomfort.  
Due to the overall deterioration trend, investigation was focused on the mean 
change and SRM in the improved groups. The larger size with a positive sign of the 
SRM for a measure, indicates the more consistent a measure with the anchor. 
Across the anchors of mobility, ADL and emotional wellbeing, both ICECAP-O and 
EQ-5D-3L had an increased mean, although not statistically significant, in the 
largely improved group. The SRM of ICECAP-O in the largely improved group 
anchored by social support is 1.041, yet this is more likely by chance given the 
sample size is very small (n=5). 
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Table 7-16: ES and SRM statistics of ICECAP-O and EQ-5D-3L, anchored by the PDQ-39 eight dimensions 
Groups defined by the change 
of anchor  (MID in bracket) 
Change of ICECAP-O score  Change of EQ-5D-3L score Which more 
responsive?a N Mean SE 95% CI p value ES SRM  N Mean SE 95% CI p value ES SRM 
Mobility (3.2)                 
Largely Improved group 82 0.011 0.011 -0.010,0.033 0.2988 0.090 0.116  88 0.016 0.028 -0.038,0.070 0.5775 0.067 0.061 
ICECAP-O 
Slightly improved group 44 -0.007 0.019 -0.045,0.031 0.7223 -0.047 -0.056  43 0.002 0.039 -0.076,0.079 0.9715 0.006 0.006 
No change group 167 -0.024 0.009 -0.042,-0.005 0.0110 -0.124 -0.197  183 -0.019 0.014 -0.046,0.009 0.1792 -0.053 -0.100 
Slightly deteriorated 96 -0.032 0.013 -0.057,-0.007 0.0116 -0.230 -0.258  98 -0.037 0.022 -0.079,0.006 0.0878 -0.135 -0.172 
Largely deteriorated group 339 -0.089 0.008 -0.105,-0.073 0.0000 -0.669 -0.602  375 -0.154 0.014 -0.181,-0.126 0.0000 -0.650 -0.568 
Activities of daily living (4.4)                 
Largely Improved group 62 0.016 0.016 -0.015,0.047 0.3208 0.094 0.127  67 0.040 0.027 -0.013,0.094 0.1404 0.158 0.180 
EQ-5D-3L 
Slightly improved group 63 -0.004 0.013 -0.028,0.021 0.7901 -0.032 -0.036  66 -0.029 0.020 -0.069,0.011 0.1528 -0.108 -0.176 
No change group 231 -0.018 0.007 -0.030,-0.005 0.0076 -0.121 -0.176  248 -0.009 0.013 -0.035,0.016 0.4788 -0.031 -0.046 
Slightly deteriorated 131 -0.047 0.009 -0.064,-0.029 0.0000 -0.362 -0.460  134 -0.064 0.019 -0.101,-0.027 0.0007 -0.241 -0.293 
Largely deteriorated group 205 -0.093 0.011 -0.114,-0.072 0.0000 -0.661 -0.608  231 -0.181 0.019 -0.218,-0.144 0.0000 -0.767 -0.630 
Emotional wellbeing (4.2)                 
Largely Improved group 66 0.015 0.017 -0.018,0.048 0.3701 0.097 0.112  70 0.048 0.031 -0.013,0.109 0.1255 0.171 0.183 
EQ-5D-3L 
Slightly improved group 92 -0.015 0.011 -0.037,0.006 0.1664 -0.116 -0.145  98 -0.042 0.023 -0.087,0.003 0.0673 -0.165 -0.185 
No change group 268 -0.031 0.006 -0.042,-0.019 0.0000 -0.238 -0.318  286 -0.038 0.012 -0.063,-0.014 0.0018 -0.147 -0.185 
Slightly deteriorated 111 -0.043 0.010 -0.063,-0.023 0.0000 -0.307 -0.400  119 -0.081 0.019 -0.119,-0.044 0.0000 -0.277 -0.393 
Largely deteriorated group 132 -0.105 0.015 -0.134,-0.076 0.0000 -0.666 -0.619  149 -0.189 0.024 -0.236,-0.143 0.0000 -0.752 -0.653 
Stigma (5.6)                 
Largely Improved group 82 -0.021 0.017 -0.053,0.012 0.2145 -0.144 -0.138  85 -0.024 0.025 -0.073,0.025 0.3512 -0.074 -0.102 
ICECAP-O 
Slightly improved group 124 -0.016 0.011 -0.038,0.005 0.1363 -0.114 -0.134  136 -0.049 0.020 -0.087,-0.010 0.0128 -0.208 -0.213 
No change group 231 -0.036 0.006 -0.049,-0.024 0.0000 -0.292 -0.369  240 -0.043 0.014 -0.070,-0.016 0.0021 -0.174 -0.199 
Slightly deteriorated 161 -0.035 0.009 -0.052,-0.018 0.0001 -0.279 -0.311  179 -0.086 0.020 -0.125,-0.047 0.0000 -0.326 -0.321 
Largely deteriorated group 97 -0.114 0.016 -0.145,-0.083 0.0000 -0.665 -0.738  111 -0.144 0.027 -0.198,-0.09 0.0000 -0.482 -0.496 
Social support (11.4)                 
Largely Improved group 5 0.080 0.034 0.013,0.147 0.0197 0.564 1.041  7 -0.049 0.195 -0.433,0.335 0.8138 -0.130 -0.095 ICECAP-O 
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Groups defined by the change 
of anchor  (MID in bracket) 
Change of ICECAP-O score  Change of EQ-5D-3L score Which more 
responsive?a N Mean SE 95% CI p value ES SRM  N Mean SE 95% CI p value ES SRM 
Slightly improved group 70 -0.017 0.018 -0.053,0.019 0.3551 -0.112 -0.112  69 -0.060 0.030 -0.119,-0.002 0.0409 -0.225 -0.246 
No change group 459 -0.027 0.005 -0.036,-0.017 0.0000 -0.208 -0.253  493 -0.057 0.010 -0.076,-0.038 0.0000 -0.226 -0.266 
Slightly deteriorated 118 -0.074 0.012 -0.098,-0.050 0.0000 -0.579 -0.557  127 -0.085 0.026 -0.135,-0.034 0.0011 -0.314 -0.291 
Largely deteriorated group 20 -0.169 0.048 -0.264,-0.074 0.0005 -0.756 -0.783  24 -0.246 0.070 -0.384,-0.108 0.0005 -0.772 -0.714 
Cognition (1.8)                 
Largely Improved group 214 -0.015 0.009 -0.032,0.003 0.1057 -0.102 -0.111  222 -0.013 0.015 -0.043,0.017 0.4012 -0.045 -0.057 
ICECAP-
O/EQ-5D-
3L 
Slightly improved group 0 -- -- -- -- -- --  0 -- -- -- -- -- -- 
No change group 114 -0.029 0.008 -0.045,-0.013 0.0003 -0.258 -0.339  125 -0.027 0.017 -0.060,0.005 0.0984 -0.110 -0.148 
Slightly deteriorated 0 -- -- -- -- -- --  0 -- -- -- -- -- -- 
Largely deteriorated group 368 -0.061 0.007 -0.074,-0.047 0.0000 -0.413 -0.465  400 -0.110 0.013 -0.136,-0.084 0.0000 -0.420 -0.411 
Communication (4.2)                 
Largely Improved group 71 -0.005 0.017 -0.038,0.028 0.7918 -0.030 -0.033  75 -0.010 0.031 -0.070,0.050 0.7579 -0.032 -0.038 
ICECAP-
O/EQ-5D-
3L 
Slightly improved group 87 -0.025 0.014 -0.052,0.002 0.0689 -0.160 -0.195  95 -0.031 0.026 -0.082,0.020 0.2292 -0.127 -0.124 
No change group 226 -0.027 0.006 -0.039,-0.015 0.0000 -0.238 -0.286  236 -0.025 0.013 -0.051,0.002 0.0657 -0.091 -0.120 
Slightly deteriorated 121 -0.027 0.010 -0.047,-0.006 0.0103 -0.221 -0.233  131 -0.060 0.018 -0.095,-0.024 0.0010 -0.257 -0.288 
Largely deteriorated group 189 -0.088 0.011 -0.109,-0.067 0.0000 -0.576 -0.602  212 -0.159 0.019 -0.196,-0.122 0.0000 -0.582 -0.573 
Bodily discomfort (2.1)                 
Largely Improved group 213 -0.037 0.008 -0.053,-0.021 0.0000 -0.257 -0.311  229 -0.036 0.017 -0.069,-0.002 0.0362 -0.130 -0.138 
EQ-5D-3L 
Slightly improved group 0 -- -- -- -- -- --  0 -- -- -- -- -- -- 
No change group 152 -0.030 0.009 -0.048,-0.012 0.0010 -0.211 -0.268  165 -0.030 0.017 -0.063,0.003 0.0725 -0.098 -0.140 
Slightly deteriorated 0 -- -- -- -- -- --  0 -- -- -- -- -- -- 
Largely deteriorated group 327 -0.049 0.008 -0.064,-0.034 0.0000 -0.354 -0.360  351 -0.108 0.013 -0.133,-0.082 0.0000 -0.431 -0.441 
Note: a. an effective size statistic below 0.2 represents ‘very small’ effect, 0.2 to 0.5 – ‘small’, 0.5 to 0.8 – ‘medium’, and a ES score higher than 0.8 represents a ‘large’ ES (377). A measure 
is judged to be more responsive when it meets the expectation of the assignment of the change group to a larger degree than the other measure. Please see Section 7.3.5.3 for details. 
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7.4.6 Regression analysis 
Four PDQ-39 dimensions showed statistical significance when predicting the 
change of ICECAP-O scores (Table 7-17). They are: (in the order of the size of 
coefficient) change in social support (-0.00168, p<0.001), change in emotional 
wellbeing (-0.00153, p=0.001), change in mobility (-0.00135, p<0.001), and the 
change in ADL (-0.00124, p=0.002). This result is slightly different from the 
complete case analysis, in which the determinants that showed statistical 
significance were only two dimensions: PDQ-39 social support (-0.00245, p=0.006), 
and PDQ-39 emotional (-0.00223, p=0.016) (result presented in Appendix F).  The 
size of coefficient became smaller after imputation. The p value also became 
smaller which may be due to the substantial increase of sample size. The median 
of the adjusted R squared among the imputed datasets was 0.383 (range: 0.340, 
0.421).  
Table 7-17: Regression analysis to predict the change of ICECAP-O index 
score from the change of the PDQ-39 eight dimensions 
Change of PDQ-39 
dimensions Coefficient SE. P 95% CI 
     
Mobility -0.00135 0.00032 0.000 -0.00198, -0.00072 
ADL -0.00124 0.00038 0.002 -0.00200, -0.00047 
Emotional wellbeing -0.00153 0.00043 0.001 -0.00239, -0.00068 
Stigma -0.00059 0.00031 0.058 -0.00121, 0.00002 
Social support -0.00168 0.00039 0.000 -0.00245, -0.00090 
Cognition -0.00020 0.00035 0.557 -0.00089, 0.00048 
Communication -0.00021 0.00035 0.547 -0.00092, 0.00049 
Bodily discomfort 0.00034 0.00028 0.222 -0.00021, 0.00089 
Constant -0.02614 0.00761 0.001 -0.04113, -0.01115 
 
Table 7-18 showed that there were four dimensions that showed a statistically 
significant difference when predicting the change of EQ-5D-3L: (in the order of 
the size of coefficient) change in ADL (-0.00309, p<0.001), change in emotional (-
0.00276, p<0.001), change in mobility (-0.00273, p<0.001), and change in bodily 
discomfort (-0.00187, p<0.001) (Table 7-18). The median of the adjusted R 
squared was 0.409 (range: 0.382, 0.447).  
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The result was also slight different from the complete case analysis, in which the 
variables that showed statistical significance were emotional wellbeing (-0.00364, 
p=0.001), mobility (-0,00247, p=0.009), and ADL (-0.00197, p=0.036).  The size of 
coefficient of ADL increased after the imputation, while the size of coefficient of 
emotional wellbeing decreased.  
Table 7-18: Regression analysis to predict the change of EQ-5D-3L index 
score from the change of the PDQ-39 eight dimensions 
Change of PDQ-39 
dimensions Coefficient SE P 95% CI 
 
    
Mobility -0.00273 0.00052 0.000 -0.00375, -0.00172 
ADL -0.00309 0.00060 0.000 -0.00428, -0.00190 
Emotional wellbeing -0.00276 0.00073 0.000 -0.00422, -0.00131 
Stigma -0.00044 0.00054 0.412 -0.00151, 0.00062 
Social support -0.00013 0.00070 0.855 -0.00153, 0.00127 
Cognition 0.00039 0.00064 0.545 -0.00089, 0.00167 
Communication 0.00031 0.00051 0.543 -0.00069, 0.00131 
Bodily discomfort -0.00187 0.00043 0.000 -0.00273, -0.00101 
Constant -0.03168 0.01317 0.017 -0.05762, -0.00573 
 
7.4.7 Sensitivity analysis 
Four missing data handling strategies including two imputation strategies and two 
complete case analyses were compared with the primary strategy and the results 
were summarized in Table 7-19. Except for imputation with long form, the effect 
size results using other strategies all agreed that the ICECAP-O was more 
responsive to the change of PDQ-39-SI than the EQ-5D-3L. When classifying the 
participants to three change groups (no change, improved/deteriorated group), 
the result agreed with the five groups that ICECAP-O is slightly more responsive to 
the change of the PDQ-39-SI than the EQ-5D-3L (Table 7-20). The conclusion 
remains the same when the cut-off between the largely change group and the 
small change group changed to 3 * MID (Table 7-20). 
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Table 7-19: Sensitivity analysis – comparing the impact of different imputation strategies to the result of responsiveness 
Groups defined by the change of PDQ-
39-SI 
Sample size*  Change of ICECAP-O score  Change of EQ-5D score Which more responsive? 
(marginal) Average  Mean SE p value ES SRM  Mean SE p value ES SRM 
Stata long form, (yr1, yr5)               
Largely Improved group 125.2  0.046 0.020 0.0188 0.204 0.209  0.126 0.030 0.0000 0.353 0.373 
EQ-5D/ 
ICECAP-O 
Slighly improved group 83.1  -0.004 0.019 0.8477 -0.020 -0.023  -0.017 0.038 0.6769 -0.046 -0.048 
No change group 73.4  -0.045 0.021 0.0374 -0.248 -0.243  0.012 0.039 0.7727 0.034 0.036 
Slightly deteriorated 141.4  -0.063 0.015 0.0000 -0.359 -0.355  -0.101 0.028 0.0003 -0.306 -0.305 
Largely deteriorated group 509.9  -0.179 0.010 0.0000 -1.287 -0.798  -0.312 0.018 0.0000 -1.148 -0.783 
Realcom Impute, wide form, (yr1, yr5)               
ICECAP-O 
Largely Improved group 36.6  0.067 0.029 0.0225 0.285 0.380  0.023 0.042 0.5991 0.075 0.091 
Slighly improved group 70.2  0.010 0.017 0.5793 0.047 0.068  -0.045 0.041 0.2742 -0.114 -0.131 
No change group 80.1  -0.027 0.017 0.1128 -0.148 -0.178  -0.004 0.035 0.9104 -0.012 -0.014 
Slightly deteriorated 207.7  -0.052 0.010 0.0000 -0.272 -0.350  -0.106 0.021 0.0000 -0.281 -0.348 
Largely deteriorated group 538.5  -0.154 0.008 0.0000 -0.830 -0.785  -0.248 0.015 0.0000 -0.854 -0.719 
Stata wide form, (yr2, yr4)               
ICECAP-O 
Largely Improved group 76.8  0.055 0.018 0.0017 0.322 0.455  0.084 0.032 0.0086 0.316 0.387 
Slighly improved group 143.1  0.011 0.011 0.3465 0.062 0.102  0.007 0.023 0.7830 0.054 0.070 
No change group 123.3  -0.015 0.012 0.2060 -0.086 -0.120  -0.011 0.022 0.6355 -0.019 -0.026 
Slightly deteriorated 271.5  -0.041 0.008 0.0000 -0.259 -0.354  -0.061 0.013 0.0000 -0.231 -0.313 
Largely deteriorated group 408.3  -0.124 0.010 0.0000 -0.766 -0.817  -0.211 0.017 0.0000 -0.808 -0.743 
Complete case, (yr1, yr5) ICECAP EQ-5D             
ICECAP-O 
Largely Improved group 5 17  0.035 0.059 0.5604 0.432 0.268  0.035 0.060 0.5693 0.187 0.142 
Slighly improved group 10 23  0.021 0.018 0.2422 0.130 0.372  0.011 0.051 0.8440 0.032 0.044 
No change group 18 37  -0.012 0.024 0.6207 -0.119 -0.121  0.052 0.036 0.1455 0.178 0.240 
Slightly deteriorated 37 61  -0.070 0.021 0.0010 -0.615 -0.544  -0.113 0.027 0.0000 -0.400 -0.532 
Largely deteriorated group 54 128  -0.142 0.024 0.0000 -1.389 -0.806  -0.216 0.026 0.0000 -0.894 -0.732 
Complete case, (yr2, yr4) ICECAP EQ-5D              
Largely Improved group 41 41  0.034 0.018 0.0619 0.245 0.291  0.041 0.031 0.1830 0.153 0.208 
ICECAP-O 
Slighly improved group 85 91  0.010 0.011 0.3910 0.075 0.094  -0.001 0.022 0.9756 -0.003 -0.004 
No change group 80 87  -0.010 0.011 0.3707 -0.074 -0.101  -0.004 0.019 0.8353 -0.015 -0.024 
Slightly deteriorated 185 187  -0.039 0.007 0.0000 -0.307 -0.400  -0.048 0.012 0.0001 -0.203 -0.297 
Largely deteriorated group 185 209  -0.087 0.011 0.0000 -0.598 -0.603  -0.162 0.020 0.0000 -0.622 -0.565 
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Table 7-20: Sensitivity analysis – results of three change groups (as versus five change groups in the base case) and 3*MID (as 
versus 5*MID in the base case) 
Groups defined by the change of 
PDQ-39-SI 
Sample size*  Change of ICECAP-O score  Change of EQ-5D score Which more 
responsive? 
(marginal) Average  Mean SE p value ES SRM  Mean SE p value ES SRM 
Three change groups               
Largely Improved group 219.9  0.026 0.010 0.0064 0.154 0.220  0.034 0.018 0.0635 0.144 0.184 
ICECAP-O No change group 123.3  -0.015 0.012 0.2060 -0.086 -0.126  -0.011 0.022 0.6355 -0.019 -0.026 
Largely deteriorated group 679.8  -0.091 0.007 0.0000 -0.568 -0.631  -0.151 0.012 0.0000 -0.576 -0.578 
3 * MID               
ICECAP-O 
Largely Improved group 149.4  0.039 0.013 0.0019 0.234 0.340  0.049 0.022 0.0241 0.201 0.251 
Slightly improved group 70.5  -0.001 0.018 0.9782 -0.027 -0.037  0.001 0.034 0.9784 0.019 0.026 
No change group 123.3  -0.015 0.012 0.2060 -0.086 -0.126  -0.011 0.022 0.6355 -0.019 -0.026 
Slightly deteriorated 159.7  -0.034 0.011 0.0015 -0.223 -0.302  -0.053 0.018 0.0032 -0.214 -0.281 
Largely deteriorated group 520.1  -0.108 0.008 0.0000 -0.672 -0.729  -0.181 0.014 0.0000 -0.682 -0.662 
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7.5 Summary of results 
This chapter has, for the first time, empirically tested the responsiveness of 
ICECAP-O in comparison to EQ-5D-3L to the change of a variety of health, QoL and 
wellbeing aspects in people with Parkinson’s. An overall deterioration of health 
status, HrQoL as well as wellbeing was found as expected in this cohort. The 
change of ICECAP-O index score and the change of EQ-5D-3L index score were 
moderately correlated and there was no substantial difference in the pattern 
shown in the scatter plots with PDQ-39-SI and in the responsiveness performance 
to all the aspects. Nevertheless, the ICECAP-O was slightly more responsive to the 
change in general health and QoL as measured by PDQ-39-SI, and in contrast, EQ-
5D-3L was slightly more responsive to the change of motor symptoms as measured 
by the clinical scale H&Y staging. Results remain the same in the sensitivity 
analyses when varying the imputation strategies (except for imputation with long 
form), dividing to three change groups, and using 3 * MID as the cut-off between 
‘largely’ and ‘slightly’ change for PDQ-39-SI.  
For PDQ-39 dimensions, the ICECAP-O was shown to be marginally more responsive 
to mobility, stigma and social support dimensions than the EQ-5D-3L, but less 
responsive to ADL, emotional wellbeing, and bodily discomfort. Again, the 
difference in their responsiveness to the PDQ-39 dimensions was minimal. The 
spike at 0 in the histogram for EQ-5D-3L adds to the existing concern that its three 
levels may lack sensitivity to small changes (e.g. patients may stay in level 2, 
‘some problems’ and the change was not big enough for patients to answer ‘no 
problem’ or ‘a lot of problems’). 
The regression analysis showed that the change in mobility, ADL, and emotional 
dimensions could predict the change of both ICECAP-O and EQ-5D-3L, however, 
the size of change that these dimensions could predict was smaller in ICECAP-O 
than in EQ-5D-3L. Besides the shared predictors, it was found that the change of 
social support strongly predicted the change in ICECAP-O value, while the change 
of bodily discomfort predicted the change in EQ-5D-3L value. 
As discussed in Chapter 5 (Section 5.4), a variety of methodological challenges 
were met in this assessment of responsiveness, including the selection of the 
Chapter 7  230 
 
optimal anchor, use of the MID method to form change groups anchored by PDQ-
39-SI and its dimensions, addressing the missing data problem, and applying the 
statistical methods in the imputed datasets. Assumptions were made to tackle 
these problems throughout the methods in this case study. These challenges will 
be further discussed in Section 7.6.3. 
7.6 Discussion 
7.6.1 Interpretation of results 
This study shows that the progression of Parkinson’s over time leads to a 
noticeable deterioration in health status, HrQoL and capability wellbeing. This is 
in line with the finding in last chapter that there is an important difference in all 
of these aspects between the Early and Later group. The result that ICECAP-O was 
more responsive than the EQ-5D to the change of PDQ-39 overall score while EQ-
5D was more responsive than ICECAP-O to the change of H&Y is as expected, 
although the difference was small and did not cross the categories of the Cohen’s 
interpretation of the effect size statistics.  
The results of PDQ-39 dimensions are mixed. The PDQ-39 dimensions are not 
mutually exclusive, for example, stigma and emotional wellbeing are conceptually 
related, however stigma is more sensitive to be measured by ICECAP-O while 
emotional wellbeing prefers EQ-5D-3L. Therefore these results should be treated 
with caution. One reason for the mixed results may be due to the fact that they 
are analysed using complete case analysis which risks selection bias. Also, both 
QoL and capability are multi-faceted concepts that have numerous determinants, 
while each of eight dimensions only represent one aspect and thus the ‘noise’ (the 
impact of other factors contributing to HrQoL or capability) is large. For these 
reasons the analysis anchored by the dimension scores can only play a 
supplementary role in concluding the research.  
One potential reason to explain the smaller sizes of change coefficient of ICECAP-
O than EQ-5D as predicted by mobility, ADL and emotional wellbeing dimensions 
is due to the difference in scoring range between the measures. EQ-5D-3L has 
wider score range than the ICECAP-O. Another contributing factor might be the 
deliberately broad nature of the ICECAP-O dimensions which could be affected by 
Chapter 7  231 
 
many determinants, thereby certain change in a few dimensions may not have as 
large an impact as the health-focused EQ-5D-3L.  
Besides the shared predictors, this study found that the change of social support 
strongly predicted the change in ICECAP-O value, while the change of bodily 
discomfort predicted the change in EQ-5D-3L value. This meets the expectation, 
which could be explained by the similar questions in the ICECAP-O or EQ-5D-3L as 
those in the PDQ-39. The attachment dimension in ICECAP-O asks “are you able to 
feel the love and friendship?”, which is similar to the PDQ-39 social support 
dimension which asks “had problems with your close relationships?”, “lacked 
support in the ways you need from your spouse or partner?”, “lacked support in 
the ways you need from your family or close friends?”. In addition, the 
‘attachment’ has the highest set of weights among the five dimensions of the 
ICECAP-O and thus determines more strongly the total capability score than the 
other dimensions, which adds to the explanation for the significance of the social 
support dimension which is similar to ‘attachment’ to predict the total capability 
score. For the EQ-5D-3L, the pain/discomfort dimension asks “have problems in 
pain/discomfort?”, which is similar to the PDQ-39 ‘bodily discomfort’, which asks 
‘had painful muscle cramps or spasms?”, “had aches and pains in your joints or 
body?”, and “felt unpleasantly hot or cold?”. This explains the stronger 
relationship between these two dimensions in EQ-5D-3L and the PDQ-39. 
7.6.2 Critique of previous studies assessing responsiveness of 
ICECAP-O 
Three studies were identified from literature which, respectively, assessed 
responsiveness of ICECAP-O in frail older adults in the Netherlands (319), among 
older adults (aged ≥ 70) at risk of mobility impairment in Vancouver (546), and in 
a cohort of patients with a hip fracture in the UK (547). These studies generated 
mixed conclusions regarding the comparison of EQ-5D and ICECAP-O in each 
population. Two out of the three studies (546, 547), unfortunately, failed to 
interpret appropriately from their results and thus their conclusions should be 
treated with caution. As it is the interest of this chapter to critique the assessment 
of methods of responsiveness, this discussion subsection will provide a brief 
critique of the methods used in these studies. 
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The earliest study of the three, Parsons et al. (2014), measured EQ-5D, ICECAP-O, 
and the Oxford Hip Score (a hip specific measure, OHS) in the patients that had 
hip operation following a hip fracture at baseline (pre-operation), 4 weeks, 4 
months post operatively (547). They concluded that ICECAP-O was not responsive 
to the change for patients recovering from hip fracture whereas EQ-5D could be 
used to measure outcome for patients recovering from hip fracture. This 
conclusion is based on two statistics: a. effect size as used in this chapter (change 
scores divided by SD of baseline scores); b. correlations between the change score 
of clinical measure OHS and the EQ-5D/ICECAP-O at each time point. The effect 
size of ICECAP-O at 4-month was found to be much smaller than that of EQ-5D, 
and the correlation between ICECAP-O and OHS at each assessment point was 
found to be smaller than the correlation between EQ-5D and OHS, based on which 
the conclusion was generated favouring the responsiveness of EQ-5D. However, 
there are two crucial methodological flaws of this study. 
Firstly, for the effect size statistics, as mentioned in Chapter 3 (Section 3.6.3.1) 
and this chapter Section 7.3.5.3, effect size statistics were initially invented to 
detect the size of clinical change by an intervention, rather than determining the 
responsiveness of measures. The difference between the former and the latter is 
that in the case of former, the responsiveness of the measure is proved, based on 
which the responsive measure is used to test whether the intervention is effective 
or not. In contrast, in the case of latter, it would require the effectiveness of the 
intervention is proved and known, based on which we could then determine 
whether the measure is responsive.  
This means that when the effectiveness of an intervention is unknown, comparison 
of the magnitude of the effect size statistic is futile to determining the 
responsiveness of measures (327, 415). In Parson et al.’s study, the effectiveness 
of hip operation on the change of capability wellbeing is unknown, and no 
assumptions were made regarding this expected change, therefore this study 
design essentially failed to measure responsiveness.  
Second, for the correlation comparison, although the authors did not mention it, 
they used OHS as a surrogate to confirm the effectiveness of the intervention, 
thereby a high correlation of EQ-5D/ICECAP- with OHS was judged in this study as 
representing high responsiveness. However, according to this study, the OHS 
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measure is a clinical measure “which quantify disability secondary to hip 
osteoarthrosis”, that gives an overall score for hip function from 0 to 48, where 
“0 indicates excellent hip function and 48 indicates very poor hip function.”. It is 
a typical clinical measure focusing specifically on hip function and thus a high 
correlation with OHS can only mean the construct of the measure is highly related 
with the hip function. In other words, the OHS was used as an ‘anchor’ in this 
study which, however, may not be an ideal anchor as it measures related but still 
quite different concepts from capability-wellbeing in general. This is similar to 
using H&Y clinical scale in this thesis which can only provide information regarding 
whether ICECAP-O is responsive to one aspect of clinical change, but not on 
‘whether it is responsive to the important changes in the concept that the measure 
is constructed to measure’, as per the definition of responsiveness (see Section 
3.5.2 for details) 
The second study, by Davis et al. (2017), had a similar issue as it compared the 
magnitude of mean change and SD between the measures in a population that did 
not have any external criteria to confirm what the change was expected to be 
(546). This study followed 359 patients who had experienced a minimum of one 
minimal displacement non-syncopal fall and attended the Vancouver Falls 
Prevention Clinic in the past 12 months for one year. It compared the 
responsiveness of EQ-5D-3L and ICECAP-O in terms of their mean change and SD; 
the larger the mean change relative to SD, the more responsiveness of the measure. 
Based on this, it concluded that EQ-5D-3L was more responsive than the ICECAP-
O. However, this conclusion was an incorrect interpretation of the results, 
because there was no external criteria to confirm what should be the real change 
for HrQoL and capability. External criteria and assumptions are key for testing 
responsiveness (327, 415); if in fact there is no real change for the patients over 
the year, then the measure that had a no mean change should be the most 
responsive one, and if in fact there is a small change for the patients over the 
year, then the measure that had a small mean change should be the most 
responsive, and so on. Therefore, it is incorrect to associate ‘more responsiveness’ 
to a higher correlation coefficient, without any external information regarding 
what the actual correlation is expected to be. 
The last study, by van Leeuwen et al. (2015), compared responsiveness of EQ-5D-
3L, ICECAP-O and ASCOT based on the correlation coefficient between each of 
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these measures and with eight external measures (319). The methods used in this 
study were appropriate as these external measures covered a broad range of 
health, HrQoL and wellbeing aspects, which provided a comprehensive concept 
examination of the three preference-based measures. The external measures 
included health GRS (Global Rating Scale), ADL limitations, impact of physical 
limitations (SF-12 physical), impact of emotional influences (SF-12 mental), QoL 
GRS, mastery (through Pearlin Mastery Scale, reflects the extent to which a person 
perceives himself or herself to be in control of events and ongoing situations), and 
client-centeredness (Client-Centered Care Questionnaire, reflects the extent to 
which respondents feel recognized and respected by nurses and to which they 
experience autonomy with respect to the way in which care is delivered).  
In addition, ex ante hypotheses were provided in van Leeuwen et al’s study with 
reasons regarding the comparative strength of correlations between the measures, 
for example, hypothesis 3a stated that “ICECAP-O change scores are less strongly 
correlated to ADL limitations than the EQ-5D-3L change scores” (319). A 
correlation table was provided which listed all the coefficients between the 
change score of each of the three measures in addition to the summary results of 
the hypothesis. Among the eight broad aspects, EQ-5D-3L change score was shown 
to be correlated strongest with the impact of physical limitations (SF-12 physical, 
r=0.23), whereas ICECAP-O was shown to be correlated strongest with ADL 
limitations (r=0.26), ASCOT (See Section 2.6.4) (r=0.31), and impact of emotional 
influences (SF-12 mental, r=0.22). This result, as concluded by the authors, is in 
line with the findings of this thesis which support the adoption of ICECAP-O as 
outcome measures in economic evaluations of care interventions for older adults 
that have a broader aim than HrQoL. 
7.6.3 Methodological considerations 
As the fourth and fifth objectives of this chapter are related to the methods (i.e. 
(4) to explore how to adapt the psychometric methods for the assessment of 
responsiveness to the assessment of PbQoL measures; (5) to investigate the impact 
of missing data on the result of assessment of responsiveness), this section will 
therefore discuss the methodological considerations of the methods used in this 
chapter. 
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7.6.3.1 Choice of anchors 
Ten anchors were chosen in this study to ensure the comprehensiveness of our 
assessments for a broadly defined QoL measure. However, the interpretation of 
the results with each anchor should be treated with caution since they are 
dependent on the underlying assumptions. As mentioned earlier, preference-
based measures are designed to be responsive to the change of overall utility 
rather than a particular aspect of clinical change. Therefore, the justification for 
using the PDQ-39 dimensions and the motor symptom scale H&Y would be that the 
improvement shown on these anchor measures are expected to lead to 
improvement of the overall QoL utilities. This study showed that the ES and SRM 
results anchored by the PDQ-39 eight dimensions were with smaller size than that 
when anchored by PDQ-39-SI. This is as expected because the change in only one 
dimension may be too small to affect the overall QoL, or it may be offset by the 
change in other areas which may not be captured by that specific dimension, or 
the change in one dimension may not affect the overall preferences. For this exact 
reason, the PDQ-39-SI is judged to be the more suitable anchor compared to the 
others since it measures similar broad QoL and wellbeing concept and thus the 
closest to the gold standard when testing the psychometric properties of ICECAP-
O in Parkinson’s population. 
7.6.3.2 The MID method 
Despite this, PDQ-39 is still not perfect as it does not measure preferences - to 
what degree the patients would judge the change to be ‘important’ so that they 
would like to trade a larger amount of length of life or accept a higher risk of 
death for it. To minimize this concern, this study used the MID to form the change 
groups by PDQ-39-SI as by definition MID is the smallest change that the patient 
considers ‘important’ and the ‘important’ should implicitly incorporate patients’ 
general perception about their health. Although ‘important’ is an inherently 
different concept from ‘preference’, this MID approach is considered the best 
approximation given the limited information. In the future, valuation of PDQ-39 
will facilitate the type of study which would provide the preference information 
for PDQ-39. This will be further discussed in Chapter 8 Section 8.6.2. 
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In addition to the reason above, to facilitate the interpretation of ‘preference’, 
the MID method also presents a feasible and justified avenue to form groups based 
on the continuous scoring measure, PDQ-39. Chapter 3 (Section 3.6.2) outlined 
four approaches to forming the change groups, including the Global rating scale 
approach, using intervention groups with confirmed effectiveness, using anchor 
measures which contain ordinal distinctive objective measures or MID for a 
continuous anchor measure. As the PD MED trials do not contain any GRS, and its 
interventions have uncertainties in their comparative effectiveness, the anchor 
measure method was used to classify the groups. This avoids the recall bias of the 
GRS approach (See Section 3.6.2.1), and the uncertainty in the outcome of the 
interventions, although this anchor approach must meet the prerequisite of the 
required correlation strength between the test measure and the condition-specific 
anchor measure (548). 
The grouping by PDQ-39-SI and its eight dimensions applies the MID method. Unlike 
the H&Y scale which can be easily used to divide the groups due to its discrete 
staging system, the PDQ-39 generates a continuous score ranging from 0, no 
impairment of QoL, to 100, worst state that every aspect of QoL is substantially 
affected (131). It would be arbitrary to simply put, say a one-point change, or 
five-point change, as the criteria for the ‘change’ of the health status. It is also 
inappropriate to apply the same amount of points change for all the dimension 
scores and the overall score as they would fundamentally mean different health 
states. For example, a five-point change in the mobility dimension score may 
indicate a two level change (5*4*10/100, the scoring system is explained 
previously in Chapter 5 Section 5.3.4) in one of the mobility questions, e.g. 
changing from ‘occasionally’ to ‘often’ for the question, ‘needed someone else to 
accompany you when you went out’.  Meanwhile, five-point change in the 
emotional wellbeing dimension may indicate roughly one level change (5*4*6/100) 
in one of the questions of the emotional dimension, e.g. changing from ‘sometimes’ 
to ‘often’ in the question ‘felt isolated and lonely?’. The actual change in these 
two situations is different to some degree, which however, translate to the same 
amount (five-point) of point change in their dimension score. Therefore, to avoid 
misjudgement on the meaning of the size of the change, the published MIDs (533) 
in the PDQ-39-SI and each of its dimension scores were determined to be the best 
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available evidence to define groups that had changed (improved or worsened) by 
equal to or greater than the MID. 
Although the MID estimates come from a published source (533) as described 
earlier in this chapter (Section 7.3.3.2), the limitation of the original study should 
be noted. The MID was calculated from the mean difference in the ‘about the 
same’ and ‘a little worse’ group (533). An underlying assumption is that the MID 
gained for the improved group is the same from the MID in the deteriorated group. 
If this assumption is not valid, using a constant MID for the both the improved and 
deteriorated groups may cause bias. Walters and Brazier (2005) compared the MID 
generated from the ‘somewhat better’ group and ‘somewhat worse’ group (400) 
in eight disease areas. They showed that those who improved and those who 
deteriorated have different MID although these difference was not statistical 
significant for most disease areas. 
In terms of EQ-5D, the difference was 0.089 (p=0.42) for leg ulcer, 0.12 (p=0.14) 
for early rheumatoid arthritis, 0.072 (p=0.57) for limb reconstruction, 0.099 
(p=0.15) irritable bowel syndrome, 0.006 (p=0.93) for acute myocardial infarction, 
0.020 (p=0.83) and 0.166 (p=0.05) respectively for the two studies with patients 
of chronic obstructive pulmonary disease. This not statistically significant 
difference could be either due to the homogeneous nature of the MID for the 
improved group and the deteriorated group, or due to the small sample size in 
most of the studies (<30 in most groups). The comparison of whose MID was higher, 
those who improved or those who deteriorated, is not consistent across diseases. 
The exceptions that have a statistically significantly different MID was SF-6D in 
patients with back pain, and the MID of EQ-5D-3L in patients with Osteoarthritis 
of the knee. For the former, MID from the patients that answered ‘somewhat 
better’ was 0.115 which became 0.035 in people who answered ‘somewhat worse’, 
p=0.02; for the latter, MID from those improved was 0.261, which became much 
smaller in those deteriorated, i.e., 0.014, p=0.001. 
Furthermore, the magnitude of MID may depend on the average health status of 
the participants, in other words, the transferability of the MID results in other 
studies. In Peto’s study, the mean age of sample (N=728) was 70.4 years and 58.9% 
were men, with an average of 8.6 years of diagnosis of Parkinson’s (533). These 
characteristics are similar to the PD MED cohort used in this thesis, and therefore 
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it was judged that the MID results from Peto’s study should be able to generalized 
to this analysis with low risk of bias. 
7.6.3.3 Missing data 
Another challenge of this analysis comes from the large amount of missing data in 
this dataset. This phenomenon is not rare for patient self-reported data. Previous 
studies (549) reported that the problem of missing patient reported outcomes is 
common in clinical trials (550-552). This creates challenges for data analysis, and 
may mislead the result and compromise the interpretability and credibility of the 
findings (553-555).  
There are various reasons for the missing data in the PD MED trials. First, with the 
progression of the disease, the physical symptoms may impair the patients’ ability 
of holding a pen and completing the questionnaires. Parkinson’s may also affect 
patients’ cognitive function and thus the patients may find the questionnaires 
difficult to grasp or answer. Sometimes the onsite guidance would help clarify the 
questions but this was unable to achieve in this trial as all the questionnaires were 
sent through post. Missing data were therefore produced, item missing in 
particular where only some items within the questionnaires were missing. Besides, 
numerous reasons may cause the whole follow-up assessment to be missing, such 
as patients drop out, loss of contact, hospitalisation, severe deterioration of 
disease or death. The loss of follow-up seems inevitable in the PD MED trial as it 
has been on-going for 15 years and circumstances of patients may change. 
Given the large amount of missing data in this dataset, simply analysing the 
participants that have complete data may lead to biased result as they may not 
be a proper representative sample of the whole group (518, 555, 556). This 
chapter tested the mechanism of missing data and the result showed that the 
missingness was associated with age, ICECAP-O attachment dimension, number of 
days treated in hospital, and whether the patient has dementia. This 
demonstrated that the complete-case analysis may be biased and necessitated the 
implementation of imputation method to the data.  
Sensitivity analysis of this study compared different missing data handling 
strategies (Table 7-19). Although the complete case analysis generated the same 
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conclusion regarding the comparative responsiveness between ICECAP-O and EQ-
5D-3L, the magnitude of effect size of the complete case analysis was smaller for 
all change groups than the imputed datasets. The imputation almost doubled the 
sample size for all groups and made use of all of the information available for the 
analysis, which enhanced the confidence in the study results. 
In the future, measures should be undertaken to improve the completeness of the 
questionnaire (549). On-site assistance could be provided if the patients may have 
problems in the interpretation of the questions . But this should be treated with 
caveats to avoid leaving the answer to be ‘contaminated’ by the varied perception 
of the question of staff for a patient-self-reported questionnaire. Computerized 
questionnaire distribution would also prevent the item-non-response by providing 
notices, explanations to the question, and completeness checking. It would also 
prevent whole-wave missingness when the participants change contact address, 
or the correspondence lost in the mail system. 
7.6.3.4 Compromised multiple imputation strategy 
MI was used to impute the missing data since the MCAR assumption was not met 
(535). It is recommended to use MI in wide form in STATA for the data with panel 
structure with repeated measurements (537). Incorporation of auxiliary variables 
which influence the probability of missing values was also found to improve the 
imputation model (537). MI in wide form has the advantage of handling the 
correlation between the data from each wave for the same patient in the 
imputation model. On the other hand, it requires computational power as it 
multiples the number of the variables in the imputation model. The original model 
specification was comprised of 19 variables with missing data to impute, plus four 
baseline variables without missing data (age, sex, H&Y stage at baseline, and years 
since diagnosis of Parkinson’s). The 19 variables included the five dimensions of 
ICECAP-O, five dimensions of EQ-5D, eight dimension of PDQ-39, H&Y staging, and 
whether the patient has dimension. After transforming the five waves to wide 
form, there were a total of 95 variables to impute in the imputation model. The 
imputation was initially carried out on the dimension level rather than the overall 
score level because this analysis need correlations between the change score of 
each dimensions and also dimension scores were used as anchors for ES statistics. 
However, despite its theoretical appropriateness, the imputation model cannot 
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be fulfilled by STATA as it cannot converge due to the large proportion of missing 
data.  
Several compromise measures were then undertaken after the failure of the 
optimal model. First, effort was taken by adding a small group of variables in the 
model gradually and it was found that the model seemed to be reaching a 
‘saturation’ state when the number of variables to impute increased to around 20 
and adding any extra variable will initiate the convergence failure. Therefore, the 
number of variables to impute in the model had to be reduced. After many 
attempts, the time horizon was adjusted to two years (wave 2 to wave 4) from 
the original four years (wave 1 to wave 5) due to the lower proportion of missing 
data at wave 2-4. The number of variables to impute was also reduced from 19 to 
4 by imputing the summary score of the QoL measures rather than the dimensions. 
In this way, an imputation in wide form for wave 2 and 4 was applied in the primary 
analysis. 
7.6.3.5 The effect size statistics 
All the effect size methods are based on mean and SDs, which has an implicit 
assumption that the data follows a normal distribution. However, our results 
showed that the distribution of the change of the PDQ-39 and the EQ-5D did not 
meet the normal distribution assumption. In this case, Fayer (2007) suggests that 
the medians and interquartile ranges may replace means and SDs however little 
work has been carried out in this area (410).  
Calculation of the effect size formula requires SD and mean change, however the 
SD cannot be calculated directly with STATA post estimation command after 
imputation. The SE (standard error) of the pooled mean result was provided in the 
result, which is the SD of the sampling distribution. SE describes how much the 
sample mean will vary from the mean for the whole population (557). A large SE 
means a wider sampling distribution and the mean from one sample may have a 
higher chance to be different from the whole population. The SE can be calculated 
by dividing the SD with the square root of the sample size (SE= SD/ square 
root(sample size)), and therefore, when the SE is known from the MI output using 
Rubin’s rule, the SD can be calculated by multiplying the SE with square root of 
the sample size (557).  
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This brought another issue which is that the calculation of sample size is 
complicated due to the imputation. When the anchor variable contains missing 
data, the values imputed may be different for each imputed dataset. The different 
values may cause the patients to be categorised to different change groups for 
each imputation datasets, leading to unequal sample size for each of the five 
change groups between the imputation datasets. Therefore, the transformation 
was used to enable the calculation of ES/SRM bypassing the difficulty with 
calculating standard deviation, and allow the pooled estimates of ES/SRM applying 
Rubin’s rule (Section 7.3.5.3). 
7.7 Chapter summary 
Following the gap identified in Chapter 4 regarding the limited responsiveness of 
EQ-5D-3L, this chapter reported the objectives, methods, and results of an 
empirical assessment of responsiveness of the capability wellbeing ICECAP-O 
instrument in comparison with EQ-5D-3L in people with Parkinson’s. It found the 
ICECAP-O was more responsive to changes in overall QoL and wellbeing, and the 
EQ-5D-3L was more responsive to change in motor symptoms. Close relationships 
(social support) and bodily discomfort from the PDQ-39 were identified as the 
unique predictors for the change score of ICECAP-O and EQ-5D respectively, which 
reflects the difference in their construct and could be highlighted as their 
respective unique advantages in future studies. Discussion surrounding the results 
and methodologies were provided, and previous studies that tested the 
responsiveness of ICECAP-O in other populations were critiqued. 
Although the differences in the estimates were small and not statistically 
significant, the results eliminate the concern that the sensitivity of a broad scoped 
measure to the specific health change might be inferior compared to a health-
related QoL measure. It shows that the ICECAP-O instrument was able to provide 
rich information on capability wellbeing in the Parkinson’s population without 
compromising its sensitivity to the clinical and specific QoL change in this patient 
group. This is a key point for its longitudinal use to measure change in a broader 
way than current practice and established a foundation of its use in economic 
evaluations of interventions in Parkinson’s population. Implications of these 
results will be further discussed in the next chapter. 
   
   
Chapter 8 Discussion and conclusion 
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8.1 Introduction 
Parkinson’s is a neurodegenerative condition which is associated with lifelong 
disability in many aspects of body function, significantly affecting patients’ lives. 
Interventions in Parkinson’s may benefit patients in a wide range of ways related 
to patients’ health, QoL and wellbeing. In an economic evaluation context, these 
benefits require sufficiently accurate measurement and valuation by preference-
based instruments in order to inform decision-making. 
The aim of this thesis was to examine the performance of the existing preference-
based outcome measures in people with Parkinson’s, and evaluate the potential 
of using a generic preference-based capability-wellbeing measure, ICECAP-O, to 
incorporate broader aspects affected by Parkinson’s in economic evaluations. 
ICECAP-O had not been used in the Parkinson’s population before and therefore it 
was unknown how this population would score using this measure, and to what 
degree it is valid compared to existing health-related QoL measures. There were 
two overarching research questions of this thesis: 
1) Are the existing PbQoL measures appropriate to be used in the Parkinson’s 
population? In other words, do existing preference-based generic measures 
capture all important aspects of QoL in People with Parkinson’s? 
and, 
2) Is the ICECAP-O capability wellbeing measure appropriate to capture the 
wellbeing impact of interventions in Parkinson’s, and is it sensitive in this 
population? 
This thesis addressed these questions through three empirical works. It firstly 
explored the use of current PbQoL measures in people with Parkinson’s and 
assessed existing evidence of the construct validity and responsiveness of these 
measures in this population through a systematic review. This was followed by two 
studies evaluating the construct validity, and responsiveness, respectively of the 
ICECAP-O, in comparison to the EQ-5D-3L measure in people with Parkinson’s. This 
chapter will provide an overall discussion of the main findings from the empirical 
works making reference to the two research questions above, and summarise the 
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implications to policy making and research. Strengths and limitations will be 
provided, as well as a summary of the contributions and conclusions. 
8.2 Summary of the findings 
8.2.1 Evaluating the performance of existing PbQoL measures in 
Parkinson’s 
Chapter 4 explored the use, the construct validity and responsiveness of PbQoL 
measures in Parkinson’s population. Not surprisingly, the EQ-5D-3L instrument was 
predominantly used as the PbQoL measure in Parkinson’s. Furthermore, PDQ-39 
was the most widely used Parkinson’s specific QoL measure among the included 
studies, which further justified the choice of PDQ-39 as a Parkinson’s-specific 
‘gold standard’ for the case studies of validation of ICECAP-O in the Parkinson’s 
population.  
8.2.1.1 Construct validity 
Overall, the EQ-5D-3L and the other identified PbQoL measures were found to be 
able to differentiate between patients with different characteristics, although the 
grouping criteria in the included studies were favourable for a difference to be 
found, e.g. general population vs. people with Parkinson’s. Despite the overall 
positive evidence, EQ-5D-3L and HUI-2’s ability to differentiate patients with mild 
Parkinson’s disease (UPDRS first quantile vs. second quantile) was found to be 
limited. This raised a query about whether EQ-5D-3L and HUI-2 would be sensitive 
to detect the benefit of interventions that may slow down the progression from a 
very early stage of Parkinson’s to a moderate stage. Many patients at early stage 
of Parkinson’s may still be working or leisurely active. Early interventions that can 
impede the progression of disease may not only keep them in reasonable 
functioning status but also may prevent them from retiring from work early (i.e. 
saving productivity cost) or keep the level of their leisure activities, and also 
reduce cost of caring. Failing to accurately value the benefit of these early 
interventions by the PbQoL measures may lead to a poorly informed resource 
allocation decision. 
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Convergent validity analysis showed that the EQ-5D-3L, DDI and HUI-II all 
correlated most strongly with the physical attributes (i.e., mobility and ADL) of 
the PDQ-39 measure and most weakly with mental and wellbeing attributes (i.e., 
social support and stigma). This finding echoed the concern that these PbQoL 
measures may not be scoped broadly enough to capture the full ‘valued’ impact 
of disease and the associated benefit of potential interventions that may improve 
those aspects.  
8.2.1.2 Responsiveness 
For responsiveness, agreement was mixed between EQ-5D-3L and the Parkinson’s-
specific QoL/clinical measures in regards to the change over time across studies. 
The inconsistency in findings of responsiveness between these measures cautioned 
that the change shown on clinical measures may not necessarily translate to the 
same change in PbQoL scores. This may be potentially explained by either of the 
following two reasons. The aspects of change on the clinical measures were not 
‘important’ to patients (i.e. patients would not trade any length of life for the 
improvement), thereby no difference was apparent in PbQoL scores. However, if 
the patients do consider the improved clinical aspects to be ‘important’, it could 
be due to the fact that the PbQoL measure does not sufficiently reflect the 
patients’ true preferences. 
8.2.1.3 Mapping 
The summary of mapping algorithms from PDQ-39/8 to EQ-5D-3L utility values 
found that half of the PDQ-39/8 eight dimensions, which are mainly related to 
mental health and wellbeing, i.e. stigma, social support, cognition and 
communication (472-475) were not included in four out of five algorithms. This, 
from an alternative perspective, suggests that these important aspects to patients 
with Parkinson’s may not be sufficiently counted in the EQ-5D.  
8.2.1.4 Summary 
In brief, the first empirical work of this thesis detailed the gap between ‘what is 
counted’ and ‘what counts’ through assessing the evidence identified in a 
systematic review.  The gap could be summarized as follows: 
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• Patients value changes in their progression of Parkinson’s from very mild to 
moderate state, however PbQoL measures may not adequately measure and 
value a change in their scores; what counts (the deterioration in health) is 
not sufficiently counted;  
• In two out of ten intervention studies, the Parkinson’s specific QoL 
measures showed a statistically significant improvement in the overall 
score and majority of dimensions, however, the EQ-5D did not find a 
difference or even showed an opposite direction of change; what counts 
(the benefit of some types of intervention) is not sufficiently counted; 
• When the EQ-5D is obtained through mapping from the PDQ-39, the four 
dimensions that are related to mental health and wellbeing, no matter 
what levels they are at, do not affect the value of the EQ-5D score and 
consequent decision-making; what counts (mental health and wellbeing) is 
not sufficiently counted. 
These gaps in PbQoL measures may have profound impact on resource allocation 
decisions related to the cost-effectiveness of interventions that have an impact 
on these aspects of people’s lives. This highlights a need to seek a broadly scoped 
mental health and wellbeing inclusive measure to incorporate such aspects in 
economic evaluations. 
8.2.2 The performance of the ICECAP-O instrument in Parkinson’s 
Following the gaps identified in Chapter 4, Chapter 6 and 7 explored if the broadly 
defined capability wellbeing measure, the ICECAP-O, is an appropriate measure 
to reflect the broader aspects of Parkinson’s that count to the patients, and if it 
is sensitive to use in the specific disease context (i.e. as additional to the social 
care and public health context which have been recommended by NICE (117, 142)). 
8.2.2.1 Construct validity 
The capability wellbeing of the group with later stage Parkinson’s was found to be 
statistically significantly lower than the group with early stage Parkinson’s. For 
the ICECAP-O attributes of ‘security’, ‘role’, ‘enjoyment’ and ‘control’, the later 
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stage group was approximately twice as likely to respond with a lower level of 
capability than the early group. This demonstrated that beyond the impact on 
health and daily functioning, the expected broader impacts of Parkinson’s were 
well captured by the ICECAP-O instrument. The ICECAP-O index value was found 
to be correlated slightly more strongly with PDQ-39-SI (r=-0.73) than with the EQ-
5D-3L index score (r=-0.65). The PDQ-39 attributes ‘social support’, ‘emotional 
wellbeing’ and ‘mobility’, and EQ-5D-3L attributes, ‘anxiety’ and ‘usual activities’, 
were found to correlate most strongly with ICECAP-O attributes.  
8.2.2.2 Responsiveness 
There was a statistically significant decline in capability wellbeing (mean change=-
0.057) as measured by the ICECAP-O over the two-year time period. Similar to the 
construct validity result, a slightly stronger correlation between the ICECAP-O and 
PDQ-39 change scores (r=-0.54) was found than between the EQ-5D-3L and PDQ-
39 change scores (r=-0.48), although differences were small. Results further 
showed that the ICECAP-O was more responsive to the change of overall QoL and 
wellbeing as confirmed by the PDQ-39, while in contrast, the EQ-5D-3L was more 
responsive to the change of motor symptoms. The differences in responsiveness 
were not statistically significant, which may be due to the fact that EQ-5D and 
ICECAP-O are moderately correlated both conceptually and statistically 
(correlation coefficient = 0.43). Nevertheless, the ‘incremental’ correlation 
between ICECAP-O and PDQ-39, compared with EQ-5D-3L and PDQ-39, was 
consistent with the effect size result when anchored by PDQ-39, both of which 
demonstrated that the ICECAP-O may be a more appropriate measure than EQ-5D 
for measuring the full impact of Parkinson’s on patients QoL and wellbeing. 
8.2.2.3 Summary 
In summary, this thesis contributed to the literature by demonstrating, for the 
first time, the construct validity and responsiveness of the ICECAP-O in people 
with Parkinson’s. As a subjective wellbeing measure, its sensitivity to the change 
in the ‘gold standard’ PDQ-39 in measuring the impact of Parkinson’s was not 
inferior to the EQ-5D, and, indeed, may even surpass EQ-5D. This thesis provided 
initial evidence to support the continued development of the ICECAP-O as a 
preference-based instrument in the Parkinson’s population. To realise the 
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potential use of ICECAP-O in decision making future research will need to address 
other barriers such as the lack of a threshold related to ICECAP-O derived benefits 
(Section 8.4.3 for further details). 
8.3 Strengths and limitations of this thesis 
8.3.1 Strengths 
This thesis has a number of strengths. The systematic review in Chapter 4 
comprehensively identified studies that reported PbQoL measures which 
facilitated a robust summary of the use of PbQoL measures in people with 
Parkinson’s and an assessment of the existing evidence on construct validity and 
responsiveness in these measures. The large sample size of the data rigorously 
collected through the ‘pragmatic’ PD MED RCT (please see details discussed in 
Section 5.3.1), containing patients with a wide variation of severity of Parkinson’s, 
provided robust estimation and generalizability of metrics for the assessment of 
construct validity and responsiveness of the ICECAP-O instrument.  
This thesis also demonstrated good practice in the assessment of construct validity 
and responsiveness of preference-based multi-dimensional measures. The issues 
regarding applying the classic psychometric methods to the assessment of 
preference-based QoL/capability measures were discussed in depth in Chapter 3 
and 5. The assumptions were extensively discussed in the assessment of 
responsiveness and tested in sensitivity analysis. The missing data in the dataset 
were investigated and appropriately handled with imputation strategies, 
recognising that missing data were unlikely to be missing completely at random. 
Several missing data handling strategies were compared to investigate the impact 
of the strategies on the assessment result in the sensitivity analysis which was not 
been explored before to my knowledge.  
8.3.2 Limitations 
There are, however, also a few limitations noted with this research. Previous 
studies have argued that given no ‘gold standard’ has been established for 
measuring PbQoL, the test of validity can only provide a reference of a measure's 
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performance rather than leading to a rigorous conclusion (432, 558). The ICECAP-
O is a capability wellbeing measure which should be tested on wellbeing attributes 
in a broader sense than health only. The other capability measures could 
potentially be options, such as the OCAP-18 which was developed for use in public 
health interventions assessing central human capabilities, or the ASCOT 
instrument as mentioned earlier in Chapter 2 (Section 2.6.4) which purport to be 
based on Sen’s capability approach as the ICECAP. However, given the family of 
capability measures are all quite new, the validity of the other capability 
measures is not quite clear yet, thereby the other capability measures cannot be 
considered as ‘gold standard’ if used in the assessment of ICECAP-O. Besides, the 
capability measures are developed for different purposes, such as ASCOT 
developed for use in social care thereby it including social care specific dimensions, 
it may be controversial to use it to validate ICECAP. 
Typically, clinical trials that compare pharmacological treatments are not 
designed to collect data on attributes of wellbeing defined in a broader sense, 
rather than solely health attributes which affect QoL. Hence, there are a lack of 
variables to test the aspects of ICECAP-O that go beyond health. Future validation 
studies may consider collecting primary survey data to expand the validation angle 
for ICECAP in this population. The case studies used the PDQ-39 measure as a ‘gold 
standard’ as the PDQ-39 contains a wide range of attributes which covers both 
HrQoL and more general wellbeing, and it was designed specifically for Parkinson’s 
and hence it should be the most relevant measure for Parkinson’s.  
Despite its relevance and broad coverage, the PDQ-39 has not been valued which 
means the attributes have not been weighted against length of life or risk of death 
and thus the meaning of their scores is not as clear as the preference-based 
measures. Although correlating the PbQoL against another non-preference QoL 
measure is arguably not the best test of convergent validity, as both instruments 
were designed to measure QoL, the trend of the scores (i.e., higher value 
represents better QoL) should be similar and hence the validity of the test should 
still provide useful information. Besides, the research of responsiveness used MID 
to inform grouping based on PDQ-39, which implicitly incorporates the 
‘importance’ in its survey question when asking the participants to determine if 
they had experienced a little better or worse in their health states, even if this 
cannot replace the valuation exercise. 
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Besides, the known-group construct validity testing did not use H&Y staging as 
grouping criteria, in addition to the existing Early vs. Advanced known-group 
testing. Using H&Y staging to classify the participants to seven groups (Stage 1, 
1.5, 2, 2.5, 3, 4, 5) will detect whether ICECAP-O is able to differentiate between 
the H&Y stages. This will potentially enable a comparison of the known-group 
results with the responsiveness results anchoring with H&Y in Chapter 7. This may 
also facilitate the potential future modelling studies that use H&Y states for 
defining the health states. 
Another limitation to note is that floor and ceiling effects were not assessed in 
this research. It was found in Chapter 4 that the EQ-5D-3L and HUI-2 have limited 
ability to discriminate between patients with varied levels of mild Parkinson’s. 
Some may argue that this may be related to the ceiling effect of the EQ-5D-3L and 
HUI-2 as found in other studies (270, 559-561). However, ceiling effect usually 
exists in a healthy general population whereby ‘no problem’ for all dimensions is 
likely to be answered, whereas Parkinson’s patients have been found to have poor 
QoL - as mentioned in Chapter 1 (Section 1.2.3), the EQ-5D-3L value of Parkinson’s 
patients was the lowest scores among 29 conditions, which was 0.440, compared 
to 0.835 among the general population in Finland (42). In this Finnish study, 6% of 
Parkinson’s patients reported no problems on all EQ-5D-3L dimension (i.e. scoring 
1), whereas typically it would need at least over 10% of respondents score to raise 
attention of ceiling effect.  
Finally, this thesis was restricted to measurement instruments and the data that 
were available in the PD MED trials and thus was limited to assessment using 
quantitative evidence. NICE recommends the use of qualitative research to 
explore the content validity of EQ-5D in specific populations when its 
appropriateness is in doubt. Qualitative research would facilitate the 
justifications for the quantitative psychometric assessment. For instance, in this 
Parkinson’s case study, ‘what counts is not counted?’ can be initially explored 
using qualitative research. However, despite the lack of qualitative investigation, 
this thesis drew upon the views from patients’ group and the difference of 
descriptive systems between the generic PbQoL and the Parkinson’s specific QoL 
measures, which are still considered to be sufficient to raise the concern that 
‘what counts is not counted’. The value of a qualitative research will be further 
discussed in 8.6 Areas for further research.   
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8.4 Implications of research for policy making 
8.4.1 Limitations of the use of EQ-5D in Parkinson’s 
The findings from this thesis have significant implications for policy making. Many 
HTA agencies across the world are using QALYs in its decision making, such as the 
Netherlands, France, Sweden, Australia, Canada, New Zealand and China (562-
564). Even in the US, a country that by statute prohibits the use of the cost-per-
QALY approach as a basis for HTA (565), the American College of Physicians issued 
a position paper (2016) explicitly calling for use of QALY approach to compare the 
value of interventions and control drug cost (566). Among all the HTA agencies, 
NICE is undoubtedly the agency that most strongly relying on CUA evidence in 
addition to effectiveness evidence to inform decision making. NICE has explicitly 
stated that EQ-5D is the preferred measure for measuring outcomes for all types 
of guidance (117, 122, 142). However, the narrow scope that is covered by EQ-5D 
and the significance of EQ-5D in decision making may create some major issues.  
8.4.1.1 From a decision-making perspective 
For decision-making, as discussed throughout this thesis, limitation of EQ-5D 
would affect the estimation of the ‘true effects’ of interventions, and lead to 
inaccurate ICER calculation which may affect funding decisions or, at least 
endangering the role of economic evaluations in decision making. For example, 
DBS is a surgery option to improve motor symptoms of Parkinson’s (as introduced 
in Chapter 1 Section 1.2.4.1) which has been shown to significantly improve 
patients’ motor symptoms and QoL (74, 86, 87), but it is expensive as well. The 
PD SURG trial demonstrated that DBS is effective compared to best medical 
therapy (BMT) in improving patients QoL as evidenced by the significant decrease 
(i.e. meaning get better) on PDQ-39-SI and five out of eight dimensions of PDQ-
39. These differences were not only statistical significant but with noticeable 
large magnititude (all much larger than MID10): -5.6 (95%CI -8.9 to -2.4, p=0.0008) 
score difference on PDQ-39-SI, -12.0 (95%CI -17.5 to -6.6, p<0.0001) on mobility, 
                                            
10
 The MID (with SD) for each of the PDQ-39 eight dimensions and summary index are: 3.2 (13.26) 
for mobility, 4.4 (16.56) for ADL, 4.2 (17.09) for emotional wellbeing, 5.6 (22.98) for stigma, 11.4 
(23.28) for social support, 1.8 (15.56) for cognition, 4.2 (18.74) for communication, 2.1 (18.68) 
for pain, and 1.6 (8.89) for overall score (533). 
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-14.0 (95% -18.7 to -9.3, p<0.0001) on ADL, stigma -9.5 (95%CI -14.9 to -4.1, 
p=0.0006) and -10.9 (95%CI -16.1 to -5.7, p<0.0001) on bodily discomfort (74). The 
EQ-5D-3L, however, only had a small and not statistically significant difference, 
0.05 (-0.01, 0.11), at one year between the DBS and the BMT group (567). The 
modest improvement on EQ-5D-3L partly led to the very large ICER estimate of 
£468,528 per QALY gained over one-year time horizon of the trial. Even after 
extrapolation of the time horizon to five years, the ICER was still estimated to be 
higher than the threshold at £45,180 (567). However, given the considerable 
difference shown on PDQ-39, the effect is likely to be underestimated by the EQ-
5D measurement and the ICER is expected to be much smaller than the current 
estimates if broader benefits were taken into account. If decision-making was 
based on ICECAP, it is likely that the considerable difference shown on PDQ-39 
could be better captured and the benefit of the intervention may be more 
sufficiently considered in decision making. 
To provide specific guidance for people with advanced Parkinson’s, NICE did not 
calculate the utility directly measured from this subgroup from the trial, instead, 
the EQ-5D data were remodelled as a function of the UPDRS, off-time, and PDQ-
39 variables (568). This generates a much larger EQ-5D difference between the 
DBS and BMT, i.e., 0.12 (95%CI 0.02, 0.22) at one year, and the lifetime ICER is 
£34,524. Even though this is still higher than the threshold, given the considerable 
improvement in PDQ-39 and some considerations on the opportunity cost of local 
NHS commissioning bodies, NICE’s 2017 latest updated guideline recommended 
that DBS could be considered for people with advanced Parkinson’s whose 
symptoms are not adequately controlled by BMT (76, 568).  
This example demonstrated firstly EQ-5D is limited in capturing all the benefit of 
the intervention. Notably, of the four dimensions that showed improvement with 
certainty, except for stigma, the other three dimensions (i.e., mobility, ADL and 
pain/discomfort) are all related directly with EQ-5D attributes, it is surprising that 
the large difference in those aspects of PDQ-39 did not reflect on EQ-5D. Secondly, 
the very small utility gain leads to the very large ICER which provides a negative 
recommendation to the funding decisions, however, the reliability of this result 
has been questioned due to the discrepancy in effectiveness based on the 
evidence provided from the disease specific measure and the EQ-5D. The 
remodelling approach demonstrated a case of taking disease specific QoL 
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measures into consideration in NICE’s decision making when the benefit of 
intervention is suspected to be not fully captured by EQ-5D. However, the 
remodelling procedure was ad-hoc and suffers from the limitations noted in 
relation to mapping (Section 2.6.1). This case study highlights a perceived 
deficiency of directly observed EQ-5D data by the relevant decision makers. 
Potentially, addition of a broader outcome measure such as ICECAP-O in the 
setting could have provided a more responsive measurement to the improvement 
of PDQ-39. 
8.4.1.2 From a manufacturer perspective 
For the manufacturers, the substantial role of EQ-5D for NICE’s decision may 
distort R&D decisions to focus on improvement of these aspects that covered by 
EQ-5D, especially the aspects that are attached with greater weights in its value 
sets, i.e. pain and discomfort. On the other hand, it will disincentivise the 
development of interventions that have little effect on the direct health related 
aspects but more broader benefits in general wellbeing. This may even move the 
disease of Parkinson’s to lower level of prioritisation. This is because Parkinson’s 
is not life threatening and thus extension of life expectancy is usually not the aim 
of interventions, but rather improvement of QoL. Its full mechanism for the wide 
range of symptoms is not yet clear and therefore developing interventions that 
would make a dramatic improvement is not likely at current stage of medicical 
innovation. Resources for R&D are limited and pharmaceutical companies aim for 
profit. Undervaluing the benefit of interventions in Parkinson’s disease by EQ-5D 
would lead to those interventions that may potentially benefit patients’ wellbeing 
being unfavourable in the decision-making process, causing equity issues across 
disease areas. Although NICE stated clearly in its guideline that a QALY has the 
same weight across all population groups and equity weighting is not included in 
economic evaluations (11), its recommendation of EQ-5D may cause inequity 
issues across population groups and disease sectors. 
8.4.2 Sensitivity of EQ-5D levels 
Chapter 7 identified a spike at zero in the histogram of the change of the EQ-5D-
3L, which adds to the existing criticism around lack of sensitivity of the EQ-5D-3L, 
especially for chronic incurable diseases like Parkinson’s. This insensitivity in the 
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three levels, however, may be addressed by the newly developed EQ-5D-5L 
measure. However, two issues should be noted. Firstly, in NICE’s latest position 
statement, it recommends the use of a mapping algorithm to map the answers 
from EQ-5D-5L to EQ-5D-3L before the validity of the newly developed EQ-5D-5L 
value set is tested (259). As indicated by summarizing the mapping algorithms in 
Chapter 4, mapping algorithms varied from each other in the characteristics of 
the original population where the statistical relationship was generated and in the 
statistical approaches taken. It is not known to what degree this NICE 
recommended mapping algorithm is valid; if repeating the original mapping study, 
whether the resulted algorithm would be the same, or (more practically) varied 
within an acceptable range. Furthermore, it is in doubt that the intended 
increased sensitivity of EQ-5D-5L could still maintain after this mapping. The 
second issue is that although EQ-5D-5L was developed in a bid to improve the 
sensitivity and indeed by judging its new five levels intuitively it will, the concern 
over the limited ability of EQ-5D still exists since the additional levels do not 
change the measuring scope. EQ-5D-5L remains a health-related QoL measure and 
its ability may remain insufficient to capture the broader impact of interventions. 
8.4.3 Use of ICECAP-O instrument for decision-making 
8.4.3.1 Role of capability approach and ICECAP-O for technology appraisal 
NICE currently recommends the use of the ICECAP-O in its social care and public 
health guideline to capture capability wellbeing (117, 142). This thesis 
demonstrated that the ICECAP-O has the potential to fill the gap of health focused 
QoL measure by providing valid information regarding broader impact of disease 
or intervention. Given the comprehensive impact of Parkinson’s disease and the 
subsequent potential broad benefit of interventions, it could be argued that NICE’s 
recommendation of the use of ICECAP-O to measure capability may be generalized 
to any interventions and populations when sufficient justification is provided that 
the intervention may significantly impact on patients’ capability wellbeing. For 
example, dance has been suggested as an alternative to traditional exercises for 
addressing the difficulties with gait and balance among people with Parkinson’s; 
notably, of all the benefits such as activation of some parts brain that controlling 
motor areas, improvement of movement and endurance, the benefits of enhancing 
social support networks, community involvement and self-expression should not 
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be ignored in their contribution to improve QoL (569). This important aspect of 
benefits due to its social nature may be more appropriately measured and valued 
by the capability wellbeing measures such as the ICECAP-O instrument.  
Lorgelly (2015) argued that the application of capability approach may not be 
confined to public health and social care, but could be of benefit to evaluations 
of pharmacotherapies and other technologies, i.e. technology appraisal (125). 
NICE’s ‘Methods for Technology Appraisal’ (119) guides the assessment of drugs 
and devices for conditions or diseases where economic evaluation is primarily used 
and has an important role to assist decision-making. Arguments for a broader 
measure in the disease / health domain have been arisen especially in the recent 
decade with the increasing awareness of the complex nature of some diseases 
and/or the corresponding complex outcome of interventions (125, 570).  
Payne et al. (2013) (570, 571) used the genetic diagnostic services and tests as an 
example for complex interventions that have broader objectives than health gain 
only, as the information provided may influence behaviour and decisions of the 
parents, affecting their wellbeing. Therefore they suggested the non-health 
benefit “may usefully be measured using the concept related to capability, which 
we called ‘empowerment’” (570). Lorgelly (2015) (125) gave a further example 
from Australia to argue for the importance of capturing non-health benefit in 
technology appraisals of pharmaceuticals. To manage the attention-
deficit/hyperactivity disorder (ADHD), a drug named lisdexamfetamine is listed 
positively by the Australisan Pharmaceutical Benefits Advisory Committee (PBAC), 
based on the evidence on its health benefit of improving the symptoms of ADHD. 
However, it is argued that the lisdexamfetamine could have considerable non-
health benefit as it will improve the impact of ADHD on children’s behaviour 
including poor education performance and increased criminal activity. These non-
health benefits should be considered in decision making, which however cannot 
be captured by EQ-5D, where capability instruments would have a role.  
In addition, given the growing awareness of diseases’ impact on carer’s burden 
and the associated invisible and substantial caring cost, incorporation of informal 
care into decision making for resource allocation purposes has attracted increasing 
amount of attention in research. However, a review published in 2012 found that 
there is a huge heterogeneity in terms of the methods applied to measure and 
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value informal care (572). Specifically, of the 17 studies that incorporated 
outcomes for carers, a mixture of outcomes were used including the generic 
health-related measures, EQ-5D-3L, HUI, SF-6D, and well as several carer specific 
measures. The issue of using generic health-related instruments to measure 
carer’s outcome is that the majority of the items on these instruments are 
unrelated to the carer’s burden; actually probably all but the psychological items 
such as anxiety/depression for EQ-5D. Accordingly using these generic health-
related measures is not ideal. On the other hand, the carer specific measures are 
specific to carers but not patients and thus inevitably creating an important issue 
regarding how to combine the carer’s outcome and the patient’s outcome and 
incorporate these together into economic evaluation. In this situation, ICECAP may 
potentially provide an alternative feasible avenue. It is a measure that is proposed 
to have an important role in the context of integration of health care and social 
care (141). Its broad capability wellbeing attributes (i.e. for ICECAP-O, 
attachment, security, role, enjoyment and control) are relevant to both patients 
and carers. As such ICECAP may have a role in the work of incorporating informal 
care into economic evaluation for decision making which will enable the 
measurement, valuation and combination of patients and carers’ outcomes. 
8.4.3.2 Issues of the use of ICECAP-O  
Chapter 2 (Section 2.7.2) showed that the ICECAP-O was valued using a best worst 
scaling approach, where individuals simply choose the best and worst attribute 
level, as opposed to the trade-off methods, where the individuals have to scarifice 
A for B. The authors argued that best worst scaling approach is appropriate as it 
reflects a value judgement which is more aligned with Sen’s capability approach 
(141). The valuation used ‘no capability’ as anchor rather than ‘death’, and as 
such when combing ICECAP value with length of life would not generate QALY and 
cannot apply the same decision rule (£20,000 – 30,000 per QALY gained). Details 
of this have been provided in Chapter 2, Section 2.7.3 ‘use of ICECAP-O for 
decision making’.  
There are, however, other outstanding issues when applying the capability 
approach in decision making as outlined by Lorgelly (2015) (125). Besides the 
ICECAP, other instruments have been developed purporting to measure capability, 
such as ASCOT and the OCAP, and for all the three measures many versions have 
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been developed to suit different populations. Just like the evidence showing that 
EQ-5D, HUI, and SF-6D index values are not interchangeable (127, 267-270), these 
measures have important difference between their descriptive systems and 
valuation methods, thereby selection of one or another as a capability wellbeing 
measure to inform decision making is challenging. 
However, a bigger picture discussion is when the scope is broadened to wellbeing, 
whether the scope for cost should also be broadened beyond the health budget 
(125). Subjective wellbeing is about life satisfaction in general and the wellbeing 
attributes in ICECAP such as attachment or role are a result of multiple sectors 
not confined to health. When the interventions provided by health sector can have 
benefit beyond health sector, the budget may need to be redistributed in a way 
that is multisectoral to match the scope of benefit. Remme et al. (2017) proposed 
a ‘cofinancing’ approach, in which the other sectors could contribute towards a 
health intervention which would achieve non-health benefit in other sectors, and 
vice versa. Research on this in health economics is still at initial stage and 
certainly more research is required to explore such bigger issues of broadening 
evaluative scope. 
8.5 Implications and recommendations for future 
research 
8.5.1 Choice of preference-based outcomes 
Awareness should be raised in Parkinson’s research regarding the potential limited 
scope of the EQ-5D in this population and it is advised that researchers should be 
mindful of the advantages and limitations of each outcome measure before using 
it to measure the effect of different types of intervention. It is recommended that 
when the main objective of an intervention is to improve specific health aspects 
that are covered by EQ-5D, the addition of other measures may not be necessary. 
When the intervention is expected to have broader impact beyond health alone, 
the addition of ICECAP-O which could capture the broader impact and incorporate 
it into economic evaluations is recommended. This should be particularly 
considered if there is a doubt that the bespoke benefit of the intervention is not 
captured by the EQ-5D questionnaire. This thesis provided a reference point to 
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future studies regarding the capability level in the early and later stages of 
Parkinson’s and the change of capability over time, which will facilitate future 
studies to set up their hypotheses, especially the intervention studies regarding 
the expected change in capability within a certain time frame. 
8.5.2 The necessity of setting up hypotheses 
For future studies to assess responsiveness, it is recommended that a priori 
hypotheses / expectations must be set based on the intended construct of the test 
measure. This has not been rigorously applied by many studies as shown in Chapter 
3 and 7. Simply giving conclusions based on the strength of correlation / size of 
ES statistics without prior expectations will lead to incorrect interpretation of the 
assessment result. Although setting up a hypothesis is crucial to the interpretation 
of results, it is usually difficult to determine precisely how strongly the generic 
QoL measures is expected to correlate with the clinical measures. There is very 
limited guidance on what constitutes reasonable correlation, or effect size, in the 
test of responsiveness of a multi-dimensional concept. Despite the COSMIN 
checklist providing a standard guidance on how the properties should be assessed, 
consensus was not reached on the criteria of adequacy of measurement properties 
(326). This will be further discussed in Section 8.6.3 for future research. 
8.5.3 Outcome measures for defining health state in decision-
analytic modelling 
Chapter 7 found that when H&Y stage changes, EQ-5D utility values do not always 
change with the same direction, especially in the group that have improved H&Y 
stage and no change H&Y stage. This raised a caveat in decision-analytic modelling 
studies when simply using H&Y to define health states in the models. Although 
there are good reasons to predict utility values based on H&Y stage, this prediction 
is not perfect since utility value, again, is obtained from a multi-dimensional 
concept, of which motor complication is only one (albeit important) of the many 
dimensions. Decision-analytic modellers in Parkinson’s are advised to consider the 
scope of the targeted effect of interventions and the available outcome measures 
in studies, and where appropriate, to use a combination of measures to enable a 
broader scope and account for the progression of the disease. 
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8.6 Areas for further research 
8.6.1 Comparison between EQ-5D-3L and ICECAP-O measure in 
economic evaluation in Parkinson’s population 
PbQoL measures are developed for use in economic evaluations, and economic 
evaluations are conducted for making recommendations for resource allocation 
between interventions. This thesis provided evidence on the use and relevance of 
the EQ-5D-3L in Parkinson’s population particularly in relation to the scope and 
sensitivity between milder disease states. This thesis demonstrated that the 
ICECAP-O, the broadly scoped measure is responsive and exhibit construct validity 
to be used in this population. This naturally leads to the next important question 
– whether an economic evaluation using ICECAP-O or EQ-5D from the same study 
would provide different recommendations of a health care intervention to the 
decision makers? The varied constructs and purposes of the two measures mean 
that if the recommendations are different, then the discrepancy is most likely to 
happen for the interventions that have a focus on broader wellbeing. This however, 
requires further research to test, and most crucially, a decision rule for using 
ICECAP-O. A health QALY and a capability QALY are not comparable; the current 
NICE decision rule, £20,000 – 30,000 per QALY gained only applies to the health 
QALY but not the capability QALY. At the moment, research led by Dr. Philip 
Kinghorn funded by the Medical Research Council is ongoing which is looking at 
establishing the social willingness to pay for gains in capability outcomes up to the 
sufficient level of capability given the consideration of equity (i.e. YSC, please 
see Chapter 2, Section 2.7.3 for details) (320, 573). This research will have vital 
methodological and practical significance in broadening the evaluative space of 
health care decision-making in the UK. 
8.6.2 Validation of ‘preference’ 
As mentioned earlier in the limitation section (8.3.2), one limitation of this thesis 
is using a non-preference based measure as a ‘gold standard’ to validate a 
preference-based measure. Some may argue that the meaning of the change on 
the non-preference based measure is not clear and thus the assumption for the 
validation studies is not valid. Although the MID method was used, with the 
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assumption that ‘importance’ is similar to ‘preference’, in fact these two terms 
have conceptual difference from each other. When patients answered ‘a little 
better’ in MID research, there is no ‘trade off’ in this preference expression, 
whereas when patients answered ‘preferred’ in preference elicitation exercise, it 
means they would trade more length of life or accept a higher risk of death for it. 
This conceptual difference should be reflected in the interpretation of results. 
Papaioannou, Brazier, and Parry (2011) previously pointed out that “where health 
dimensions and changes appear to have been missed by preference-based HRQoL 
measures, these may not actually be important to patients or valued by the 
general population’ thus it cannot be determined as a weakness of the measure” 
(246). This is indeed the truth. However, it could be argued that this thesis 
assumed PDQ-39 as ‘gold standard’ because its dimensions were developed based 
on extensive qualitative and quantitative research and therefore all these 
dimensions are deemed important to patients to some degree. One avenue to test 
this assumption is to conduct a valuation exercise of the PDQ-39 measure, i.e. 
generate preference values for this condition-specific measure. This would 
strengthen the fundamental assumption of Chapter 6 and 7 of this thesis – PDQ-39 
is the current best available instrument to measure ‘what counts’ for people with 
Parkinson’s, and would add weight to the validation of generic preference-based 
measures in the context of Parkinson’s population in the future. In addition, this 
valuation should be conducted in both a patient population and among the general 
public to identify the differences, if any, between the elicited values. 
8.6.3 Developing robust methods of demonstrating psychometric 
properties for generic PbQoL measures 
NICE methods guideline recommends the assessment of content validity, construct 
validity, and responsiveness to make a case that the EQ-5D is inappropriate. This 
requires a standard and robust method to implement. Many studies have tested 
the construct validity and responsiveness of the EQ-5D but may generate different 
conclusions depending on the patient population, the hypotheses tested and 
quality of the methods. There is no standard for how hypotheses should be set, 
what hypothesis is important to a PbQoL measure, and what size of the statistics 
should be expected.  
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For example, for known-group validity, it is not difficult for the measure to 
differentiate between the groups with later stage Parkinson’s and early 
Parkinson’s given there are a lot of patients characteristics that are expected to 
differ, however a large difference does not automatically mean a higher construct 
validity – it all depends on how it matches the expectation as stated by outlined 
hypothesis. Therefore, how to determine what the expectation should be is quite 
crucial, which requires future research. Similarly, for responsiveness, larger size 
of effect size does not necessarily mean a measure being more responsive – again, 
it is dependent upon the expectations. The COSMIN checklist and previous studies 
(246, 327) recommended to be explicit in the hypothesis about the expected mean 
difference or correlation however this is challenging to implement in practice, 
especially for a measure used in a population for the first time. 
Modelling methods may be one solution to help set up expectations and resolve 
hypotheses of a multi-dimensional ‘no agreement’ concept like QoL/capability. 
When there is gold standard, the test measure is expected to make exactly the 
same judgement as the gold standard, e.g. a diagnostic test. However, when there 
is no gold standard such as QoL/capability, it is difficult to set up expectations on 
the strength of the correlation or the ES statistics. This is because beside what is 
measured by the anchor, there may be other underlying factors that also 
contributing to the score of the test measure, especially when the anchor measure 
only measures one dimension of the multi-dimensional concept. For example, 
Chapter 6 found that when using the disease severity measure, H&Y as an anchor, 
there were good reasons to predict that very strong correlations might exist 
between H&Y and ICECAP-O. The patients with more advanced stage of H&Y are 
more likely to have poor independence, feel worried about their future, less 
ability to do activities with family and friend or social. However, in our results, 
this relationship was not strong and there are other factors contributing to ICECAP-
O beyond H&Y. In these circumstances, potentially, a modelling method that can 
adjust for other factors affecting the size of the measure would help to set up a 
hypothesis or expectations for the relationship between the test measure and the 
anchor measure. There is little guidance in the literature regarding how to use 
modelling methods to adjust for other factors so this could be an important 
direction for future research in the area of psychometrics testing. 
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Overall, a comprehensive assessment of PbQoL measures would also require the 
investigation of the routine criteria, as with other non-preference-based measures, 
i.e., practicality, reliability and validity, but with an additional layer of 
complexity due to the nature of no gold standard, self-reported responses, and a 
scoring algorithm based on preferences elicited from general public (118). The 
COSMIN checklist as previously mentioned in Chapter 3 (326) and Brazier et al. 
(2017) (118) provide the current best available guidance on the assessment. In 
particular, built on the earlier checklist of psychometric criteria written by Brazier 
and Deverill (1999) (148), the book by Brazier et al. (2017) focused on the 
assessment of preference based measures and provides an updated checklist of 
criteria that should be assessed for this special type of measures. These criteria 
include: practicality (i.e., acceptability to respondents, and burden of 
administration and completion), reliability (i.e., test-retest, inter-rater, and 
between methods of administration), and validity. Within validity, the tests are 
categorized to three aspects: (a) the assessment of the description, including 
content validity and face validity; (b) assessment of the valuation including whose 
preference was elicited, technique of valuation, and the quality of data, and; (c) 
empirical validity which relies on empirical data to test which includes the testing 
of stated preference, and hypothesized preferences including the test of construct 
validity and responsiveness using empirical data. Future research of validation of 
ICECAP may assess other criteria contained in this checklist and thus provides 
together with this thesis a more comprehensive picture of the merit of ICECAP.  
8.6.4 Value of qualitative research 
One of the ideas behind this thesis stemmed from the expressed concern from the 
Parkinson’s UK and the large difference between the Parkinson’s specific QoL 
measures and the EQ-5D. Hence, qualitative research on content validity to 
explore the relevance of EQ-5D to the Parkinson’s disease would be a useful 
addition to the literature. Interviews with patients as well as clinicians, 
researchers, physiotherapists and other stakeholders, would provide an in-depth 
insight into the gap between ‘what counts’ and ‘what is counted’. In addition, an 
interview with Parkinson’s patients, experts and manufacturers regarding the 
comparison between ICECAP-O and EQ-5D would also provide important 
information from their perspectives to what extent QoL and wellbeing should be 
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incorporated into decision-making. Psychometric testing is an iterative process. 
Qualitative interviews based on the finding of this research will further inform 
setting up hypotheses on the relationships tested in the quantitative studies in the 
future.  
8.7 Contribution of the thesis 
The contribution of this thesis can be summarized as follows: 
• This is the first study to provide information regarding the capability 
wellbeing of Parkinson’s patients. This extends our knowledge of capability 
wellbeing of different patient groups.  
• This is the first study to test construct validity and responsiveness of the 
ICECAP-O in Parkinson’s population. This thesis revealed that the use of the 
ICECAP-O in Parkinson’s population is warranted. 
• This thesis provided evidence to eliminate the concern that a broadly 
defined subjective measure would not be sensitive to specific health 
aspects; sensitivity of ICECAP-O was not inferior to the HrQoL measure EQ-
5D-3L. 
• This thesis provided guidance on the choice of measure in the studies of 
Parkinson’s – when the benefit of the intervention is projected /suspected 
to be broad and beyond health, ICECAP-O is recommended in addition to 
the EQ-5D (3L/5L) instrument required by NICE.  
• This thesis demonstrated good practice in the assessment of construct 
validity and responsiveness of a preference-based multi-dimensional 
measure. This was achieved through the application of rigorous 
methodological critique, statistical testing, multiple imputation and 
extensive sensitivity analysis surrounding the methodological assumptions. 
• This thesis provided a reference point to future studies regarding the 
capability level in early and later stages of Parkinson’s and the change of 
capability over time and the natural history of the disease in this group of 
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patients. This will facilitate future studies to set up their hypothesis 
regarding the expectations on capability in this population. 
8.8 Conclusions 
This thesis identified the gap between ‘what counts’ to people with Parkinson’s 
and ‘what is counted’ in the current PbQoL measures, with a focus on the NICE 
recommended PbQoL measure EQ-5D, and demonstrated the appropriateness of 
using ICECAP-O in the Parkinson’s population, which may potentially fill this gap 
in decision-making process.  
Through a systematic review, this thesis has detailed the limited ability of the 
existing preference-based measures in people with Parkinson’s and suggested that 
EQ-5D may underestimate the value placed on the mental and social wellbeing 
aspects in Parkinson’s disease. This highlights the need to seek a broadly scoped 
mental health and wellbeing inclusive measure to incorporate such aspects in 
economic evaluations. This thesis established the construct validity and 
responsiveness of the ICECAP-O in Parkinson’s and demonstrated that there are 
valued capability wellbeing attributes in Parkinson’s beyond those reflected by 
the EQ-5D instrument. This thesis contributes to understanding the use of broadly 
scoped outcome measure for economic evaluations in Parkinson’s by showing that 
the ICECAP-O instrument was able to provide rich information on these under-
represented aspects in the Parkinson’s population, without compromising its 
sensitivity to the clinical and specific physical QoL dimensions in this patient group. 
It should be also noted that choosing one or the other measure does not simply 
depend on whichever performed better in the psychometric test, it can also 
depend on many other factors, such as: which one is more acceptable to decision 
makers, which one uses an evaluative space that best matches with the aim of 
NHS, which one has a decision rule (threshold) that can be applied, which one the 
patients more willing to answer and the clinical researchers prefer, and so on. 
This thesis, therefore, achieved progress within a bigger picture towards the use 
of ICECAP-O in economic evaluations to measure the impact of interventions in a 
broader way than current practice in Parkinson’s populations. 
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This thesis has contributed to the goal of making what counts to patients with 
Parkinson’s become what is counted in the decision-making process - letting 
decision-making meet patients’ need. Although there are differences in 
preferences from patients’ and decision makers’ perspectives, there is one 
fundamental principle in the NHS since it was launched in 1948 – ‘it meets the 
needs of everyone’. Making what counts counted is a necessary step to make the 
needs met. What is measured and valued by the PbQoL measures in the health 
care decision-making process determines what is valued by the health care system, 
and jointly determines with cost what is prioritised for NHS funding. Scoping issues 
are unavoidable, due to the broad ranging disease symptoms, their impact on life, 
and the subsequent benefit of interventions. This thesis demonstrated that the 
broadly scoped capability/wellbeing measure, ICECAP-O, should be considered as 
an instrument for evaluations of interventions in Parkinson’s, looking beyond 
health gains to produce an overall valuation of their benefit. 
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Appendices 
Appendix A: Search strategy 
Search strategy and number of results in each database  
Search first run: inception of each database - 26 November, 2013 
Search update: 9 June 2015 (same search strategy, only limit the date, 
01/01/2013- present (9 June 2015)) 
 
PUBMED 
1st Result: 1196 
2nd Result: 314 
Search Strategy: 
Search (((parkinsonian disorders[MeSH Terms]) OR parkinson*[Title/Abstract])) 
AND ((((((((((((((((((((((((((((((((((((((((cost effective*[Title/Abstract]) OR Cost-
Benefit Analysis[Mesh]) OR Quality of Wellbeing[Title/Abstract]) OR Quality of 
Wellbeing[Title/Abstract]) OR QWB[Title/Abstract]) OR Health Utilities 
Index[Title/Abstract]) OR cost benefit*[Title/Abstract]) OR visual analogue 
scale[Title/Abstract]) OR time trade off) OR time tradeoff) OR standard gamble) 
OR discrete choice) OR dce) OR conjoint analysis) OR contingent valuation) OR 
preference*[Title/Abstract]) OR utility[Title/Abstract]) OR willingness to 
pay[Title/Abstract]) OR wtp[Title/Abstract]) OR QALY[Title/Abstract]) OR 
Quality-Adjusted Life Years[MeSH Terms]) OR QALE[Title/Abstract]) OR 
QALD[Title/Abstract]) OR Qtime[Title/Abstract]) OR quality adjusted life 
expectancy[Title/Abstract]) OR DALY[Title/Abstract]) OR Disability adjusted 
life[Title/Abstract]) OR HYE[Title/Abstract]) OR HYEs[Title/Abstract]) OR healthy 
year equivalent) OR SF-6D[Title/Abstract]) OR SF6D[Title/Abstract]) OR 
EuroQOL[Title/Abstract]) OR Euro qol[Title/Abstract]) OR EQ-5D[Title/Abstract]) 
OR HUI[Title/Abstract]) OR EQ5D[Title/Abstract]) OR HUI1[Title/Abstract]) OR 
HUI2[Title/Abstract]) OR HUI3[Title/Abstract]) Filters: English 
 
 
Ovid MEDLINE® In-Process & Other Non-Indexed Citations and Ovid MEDLINE®
  1946 to Present with Daily & Weekly Update 
1st Result: 1202 
2nd Result: 300 (01/01/2013-current) 
Search Strategy: 
1     exp "cost effective"/  
2     cost effective*.ab.  
3     cost utility*.ab.  
4     cost benefit*.ab.  
5     cost benefit analysis.sh.  
6      visual analogue scale.ab.  
Appendices  303 
 
7      standard gamble.af.  
8      time trade off.af.  
9      time tradeoff.mp  
10     dce.mp.  
11     discrete choice.mp.  
12     conjoint analysis.af.  
13     willingness to pay.mp.  
14     wtp.mp. 
15     Patient Preference/ or preference.mp.  
16     preference*.ab. 
17     contingent valuation.mp. 
18     QALY$.mp. or Quality-Adjusted Life Years/  
19     QALE$.mp.  
20     QALD$.mp.  
21     Qtime$.mp.  
22     quality adjusted life expectancy.mp.  
23     quality adjusted life day$.mp. 
24     DALY$.mp. 
25     Disability adjusted life.mp. 
26     HYE.mp. 
27     HYEs.mp.  
28     Health$ year$ equivalent$.mp. 
29     SF-6D.mp.  
30     SF6D.mp.  
31     EuroQOL.mp. 
32     Euro qol.mp.  
33     EQ-5D.mp.  
34     EQ5D.mp. 
35     HUI.mp. 
36     HUI1.mp. 
37     HUI2.mp. 
38     HUI3.mp. 
39     Health Utilities Index.mp.  
40     QWB.mp. 
41     Quality of Wellbeing.mp.  
42     Quality of Wellbeing.mp.  
43     utilit$.mutilitp.  
44     or/1-43  
45     parkinson*.ab.  
46     parkinsonian disorders.sh.  
47     45 or 46  
48     44 and 47  
49     limit 48 to english language  
 
 
Embase 
1947 – Present, updated daily 
1st Result: 1516 
2nd Result: 553 (01/01/2013-current) 
Search strategy: 
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1. Parkinsonian Disorders/  
2. parkinson*.ab.  
3. Parkinsonian Disorders.sh.  
4. 1 or 2 or 3  
5. cost effective*.ab.  
6. cost utility*.ab.  
7. cost benefit*.ab.  
8. cost benefit analysis.sh.  
9. visual analogue scale.ab.  
10. time trade off.af.  
11. standard gamble.af.  
12. Patient Preference/ or preference.mp.  
13. preference*.ab.  
14. discrete choice.mp.  
15. conjoint analysis.af.  
16. utilit$.mp.  
17. willingness to pay.mp.  
18. wtp.mp.  
19. dce.mp.  
20. contingent valuation.mp.  
21. QALY$.mp. or Quality-Adjusted Life Years/  
22. QALE$.mp.  
23. QALD$.mp.  
24. Qtime$.mp.  
25. quality adjusted life expectancy.mp.  
26. quality adjusted life day$.mp.  
27. DALY$.mp.  
28. Disability adjusted life.mp.  
29. HYE.mp.  
30. HYEs.mp.  
31. Health$ year$ equivalent$.mp.  
32. SF-6D.mp.  
33. SF6D.mp. 
34. EuroQOL.mp.  
35. Euro qol.mp.  
36. EQ-5D.mp.  
37. EQ5D.mp.  
38. HUI.mp.  
39. HUI1.mp. 
40. HUI2.mp. 
41. HUI3.mp. 
42. Health Utilities Index.mp.  
43. QWB.mp. 
44. Quality of Wellbeing.mp.  
45. Quality of Wellbeing.mp.  
46. time tradeoff.mp.  
47. exp "cost benefit analysis"/ or exp "cost effectiveness analysis"/  
48. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 
34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47  
49. 4 and 48  
50. limit 49 to (human and english language)  
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CINAHL (EBSCO) 
1st Result: 102 
2nd Result: 25 (01/01/2013-present) 
Search strategy: 
S1 MW parkinsonian disorders 
S2 AB parkinson* 
S3 S1 OR S2 
S4 MW quality adjusted life years 
S5 AB cost effective* 
S6 AB cost utility 
S7 MW cost benefit analysis 
S8 AB cost benefit 
S9 TX visual analogue scale 
S10 TX time trade off 
S11 TX standard gamble 
S12 AB preference* 
S13 TX discrete choice 
S14 TX conjoint analysis 
S15 TX willingness to pay 
S16 TX time tradeoff 
S17 TX dce 
S18 AB utilit* 
S19 TX wtp 
S20 TX contingent valuation 
S21 (MH "Quality-Adjusted Life Years") OR "QALY" 
S22 TX hye 
S23 TX hyes 
S24 TX qaly 
S25 TX qale 
S26 TX Quality adjusted life expectancy 
S27 TX QALD 
S28 TX quality adjusted life days 
S29 TX DALY 
S30 TX disability adjusted life 
S31 TX health* year* equivalent 
S32 TX eq5d 
S33 TX hui1 
S34 TX hui2 
S35 TX hui3 
S36 TX eq-5d 
S37 TX euroqol 
S38 TX euro qol 
S39 TX sf 6d 
S40 TX sf6d 
S41 TX health utilit* index 
S42 TX qwb 
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S43 TX quality of wellbeing 
S44 TX quality of well being 
S45 
S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 
OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR 
S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 
OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR 
S43 OR S44 
S46 S3 AND S45 
S47 S3 AND S45 (Limiters - English Language ) 
  
 
 
PsycINFO(EBSCO) 
1st Result: 440 
2nd Result: 213 (01/01/2013-present) 
Search strategy: 
S1 MM "Parkinsonism" 
S2 AB parkinson* 
S3 S1 AND S2 
S4 MM "Quality of Life" OR MM "Quality of Work Life" 
S5 AB cost effective* 
S6 AB cost utility 
S7 TX visual analogue scale 
S8 TX time trade off 
S9 TX standard gamble 
S10 AB preference* 
S11 TX discrete choice 
S12 TX conjoint analysis 
S13 TX willingness to pay 
S14 TX time tradeoff 
S15 TX dce 
S16 TX wtp 
S17 TX contingent valuation 
S18 QALY 
S19 TX qaly 
S20 TX disability adjusted life 
S21 TX quality adjusted life year* 
S22 TX eq5d 
S23 TX EQ-5D 
S24 TX hui1 
S25 TX hui2 
S26 TX hui3 
S27 TX euroqol 
S28 TX utilit* 
S29 TX sf 6d 
S30 TX sf6d 
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S31 
S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 
OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR 
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 
S32 S1 OR S2 
S33 S31 AND S32 
 
 
Applied Social Sciences Index and Abstracts (ASSIA) (Proquest) 
1st Result: 30 
2nd Result: 6 (01/01/2013-present) 
Search strategy: 
 (ab(parkinson*) OR su(parkinsonian disorders))  AND (su(cost effective*) OR 
ab(cost effective*) OR ab(cost utility) OR ab(cost benefit) OR su(cost - benefit 
analysis) OR (standard gamble) OR (time trade off) OR (visual analogue scale) OR 
(discrete choice) OR ab(preference*) OR (conjoint analysis) OR (willingness to pay) 
OR (contingent valuation) OR (time tradeoff) OR (dce) OR (wtp) OR su(Quality-
Adjusted Life Years) OR (QALY) OR (QALE) OR (QALD) OR (Qtime) OR (quality 
adjusted life expectancy) OR (quality adjusted life day*) OR (DALY) OR (disability 
adjusted life) OR (hye) OR (hyes) OR (health* year* equivalent*) OR (sf6d) OR (sf 
6d) OR (euroqol) OR (euro qol) OR (eq 5d) OR (eq5d) OR (hui) OR (hui1)  OR (hui2) 
OR (hui3) OR (health utilities index) OR (qwb) OR (quality of wellbeing) OR (quality 
of well being) OR ab(utility*)) 
 
 
SOCIAL service abstract (SSA) (Proquest) 
1st Result: 2 
2nd Result: 1 (01/01/2013-present) 
Search strategy: 
(ab(parkinson*) OR su(parkinsonian disorders))  AND (su(cost effective*) OR ab(cost 
effective*) OR ab(cost utility) OR ab(cost benefit) OR su(cost - benefit analysis) 
OR (standard gamble) OR (time trade off) OR (visual analogue scale) OR (discrete 
choice) OR ab(preference*) OR (conjoint analysis) OR (willingness to pay) OR 
(contingent valuation) OR (time tradeoff) OR (dce) OR (wtp) OR su(Quality-
Adjusted Life Years) OR (QALY) OR (QALE) OR (QALD) OR (Qtime) OR (quality 
adjusted life expectancy) OR (quality adjusted life day*) OR (DALY) OR (disability 
adjusted life) OR (hye) OR (hyes) OR (health* year* equivalent*) OR (sf6d) OR (sf 
6d) OR (euroqol) OR (euro qol) OR (eq 5d) OR (eq5d) OR (hui) OR (hui1)  OR (hui2) 
OR (hui3) OR (health utilities index) OR (qwb) OR (quality of wellbeing) OR (quality 
of well being) OR ab(utility*)) 
 
 
AgeInfo open search 
1st Result: 15 
2nd Result: 1 (01/01/2013-present) 
Search strategy: 
Parkinson* and quality of life 
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Database of Abstracts of Reviews of Effects (DARE) (CRD York) 
1st Result: 51 
2nd Result: 8 (01/01/2013-present) 
Search strategy: 
(Parkinson*) AND (quality of life) OR (utility*) IN DARE 
 
 
NHS Economic evaluation database (NHS EED) 
1st Result: 26 
2nd Result: 2 (01/01/2013-present) 
Search strategy: 
(Parkinson*) AND (quality of life) OR (utility*) IN NHSEED 
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Appendix B: Stata codes for multiple imputation 
This appendix contains the STATA codes for the multiple imputation with chained 
equations implemented for imputing missing values in Chapter 6 (B-1) and Chapter 
7 (B-2). 
B-1. STATA codes for multiple imputation in Chapter 6 
A description for this imputation model is provided in Section 6.4.2.3. 
 
 
B-2. STATA codes for multiple imputation in Chapter 7 .  
A description for this imputation model is provided in Section 7.3.4.2. Note: the 
panel data structure have been reshaped to wide form prior to the beginning of 
the imputation procedure. This generated the “2” and “4” at the end of each 
variable name which represents respectively the variable value at year 2 and year 
4.  
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Appendix C: Results of statistical tests for the 
comparison of correlation coefficients using the R 
cocor package. 
This appendix provides the results of the statistical tests for comparison of 
correlation coefficients using the R cocor package in Chapter 6 (C-1) and 7 (C-2).  
C-1: hypothesis in Chapter 6 for testing the correlation coefficient using the cross-
sectional data: the correlation coefficient for the ICECAP-O and PDQ-39 was 
expected to be larger than that of the ICECAP-O and EQ-5D-3L. Null hypothesis: 
The correlation coefficient for the ICECAP-O and PDQ-39 was equal to that of the 
ICECAP-O and EQ-5D-3L. 
Results: 
cocor - comparing correlations, 1.1-3, http://comparingcorrelations.org 
 
INPUT: 
require(cocor) # load package 
cocor.dep.groups.overlap(r.jk=0.733, r.jh=0.654, r.kh=0.724, n=1010, 
alternative="greater", alpha=0.05, conf.level=0.95, null.value=0) 
 
OUTPUT: 
Results of a comparison of two overlapping correlations based on 
dependent groups 
 
Comparison between r.jk = 0.733 and r.jh = 0.654 
Difference: r.jk - r.jh = 0.079 
Related correlation: r.kh = 0.724 
Group size: n = 1010 
Null hypothesis: r.jk is equal to r.jh 
Alternative hypothesis: r.jk is greater than r.jh (one-sided) 
Alpha: 0.05 
 
pearson1898: Pearson and Filon's z (1898) 
z = 4.9579, p-value = 0.0000 
Null hypothesis rejected 
 
hotelling1940: Hotelling's t (1940) 
t = 5.1411, df = 1007, p-value = 0.0000 
Null hypothesis rejected 
 
williams1959: Williams' t (1959) 
t = 5.0790, df = 1007, p-value = 0.0000 
Null hypothesis rejected 
 
olkin1967: Olkin's z (1967) 
z = 4.9579, p-value = 0.0000 
Null hypothesis rejected 
 
dunn1969: Dunn and Clark's z (1969) 
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z = 5.0510, p-value = 0.0000 
Null hypothesis rejected 
 
hendrickson1970: Hendrickson, Stanley, and Hills' (1970) modification of 
Williams' t (1959) 
t = 5.1411, df = 1007, p-value = 0.0000 
Null hypothesis rejected 
 
steiger1980: Steiger's (1980) modification of Dunn and Clark's z (1969) 
using average correlations 
z = 5.0389, p-value = 0.0000 
Null hypothesis rejected 
 
meng1992: Meng, Rosenthal, and Rubin's z (1992) 
z = 5.0336, p-value = 0.0000 
Null hypothesis rejected 
95% confidence interval for r.jk - r.jh: 0.0934 0.2125 
Null hypothesis rejected (Lower boundary > 0) 
 
hittner2003: Hittner, May, and Silver's (2003) modification of Dunn and 
Clark's z (1969) using a backtransformed average Fisher's (1921) Z 
procedure 
z = 5.0291, p-value = 0.0000 
Null hypothesis rejected 
 
zou2007: Zou's (2007) confidence interval 
95% confidence interval for r.jk - r.jh: 0.0481 0.1109 
Null hypothesis rejected (Lower boundary > 0) 
 
C-2: comparing the correlation coefficients between the change scores of ICECAP-
O – PDQ-39 and ICECAP-O – EQ-5D. Null hypothesis: the correlation coefficient 
between the change scores of ICECAP-O and PDQ-39 is equal to that of the ICECAP-
O and EQ-5D. 
Results: 
cocor - comparing correlations, 1.1-3, http://comparingcorrelations.org 
 
INPUT: 
require(cocor) # load package 
cocor.dep.groups.overlap(r.jk=0.526, r.jh=0.483, r.kh=0.401, n=933, 
alternative="greater", alpha=0.05, conf.level=0.95, null.value=0) 
 
OUTPUT: 
Results of a comparison of two overlapping correlations based on 
dependent groups 
 
Comparison between r.jk = 0.526 and r.jh = 0.483 
Difference: r.jk - r.jh = 0.043 
Related correlation: r.kh = 0.401 
Group size: n = 933 
Null hypothesis: r.jk is equal to r.jh 
Alternative hypothesis: r.jk is greater than r.jh (one-sided) 
Alpha: 0.05 
 
pearson1898: Pearson and Filon's z (1898) 
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z = 1.4669, p-value = 0.0712 
Null hypothesis retained 
 
hotelling1940: Hotelling's t (1940) 
t = 1.5033, df = 930, p-value = 0.0665 
Null hypothesis retained 
 
williams1959: Williams' t (1959) 
t = 1.4663, df = 930, p-value = 0.0715 
Null hypothesis retained 
 
olkin1967: Olkin's z (1967) 
z = 1.4669, p-value = 0.0712 
Null hypothesis retained 
 
dunn1969: Dunn and Clark's z (1969) 
z = 1.4655, p-value = 0.0714 
Null hypothesis retained 
 
hendrickson1970: Hendrickson, Stanley, and Hills' (1970) modification of 
Williams' t (1959) 
t = 1.5033, df = 930, p-value = 0.0665 
Null hypothesis retained 
 
steiger1980: Steiger's (1980) modification of Dunn and Clark's z (1969) 
using average correlations 
z = 1.4652, p-value = 0.0714 
Null hypothesis retained 
 
meng1992: Meng, Rosenthal, and Rubin's z (1992) 
z = 1.4650, p-value = 0.0715 
Null hypothesis retained 
95% confidence interval for r.jk - r.jh: -0.0195 0.1349 
Null hypothesis retained (Lower boundary <= 0) 
 
hittner2003: Hittner, May, and Silver's (2003) modification of Dunn and 
Clark's z (1969) using a backtransformed average Fisher's (1921) Z 
procedure 
z = 1.4650, p-value = 0.0715 
Null hypothesis retained 
 
zou2007: Zou's (2007) confidence interval 
95% confidence interval for r.jk - r.jh: -0.0145 0.1006 
Null hypothesis retained (Lower boundary <= 0) 
Appendices  314 
 
Appendix D: Calculation of Pearson correlation 
coefficient of the imputed dataset  
The Pearson correlation coefficient of the imputed datasets was calculated with 
Harel’s Fisher’s r to z transformation utilizing the normal distribution of z (539). 
This was realized with the user-written STATA command ‘mibeta’ with the option 
‘fisherz’ (539).  In normal cases, the Pearson correlation coefficient can be 
obtained with the routine STATA command, ‘correlate’, however it does not work 
after imputation since it is not a supported post estimation command. The linear 
regression of the imputed data also does not provide the R-square statistic (the 
squared correlation between the observed and expected values of the dependent 
variable) so that the correlation coefficient cannot be obtained from this way 
either (the square root of R-square statistic). Due to the abnormal distribution of 
the R2 for the 30 imputations, it may be inappropriate to simply averaging the R2 
values (539). Harel (574) suggested to use the Fisher’s r to z transformation 
method to firstly transform the R2 from each of the imputed datasets into z, which 
is supposed to have a normal distribution, then the mean of the z values among 
the imputed datasets is transformed back into an r, which becomes the Pearson 
correlation coefficient. This was realized with the user-written STATA command 
‘mibeta’ with the option ‘fisherz’ (539). 
STATA code: 
Mibeta mi_diff_eq5d_score mi_diff_pdq39SI, fisherz 
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Appendix E: Checking normality of residuals 
To choose whether it is appropriate to conduct Pearson correlation or Spearman 
correlation, the normality of the residual of regressions of EQ-5D/ICECAP-O 
predicted PDQ-39 were checked. Five imputed datasets (n=1, 3, 10, 20 and 30) 
were checked. 
 
The results include: 
1. regression of change of ICECAP-O, predicted by the change of PDQ-39 
2. regression of change of EQ-5D-3L, predicted by the change of PDQ-39 
 
MI: wide form, year 2 and years 4. 
 
For each regression, three methods were undertaken: 
• Shapiro-Wilk W test 
• Kernal density estimate 
• Scatter plot of the residual against the fitted value of the response variable 
(ICECAP-O/EQ-5D)  
 
1.  Change of ICECAP-O predicted by change of PDQ-39 
• Shapiro-Wilk W test 
 
Table Appendix E-1: Shapiro-Wilk W test result to determine the normality of the residuals of 
change of ICECAP-O predicted by change of PDQ-39 
Imputed 
dataset # 
(m=) 
Variable Obs W V z Prob>z 
1 residual 1238 0.986 10.576 5.891 0.00000 
3 residual 1238 0.983 13.276 6.459 0.00000 
10 residual 1238 0.989 8.37 5.307 0.00000 
20 residual 1238 0.987 9.725 5.682 0.00000 
30 residual 1238 0.990 7.876 5.155 0.00000 
 
 
• Kernel density estimate 
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Figure Appendix E-1: Kernel density graph in each of the randomly selected imputed datasets 
(m=1,3,10,20,30) to determine the normality of the residuals of change of ICECAP-O predicted 
by change of PDQ-39 
 
 
• Scatter plot of the residual against the fitted value of the ICECAP-O 
 
Figure Appendix E-2: scatter plot of residual against the fitted value of the ICECAP-O in each 
of the randomly selected imputed datasets (m=1,3,10,20,30). 
 
 
2. Change of EQ-5D-3L vs. PDQ-39 
 
• Shapiro-Wilk W test 
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Table Appendix E-2: Shapiro-Wilk W test result to determine the normality of the residuals of 
change of EQ-5D-3L predicted by change of PDQ-39 
Imputed 
dataset 
# (m=) 
Variable Obs W V z Prob>z 
1 residual 1238 0.986 10.576 5.891 0.00000 
3 residual 1238 0.983 13.276 6.459 0.00000 
10 residual 1238 0.989 8.370 5.307 0.00000 
20 residual 1238 0.987 9.725 5.682 0.00000 
30 residual 1238 0.990 7.876 5.155 0.00000 
 
 
• Kernel density estimate 
 
Figure Appendix E-3: Kernel density graph in each of the randomly selected imputed datasets 
(m=1,3,10,20,30) to determine the normality of the residuals of change of EQ-5D-3L predicted 
by change of PDQ-39 
 
 
 
• Scatter plot of the residual against the fitted value of the ICECAP-O 
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Figure Appendix E-4: scatter plot of residual against the fitted value of the EQ-5D-3L in each 
of the randomly selected imputed datasets (m=1,3,10,20,30). 
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Appendix F: Regression analysis of responsiveness: 
complete case analysis 
This appendix contains the regression analysis result with the complete case 
analysis for determining which PDQ-39 dimensions are strong predictors of the 
change of ICECAP-O (Table Appendix F-1) /EQ-5D-3L (Table Appendix F-2) over 
five years. 
Table Appendix F – 1: Regression analysis to predict the change of ICECAP-O 
index score from the change of the PDQ-39 eight dimensions (complete case 
analysis) 
Change of PDQ-39 
dimensions to predict 
ICECAP-O 
Coefficient SE. P value 95% CI 
Mobility -0.00154 0.00082 0.063 -0.00316 ,0.00008 
ADL -0.00116 0.00074 0.121 -0.00263 ,0.00031 
Emotional wellbeing -0.00223 0.00092 0.016 -0.00405 ,-0.00042 
Stigma 0.00020 0.00094 0.835 -0.00167 ,0.00207 
Social support -0.00245 0.00087 0.006 -0.00418 ,-0.00072 
Cognition -0.00108 0.00076 0.16 -0.00259 ,0.00043 
Communication 0.00155 0.00076 0.044 0.00004 ,0.00307 
Bodily discomfort -0.00083 0.00069 0.231 -0.00219 ,0.00053 
Constant -0.00948 0.01752 0.589 -0.04418 ,0.02522 
 
Table Appendix F – 2: Regression analysis to predict the change of EQ-5D 
index score from the change of the PDQ-39 eight dimensions (complete case 
analysis) 
Change of PDQ-39 
dimensions to predict EQ-
5D 
Coefficient SE. P value 95% CI 
Mobility -0.00247 0.00094 0.009 -0.00431 ,-0.00062 
ADL -0.00197 0.00093 0.036 -0.0038 ,-0.00013 
Emotional wellbeing -0.00364 0.00112 0.001 -0.00583 ,-0.00144 
Stigma -0.00152 0.00102 0.137 -0.00352 ,0.00049 
Social support -0.00003 0.00107 0.98 -0.00213 ,0.00207 
Cognition -0.00132 0.00091 0.149 -0.0031 ,0.00047 
Communication 0.00201 0.00086 0.02 0.00032 ,0.0037 
Bodily discomfort -0.00135 0.00075 0.071 -0.00282 ,0.00012 
Constant -0.02108 0.01959 0.283 -0.05965 ,0.01749 
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Appendix G: Permission for including published 
materials in this thesis 
This appendix contains the permissions obtained for the following pieces of 
published content from the publisher that are included in this thesis. They are: 
• Part of the content in Chapter 4 has been published by Springer in the 
journal ‘Quality of life research’: 
Xin Y & McIntosh E. (2017) Assessment of the construct validity and responsiveness of 
preference-based quality of life measures in people with Parkinson's: a systematic review. 
Quality of Life Research, 26(1): 1-23. 
 
• Two figures are cited from the following book chapter: 
Zumbo BD, Chan EKH. Setting the Stage for Validity and Validation in Social, Behavioral, and 
Health Sciences: Trends in Validation Practices. In: Zumbo BD, Chan EKH, editors. Validity and 
Validation in Social, Behavioral, and Health Sciences. 1 ed: Springer International Publishing; 
2014. 
 
• One figure is cited from each of the following publications: 
Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, de Vet HCW. 
International consensus on taxonomy, terminology, and definitions of measurement 
properties: results of the COSMIN study. J Clin Epidemiol 2010;63:737-745. 2012. 
 
Smith GT. On construct validity: issues of method and measurement. Psychological 
assessment. 2005;17(4):396-408. 
 
• One figure is cited from the following archived material: 
Gumber A, Ramaswamy B, Ibbotson R, Ismail M, Thongchundee O, Harrop D, et al. Economic, 
Social and Financial Cost of Parkinson's on Individuals, Carers and their Families in the UK. 
Project report. Centre for Health and Social Care Research, Sheffield Hallam University; 2017 
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